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A major goal of this research was to evaluate a variety of cell lines for their 
permissiveness to equine arteritis virus (EAV) infection and then identify the mechanism 
that restricts EAV infection in certain cell lines. The cell lines BHK-21, RK-13, and 
C2C12 were found to support productive infection with EAV strain VBS53, whereas 
Hela, Hep-2, and L-M cell lines exhibited limited susceptibility to infection with this 
virus. In the course of the study, it was found that the Hela cell line became more 
susceptible to infection with EAV strain VBS53 after extended serial passage. The 
respective cell lines were referred to as Hela High (passage 170-221) and Hela Low 
(passage 95-115) lines. While the Hela High cell line was more susceptible than the Hela 
Low cell line, it was still considerably less susceptible than the BHK-21 cell line to EAV 
infection. Subsequent studies demonstrated that infection with EAV strain VBS53 was 
restricted at the entry step in Hela, Hep-2, and L-M cell lines.  
The second major goal of this research was to establish an in vitro model of 
persistent EAV infection using cell culture and then use the persistently infected cultures 
as a tool to study virus-host cell interactions, and to investigate virus and host cell 
evolution. Persistent infection was successfully established in the Hela High cell line with 
the VBS53 strain of EAV. Properties of the persistently infected Hela High cell line were 
characterized. Virus evolution with respect to virus growth characteristics, ability of the 
virus to initiate secondary persistent infection, and genetic changes during persistent 
EAV infection in Hela cells was investigated. Neutralization phenotypic changes of 
viruses were observed during the course of persistent EAV infection in Hela cells. 
Reverse genetics studies identified that amino acid 98 of the GP5 protein is a new 
neutralization determinant of EAV. Using an in vitro assay, it was found that EAV 
probably became progressively less virulent during the course of persistent infection in 
Hela cells. The potential changes in pathogenicity of EAV during persistent infection of 
Hela cells need to be verified by inoculation of horses.     
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Chapter One: General Introduction 
 
I. INTRODUCTION 
Equine viral arteritis (EVA) is a globally distributed infectious disease of equids 
caused by equine arteritis virus (EAV). EAV was first isolated from the lung of an 
aborted fetus in the course of an outbreak of respiratory disease and abortion in 
Standardbred horses at Bucyrus, Ohio, USA, in 1953 (Doll et al. 1957a; 1957b). The 
majority of horses develop a subclinical infection following natural exposure to EAV. 
Occasionally, clinical disease can occur: influenza-like illnesses in adult horses, abortion 
in pregnant mares, and interstitial pneumonia, or enteritis, or pneumonoenteritis in young 
foals (Glaser et al. 1997; Timoney and McCollum 1993). Up to 30% to 70% of stallions 
infected with EAV can subsequently become carriers which constantly shed the virus in 
semen (Timoney and McCollum 1993). Persistently infected stallions are the principal 
reservoir of EAV and are responsible for perpetuation and dissemination of EAV in 
equine populations (Timoney et al. 1987; Timoney and McCollum 1993). Carrier 
stallions are also thought to be a significant natural source of genetic and phenotypic 
diversity of EAV (Balasuriya et al. 1999a; 2004a; Hedges et al. 1999a). 
Persistent infection of cell culture has been documented with many viruses. Such 
infections have been used to study virus-host cell interactions and they have also been 
shown to be a useful tool for investigating virus and cell evolutions (Ahmed et al. 1981; 
Colbere-Garapin et al. 1989; de la Torre et al. 1988a; Kaplan et al. 1989). Persistent 
infection in cell culture could possibly serve as a model system for elucidating 
mechanisms of viral persistence in vivo.  
In this introductory chapter, the molecular biology of EAV is addressed in section II 
with EAV infection and persistently infected stallions discussed in section III. Persistent 
infections of cell cultures with RNA viruses will be reviewed in section IV followed by 
the research objectives of this study in section V. 
 
II. EQUINE ARTERITIS VIRUS 
1. Classification and genome organization 
Based on similarities in genomic organization and protein expression strategies, the 
Arteriviridae (genus Arterivirus), Coronaviridae (genera Coronavirus and Torovirus), 
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and Roniviridae (genus Okavirus) were grouped together in the order Nidovirales (Table 
1.1; Cavanagh 1997; de Vries et al. 1997). Arteriviruses comprise four members: equine 
arteritis virus (EAV), porcine respiratory and reproductive syndrome virus (PRRSV), 
lactate dehydrogenase-elevating virus (LDV), and simian hemorrhagic fever virus (SHFV) 
(Snijder and Meulenberg 1998). Coronaviruses can be grouped into three clusters on the 
basis of serological and genetic properties (Lai and Cavanagh 1997; Stephensen et al. 
1999). Grouping of newly discovered SARS-CoV has been of controversy. Phylogenetic 
analysis of different SARS-CoV proteins using unrooted trees showed that SARS-CoV 
does not segregate into any of the three established coronavirus groups and it was 
suggested that SARS-CoV may be classified as the prototype of a novel, fourth group of 
coronaviruses (Marra et al. 2003; Rota et al. 2003). However, phylogenetic analysis of 
coronavirus replicase genes using a rooted tree (the equine torovirus was used as an 
outgroup for coronaviruses) indicated that the SARS-CoV lineage was an early split-off 
from the coronavirus group 2 branch and it was suggested that SARS-CoV could be 
classified as the prototype of subgroup 2b if the established group 2 coronaviruses would 
be referred to as subgroup 2a (Snijder et al. 2003). Four torovirus species have been 
recognized: equine torovirus (Berne virus), bovine torovirus (Breda virus), human 
torovirus, and porcine torovirus (Koopmans and Horzinek 1994; Kroneman et al. 1998). 
The recently discovered okaviruses that infect prawns comprise two members thus far: 
gill-associated virus and yellow head virus (Cowley et al. 2002a; Cowley and Walker 
2002b; Sittidilokratna et al. 2002).  
Nidoviruses have in common a characteristic genome organization: the most 5’ end 
open reading frames (ORF), 1a and 1b, encode the viral replicase polyproteins that are 
subsequently proteolytically processed; the 3’-terminals of the genome encode structural 
proteins (Snijder and Meulenberg 1998). Nidoviruses have a unique mechanism to 
regulate structural protein gene expression. The structural protein genes are not directly 
expressed from the genome, but from a nested set of 3’-coterminal subgenomic mRNAs 
(sg mRNAs). In the case of arteriviruses and coronaviruses, subgenomic mRNAs also 
contain a common 5’ leader sequence derived from the 5’ end of the genome (Lai and 
Cavanagh 1997; Snijder and Meulenberg 1998). On the other hand, subgenomic mRNAs 
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of okaviruses do not have a common 5’ leader sequence (Cowley et al. 2002c), neither do 
torovirus sg mRNAs with exception of sg mRNA2 (Snijder et al. 1990). 
The EAV genome is a single-stranded, positive-sense RNA molecule of 12,704 
nucleotides [sizes excluding the 3’ poly(A) tail] in length. The 3’ end of the genome is 
polyadenylated (van Berlo et al. 1982) and the 5’ end is believed to be capped (Snijder 
and Meulenberg 1998). Its genomic organization is depicted in Fig 1.1 and Table 1.2. The 
coding regions of the EAV genome are flanked by 5’ and 3’ non-translated regions 
(NTRs) of 224 nucleotides (nt) and 59 nt, respectively (Table 1.2). Nucleotides (1-211) 
are often referred to as the 5’ leader sequence which is present in genomic RNA and in 
all sg mRNAs. An intraleader ORF (nt 14-127, encoding a hypothetical 37 aa peptide) 
was suggested by Kheyar et al. (1996). However, the expression of this ORF has never 
been observed and the role of this putative intraleader ORF has yet to be determined. The 
EAV genome includes nine functional ORFs. The replicase gene comprises the 5’-
terminal three-quarters of the genome and includes two large ORFs (1a and 1b), which 
are both expressed directly from the genomic RNA. The translation of ORF1a generates a 
multi-domain precursor polyprotein: the 1727-amino-acid ORF1a polyprotein (187 kD). 
Following ORF1a translation, a -1 ribosome frameshift into ORF1b occurs with an 
estimated efficiency of 15 to 20% (den Boon et al. 1991). This results in the generation of 
a 3175-amino-acid ORF1ab polyprotein (345 kD). Two large replicase polyproteins 
(polyprotein 1a and polyprotein 1ab) are proteolytically processed by three ORF1a-
encoded proteases (Snijder et al. 1992; 1995; 1996) and produce 12 nonstructural 
proteins (nsp1-12; Table 1.2) and multiple processing intermediates (den Boon et al. 
1995a; Snijder et al. 1993, 1994; van Dinten et al. 1996; 1999; Wassenaar et al. 1997). 
The 3’ one-quarter of the genome is composed of seven ORFs (2a, 2b, 3-7), which 
encode structural proteins E, GP2b (Gs), GP3, GP4, GP5 (GL), M, and N, respectively. 
Most of these ORFs that encode structural proteins have both 5’- and 3’- terminal 
sequences that overlap with neighboring genes (Fig 1.1A and Table 1.2; de Vries et al. 
1992; Snijder and Meulenberg 1998; Snijder et al. 1999). These structural proteins are 
expressed from a 3’-coterminal nested set of six subgenomic mRNAs that also contain a 
common 5’ leader sequence, which is derived from the 5’ end of the viral genome (Fig 
1.1A; de Vries et al. 1990; van Berlo et al. 1982). The following 13, 3.2, 2.7, 2.2, 1.9, 1.2, 
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and 0.8 kb [including a poly(A) tail] were estimated for EAV genomic RNA and sg 
mRNAs 2-7, respectively (den Boon et al. 1991). In sg mRNAs, the leader sequence is 
linked to different sequences derived from the 3’ region of the genome, which are 
referred to as “mRNA bodies”. The leader sequences are connected to the mRNA bodies 
by a short, conserved transcription-regulating sequence (TRS) which is present both at 
the 3’ end of the leader sequence and at the 5’ end of the mRNA bodies (Fig 1.1A).  
2. Virion architecture and properties 
Equine arteritis virus is a small, spherical, enveloped, positive-strand RNA virus. 
The virus particles are 40-60 nm in diameter (Horzinek et al. 1971) and have a buoyant 
density of 1.17 to 1.20 g/ml in sucrose, 1.18 to 1.22 g/ml in cesium chloride (Hyllseth 
1970). The sedimentation coefficient of EAV particles has been reported to be between 
216S and 232S (van der Zeijst and Horzinek 1975). The stability of EAV is influenced by 
temperature and pH and EAV can be stored at -70ºC for years without significant loss of 
the infectivity (Burki 1966; Harry and McCollum 1981; McCollum et al. 1961). Equine 
arteritis virus can be inactivated by lipid solvents (ether and chloroform) and by 
disinfectants and detergents (Burki 1965; Zeegers et al. 1976). 
A schematic representation of the EAV virion architecture is shown in Fig 1.1B. 
Virions consist of an icosahedral nucleocapsid (25-35 nm in diameter) which is 
surrounded by a lipid-containing envelope with tiny surface projections (Horzinek et al. 
1971). The viral nucleocapsid is composed of the linear viral genomic RNA (12.7 kb) and 
a 14-kDa phosphorylated nucleocapsid (N) protein (de Vries et al. 1992; Hyllseth 1973; 
Zeegers et al. 1976). The virion envelope contains six envelope proteins. The two major 
envelope proteins are 16-kDa nonglycosylated membrane protein (M) and the relatively 
large envelope glycoprotein GP5 (previously named GL) of 30 to 42 kDa (de Vries et al. 
1992). The M and GP5 proteins occur in the virion as disulfide-linked heterodimers (de 
Vries et al. 1995b). The unglycosylated envelope protein E of 8 kDa is of intermediate 
abundance in the virion (Snijder et al. 1999). The three minor envelope proteins of EAV 
are 25-kDa glycoprotein GP2b (previously named Gs), the heterogeneously N-
glycosylated GP3 glycoprotein of 36 to 42 kDa, and the 28-kDa GP4 glycoprotein, 
respectively (de Vries et al. 1992; 1995a; Hedges et al. 1999b; Wieringa et al. 2002). The 
GP2b, GP3, and GP4 proteins occur in the virion as heterotrimers (Wieringa et al. 2003a).  
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The EAV nucleocapsid protein, encoded by ORF7, is a small protein with a high 
content of basic amino acids and a hydrophilic nature (de Vries et al. 1992). The N 
protein is expressed abundantly in infected cells and constitutes about 35 to 40% of the 
protein moiety in the virion (de Vries et al. 1992). The N protein was shown to be 
phosphorylated and present in the virion as a monomer (Snijder and Meulenberg 1998). 
The N protein is necessary for virus assembly and the production of infectious virus 
particles (Molenkamp et al. 2000; Wieringa et al. 2004). It is predicted that the N protein 
plays an important role in encapsidating viral genomic RNA and in the interactions with 
envelope proteins during virus assembly. However, the regions of the N protein 
responsible for RNA encapsidation and interactions with envelope proteins have not yet 
been determined. The EAV virion biogenesis is assumed to be a strictly cytoplasmic 
event, however, besides existing in the cytoplasm, small quantities of the N protein have 
also been observed in the nucleus (Molenkamp et al. 2000; Tijms et al. 2002). The 
mechanism and significance of the nuclear translocation of EAV N protein remain 
unknown. 
The GP5 and M proteins are the two major envelope proteins and are encoded by 
ORF5 and 6, respectively (de Vries et al. 1992). The M and GP5 proteins are present in 
virions in equimolar amounts and appear as disulfide-linked heterodimers which 
constitute the basic protein matrix of the envelope (de Vries et al. 1992; 1995b). In cells 
infected with EAV, disulfide-linked M protein homodimers were also observed but these 
were not incorporated into virions (Snijder and Meulenberg 1998). The M protein, like 
the N protein, lacks potential N-glycosylation sites and lacks a potential amino-terminal 
signal sequence (de Vries et al. 1992). The M protein is assumed to span the viral 
envelope three times with its internal transmembrane segments, leaving a short stretch of 
10-18-amino-acid N-terminal domain (ectodomain) exposed at the outside of the virion 
and an approximately 72-residue C-terminal domain buried at the inside (de Vries et al. 
1992; 1995b; Snijder and Meulenberg 1998). The single Cys residue (Cys-8) in the M 
ectodomain is crucial for the formation of both the GP5-M heterodimer and the M-M 
homodimer (Snijder et al. 2003). The GP5 protein (255 aa) is a heterogeneously 
glycosylated protein that contains an N-terminal signal sequence (aa 1-18) which is 
cleaved off during transport through the endoplasmic reticulum (ER). The hydropathy 
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profile of the GP5 protein would suggest that amino acid residues 19-116 constitute the 
hydrophilic ectodomain of the protein, while the C-terminal half consists of three 
membrane-spanning domains followed by an endodomain of about 64 amino acids 
(Balasuriya and MacLachlan 2004c; de Vries et al. 1992; Snijder et al. 2003). The 
ectodomain of the GP5 protein possesses one or two N-glycosylation sites (Asn-56 is a 
N-glycosylation site which is conserved amongst all strains of EAV and Asn-81 is 
another potential N-glycosylation site occurring in some field and laboratory strains of 
EAV) to which variable numbers of lactosamine side chains were added (Balasuriya et al. 
1995a; de Vries et al. 1992). The ectodomain of the GP5 protein also contains five 
conserved Cys residues: Cys-34, Cys-57, Cys-63, Cys-66, and Cys-80. The Cys-34 in the 
GP5 ectodomain and the Cys-8 in the M ectodomain form a disulfide bond which 
mediates GP5-M heterodimerization (Snijder et al. 2003). The GP5 and M proteins are 
indispensable for both virus assembly (Wieringa et al. 2004) and the production of 
infectious virus particles (Molenkamp et al. 2000; Snijder et al. 2003; Wieringa et al. 
2004). The GP5 protein expresses neutralization determinants of the virus. All of the 
neutralization determinants of EAV identified to date are located on the ectodomain of 
the GP5 protein (Balasuriya et al. 1993; 1995b; 1997; 2004b; Chirnside et al. 1995; 
Deregt et al. 1994; Glaser et al. 1995).  
Besides the three major structural proteins, the EAV virion contains four other 
envelope proteins: small hydrophobic envelope protein E, and minor envelope proteins 
GP2b, GP3, and GP4 which occur as heterotrimers (Snijder et al. 2003; Wieringa et al. 
2002). Also, it has been recently demonstrated that incorporation of the E protein is 
somehow linked to that of GP2b/GP4/GP3, suggesting the existence of a 
GP2b/GP4/GP3/(E) complex (Wieringa et al. 2004). The small envelope protein E (67 
aa), encoded by EAV ORF2a, is an integral membrane protein with a central hydrophobic 
domain of 40 residues and a cluster of basic amino acid residues in the hydrophilic C-
terminal domain (Snijder et al. 1999). The EAV E protein does not have a N-terminal 
signal sequence and lacks potential N-glycosylation sites (Snijder et al. 1999). The E 
protein proved to be stable and did not form covalently linked multimers (Snijder et al. 
1999). The E protein was found to associate with intracellular membranes (both the ER 
and Golgi complex) in EAV-infected cells or upon independent expression(Snijder et al. 
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1999). Minor envelope proteins GP2b, GP3, and GP4, encoded by EAV ORF2b, 3, 4, 
respectively, are abundantly expressed in EAV-infected cells, but only a small fraction of 
them is assembled into the virion. In the virion, the molar ratio of GP2b to GP5 and M is 
approximately 1:25 (de Vries et al. 1992; 1995a; Wieringa et al. 2003a). Both GP2b and 
GP4 proteins are type I integral membrane proteins, containing one and three functional 
N-glycosylation sites, respectively (de Vries et al. 1995a; Wieringa et al. 2002). Both 
GP2b and GP4 proteins contain a 22-24 amino acid residue of an N-terminal signal 
sequence which is cleaved off during transport through the ER (de Vries et al. 1995a; 
Wieringa et al. 2002). The GP3 protein is a heavily glycosylated integral membrane 
protein with six N-glycosylation sites. It contains an uncleaved hydrophobic amino-
terminal signal sequence and a hydrophobic C-terminus (Hedges et al. 1999b; Wieringa 
et al. 2002). The GP3 protein is anchored to the membrane by either one or both of its 
hydrophobic terminal domains; no part of its structure is detectably exposed 
cytoplasmically (Hedges et al. 1999b; Wieringa et al. 2002). It has been shown that the 
EAV E, GP2b, GP3, and GP4 proteins are dispensable for the formation of virus-like 
particles (Wieringa et al. 2004) while they are essential for the production of infectious 
virus particles (Molenkamp et al. 2000). It implies that the GP2b/GP4/GP3/(E) complex 
may be involved in the virus attachment and cell entry process.  
3. The replication cycle of equine arteritis virus 
Equine arteritis virus can be propagated in a variety of primary cultures such as 
equine macrophages (Moore et al. 2003a), equine endothelial cells (Moore et al. 2003b), 
equine kidney cells (McCollum et al. 1961), hamster kidney cells (Wilson et al. 1962), 
and so on. The virus can also replicate efficiently in several continuous cell lines such as 
rabbit kidney (RK-13; McCollum et al. 1962), baby hamster kidney (BHK-21; Hyllseth 
1969), African green monkey kidney (Vero; Konishi et al. 1975) and so on. EAV 
infection of primary cells and continuous cell lines is highly cytocidal. The appearance of 
cytopathic effect (CPE) and the titer of infectious virus produced in different cell lines 
vary. The cytopathic effect exhibited in EAV-infected cells is characterized by rounding 
of cells and cell detachment from the culture plate surface (Hyllseth 1969; McCollum et 
al. 1962). Like other viruses, EAV infection of cells involves virus attachment and entry, 
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biosynthesis (viral genome replication, mRNA transcription, and viral protein synthesis), 
virus assembly, budding, and release.  
(1) Virus attachment and entry 
The first step of virus infection is viral attachment to a specific receptor on a 
susceptible cell. In the case of EAV, neither a virus attachment molecule nor a specific 
cell receptor has yet been identified. By analogy with many other animal RNA viruses 
and in view of its recognition by neutralizing antibodies, the EAV GP5 protein had been 
postulated to serve as the virus attachment protein and to mediate receptor recognition. 
However, exchange of the ectodomain of the EAV GP5 protein with that of PRRSV or 
LDV in the context of an infectious EAV cDNA clone did not alter the cell tropism of the 
virus (Dobbe et al. 2001). In that study, the EAV GP5 ectodomain (aa 1-114) in a full-
length EAV cDNA clone was replaced by the GP5 ectodomain (aa 1-64) of PRRSV or 
LDV to yield chimeric EAV. It was found that these chimeric viruses were still able to 
infect BHK-21 and RK-13 cells. It is well known that these cells can be infected by EAV, 
but not by either PRRSV or LDV (Dobbe et al. 2001). The authors concluded that the 
ectodomain of GP5 is not the main determinant of EAV tropism in cell culture. Similarly, 
PRRSV mutants in which the ectodomain of the M protein was replaced by that of EAV 
or LDV still retained their ability to infect porcine alveolar macrophages and did not 
acquire tropism to cells susceptible to the respective viruses (e.g. BHK-21 cells for EAV 
and mouse macrophages fro LDV) from which the foreign ectodomains were derived 
(Verheije et al. 2002). This would suggest that, in the case of arteriviruses, the M protein 
is not responsible for receptor binding either. Recently, Wieringa et al. (2003a) have 
shown that minor structural proteins are present in EAV virions as disulfide-linked 
GP2b/GP4/GP3 heterotrimeric complexes. Also, there are indications that the E protein is 
noncovalently associated with the GP2b/GP4/GP3 trimers (Wieringa et al. 2004). It has 
also been demonstrated that the E, GP2b, GP3, and GP4 proteins are not required for the 
formation of EAV particles, although these proteins are believed essential for ensuring 
that the virus particles are infectious (Molenkamp et al. 2000; Wieringa et al. 2004). 
These findings would suggest that the GP2b/GP4/GP3/(E) complex might be involved in 
the EAV attachment/entry process. However, it must be realized that it is possible that a 
virus utilizes more than one attachment molecule for binding to cells. For example, 
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Delputte et al. (2002) showed that the PRRSV M protein alone or in a complex with GP5 
were involved in virus attachment to the receptor heparan sulfate on porcine alveolar 
macrophages; it has also been found that sialic acids on the PRRS virion can mediate 
virus attachment to another receptor sialoadhesin on porcine alveolar macrophages 
(Delputte and Nauwynck 2004). Sialic acids may be present on one or more viral 
glycoproteins. Moreover, viruses do not necessarily utilize the same attachment molecule 
to attach to different cells, e.g. PRRSV uses some unidentified molecules other than sialic 
acids to attach to Marc-145 cells (Delputte and Nauwynck 2004). 
The cell receptor for EAV has not been identified either. Asagoe et al. (1997) 
showed that heparin can reduce EAV infection of RK-13 cells and that this inhibition was 
due to the direct interaction between heparin and EAV rather than the interaction between 
heparin and RK-13 cells. Furthermore, treatment of RK-13 cells with heparinase before 
virus inoculation decreased EAV infection of the cells (Asagoe et al. 1997). The data 
suggested that a heparin-like molecule on the surface of RK-13 cells might serve as a cell 
receptor for EAV. Similar studies have shown that a heparin-like molecule on Marc-145 
cells and porcine alveolar macrophages serves as the cell receptor for PRRSV (Delputte 
et al. 2002; Jusa et al. 1997). However, heparinase treatment of RK-13 cells could not 
completely block EAV infection (Asagoe et al. 1997). Furthermore, EAV infection could 
not be reduced below 13% even in the presence of a very high concentration of heparin 
(Asagoe et al. 1997). This implied that other molecules on the cell surface might serve as 
EAV receptors as well. In fact, for PRRSV, another arterivirus, two receptors have been 
identified on porcine macrophages: heparan sulfate and porcine sialoadhesin (Delputte et 
al. 2002; Vanderheijden et al. 2003). Both heparan sulfate and sialoadhesin mediate 
PRRSV attachment to porcine macrophages, and early attachment is mediated mainly via 
an interaction with heparan sulfate, followed by gradual increase of attachment via the 
interaction with sialoadhesin (Delputte et al. 2005). It was observed that PRRSV can 
attach to but not be internalized into wild-type CHO K1 cells, which express heparan 
sulfate but not sialoadhesin, suggesting that heparan sulfate alone is sufficient to mediate 
virus attachment but not entry (Delputte et al. 2005). Upon transfection and expression of 
recombinant sialoadhesin, CHO A745 and D667 cells which are naturally deficient in 
both heparan sulfate and sialoadhesin expression are capable of binding and internalizing 
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PRRSV, indicating that sialoadhesin expression is sufficient for both PRRSV attachment 
and internalization and heparan sulfate is not essential for internalization (Delputte et al. 
2005). However, heparan sulfate may enhance PRRSV binding to porcine sialoadhesin 
(Delputte et al. 2005).  
EAV is assumed to enter cells through a process of receptor-mediated endocytosis, 
since the same family member PRRSV has been shown to enter cells through a 
mechanism of clathrin-dependent, receptor-mediated endocytosis in which low pH is 
necessary for the fusion between the endosomal membrane and the viral envelope and 
subsequent virus uncoating (Kreutz and Ackermann 1996; Nauwynck et al. 1999). It was 
observed that PK-15 cells expressing recombinant sialoadhesin can bind and internalize 
PRRSV but they are not productively infected (Vanderheijden et al. 2003). It was also 
reported that Vero cells, which are non-permissive to PRRSV infection but can support 
PRRSV replication after transfection with viral RNA, were able to bind and internalize 
the virus almost as efficiently as the permissive cell line Marc-145 (Kreutz 1998). This 
may possibly be due to the fact that the fusion of viral and endosomal membranes does 
not occur after virus internalization, and virus remains in the endosome and the viral 
genome is not released into the cytoplasm. If this should prove to be true, it would 
indicate that some cellular factor(s), which are essential for viral and endosomal 
membrane fusion and virus uncoating, are lacking in these cells. 
EAV attachment and the entry process still need further study. Firstly, the virus 
attachment molecule(s) need to be determined. Secondly, EAV specific cell receptor(s) 
wait to be defined. Thirdly, mechanism of fusion between EAV envelope and endosomal 
membrane need to be studied. It is still unknown how many receptors or coreceptors are 
needed for EAV attachment and entry. Also, it is not clear whether EAV utilizes the same 
receptor(s) in different cells and whether different EAV strains use the same receptor(s).   
(2) Biosynthesis: viral genome replication, mRNA transcription, and viral 
protein synthesis 
Once the viral RNA is released into the cytoplasm, arteriviruses start their 
replication cycle in the cell. The EAV replication cycle commences with translation of 
the replicase polyproteins from the genome, followed by genome replication, subgenomic 
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RNA transcription, and translation of structural proteins from sg mRNAs (Fig 1.2; 
Snijder and Meulenberg 1998).  
A. Genome translation and post-translational processing of replicase 
polyproteins  
There are two general mechanisms for translation initiation: classical cap-dependent 
initiation followed by linear ribosome scanning and initiation via internal ribosome entry 
site (IRES) element. The EAV genome is assumed to be 5’ capped based on two findings: 
another arterivirus SHFV has been shown to contain a type I cap structure (Sagripanti et 
al. 1986) and a cap analogue is known to be essential to make in vitro transcribed full-
length infectious RNA (Meulenberg et al. 1998; van Dinten et al. 1997). Therefore, it 
was suggested that EAV genome translation is initiated via a cap-dependent mechanism. 
van den Born et al. (2005) has further demonstrated that EAV genome translation is not 
IRES mediated. The EAV replicase polyprotein 1a is translated directly from ORF1a. 
However, ORF1b translation requires a -1 ribosomal frameshift just before ORF1a 
translation is terminated (den Boon et al. 1991). The ribosomal frameshift is assumed to 
be directed by two signals in the ORF1a/ORF1b overlap region: a ‘shifty’ 
heptanucleotide sequence 5’ GUUAAAC 3’, and a downstream RNA pseudoknot 
structure (Fig 1.3; Snijder and Meulenberg 1998).  
Translation of the EAV replicase gene yields two polyproteins: the polyprotein 1a 
and the polyprotein 1ab. The EAV polyprotein 1a is cleaved seven times and the 
polyprotein 1ab is cleaved ten times by three different viral proteases, which in total, 
generates 12 end-products, named nonstructural protein (nsp) 1-12, and multiple 
processing intermediates (Fig 1.4A; Table 1.2). Three EAV proteases are located in nsp1, 
nsp2, and nsp4. The nsp1 protease has been characterized as a papain-like cysteine 
protease (PCP) (Snijder et al. 1992). The nsp1 of PRRSV and LDV contains two active 
proteases: PCP1a and PCP1ß (Ziebuhr et al. 2000). However, in the case of EAV, PCP1a 
is inactive and only PCP1ß is active (Ziebuhr et al. 2000). The catalytic dyad of the EAV 
PCP has been identified as Cys-164 and His-230 (den Boon et al. 1991; Snijder et al. 
1992). The EAV PCP has been found to direct an autoproteolytic cleavage at its C 
terminus (Gly-260 | Gly-261 site) and to result in the rapid release of nsp1 (aa 1-260) 
from the polyprotein (Fig 1.4A and Table 1.2; Snijder et al. 1992). It was observed that 
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the EAV PCP mediates probably exclusively in cis cleavage, and attempts to achieve 
cleavage in trans were unsuccessful (den Boon et al. 1995a; Snijder et al. 1992). The 
second protease of EAV is the cysteine protease of nsp2 (CP2), which mediates the single 
cleavage at Gly-831 | Gly-832 to release nsp2 (Snijder et al. 1995). The putative catalytic 
residues of the EAV CP2 are Cys-270 and His-332, though the entire nsp2 protein 
appears to be essential for the nsp2|3 cleavage (Snijder et al. 1995). The nsp2|3 cleavage 
can be performed by the EAV CP2 in cis or in trans, though trans-cleavage activity is 
relatively low (Snijder et al. 1995; Ziebuhr et al. 2000). The EAV nsp4 protease has 
some unique characteristics. On one hand, the nsp4 protease utilizes the His-Asp-Ser 
(His-1103, Asp-1129, and Ser-1184 in EAV) catalytic triad, a typical characteristic of 
classical chymotrypsin-like proteases (Snijder et al. 1996). On the other hand, the 
putative substrate-binding region of the EAV nsp4 protease contains Thr and His residues 
(Thr-1179 and His-1198 in EAV), which are conserved in viral 3C-like cysteine 
proteases and determine their specificity for cleavage sites containing a (Glu/Gln) | 
(Gly/Ser) dipeptide (Snijder et al. 1996). Based on these characteristics, the EAV nsp4 
protease was classified as the prototype of a novel group of chymotrypsin-like enzymes,  
the 3C-like serine proteases (3CLSP) (Snijder et al. 1996). The EAV 3CLSP was shown 
to mediate eight cleavages in the EAV replicase proteins: five in the polyprotein 1a and 
three in the ORF1b-encoded polypeptide (Snijder et al. 1996; van Dinten et al. 1999; 
Wassenaar et al. 1997). Four of the known EAV 3CLSP cleavages occur at Glu | Gly 
sites (nsp3|4, nsp5|6, nsp7|8/9, and nsp11|12), three at Glu | Ser sites (nsp4|5, nsp6|7, and 
nsp9|10), and one at Gln | Ser site (nsp10|11) (Fig 1.4A and Table 1.2; Snijder et al. 1996; 
van Dinten et al. 1999; Wassenaar et al. 1997; Ziebuhr et al. 2000). Whether EAV 
3CLSP cleaves each site in cis or in trans has not yet been studied in detail. However, it 
is clear that EAV 3CLSP has in trans cleavage activity, since a nsp4 expression product 
has been shown to efficiently cleave the nsp9|10 and nsp10|11 sites in a separately 
expressed, ORF1b-encoded polypeptide (van Dinten et al. 1999).  
As mentioned above, the nsp1|2 and nsp2|3 cleavages are mediated by EAV PCP 
and EAV CP2, respectively; the other sites in the EAV polyproteins 1a and 1ab are 
cleaved by EAV 3CLSP. But these sites are not equally sensitive to processing by EAV 
3CLSP. In fact, two alternative pathways have been reported to process the carboxyl-
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terminal part of the EAV polyprotein 1a (Fig 1.4B; Wassenaar et al. 1997). In the major 
processing pathway, the EAV 3CLSP first cleaves at the nsp4|5 site, followed by 
cleavage of the nsp3|4 and nsp7|8 junctions, and the nsp5-7 remained uncleaved (Fig 
1.4B; Snijder et al. 1994; 1996). But it was found that cleavage at the nsp4|5 site requires 
the association of cleaved nsp2 with the nsp3-8 precursor (Wassenaar et al. 1997). If the 
nsp2 is absent, the nsp4|5 site cannot be processed and an alternative minor processing 
pathway is utilized (Wassenaar et al. 1997). In the minor processing pathway, the nsp4|5 
site is not cleaved; instead, the nsp5|6 and nsp6|7 sites are cleaved. Subsequently, 
cleavages at the nsp3|4 and nsp7|8 sites occur (Fig 1.4B; Wassenaar et al. 1997). It 
appears that the two pathways are mutually exclusive (Wassenaar et al. 1997). In either 
processing pathway, multiple processing intermediates are generated. In the major 
processing pathway, the nsp2 is required for the cleavage at the nsp4|5 site. But nsp2 
protease activity is not involved, since it has been demonstrated that the nsp2 mutants in 
which the nsp2 cysteine protease is inactivated can still induce the nsp4|5 cleavage 
(Wassenaar et al. 1997). Consequently, it was suggested that the association of nsp2 with 
nsp3-8 may affect conformation of the nsp2/nsp3-8 complex which allows the cleavage 
of the nsp4|5 site by EAV 3CLSP (Wassenaar et al. 1997).   
B. Genome replication 
The RNA synthesis (including genome replication and mRNA transcription) of 
RNA viruses (except retroviruses) relies on viral-encoded RNA-dependent RNA 
polymerase (RdRp). Equine arteritis virus replicase proteins are processed into 12 end 
products (nsp1-12) and multiple processing intermediates. The nsp1, nsp2, and nsp4 
contain viral proteases (Snijder et al. 1992; 1995; 1996). The nsp9 contains the putative 
RNA-dependent RNA polymerase activity, the nsp10 comprises a zinc-binding domain 
and the nucleoside triphosphate-binding/helicase activity, and the nsp11 harbors a 
conserved nidovirus-specific domain with unknown function (Fig 1.4A and Table 1.2; 
van Dinten et al. 1996). Immunofluorescence studies have revealed that the nsp9, nsp10 
and the majority of replicase polyprotein 1a cleavage products (nsp2, nsp4, nsp7-8, and 
nsp8) colocalize in the perinuclear region of EAV-infected cells and the distribution 
pattern of these proteins suggest that they are associated with intracellular membranes 
(van der Meer et al. 1998; van Dinten et al. 1996). Colocalization of these proteins 
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suggests that they might assemble into a large complex which is likely involved in viral 
RNA synthesis. In situ labeling of nascent viral RNA with bromouridine triphosphate 
(BrUTP) further revealed that viral RNA synthesis colocalizes with the membrane-bound 
complex in which the replicase subunits accumulate, demonstrating that the membrane-
bound complex is indeed the site of viral RNA synthesis (van der Meer et al. 1998). A 
typical feature of EAV and other arterivirus infections is the formation of paired 
membranes and double-membrane vesicles (DMVs) observed under electron microscope 
(Breese and McCollum 1970; Pol et al. 1997; Stueckemann et al. 1982; Wood et al. 
1970). These double-membrane vesicles appear to be derived from paired endoplasmic 
reticulum membranes and they are most likely formed by protrusion and detachment of 
vesicular structures with a double membrane (Pedersen et al. 1999). Using replicase-
specific antibodies, BrUTP-specific monoclonal antibody, and cryoimmunoelectron 
microscopy, Pedersen et al. (1999) have shown that the EAV replicase subunits and RNA 
synthesis localize to double-membrane vesicles. This indicates that the EAV replicase 
subunits, including nsp9 which contains the putative RNA polymerase function, assemble 
into a viral replication complex, which is membrane-associated with DMVs where the 
viral RNA synthesis occurs. How are the ORF1b-encoded replicase subunits (nsp9, nsp10, 
etc), which do not contain any transmembrane hydrophobic domains, membrane-
associated with DMVs? Hydrophobic domains located in nsp2, nsp3, and nsp5 were 
postulated to mediate the membrane association of the EAV replication complex (van der 
Meer et al. 1998). This also suggests the presence of multiple protein-protein interactions 
between replicase subunits in the replication complex. Interestingly, it was observed that 
double-membrane vesicles could be induced, in the absence of EAV infection, upon 
expression of ORF1a-encoded replicase subunits nsp2 to nsp7 from an alphavirus-based 
expression system (Pedersen et al. 1999). Snijder et al. (2001) further demonstrated that 
the co-expression of nsp2 and nsp3 is both necessary and sufficient to induce the 
formation of double-membrane vesicles. Taken together, these data indicate that EAV 
ORF1a replicase proteins play an important role in the formation of a membrane-bound 
scaffold for the viral replication/transcription complex (Snijder et al. 2001). 
As described above, the EAV replication complex, assembled on the membrane of 
virus-induced and host cell-derived DMVs, directs the viral RNA synthesis. The RNA 
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polymerase copies (+) genomic strands into full-length (-) genomic strands and then 
utilizes (-) genomic strands as templates to synthesize (+) genomic strands. But the cis-
acting elements essentially involved in EAV replication and transcription have not been 
defined. Also, the exact components of the EAV replication complex need to be 
elucidated. It has been shown that the EAV replicase is the only viral protein required for 
genome replication and none of the structural proteins (E, GP2b, GP3, GP4, GP5, M, and 
N) are essential for genomic replication (Molenkamp et al. 2000). Among EAV replicase 
proteins, nsp1 was also shown to be dispensable for genome replication (Tijms et al. 
2001). However, it is still uncertain whether any host cell proteins are involved in 
genomic replication. Recently, four MA-104 cell proteins have been shown to bind to in 
vitro-generated transcripts representing the 3’ noncoding region of the genomic negative 
strand of several arteriviruses, including EAV (Hwang and Brinton 1998). This region, 
which is complementary to the (+) strand genomic leader sequence, is assumed to be 
important for the initiation of (+) strand RNA synthesis. Archambault et al. (2005) have 
also shown that some proteins in Vero cell cytoplasmic extracts can bind to the (+) and (-) 
strands of the EAV leader sequence. These suggest that host cell proteins may be utilized 
as components of the EAV replication complex. However, this topic definitely needs 
further study. Construction of an EAV replicon may be a solution to resolve these issues 
concerning EAV replication. 
C. Subgenomic RNA transcription 
One striking characteristic of the nidovirus replication cycle is the generation of a 
nested set of 3’-coterminal sg mRNAs from which the structural proteins are expressed 
(Snijder and Meulenberg 1998). For coronaviruses and arteriviruses, these sg mRNAs 
also contain a common 5’ leader sequence, which is derived from the 5’ end of the viral 
genome (Fig 1.1A and Fig 1.2; Snijder and Meulenberg 1998). These sg mRNAs 
comprise leader and body sequences that are not contiguous on the viral genome. It was 
observed that coronaviruses and arteriviruses use transcription-regulating sequences to 
join the leader and the body of sg mRNAs (Chen et al. 1993; de Vries et al. 1990; den 
Boon et al. 1996; Godeny et al. 1998; Makino et al. 1991; Meulenberg et al. 1993; Spaan 
et al. 1983; Zeng et al. 1995).  
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How is the 5’ leader sequence joined to the sg mRNA bodies? Studies for both 
coronaviruses and arteriviruses have ruled out conventional cis-splicing as the major 
mechanism for the production of sg mRNAs (den Boon et al. 1995b; Jacobs et al. 1981; 
Yokomori et al. 1992). Moreover, nidoviruses replicate in the cytoplasm, while 
conventional splicing mainly occurs in the nucleus. Thus, it is generally accepted that 
nidovirus sg mRNAs are generated via a discontinuous transcription process. The first 
model proposed to explain this discontinuous process was the so-called ‘leader-primed 
transcription’ model (Fig 1.5A; Baric et al. 1983; Spaan et al. 1983). In this model, 
discontinuous transcription was assumed to occur during positive-strand RNA synthesis 
using the full-length negative genomic strand as a template. The sense TRS at the 3’ end 
of the leader transcript base pairs with the antisense body TRS in the negative-strand 
template, after which the leader transcript is extended to generate a sg mRNA. In this 
model, the genome-length negative strand serves as the template for the synthesis of 
genomic RNA as well as sg mRNAs. However, the discovery of sg negative-strand 
RNAs and the fact that these sg negative-strand RNAs appear to be transcriptionally 
active argued against the above model (Baric and Schaad 1995; Brian et al. 1994; den 
Boon et al. 1996; Sawicki and Sawicki 1990; Schaad and Baric 1994; Sethna et al. 1989, 
1990; 1991). Subsequently, several models were put forward to explain the presence of 
sg negative strands. Sethna et al. (1989; 1990) hypothesized that sg mRNAs could be 
amplified as independent replicons. According to their hypothesis, leader-primed 
transcription could produce the first generation of sg mRNAs and these sg mRNAs could 
subsequently function as templates for the synthesis of sg negative strands, which could 
in turn be used to generate the second generation of sg mRNAs. In Sethna’s model, sg 
mRNAs are generated from two templates: genome-length negative strands and sg 
negative strands. However, direct evidence for replication of sg mRNAs has never been 
obtained. When sg-length RNA was transfected into coronavirus-infected cells, 
amplification of sg RNA was not observed (Chang et al. 1994; Makino et al. 1991). 
Sawicki and Sawicki (1990; 1995) proposed another model called ‘discontinuous 
negative strand extension’ model (Fig1.5B,C). In their model, discontinuous transcription 
was proposed to occur during negative-strand RNA synthesis using the full-length 
positive genomic strand as a template. The antisense body TRS at the 3’ end of the 
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nascent (-) strand base pairs with the sense leader TRS in the positive genomic template, 
thereby allowing the addition of the anti-leader sequence. The sg negative-strand RNAs 
further function as templates for sg mRNAs synthesis. In this model, sg negative strands 
are produced directly from genome-length positive strand and are the only templates for 
sg mRNAs synthesis. More and more studies of arterivirus and coronavirus sg mRNAs 
synthesis have provided convincing evidence which is consistent with the discontinuous 
negative strand extension model (Baric and Yount 2000; Pasternak et al. 2001; Sawicki et 
al. 2001; van Marle et al. 1999a).  
The availability of full-length infectious cDNA clones of arteriviruses has provided 
a powerful tool to investigate sg mRNAs synthesis. Through genetic manipulation of the 
body and leader TRS of an infectious EAV clone, van Marle et al. (1999a) has 
experimentally demonstrated that EAV discontinuous mRNA transcription is guided by a 
direct base pairing interaction between the sense leader TRS and the antisense body TRS. 
Using a number of TRS mutants with partial transcriptional activity, they also showed 
that the TRS sequence at the leader-body junction of the sg mRNA is derived exclusively 
from the body TRS rather than from the leader TRS, supporting the theory that sg 
mRNAs are generated by a ‘discontinuous negative strand extension’ mechanism rather 
than by a ‘leader-primed transcription’ mechanism (van Marle et al. 1999a). For 
discontinuous transcription, viral RNA polymerase has to stop transcription at one site 
and reinitiate transcription at another site. Therefore, it has been proposed that nidovirus 
discontinuous negative strand extension resembles similarity-assisted, copy-choice RNA 
recombination (Fig 1.5C; Brian and Spaan 1997; Nagy and Simon 1997; van Marle et al. 
1999a). During this process, the RdRp complex and nascent (-) strand transcript are 
released from the primary site (a body TRS) in the positive-strand genomic template and 
translocated to the secondary site (the leader region) of the template where transcription 
is reinitiated. Base pairing between the sense leader TRS and the antisense body TRS at 
the 3’ end of the nascent (-) strand plays a crucial role in guiding this RNA strand transfer 
(Pasternak et al. 2003; van Marle et al. 1999a). Recent studies have shown that, besides 
base pairing between sense leader TRS and antisense body TRS, the secondary structure 
of the leader is also essential for efficient sg RNAs synthesis (van den Born et al. 2004; 
2005). According to the predicted secondary structure of the leader sequence of 
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arteriviruses (in the case of EAV, leader sequence is nt 1-211), the leader TRS is located 
in the loop of a hairpin structure and this hairpin is named as leader TRS hairpin (LTH) 
(Fig 1.5C; van den Born et al. 2004; van Marle et al. 1999a). By mutagenesis studies of 
the leader sequence using an infectious EAV clone, it has been demonstrated that the 
leader TRS hairpin and its immediate flanking sequences are essential for efficient sg 
RNA synthesis (van den Born et al. 2004; 2005). It is predicated that proably the 
antisense body TRS at the 3’ end of the nascent (-) strand can base pair with the sense 
leader TRS only when the latter is present in the loop of a hairpin structure (van den Born 
et al. 2004; 2005; van Marle et al. 1999a).  
Another open question is about the functionality of body TRSs and the 
heterogeneity of sg mRNAs. In addition to the leader TRS (5’UCAAC3’), the EAV 
genome contains 17 other 5’UCAAC3’ motifs, of which only 6 function as body TRSs 
participating in leader-body junction to generate major sg mRNAs2-7 (den Boon et al. 
1991) from which structural proteins E/GP2b, GP3, GP4, GP5, M, and N are expressed, 
respectively. The proteins E and GP2b are expressed from the same sg mRNA2. Using sg 
mRNA-specific RT-PCR approach, studies have shown that there exist subspecies for sg 
mRNAs 3, 4, and 5: namely sg mRNA3.1, -3.2, -3.3, sg mRNA4.1, -4.2, sg mRNA5.1, 
and -5.2 (den Boon et al. 1996; Pasternak et al. 2000). This heterogeneity of sg mRNAs 
originates from the use of alternative body TRSs for the joining of leader and body (den 
Boon et al. 1996; Pasternak et al. 2000). The reason that sg mRNA3.3, -4.1, and -5.2 
subspecies went unnoticed in previous studies may be due to two facts: a) these 
subspecies are minor mRNA subspecies and are in low abundance in infected cells. For 
example, sg mRNA5.2 is 125- to 625-fold less abundant than the major sg mRNA5.1 
subspecies; body TRS4.1 is 40 times less active than body TRS4.2. b) The size 
differences of subspecies for respective mRNA are very small. For example, sg 
mRNA3.1 is 32 nt larger than sg mRNA3.2 which is 42 nt larger than sg mRNA3.3; sg 
mRNA4.1 is 17 nt larger than sg mRNA4.2. These small size differences can hardly be 
detected by northern hybridization assay used in previous studies. Taken together, it must 
be realized that the same sequence motif 5’UCAAC3’ can be actively, less actively, or 
not used for leader-body junction to generate sg mRNAs. Thus, the primary sequence 
5’UCAAC3’ itself is clearly not sufficient to determine whether it is used for sg mRNA 
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transcription or not. Other factors, such as flanking sequences and/or RNA secondary 
structure, are likely to contribute to determining the functionality of the sequence motif 
5’UCAAC3’. Probably the sequences 5’UCAAC3’ at certain positions are more active 
and at other positions are less active or not active.  
Just as in viral genomic replication, synthesis of sg mRNAs is also directed by the 
RdRp complex. So, it can be assumed that sg mRNA transcription of EAV also occurs on 
the membrane of virus-induced and host cell-derived double membrane vesicles. Similar 
to viral replication, none of the structural proteins is required for EAV sg mRNA 
transcription (Molenkamp et al. 2000). However, the EAV nsp1, which is dispensable for 
viral replication, has been found to be essential for sg mRNA transcription (Tijms et al. 
2001). How the nsp1 is involved in sg RNA synthesis is still unclear. Interestingly, it has 
been found that the EAV nsp1 is able to interact with the cellular transcription co-factor 
p100 (Tijms and Snijder 2003). It remains to be determined whether the interaction 
between the nsp1 and p100 plays any role in sg mRNA transcription.  
EAV structural proteins are expressed from respective sg mRNAs. Since all of the 
EAV sg mRNAs are 5’ and 3’ co-terminal as the viral genome, it is reasonable to assume 
that translational machinery for genomic RNA and sg mRNAs are the same. With 
exception of the sg mRNA7, the EAV sg mRNAs are structurally polycistronic (Fig 1.2). 
However, in each of these sg mRNAs, only the most 5’-proximal gene positioned 
immediately downstream of the leader sequence is translated, with exception of sg 
mRNA2, from which both E and GP2b proteins are translated (Snijder et al. 1999). As 
mentioned afore, there exist subspecies for sg mRNAs 3, -4, and -5. But, since all TRSs 
used to generate sg mRNA subspecies are located upstream of the translation initiation 
codons in respective ORFs (Fig 1.6), sg mRNA subspecies can be used to express the 
same corresponding structural protein.    
D. The link among translation, replication, and transcription 
The EAV replicase is expressed directly from the viral genome as two polyproteins 
which subsequently are extensively processed by three viral proteases to generate 12 end-
products and multiple processing intermediates which direct viral replication and sg 
mRNA transcription. Equine arteritis virus genomic replication and sg mRNA 
transcription are both based on viral replicase proteins and occur at the same intracellular 
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location, following the same principles of RNA synthesis. The only difference is that 
genomic replication is a continous process and sg mRNA transcription involves a 
discontinuous mechanism. The continuity or discontinuity may be directed by some viral 
or cellular proteins which are associated with the transcription complex but not the 
replication complex. 
(3) Virus assembly, budding, and release  
Equine arteritis virus acquires its envelope from internal membranes of the infected 
cell rather than from the plasma membrane. The assembly of EAV takes place at the 
cytoplasmic faces of the endplasmic reticulum (ER), and/or the Golgi complex 
(Magnusson et al. 1970).  
It has been shown that all seven EAV structural proteins (E, GP2b, GP3, GP4, GP5, 
M, and N proteins) are indispensable for the production of infectious progeny virus 
(Molenkamp et al. 2000; Snijder et al. 1999; Snijder et al. 2003). However, only the 
structural proteins GP5, M, and N are essential for the formation of virus-like particles 
(VLPs) (Wieringa et al. 2004). None of the other structural proteins, E, GP2b, GP3, and 
GP4, is required to generate virus-like particles (Wieringa et al. 2004). When any one of 
GP5, M, and N genes was disrupted in the infectious cDNA clone, the virus particle 
formation was abrogated (Wieringa et al. 2004). In contrast, following inactivation of any 
of E, GP2b, GP3, and GP4 genes, virus particles were still generated although these 
particles were noninfectious (Wieringa et al. 2004). Strangely, all attempts to produce 
virus-like particles by the cotransfection of cells with expression plasmids encoding the 
EAV GP5, M, and N proteins were unsuccessful (Snijder et al. 1999; Wieringa et al. 
2004). This suggests that, besides the GP5, M, and N proteins, there must be additional 
factors involved in EAV particle formation. For instance, EAV particle formation may 
depend on pre-formation of the nucleocapsid which constitutes of the N protein and the 
viral genomic RNA; if the icosahedral nucleocapsid containing viral genomic RNA is not 
formed, the subsequent steps of EAV assembly will not take place.  
How the EAV N protein interacts with viral genomic RNA to form the icosahedral 
nucleocapsid remains unknown. Is the EAV N protein the sole protein required to form 
the icosahedral nuclocapsid or does the formation of icosahedral nucleocapsids need the 
assistance of other viral or cellular proteins? How many copies of the EAV N protein are 
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needed to form the nucleocapsid? Is the EAV nucleocapsid assembly a concerted 
assembly or a sequential assembly? In a concerted assembly, the structural units of the 
protein shell assemble productively only in association with the viral genome. In the 
alternative sequential assembly, the viral genome is inserted into a preformed protein 
shell. In EAV-infected cells, there are many forms of RNAs, e.g. full-length (+) and (-) 
viral genomic RNAs, (+) and (-) viral sg mRNAs, and cellular RNAs.  But only full-
length (+) viral genomic RNA is selectively packaged into the EAV virion (Molenkamp 
et al. 2000). How does the EAV N protein distinguish (+) viral genomic RNA from other 
forms of RNAs? The RNA sequences required for encapsidation of the EAV genome 
have not yet been determined. What parts of the EAV N protein recognize the RNA-
packaging sequences? All of these questions remain to be answered. 
How does the EAV nucleocapsid acquire an envelope? As mentioned above, the 
EAV N, GP5, and M proteins are the only structural proteins required for the production 
of viral particles (Wieringa et al. 2004).  It is generally thought that the disulfide-linked 
GP5/M heterodimers constitute the basic protein matrix of the envelope (de Vries et al. 
1995b) and are a prerequisite for virus assembly (Snijder et al. 2003). When expressed 
individually, EAV GP5 and M proteins were observed to be retained only in the 
endoplasmic reticulum (ER); in contrast, when co-expressed, the M protein localized 
both in ER and the Golgi complex and the GP5 protein consistently colocalized with the 
M protein in the Golgi complex (Balasuriya et al. 2000). The authors concluded that 
transport of EAV GP5 and M proteins from ER to the Golgi complex is dependent upon 
the formation of a GP5-M heterodimer (Balasuriya et al. 2000). Snijder et al. (2003) 
further confirmed this conclusion with their observation that mutations of Cys residues in 
GP5 or M, which would block GP5-M heterodimer formation, abrogated the transport of 
both GP5 and M to the Golgi complex and resulted in the accumulation of both proteins 
in the ER with no infectious virus produced. The authors assumed that the GP5/M 
heterodimers are a prerequisite for virus assembly, which obviously needs to be 
confirmed. Actually this can be easily affirmed by investigating whether mutations 
blocking GP5-M heterodimerization will also abrogate the virus particle formation. The 
above data also suggested that the heterodimerization of GP5 and M proteins occur in the 
ER. The luminal (ecto-) domains of GP5 and M proteins form a disulfide linkage 
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between GP5 Cys-34 and M Cys-8 (Snijder et al. 2003). The cytoplasmically exposed 
domains of the disulfide-bonded GP5/M heterodimers may interact with the synthesized 
nucleocapsid. Thus, the EAV nucleocapsids bud into the lumen of ER or Golgi network 
and acquire lipid membrane carrying viral envelope proteins. Since the EAV E, GP2b, 
GP3, and GP4 proteins are also integral membrane proteins and are anchored to the lipid 
membrane of ER or Golgi complex, the EAV nucleocapsids also acquire these envelope 
proteins when budding into the lumen. However, the formation of GP2b/GP4/GP3 
heterotrimers is not simple. In EAV-infected cells, the GP2b protein occurs in four 
monomeric conformations due to the formation of different intrachain disulfide bonds 
between the cysteine residues (Cys 48, 102, 137), and a disulfide-linked dimer (de Vries 
et al. 1995a; Wieringa et al. 2003a; 2003b). The disulfide-linked dimer, previously 
identified as homodimer of the GP2b protein (de Vries et al. 1995a), has been redefined 
as a covalently linked heterodimer of GP2b and GP4 (Wieringa et al. 2003a). In EAV-
infected cells, no disulfide-bonded GP2b/GP3/GP4 heterotrimers could be detected, 
despite the fact that such heterotrimers occur in the EAV virion (Wieringa et al. 2003a). 
It is speculated that the formation of disulfide-bonded GP2b/GP3/GP4 heterotrimers 
involves two disulfide-bond linkages: the disulfide bond between GP2b and GP4 and the 
disulfide bond between GP4 and GP3. It is known that GP2b Cys-102 is responsible for 
the disulfide bond linkage with GP4 (Wieringa et al. 2003b). However, it is still unknown 
which cysteine residue in GP4 interacts with Cys-102 of GP2b. Likewise, the cysteine 
residues that are involved in the disulfide bond formation between GP4 and GP3 remain 
undefined. So, what is the process of the formation of disulfide-bonded GP2b/GP4/GP3 
heterotrimers in the virion? It has been postulated that the GP2b protein and the GP4 
protein first form a covalently linked heterodimer, then GP3 protein interacts 
noncovalently with the disulfide-bonded GP2b/GP4 heterodimer and the complex is 
finally assembled into the virion, but disulfide bond linkage between GP2b/GP4 and GP3 
takes place only after virus particles have been released (Wieringa et al. 2003a; 2003b). 
Also, it has been recently found that, when one of the GP2b, GP3, or GP4 proteins was 
missing, incorporation of the remaining two minor envelope proteins was completely 
blocked and incorporation of the E protein was greatly reduced (Wieringa et al. 2004). 
The absence of E protein entirely prevented incorporation of the GP2b, GP3, and GP4 
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proteins into the virion (Wieringa et al. 2004). The detailed molecular interactions 
between EAV structural proteins are unclear. Wieringa et al. (2004) proposed a model to 
describe the interactions between EAV structural proteins. In this model, the E protein is 
thought to be the component which, on the one hand interacts with the GP2b/GP4/GP3 
heterotrimer, and on the other hand interacts with the GP5/M heterodimer and/or the 
nucleocaspid. It is through these interactions that the E protein draws the GP2b/GP4/GP3 
complex into nascent particles.  
After the EAV nucleocapsids bud into the lumen of ER or Golgi complex and 
acquire a lipid membrane carrying viral envelope proteins, virus particles are formed. 
Then the virus particles are transported from the intracellular compartments to the plasma 
membrane where the virus particles are released via exocytosis. After the virus particles 
are released, the noncovalent linkage between the GP3 protein and the GP2b/GP4 
heterodimer become covalently linked; thus, the disulfide-bonded GP2b/GP4/GP3 
heterotrimers are formed.  
4. Neutralization determinants of equine arteritis virus 
Long-lived EAV-neutralizing antibodies are induced following natural infection, 
experimental infection or vaccination (with the modified live virus vaccine) of horses 
(Timoney and McCollum 1993), and neutralizing antibodies can protect horses from 
subsequent challenge with EAV (Doll et al. 1968; McCollum 1970, 1976, 1986; 
McCollum et al. 1988). Identification and characterization of immunogenic epitopes has 
important implications for disease diagnosis and development of improved vaccines. 
Neutralizing monoclonal antibodies to EAV have been developed by several laboratories, 
and all of them have been shown to recognize the GP5 protein using Western blot and/or 
immunoprecipitation assays (Balasuriya et al. 1993; 1995b; 1997; Deregt  et al. 1994; 
Glaser et al. 1995). The hydropathy profile of the GP5 protein predicts that amino acid 
residues 1-18 constitute the putative signal sequence, 19-116 constitute the hydrophilic 
ectodomain of the protein, while the C-terminal half consists of three membrane-
spanning domains followed by an endodomain of about 64 amino acids (de Vries et al. 
1992; Snijder et al. 2003).  Chirnside et al. (1995) have shown that horses developed 
EAV-neutralizing antibodies after they were inoculated with either a fusion protein 
covering GP5 aa 55-98 or a synthetic peptide corresponding to GP5 aa 75-97. It was 
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further demonstrated that an E. coli-expressed recombinant protein comprising the entire 
ectodomain (aa 18-122) of EAV GP5 protein induced high levels of neutralizing 
antibodies in ponies (Castillo-Olivares et al. 2001). These support the hypothesis that the 
ectodomain (aa 19-116) of EAV GP5 protein is immunodominant. By comparing the 
sequences of neutralization-sensitive EAV and neutralization-resistant viruses (escape 
mutants, EM), Glaser et al. (1995) identified that amino acid residues at 99 and 100 are 
critical for virus neutralization. After extensive comparison of GP5 amino acid sequences 
and neutralization phenotypes of a large number of field and laboratory EAV strains 
using both neutralizing MAbs and EAV strain-specific polyclonal equine antisera, 
Balasuriya et al. (1993; 1995b; 1997) have identified four distinct neutralization sites. 
These sites include amino acids 49 (site A), 61 (site B), 67-90 (site C), and 99-106 (site D) 
in the GP5 protein. In a recent study, the ORF5 of an infectious EAV clone was replaced 
with that of different laboratory, field, and vaccine strains of EAV, thus generating 
various chimeric viruses (Balasuriya et al. 2004b). The comparative characterization of 
neutralization phenotypes of chimeric viruses and parental viruses has further confirmed 
the importance of the aforementioned four neutralization sites in the GP5 protein. Taken 
together, these studies demonstrated that the ectodomain of the GP5 protein contains 
EAV neutralization determinants. Site D includes several overlapping linear epitopes. 
The four neutralization sites (A-D) are conformationally interactive (Balasuriya et al. 
1997; 2004b). However, it was also observed that a monoclonal antibody (1H7) failed to 
neutralize some chimeric viruses but was able to neutralize their respective parental 
viruses, though chimeric viruses and parental viruses have the same ORF5 sequences 
(Balasuriya et al. 2004b). This suggests that some of the neutralization epitopes are 
conformationally dependent and may interact with other structural proteins. Moreover, it 
remains to be determined whether there exist additional neutralization determinants in the 
EAV GP5 protein. The ectodomain of the EAV GP5 protein possesses one or two N-
glycosylation sites: Asn-56 is the conserved N-glycosylation site amongst all strains of 
EAV and Asn-81 is another potential N-glycosylation site occurring in some field and 
laboratory strains of EAV. There is no evidence that the presence of a second 
glycosylation site on EAV GP5 protein interferes with virus neutralization. In the case of 
EAV, all of the neutralization determinants identified thus far are located in the GP5 
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protein; however, neutralization determinants have been found in both the GP4 and GP5 
proteins of PRRSV. Monoclonal antibodies against the GP4 protein of the Lelystad strain 
of PRRSV have been reported to be neutralizing (Meulenberg et al. 1997), although 
MAbs against the GP5 protein of PRRSV are more effective in virus neutralization than 
MAbs against the GP4 protein (Weiland et al. 1999). The primary neutralization 
determinants of PRRSV are located in the middle of the GP5 ectodomain (Pirzadeh and 
Dea 1997; Plagemann et al. 2002; Zhang et al. 1998), but a neutralization epitope (aa 24) 
has also been observed in the predicted signal sequence of the GP5 protein of PRRSV 
(Wissink et al. 2003).  
5. Genetic and phenotypic diversity of equine arteritis virus 
The virus-encoded RNA-dependent RNA polymerases (RdRp) are low fidelity 
enzymes with mutation rates as high as the order of 10-3 to 10-5 errors per nucleotide per 
replication cycle (Domingo and Holland 1997; Drake 1993). In addition, RNA viruses 
have very short replication times and generate very large populations during replication. 
Therefore, RNA viruses exist not as a single genotype but rather as a heterogeneous 
mixture of related genomes known as a viral quasi-species (Holland et al. 1992). The 
quasi-species nature of RNA viruses allows viruses to adapt to environmental changes 
more rapidly and facilitates the emergence of viral variants (Castro et al. 2005). Genetic 
and phenotypic variation among equine arteritis virus isolates have been demonstrated, 
although only one neutralization serotype of EAV has been identified so far (Fukunaga 
and McCollum 1977; Golnik et al. 1986). Murphy et al. (1988; 1992) first demonstrated 
that genomic variation exists among EAV isolates using RNase T1 oligonucleotide 
fingerprinting. Nucelotide sequence comparison of ten EAV isolates revealed that the 
leader sequence identity between different isolates and the Bucyrus reference strain 
ranged from 94.2 to 98.5% (Kheyar et al. 1998). In the case of the replicase gene, the 
nsp2 is highly variable among field isolates of EAV (Balasuriya et al. 2004a). Most 
studies of genetic variation of EAV have focused on structural proteins. Nucleotide and 
amino acid comparison of various EAV isolates in ORFs 2-7 have been performed 
(Archambault et al. 1997; Balasuriya et al. 1995a; 2004a; Chirnside et al. 1994; Hedges 
et al. 1996; 2001; Larsen et al. 2001; Lepage et al. 1996; St-Laurent et al. 1997; Stadejek 
et al. 1999). These studies revealed that the EAV M and N proteins are more conserved 
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than other structural proteins, the ORF4 and ORF2 protein sequences are moderately 
conserved, and the ORF3 and ORF5 protein sequences are most variable. Phylogenetic 
analysis of EAV ORF5 sequences have suggested classification of various EAV isolates 
into two large groups: North American group (group I) and European group (group II) 
(Balasuriya et al. 1995a; Stadejek et al. 1999). The geographic origin of the viruses 
(where the viruses were isolated) may be different from phylogenetically predicted 
relationships. For example, some of the EAV strains were isolated from horses in North 
America, but are grouped with European isolates according to phylogenetic analysis, 
suggesting dispersal of the virus between continents by movement of horeses. Therefore, 
phylogenetic analyses of ORF5 sequences between strains are a useful molecular 
epidemiological tool for tracing the origin of an EAV isolate. 
As mentioned above, there is only one serotype of EAV (Fukunaga and McCollum 
1977; Golnik et al. 1986) and all strains evaluated thus far are neutralized by polyclonal 
equine sera raised against the virulent Bucyrus strain of EAV (Balasuriya and 
MacLachlan 2004c). However, EAV strains frequently exhibit neutralization phenotypic 
differences; e.g., different EAV strains are neutralized to various degrees with different 
polyclonal antisera and monoclonal antibodies (Balasuriya et al. 1997; 2004a; 2004b; 
Hedges et al. 1999a). In addition, geographically and temporally distinct EAV isolates 
vary markedly in the severity of the clinical disease they induce and in their abortigenic 
potentials (Balasuriya et al. 1998; 1999b; Balasuriya and MacLachlan 2004c; McCollum 
and Timoney 1999; Timoney and McCollum 1993). For example, the virulence of some 
EAV strains for horses have been defined: severely virulent (VBS53 and ATCC EAV), 
moderately virulent (KY84, CAN86, AZ87, and IL93), mildly virulent (SWZ64, AUT68, 
IL94, and CA97), and putatively avirulent (KY63, PA76, KY77, CA95G, and ARVAC 
vaccine) strains of EAV (MacLachlan et al. 1996; McCollum 1981; McCollum and 
Timoney 1984; McCollum et al. 1995; McCollum and Timoney 1999; Moore et al. 
2003b; Patton et al. 1999; Timoney and McCollum 1993). However, the genetic 
determinants of viral virulence have not yet been defined. 
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III. EAV INFECTION AND PERSISTENTLY INFECTED STALLIONS 
Natural EAV infection occurs in both horses and donkeys, and the virus is 
distributed in many equid populations throughout the world (McCollum et al. 1995; 
Timoney and McCollum 1993). Most EAV infections are subclinical in nature; 
occasionally, infection results in a respiratory type syndrome, abortion in pregnant mares, 
and interstitial pneumonia or pneumonoenteritis in young foals (Timoney and McCollum 
1993; 1996). Up to 30% to 70% of stallions infected with EAV can subsequently become 
persistently infected and constantly shed the virus in semen. On the other hand, neither 
mares, geldings, nor foals have been shown to become carriers of the virus (Timoney and 
McCollum 1993). 
1. Modes of transmission  
The two major routes of EAV transmission between horses are the respiratory and 
venereal routes (Timoney and McCollum 1993). During the acute phase of the infection, 
virus is shed significant amounts in the respiratory tract secretions and transmission to 
other susceptible horses occurs through aerosolized respiratory tract secretions (Timoney 
and McCollum 1993). Acutely infected horses also shed virus in their urine, feces, 
vaginal and other body secretions, although in smaller amounts than via the respiratory 
tract (McCollum et al. 1971; Timoney and McCollum 1993).  EAV can also be found in 
aborted fetuses, placenta, and their membranes and fluids from a mare that has aborted as 
a result of EAV infection (Timoney and McCollum 1993). These sources of virus may 
also contribute to aerosol transmission of EAV to other horses. Aerosol transmission of 
infectious particles is the most important and primary route of EAV dissemination during 
outbreak of the disease. However, it should be emphasized that direct and close contact 
appears to be necessary for aerosol transmission of EAV (Collins et al. 1987; Timoney 
1988). Venereal transmission is another important route of dissemination of EAV. The 
virus can be transmitted venereally not only by the acutely infected mare and stallion, but 
also by persistently infected stallions (Timoney et al. 1986; 1987). Approximately 85 to 
100% of seronegative mares become infected when they are bred to persistenlty infected 
stallions or artificially inseminated with infective semen from these carrier animals 
(Timoney and McCollum 1993). The infected mares can in turn transmit the virus to 
susceptible horses via the respiratory route. Reciprocal venereal transmission from an 
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acutely infected mare to a seronegative stallion, though plausible, has not been 
documented. Carrier stallions are believed to be the natural reservoir of EAV and are 
responsible for perpetuation and dissemination of EAV in equine populations (Timoney 
et al. 1987; Timoney and McCollum 1993).   
Besides the two aforementioned major routes of transmission, EAV can also be 
transmitted less commonly by other means. For example, the foal can congenitally 
acquire EAV infection through transplacental transmission when a pregnant mare is 
exposed to the virus in late gestation (Vaala et al. 1992). In this case, infected foals may 
develop rapidly progressive fulminating interstitial pneumonia and in some cases, also a 
fibronecrotic enteritis (Carman et al. 1988; Del Piero et al. 1997; Vaala et al. 1992; 
Wilkins et al. 1995). Transmission of EAV through indirect contact with virus- 
contaminated fomites or by an infected teaser stallion or nurse mare may also occur 
infrequently (Timoney and McCollum 1996). 
2. Carrier state 
A. General information 
As early as the latter half of the nineteeth century, it had been observed that healthy 
stallions could transmit so called pink-eye or influenza disease, which very likely was 
equine viral arteritis, to mares at breeding (Clark 1892; Pottie 1888). At that time, it was 
postulated that the causative agent is shed in the semen of those healthy stallions (Clark 
1892; Pottie 1888). These are the earliest reports of occurrence of an ‘EAV’ carrier state. 
However, not until the 1984 epizootic of equine viral arteritis in Kentucky was the EAV 
carrier state extensively studied by Timoney and McCollum (Timoney et al. 1986; 1987). 
After natural infection with EAV, up to 30% to 70% of stallions can become persistently 
infected with the virus (Timoney and McCollum 1993). Persistently infected stallions 
shed EAV constantly in their semen; virus has not been detected in their urine, blood, or 
nasopharyngeal secretions (Timoney and McCollum 1993). Equine arteritis virus appears 
to be restricted to the reproductive tract of carrier stallions, and the ampulla of the vas 
deferens seems to be the primary site of EAV persistence (Neu et al. 1987; Timoney and 
McCollum 1993). Virus is present in the sperm-rich fraction of the ejaculate and is not 
detected in the preejaculatory fluids (Timoney et al. 1987). There appears to be little 
variation of virus titer among semen samples sequentially collected from the same 
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stallion over time. Duration of the carrier state varies and it has been arbitrarily divided 
into three categories: short-term or convalescent carrier state lasting several weeks; 
intermediate carrier state lasting 3 to 7 months; and the long-term or chronic carrier state 
lasting for years and even the lifetime of particular stallions (Timoney et al. 1986; 
Timoney and McCollum 1993). It has also been observed that some carrier stallions 
spontaneously cease to shed virus after years of persistent infection, with no indication of 
reversion to a shedding state later on (Timoney and McCollum 1993). A longitudinal 
field study provided no evidence that carrier stallions are or can become intermittent 
shedders of the virus (Timoney et al. 1991) .  
B. The mechanisms of EAV persistence in carrier stallions 
The detailed mechanisms of virus persistence in the host have not been clearly 
understood. It has been proposed that viral persistence maybe involves two essential 
ingredients: an ineffectual immune response, and a unique component or strategy of viral 
replication (de la Torre et al. 1991; Oldstone 1989, 1991). EAV persistence in carrier 
stallions may also involve the factors in these two aspects.  
In carrier stallions, EAV persists exclusively in the reproductive tract and not in 
other sites. It seems unlikely that the EAV has obtained a restricted tropism to the 
reproductive tract of stallions, since EAV in the reproductive tract of carrier stallions can 
be venereally transmitted to susceptible mares in which the virus has an apparent wide 
tissue distribution (McCollum et al. 1988; Timoney et al. 1987). It seems more likely that 
the immune effectors have eliminated EAV from other sites but have failed to eliminate 
the virus from reproductive tract of carrier stallions. The observation that carrier stallions 
usually have moderate to high titers of serum neutralizing antibody to EAV (Timoney 
and McCollum 1993) further support the conclusion that humoral immunity does not 
prevent establishment or maintenance of persistent EAV infection in the reproductive 
tract of stallions. How the virus in the reproductive tract of carrier stallions evades 
immune clearance by neutralizing antibodies is unknown. It seems unlikely that immune 
escape mutants of virus play a significant role, because the emerging virus variants in 
carrier stallions can still be neutralized by polyclonal neutralizing antibodies (Balasuriya 
and MacLachlan 2004c). Virus persistence may be related to the fact that the 
reproductive tract of mature male is an immunologically priviledged site (Johnson 1973). 
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The physiologic mechanisms responsible for this privileged site are multifactorial, 
develop at puberty, and in some species depend on androgens (Pelletier 1986). Maybe the 
virus in the reproductive tract of stallions is inaccessible to circulating neutralizing 
antibodies or that neutralizing antibodies can only partially downregulate virus 
replication but are inadequate to completely prevent ongoing virus replication. Also, the 
role of cellular immune responses in persistent EAV infection is not known.  
There is convincing evidence that establishment and maintenance of the carrier state 
in the stallion is testosterone-dependent (Little et al. 1991; McCollum et al. 1994). When 
persistently infected stallions were castrated and administered testosterone, they 
continued to shed virus in semen, whereas castrated stallions given a placebo ceased 
shedding virus (Little et al. 1991). Investigation of the persistence of EAV in prepubertal 
and peripubertal colts showed that EAV can replicate in the reproductive tract of a 
significant proportion of colts for a variable period of time after clinical recovery in the 
absence of circulating concentrations of testosterone equivalent to those found in sexually 
mature stallions. However, long-term persistent EAV infection does not appear to occur 
in colts exposed to the virus before the onset of peripubertal development (Holyoak et al. 
1993). The mechanism by which testosterone contributes to the establishment and 
maintenance of the persistent EAV infection in stallions remains undetermined. It is 
speculated that testosterone may be involved in (i) the development of mature 
reproductive tract and (ii) the replication of androgen-dependent cells in the reproductive 
tract of stallions to maintain EAV persistence.   
It remains to be determined whether other host factor(s) or viral factor(s) contribute 
to the establishment and maintenance of persistent EAV infection in stallions. Frequency 
of the carrier state varies between different groups of stallions; however, extensive 
epidemiological study involving Standardbred and Thoroughbred horses failed to 
demonstrate any breed predilection for establishment of persistent EAV infection 
(Timoney et al. 1986; 1987). Analysis of two carrier stallions and a number of their male 
offspring did not demonstrate a significant association between inherited MHC haplotype 
and the carrier state (Albright-Fraser 1998). Moreover, the mechanism accounting for the 
spontaneous clearance of EAV from some carrier stallions is not clear. So far, no fully 
validated therapy (except castration) has been available to eliminate the EAV carrier state 
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in stallions. One group of researchers have investigated the effects of a GnRH antagonist 
on testosterone secretion, spermatogenesis, and viral excretion in EAV carrier stallions, 
but the results were not conclusive (Fortier et al. 2002).  
C. The significance of EAV carrier stallions 
Carrier stallions occupy a significant niche in the epidemiology of EAV infection. 
Carrier stallions are not only a natural reservoir of EAV responsible for maintenance and 
dissemination of EAV in equine populations (Timoney et al. 1987; Timoney and 
McCollum 1993), but also a natural source of genetic and phenotypic diversity of EAV 
(Balasuriya et al. 2004a; Balasuriya and MacLachlan 2004c; Hedges et al. 1999a). 
Equine arteritis virus exists as a quasi-species. It has been observed that EAV 
quasispecies was relatively limited and the virus remained relatively genetically stable 
during horizontal and vertical transmission in the course of an outbreak of EVA  
(Balasuriya et al. 1999a); in contrast, virus quasi-species expanded and genetic and 
phenotypic variants of EAV emerged during persistent infection of stallions (Balasuriya 
et al. 2004a; Hedges et al. 1999a). Therefore, carrier stallions are probably the major 
source of EAV evolution. Some new virus variants generated during the course of 
persistent infection may have significant pathogenic potential and give rise to 
occurrences of EVA.  
 
IV. PERSISTENT INFECTION OF CELL CULTURES WITH RNA VIRUSES 
Viral infection of various hosts result in an acute infection, which is characterized 
by rapid production of infectious virus followed by rapid resolution and clearance of the 
infection by the host, or persistent infection, in which viral particles or viral products 
continue to be produced for long periods of time. The mechanisms employed by different 
viruses for their persistence in vivo vary. One common feature is that the host defense 
systems fail to clear the virus from the host. It is generally thought that both host and 
viral factors may contribute to the establishment and maintenance of persistent infection. 
Persistent viral infections in cell culture are valuable in studying virus-host cell 
interactions and in providing insights into how virus persistence is established and 
maintained. The following is an attempt to summarize persistent infection in cell culture 
by RNA viruses.  
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1. Properties of persistent infection 
Many RNA viruses have been found capable of establishing persistent infection in 
tissue culture cells (Rima and Martin 1976). One virus may establish persistent infections 
in a number of cell lines, e.g. poliovirus is able to establish persistent infections in human 
neuroblastoma cells (Colbere-Garapin et al. 1989), human erythroblastoid K562 cells 
(Lloyd and Bovee 1993), Hep-2 cells (Calvez et al. 1993), and Hela cells. Persistent 
infection in Hela cells was established by cotransfecting the cells with poliovirion type 2 
RNA and R1, an in vitro-synthesized poliovirus subgenomic replicon which contains a 
deletion of nearly all the capsid region (Kaplan et al. 1989). Sindbis virus is able to 
initiate persistent infections in BHK-21 cells (Schwobel and Ahl 1972; Weiss et al. 1980) 
and mouse L cells (Inglot et al. 1973). Persistently infected cell cultures may have 
common properties in some respects, as well as distinct properties in other respects. 
A. Cytopathic effect, virus-positive cells, and production of virus 
Persistently infected cells may or may not exhibit virus-specific cytopathic effect 
despite the fact that they continuously produce infectious virus. For example, CV-1 cells 
persistently infected with human parainfluenza virus-3 (Moscona and Galinski 1990) and 
rhabdomyosarcoma cells persistently infected with coxsackievirus B4 (Frisk et al. 1999) 
continuously produced infectious virus without cellular destruction; however, Hela cells 
persistently infected with human rhinovirus-2 and Hela cells persistently infected with 
poliovirus continually produced low levels of infectious virus and cell cultures underwent 
multiple episodes of partial destruction and subsequent recovery (Gercel et al. 1985; 
Kaplan et al. 1989). The percentage of virus-positive cells varies from one persistent 
system to another. In some persistent systems, the percentage of virus-positive cells even 
undergoes cyclic variation. For instance, in rabies virus/BHK21 cells, the percentage of 
cells showing positive immunofluorescence varied from 5% to 100% in cycles of 6-8 
subcultures (Wiktor and Clark 1972); in human rhinovirus-2/Hela cells, the percentage of 
cells producing infectious centers varied from 0.03% to 23% (Gercel et al. 1985). Most 
of the persistently infected cells continuously produce small amounts of infectious virus. 
In measles virus/Hela cells, the yield of cell-associated virus was high and similar to that 
in lytic infections, whereas the yield of released (extracellular) virus was very small 
(Rustigian 1966a). In mumps virus/conjunctiva cells, the yield of cell-associated virus 
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was consistently about one log unit lower than that of released virus (Walker and Hinze 
1962). The amount of released virus may show cyclic variation coinciding with variation 
in the appearance of CPE and cell destruction in some persistent systems such as Sindbis 
virus/BHK-21 cells (Schwobel and Ahl 1972), Sindbis virus/mouse L cells (Inglot et al. 
1973), lymphocytic choriomeningitis virus (LCMV)/BHK-21 cells (Staneck et al. 1972), 
rabies virus/BHK-21 cells (Kawai et al. 1975; Wiktor and Clark 1972) and so on. 
Occasionally persistently infected cells may stop producing infectious virus after long-
term subculturing. For example, during routine subcultivation of Hela cells persistently 
infected with human rhinovirus-2, some spontaneous cures were observed (Gercel et al. 
1985). In spontaneously cured cells, no extracellular virus or infectious centers could be 
detected and no viral antigen could be detected by immunofluorescence (Gercel et al. 
1985). Whether these cells were free of viral RNA was not reported.     
B. Effect of antibodies and anti-viral compounds 
Addition of virus-specific antibodies or anti-viral compounds to the media of 
persistently infected cells may result in distinct outcomes: non-cured or cured. It has been 
shown that cloning or subculture of measles virus/Hela cells in the presence of anti-
measles serum in the culture medium led to a state in which no infectious virus was 
released (non-yielder state), whereas the large majority of these cells were still 
immunofluorescence positive (Rustigian 1966b), indicating the existence of viral antigen. 
When human influenza C virus/MDCK cells (Goshima and Maeno 1989) or 
poliovirus/human erythroblastoid K562 cells (Lloyd and Bovee 1993) were subcultured 
with growth medium containing virus-neutralizing antibodies for several continuous 
passages, extracellular virus became undetectable. However, further passage in the 
absence of antiserum resulted in the return of infectious virus yield. Similarly, addition of 
the antiviral compound disoxaril did not cure rhabdomyosarcoma cells persistently 
infected with coxsackievirus B4 (Frisk et al. 1999). In contrast, it was observed that three 
serial subcultivations of human rhinovirus-2/Hela cells in the presence of antiserum 
resulted in a cure (no extracellular virus or infectious centers or viral antigens could be 
detected) (Gercel et al. 1985). In addition, after removal of antiserum, no renewed virus 
production or viral antigen expression could be detected upon 12 further passages (Gercel 
et al. 1985), indicating that the persistently infected cells were cured. Similarly, it has 
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been reported that mouse L cells persistently infected with reovirus can be cured by 
antireovirus serum (Ahmed et al. 1981). It was also found that anti-viral compound 
ribavirin was able to eliminate foot-and-mouth disease virus (FMDV) from persistently 
infected BHK-21 cells (de la Torre et al. 1987). In ribavirin-cured cultures, no FMDV 
RNA or antigens were detected by dot-blot hybridization to cDNA probes or by indirect 
immunofluorescence, respectively. No renewed FMDV production occurred after the 
cells underwent at least 20 serial passages in the absence of ribavirin (de la Torre et al. 
1987). Curing of FMDV from persistently infected cells by ribavirin involves ribavirin’s 
ability to enhance mutagenesis (Airaksinen et al. 2003). RNA viruses replicate with a 
high spontaneous mutation frequency which is near the error threshold for maintenance 
of genetic information. When the mutation rate of the viral genome increases and exceeds 
this error threshold, the viral fitness decreases significantly and the virus may fall into 
error catastrophe or lethal mutagenesis leading to virus extinction (Castro et al. 2005; 
Domingo et al. 2005; Manrubia et al. 2005). Ribavirin is an RNA virus mutagen which 
can increase mutation frequency during virus replication and increase in mutation 
frequency may drive RNA viruses to error catastrophe leading to extinction of viruses 
(Crotty et al. 2000; 2001; 2002; Pariente et al. 2003).  
C. Resistance to superinfection 
Another interesting property of persistently infected cells is that they are immune to 
superinfection with homologous virus but are still susceptible to infection with 
heterologous viruses. In an investigation of human rhinovirus-2 (HRV-2)/Hela cells to 
superinfection, normal Hela cells infected with homologous viruses (HRV-2, HRV-2 TS-
1 mutant, and HRV-4) or heterologous viruses (poliovirus type 2 and vesicular stomatitis 
virus (VSV)), HRV-2/Hela cells superinfected with the same homologous or 
heterologous viruses, and HRV-2/Hela cells not superinfected with any virus were 
compared (Gercel et al. 1985). It was found that the cytopathic effects and virus yields in 
HRV-2/Hela cells superinfected with HRV-2, TS-1 mutant, and HRV-4 were similar to 
those produced in HRV-2/Hela cells alone (not superinfected) but were less pronounced 
than those produced in normal Hela cells infected with the respective virus. In contrast, 
virus yields in HRV-2/Hela cells superinfected with poliovirus type 2 or VSV were 
comparable to those obtained in normal Hela cells infected with respective virus (Gercel 
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et al. 1985). Both yielder (with production of infectious virus) and non-yielder (with no 
production of infectious virus but with existence of viral antigen) measles virus/Hela cells 
were shown to be resistant to superinfection with measles virus, but these cells supported 
normal growth of vaccinia virus, herpes virus and poliovirus (Rustigian 1966a). Similarly, 
Sindbis virus/mouse L cells were found to be resistant to superinfection with Sindbis 
virus but not with VSV or encephalomyocarditis virus (Inglot et al. 1973). LCMV/BHK-
21 cells were resistant to superinfection with homologous arenaviruses but not with 
dengue virus, rubella virus, Sindbis virus, and VSV (Staneck et al. 1972). Rabies 
virus/BHK-21 cells were resistant to superinfection with rabies virus but not with VSV 
(Kawai et al.  1975). FMDV/BHK-21 cells were resistant to superinfection with FMDV 
but not with encephalomyocarditis virus, VSV, and Semliki Forest virus (de la Torre et al. 
1985). Poliovirus/human neuroblastoma IMR-32 cells were resistant to superinfection 
with Sabin 1, 2, and 3 poliovirus but sensitive to another enterovirus coxsackievirus B3 
(Colbere-Garapin et al. 1989). Above examples uniformly demonstrated that all 
persistently infected cells are resistant to superinfection with the same virus that was used 
to initiate the persistent infection. The mechanism by which persistently infected cells are 
resistant to superinfection with homologous viruses but are sensitive to heterologous 
virus infection is not clear. It is speculated that it may be associated with virus-specific 
cell receptors or the production level of interferon: i) interference at one of the early steps 
of virus growth cycle (e.g. attachment, penetration, or uncoating) is probably involved in 
the resistance of persistently infected cells to superinfection by the homologous virus; ii) 
in contrast, cell receptors of ‘heterologous’ viruses are distinctly different from that of 
homologous virus, thus there are no such interferences with heterologous virus infection; 
lack or low levels of interferon produced in these persistently infected cells may also 
contribute to the growth of heterologous virus in carrier cultures. 
D. Evolution of viruses and cells 
A number of studies have shown that the viruses recovered from persistently 
infected cells are genetically and phenotypically different from the parental viruses which 
were used to establish the persistent infections. Temperature-sensitive (ts) virus mutants 
were isolated from mouse L cells persistently infected with Newcastle disease virus 
(Preble and Youngner 1972, 1973a, 1973b) and mouse L cells persistently infected with 
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VSV (Youngner et al. 1976). The production of defective interfering (DI) viral particles 
was reported in mouse L cells persistently infected with LCMV (Lehmann-Grube et al. 
1969; Welsh et al. 1972) and BHK-21 cells persistently infected with Parana virus 
(Staneck and Peau 1974). Defective interfering viral RNA has also been detected in Vero 
cells persistently infected with Murray Valley encephalitis (MVE) virus (Lancaster et al. 
1998). Small plaque virus mutants were observed in BHK-21 cells persistently infected 
with rabies virus (Kawai et al. 1975) and in mouse neuroblastoma cells persistently 
infected with yellow fever 17D virus (Vlaycheva and Chambers 2002). Fusion-defective 
mutants of mouse hepatitis virus A59 were produced in persistently infected primary 
mouse glial cells and the phenotype was probably due to a mutation at the viral spike 
(fusion) protein cleavage signal (Gombold et al. 1993). Genetic and antigenic changes 
have been demonstrated in hepatitis A virus (HAV) variants arising during persistent 
infection of BS-C-1 cells (Lemon et al. 1991). FMDV is able to initiate persistent 
infection in BHK-21 cells (de la Torre et al. 1985) and the virus isolated from persistently 
infected culture (carrier culture) was more cytolytic than parental FMDV for BHK-21 
cells (de la Torre et al. 1988a). Further studies showed that nine amino acid substitutions 
were fixed on the viral capsid protein during persistence and these amino acid 
substitutions resulted in altered antigenicity, as revealed by reactivity with monoclonal 
antibodies (Diez et al. 1990a). Moreover, FMDV became progressively less virulent for 
mice and cattle during the course of persistence in BHK-21 cells (Diez et al. 1990b). 
Virus evolution was also observed in carrier cultures of poliovirus. The poliovirus 
mutants selected from human neuroblastoma IMR-32 cells persistently infected with the 
Sabin strains could reach 1-3 log10 units higher titer in IMR-32 cells than that in non-
neural Hep-2 cells, while parental viruses had similar titers in both cell lines (Colbere-
Garapin et al. 1989). Correlated with this modified cell tropism, the poliovirus mutants 
recovered from carrier culture could establish secondary persistent infection in non-
neural Hep-2 cells (Pelletier et al. 1991). Interestingly, these poliovirus mutants harbor 
major mutations at capsid proteins VP1 and VP2 which are known to be involved in 
interactions between poliovirus and its receptor (Borzakian et al. 1993; Calvez et al. 1993; 
Colbere-Garapin et al. 1989; Duncan et al. 1998; Pavio et al. 1996; Pelletier et al. 1991; 
1998a). Poliovirus type 1 mutants selected from human neuroblastoma cells persistently 
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infected with the wild-type Mahoney strain exhibited neurovirulent phenotype in mice, 
while the wild-type Mahoney strain is avirulent in mice (Couderc et al. 1994). And this 
conversion of mouse-neurovirulent phenotype is caused by several amino acid 
substitutions on the viral capsid protein (Couderc et al. 1993; 1994). 
Coevolution of viruses and the host cells have been observed in mouse L cells 
persistently infected with reovirus (Ahmed et al. 1981), BHK-21 cells persistently 
infected with FMDV (de la Torre et al. 1988a), and Hela cells and human neuroblastoma 
cells persistently infected with poliovirus (Kaplan et al. 1989; Pavio et al. 2000). In the 
study performed by Ahmed et al (1981), persistent infection was established in mouse L 
cells with a reovirus stock, more than 90% of which was made up of defective interfering 
particles. Mutant mouse L cells and reovirus were isolated from carrier cultures. Reovirus 
isolated from carrier culture grew more efficiently than cloned wild-type reovirus in 
mutant L cells, indicating the evolution of viruses during persistent infection. On the 
other hand, infection of mutant L cells with either wild-type reovirus or reovirus isolated 
from carrier cultures led to establishment of persistent infections, while infection of the 
original L cells with either wild-type reovirus or reovirus isolated from carrier cultures 
resulted in a lytic infection with no surviving cells, demonstrating the evolution of the 
host cells during persistent infection. Virus evolution during persistent FMDV infection 
of BHK-21 cells has been discussed above. It has also been observed that BHK-21 cell 
mutants selected during serial passage of the carrier culture were constitutively more 
resistant to the parental FMDV infection than the parental BHK-21 cells (de la Torre et al. 
1988a), indicating the evolution of the host cells during persistent infection. The 
increased resistance of BHK-21 cell mutants to parental FMDV was not due to an 
impairment of attachment, internalization, or uncoating of the viral particles but was 
because of some intracellular block that downregulated FMDV RNA synthesis (de la 
Torre et al. 1988a). Further studies showed that BHK-21 cells evolved and exhibited 
extensive heterogeneity during persistent infection with FMDV (de la Torre et al. 1989). 
Analysis of 248 stable cell clones isolated from FMDV carrier culture revealed that at 
least six distinct cell phenotypes could be distinguished with regard to cell morphology, 
susceptibility to parental FMDV infection, and cell growth characteristics (de la Torre et 
al. 1989). These altered phenotypes were maintained as stable genetic traits. Genetic and 
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phenotypic variation of the host cells enables the selection of cells with increased 
resistance to FMDV and thus contributes to the maintenance of viral persistence (Martin 
Hernandez et al. 1994). During persistent poliovirus infection in Hep-2 cells, the 
evolution and heterogeneity of the host cells have also been reported (Borzakian et al. 
1992). Cell evolution was also observed in other persistent poliovirus infections. After 
passage of poliovirus/Hela cells for 6 months, a stable cell line termed SOFIA emerged 
that no longer produced infectious virus and did not contain viral proteins or viral RNA 
(Kaplan et al. 1989). In SOFIA cells, the poliovirus receptor (PVR) gene did not contain 
gross alteration at DNA level; however, the transcription of PVR-specific RNA was 
reduced. Therefore, it was suggested that resistance of SOFIA cells to poliovirus 
infection appears to result from down-regulation of PVR RNA which leads to lack of 
PVR protein expression at the cell surface (Kaplan and Racaniello 1991). During 
persistent poliovirus infection in human neuroblastoma IMR-32 cells, cells expressing 
mutated poliovirus receptor emerged and the mutations at the N-terminal domain of PVR 
increased the resistance of cells to poliovirus-induced lysis (Pavio et al. 2000). Moreover, 
when the wild-type PVR and mutated PVR were expressed independently in murine LM 
cells which lack the poliovirus receptor gene, it was found that the level of poliovirus-
induced apoptosis was lower in cells expressing mutated PVR which was selected during 
persistent poliovirus infection in IMR-32 cells than in cells expressing the wild-type 
receptor (Gosselin et al. 2003).       
2. Virus-specific factors involved in persistent infection 
Various viral factors could be involved in the establishment and maintenance of 
persistent infection, e.g. temperature-sensitive (ts) viral mutants, defective interfering (DI) 
viral particles, alteration of viral RNA or protein synthesis, and so on.  
A few studies have shown that viruses released from persistently infected cells 
contain ts mutants (Preble and Youngner 1972, 1973a, 1973b; Youngner et al. 1976). 
However, there has been no convincing evidence to demonstrate the role of ts mutants in 
the establishment or maintenance of persistent infection. 
The possible involvement of defective interfering viral particles in some persistent 
infections is based upon: i) the presence of DI particles in the viral preparation used to 
initiate persistent infection; or ii) the presence of DI particles in the medium of 
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persistently infected cells. A number of viruses are usually highly cytolytic in permissive 
cells and within a few days after infection all of the cells die. However, when infected 
with the viral preparation containing DI particles, cells can survive the infection and 
eventually became persistently infected. In 1970s, it was reported that noncytocidal 
persistent infection of BHK-21 cells (Holland and Villarreal 1974) or mouse L cells 
(Youngner et al. 1976) with wild-type VSV particles could be established only in the 
presence of large number of DI particles. During persistent infection, wild-type and DI 
VSV particles were continuously produced accompanied with viral protein changes and 
RNA sequence alterations (Holland and Villarreal 1974; Holland et al. 1976; 1979; 
Rowlands et al. 1980; Semler and Holland 1979; Villarreal and Holland 1976). Similarly, 
in the presence of their respective DI particles, wild-type reovirus, Sindbis virus, and 
Ebola virus establish persistent infections in mouse L cells, BHK-21 cells, and Vero cells, 
respectively (Ahmed et al. 1981; Calain et al. 1999; Weiss et al. 1980). Interestingly, 
when Hela cells were cotransfected with poliovirus type 2 RNA plus R1, an in vitro-
synthesized poliovirus subgenomic replicon which contains a deletion of nearly all the 
capsid region, persistent infection was established, whereas Hela cells transfected only 
with poliovirion RNA all died (Kaplan et al. 1989). The detailed mechanism by which DI 
particles change a lytic infection to a persistent infection is unclear. DI genomes are 
truncated and their replication depends on the replicative enzymes encoded by the helper 
virus. Since DI genomes are usually much smaller than the helper virus genome, they are 
replicated more efficiently. Because of competition of DI RNAs, synthesis of the helper 
virus genome is decreased. It is speculated that the decrease of the helper virus genome 
may result in downregulation of determinants of cell killing which have yet to be 
identified.  
The foregoing discussion of virus evolution during persistent infection would 
suggest that viral factors play an important role in establishment and maintenance of 
persistent infection. The following are several additional examples supporting the 
hypothesis that alteration of viral gene products is involved in persistent infections. It was 
observed that persistence of Japanese encephalitis virus (JEV) in several cell lines 
(murine neuroblastoma N18 cells, Vero cells, and murine astrocytoma DBT cells) was 
associated with expression of truncated viral nonstructural protein 1 (NS1) in host cells 
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(Chen et al. 1996). Sindbis virus is highly cytopathic in BHK-21 cells and establishment 
of persistent infection with wild-type Sindbis virus needed the presence of high 
concentration of DI particles (Weiss et al. 1980). However, Sindbis virus mutants (free of 
DI particles) isolated from the carrier culture were able to establish secondary persistent 
infection in BHK-21 cells. Through reverse genetics studies, it was found that a single 
coding mutation in the nsP2 gene (a predicted change of Pro-726? Ser) was responsible 
for the ability of mutated virus to establish persistent infection in BHK-21 cells (Dryga et 
al. 1997). It has been suggested that persistence of VSV mutants on fibroblast cells is 
associated with shutoff levels of cellular gene expression which may be determined by 
the VSV matrix protein (Desforges et al. 2001). Poliovirus mutants selected in the 
persistently infected human neuroblastoma cells initiated by either the Sabin 1 strain or 
the type 3 wild-type Leon strain can establish secondary persistent infection in non-neural 
Hep-2 cells, while both the Sabin 1 strain and the type 3 wild-type Leon strain cause a 
lytic infection in Hep-2 cells (Duncan et al. 1998; Pelletier et al. 1991). Further studies 
have shown that several amino acid residues in capsid proteins VP1 and VP2 are the viral 
determinants which control whether the outcome of an infection in Hep-2 cells is a lytic 
infection or a persistent infection (Borzakian et al. 1993; Calvez et al. 1993; Duncan et al. 
1998; Pelletier et al. 1998a). It was proposed (Duncan et al. 1998) that these viral 
determinants may affect the early steps of the virus life cycle such as virus attachment 
and the receptor-mediated conformational changes which are believed to be necessary for 
viral penetration and uncoating. Modification of these steps could be the mechanism by 
which poliovirus mutants are able to establish persistent infection in Hep-2 cells. It has 
also been reported that a single amino acid change (Phe-260? Leu) in viral glycoprotein 
markedly increased the capacity of lymphocytic choriomeningitis virus to persist in adult 
mice (Matloubian et al. 1990).    
3. Host-specific factors involved in persistent infection 
Various host factors such as host cell type, host cell mutants, host cell 
differentiation stage, production level of interferon and so on may be involved in the 
establishment and maintenance of persistent viral infection.  
Many viruses show marked differences in interaction with various types of host 
cells. For example, Newcastle disease virus (NDV) infection in BHK-21 cells led to large 
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amounts of fusion of the cells with production of infectious virus; in NDV-infected Hep-
2 cells, less cell fusion was observed; while in NDV-inoculated mouse L cells, no 
apparent cell fusion was observed and a persistent infection was established (Hecht and 
Summers 1974; Poste et al. 1972). Mouse cells are not susceptible to echovirus 1 (EV-1) 
infection since they lack the viral receptor, human VLA-2. By transforming mouse L 
cells and 3T3 cells with cDNAs of human VLA-2, stable mouse L cell and 3T3 cell 
transformants that express human VLA-2 were obtained. Upon infection with EV-1, 
cytopathic effect developed on mouse L cell transformants but not on 3T3 cell 
transformants and a persistent infection was established on 3T3 cell transformants (Zhang 
and Racaniello 1997). The study also revealed that receptor down-regulation is not 
involved in the establishment of persistent infection (Zhang and Racaniello 1997).  
 The contribution of host cell mutants to the maintenance of persistent infection has 
been addressed in discussion of cell evolution during persistent infection. 
Effects of the state of cell differentiation on viral infection have been documented. 
Human erythroleukemia K562 cells can differentiate into several cell lineages. Four cell 
strains were analyzed for their responses to poliovirus infection (Benton et al. 1995). 
Poliovirus readily establishes persistent infections in K562-Mu cells and K562-ATCC 
cells, while the majority of K562-KI cells and K562-We cells were killed after poliovirus 
infection (Benton et al. 1995). Surface poliovirus receptor levels are similar in all K562 
cell strains and there are no significant differences in viral RNA and protein synthesis 
between these cell strains. It was proposed that some host factors related to virus-
mediated cytopathology may be responsible for the observed phenomenon (Benton et al. 
1995). Further studies showed that after hemin-induced differentiation, poliovirus 
infection of K562-Mu cells became cytolytic rather than leading to persistent infection 
(Benton et al. 1996), demonstrating the influence of cell differentiation on the outcome of 
virus infection. It is speculated that hemin treatment alters the expression of specific host 
proteins in K562-Mu cells, which changes their response to poliovirus infection from 
persistent to lytic (Benton et al. 1996). In addition, it has been observed that upon 
poliovirus infection, well differentiated human blood cell lines develop CPE more rapidly 
than less differentiated cell lines (Okada et al. 1987).  
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In some persistent infections, such as Newcastle disease virus/mouse L cells 
(Thacore and Youngner 1969) and human influenza C virus/MDCK cells (Goshima and 
Maeno 1989), low levels of interferon were detected. However it is unclear whether 
interferon plays a role in the maintenance of persistent infection in these cells. In most 
persistent viral infections, such as measles virus/Hela cells (Rustigian 1966a), mumps 
virus/conjunctiva cells (Walker and Hinze 1962), human rhinovirus-2/Hela cells (Gercel 
et al. 1985), and poliovirus/human neuroblastoma IMR-32 cells (Colbere-Garapin et al. 
1989), interferon was below detectable levels. It would appear therefore, that interferon 
does not play a significant role in establishment and maintenance of persistent infection.   
 
V. RESEARCH OBJECTIVES OF THIS DISSERTATION  
As discussed previously, neither a virus attachment molecule nor a specific cell 
receptor has been identified for EAV. The early steps (e.g. attachment, penetration, and 
uncoating) of the EAV infection cycle have not been elucidated. A major goal of this 
study is to identify and characterize the cell receptor(s) involved in EAV attachment to 
and entry into cells. However, identification of the cellular receptor(s) used by EAV for 
attachment and entry has been hampered by the unavailability of a cell line that lacks the 
appropriate EAV receptor(s). Identification of EAV non-permissive cell lines in which 
EAV infection is restricted at different steps in its replication and comparison of these 
non-permissive cell lines with permissive cell lines should help to identify the cellular 
factor(s) that are involved in EAV infection. The specific objective of this research is to 
evaluate a variety of cell lines for their permissiveness to EAV infection and then identify 
the mechanism that restricts EAV infection. To achieve this objective, two hypotheses 
and aims are proposed.  
Hypothesis 1: Within selected cell lines (RK-13, BHK-21, C2C12, Hela, Hep-2, 
and L-M), some cell lines are permissive to VBS53 EAV infection and some cell lines 
are non-permissive to VBS53 EAV infection. 
Aim 1: to test the permissiveness of various cell lines to EAV infection by one-step 
growth of the virus in these cell lines as well as by indirect immunofluorescence assay 
using EAV-specific monoclonal antibodies.  
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Hypothesis 2: In non-permissive cell lines, EAV infection is restricted at certain 
step(s) of the virus life cycle.  
Aim 2: to determine whether restriction of EAV infection in non-permissive cell 
lines is due to a block at the virus attachment step, a block at the cell entry step, or an 
intracellular block.  
After EAV infection, up to 30% to 70% of stallions can subsequently become 
persistently infected. The detailed mechanism by which EAV establishes persistent 
infection in stallions is unknown. Carrier stallions are not only a natural reservoir of EAV 
responsible for maintenance and dissemination of EAV in equine populations, but also a 
natural source of genetic and phenotypic diversity of EAV. Persistent viral infections in 
cell culture have been demonstrated as a valuable tool to study virus-host cell interactions, 
virus and host cell evolutions, and to elucidate the mechanisms of viral persistence. In 
fact, genetic and phenotypic characterization of virus mutants and host cell mutants 
during persistent infection has already greatly helped study virus-receptor interactions, 
define virus virulence gene, and identify viral and host cell determinants involved in 
persistent viral infection. The second major goal of this study is to establish persistent 
EAV infection in cell cultures and then use the persistently infected cultures as a tool to 
study virus-host cell interactions, virus and host cell evolutions, and to identify viral and 
host cell determinants involved in EAV persistence. Specific hypotheses and objectives 
relating to this goal are as follows.  
Hypothesis 1: Persistent EAV infection can be established in certain cell lines. 
Aim 1: to test a variety of cell lines and determine in which cell lines persistent 
EAV infection can be established. 
Hypothesis 2: During persistent infection of cell cultures, EAV undergoes genetic 
and phenotypic evolution; genetic variations result in phenotypic changes.  
Aim 2: to investigate genetic and phenotypic (such as growth characteristics, 
neutralization phenotypes, and pathogenicity) variations of the viruses recovered from 
different passages of the persistently infected culture; to define genetic variations that are 
responsible for corresponding phenotypic changes.   
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Table 1.1. The order of Nidovirales 
 
Order Nidovirales 
Family Arteriviridae Coronaviridae Roniviridae 
Genus Arterivirus Coronavirus Torovirus Okavirus 
Canine coronavirus (CCV) 
 
Feline coronavirus (FCoV) 
 
Human coronavirus 229E (HCoV-229E) 
 
Porcine epidemic diarrhea virus (PEDV) 
 
Transmissible gastroenteritis virus (TGEV) 
 
 
 
 
Group 1 
species 
Bovine coronavirus (BCoV) 
 
Human coronavirus OC43 (HCoV-OC43) 
 
Mouse hepatitis virus (MHV) 
 
Porcine hemagglutinating encephalomyelitis 
virus (HEV) 
 
Rat coronavirus (RCV) 
 
 
 
 
Group 2 
species 
Infectious bronchitis virus (IBV) 
 
Turkey coronavirus (TCoV) 
Group 3 
species 
Species Equine arteritis virus (EAV) 
 
Porcine respiratory and 
reproductive syndrome virus 
(PRRSV) 
 
Lactate dehydrogenase-elevating 
virus (LDV) 
 
Simian hemorrhagic fever virus 
(SHFV) 
 
 
 
 
 
Severe acute respiratory syndrome 
coronavirus (SARS-CoV) 
Not 
grouped 
Equine torovirus (EqTV) 
 
Bovine torovirus (BoTV) 
 
Human torovirus (HuTV) 
 
Porcine torovirus (PoTV) 
 
 
 
 
 
 
Gill-associated virus 
(GAV) 
 
Yellow head virus 
(YHV) 
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Table 1.2. The ORFs of the EAV genome  
    
Leader or ORFs                            
(nt location)* 
Protein (aa length† and molecular 
weight§ kDa) 
Putative functional domain‡ 
5' NTR (1-224) N/A  
5' Leader (1-211) N/A  
 Nonstructural proteins (nsp)  
ORF1a (225-5408) 1a polyprotein (1727 aa; 187 kDa)  
ORF1ab (225-5405, 
5405-9751) 1ab polyprotein (3175 aa; 345 kDa)  
 nsp1: Met1-Gly260 (260 aa; 29 kDa) Zinc finger, PCP1ß 
 nsp2: Gly261-Gly831 (571 aa; 61 kDa) CP2 
 nsp3: Gly832-Glu1064 (233 aa) HD 
 nsp4: Gly1065-Glu1268 (204 aa) 3CLSP 
 nsp5: Ser1269-Glu1430 (162 aa) HD 
 nsp6: Gly1431-Glu1452 (22 aa) ? 
 nsp7: Ser1453-Glu1677 (225 aa) ? 
 nsp8: Gly1678-Asn1727 (50 aa) ? 
 nsp 9: Gly1678-Glu2370 (693 aa; 80 kDa) RdRp 
 nsp10: Ser2371-Gln2837 (467 aa; 50 kDa) MB, NTPase, HEL 
 nsp11: Ser2838-Glu3056 (219 aa; 26 kDa) ? 
 nsp12: Gly3057-Val3175 (119 aa; 12 kDa) ? 
   
 Structural proteins  
ORF2a (9751-9954) E (67 aa; 8 kDa) intermediate envelope protein 
ORF2b (9824-10507) GP2b (227 aa; 25 kDa) minor envelope protein;  1 N-glycosylation 
ORF3 (10306-10797) GP3 (163 aa; 36-42 kDa) minor envelope protein;  6 N-glycosylation 
ORF4 (10700-11158) GP4 (152 aa; 28 kDa) minor envelope protein;  3 N-glycosylation 
ORF5 (11146-11913) GP5 (255 aa; 30-42 kDa) 
major envelope protein;  
1 N glycosylation; expressing 
neutralization determinants 
ORF6 (11901-12389) M (162 aa; 16 kDa) major envelope protein 
ORF7 (12313-12645) N (110 aa; 14 kDa) nucleocapsid protein;  3 phosphorylation 
3' NTR (12646-12704) N/A   
 * Nucleotides are numbered according to the published sequence of EAV030 virus (van Dinten et al., 
1997). 
 † Amino acids of non-structural proteins are numbered according to their locations in polyprotein 1ab. 
Amino acids of structural proteins are numbered according to their locations in individual structural 
protein. N/A: Not Applicable. 
§ Molecular weight (kDa) of structural proteins shown here was the size after modification, e.g. 
glycosylation. 
‡ PCP1ß: papain-like cysteine proteinase 1ß; CP2: cysteine proteinase of nsp2; HD: hydrophobic 
domain; 3CLSP: 3C-like serine proteinase; RdRp: RNA-dependent RNA polymerase; MB: metal ion-
binding domain; NTPase: NTPase domain; HEL: helicase domain; ?: function unknown.   
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Fig. 1.1. (A) Schematic diagram of the genome organization and expression of EAV. The 
regions of the genome specifying the leader (L) sequence, the replicase gene (ORFs 1a 
and 1b), and the structural protein genes are indicated. The nested set of EAV mRNAs 
(genome and sg mRNAs 2 to 7) is depicted below. The black boxes in the genomic RNA 
indicate the position of leader and major body TRSs. The figure A is reprinted from van 
den Born et al. (2005). (B) Schematic representation of EAV virion, showing an 
icosahedral nucleocapsid and an envelope containing six viral membrane proteins which 
include a GP5-M heterodimer, an E protein, and a GP2b/GP3/GP4 heterotrimer. The E 
protein is proposed to be the component which, on the one hand interacts with the 
GP2b/GP4/GP3 heterotrimer, and on the other hand interacts with the GP5/M 
heterodimer and/or the nucleocaspid. It is through these interactions that the E protein 
draws the GP2b/GP4/GP3 complex into nascent virus particles (Wieringa et al. 2004). 
(A)  
 
(B)  
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Fig 1.2. Overview of the replication cycle of EAV. The viral genome and the nested set 
of subgenomic mRNAs are indicated, with the small black boxes representing the 
common 5’ leader sequence. The white boxes in sg mRNAs represent the translationally 
active ORF(s) for each mRNA. The figure is reprinted from Snijder et al. (1999). 
 
 
 
 
 
 
       
 
 
Fig 1.3. Schematic diagram of the EAV ORF1a/1b frameshift-directing signals: the 
‘shifty’ codons (5’ GUUAAAC 3’) and RNA pseudoknot structure. The codons of the 
reading frames 1a including its termination codon and 1b are indicated. The figure is 
reprinted from Snijder and Meulenberg (1998) with permission.  
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Fig 1.4. Overview of the proteolytic processing of the EAV replicase polyproteins. (A) 
The processing schemes for the EAV polyproteins 1a and 1ab are depicted. The three 
EAV proteases and their corresponding cleavage sites are shown: PCP1ß, nsp1 papain-
like cysteine protease 1ß; CP2, nsp2 cysteine protease; 3CLSP, nsp4 3C-like serine 
protease; the a* domain represents the inactive PCP1a domain. Hydrophobic domains 
(HD) in nsp2, nsp3, and nsp5 are indicated. In the ORF1b-encoded polypeptide, the four 
major conserved domains are depicted: RdRp, RNA-dependent RNA polymerase; Z, 
putative zinc-binding domain; HEL, helicase domain; C, conserved, nidovirus-specific C-
terminal domain. (B) Two alternative processing pathways of the EAV ORF1a protein. 
The association of cleaved nsp2 with nsp3-8 was shown to direct cleavage at the nsp4|5 
site by the nsp4 3CLSP (major pathway). Alternatively, in the absence of nsp2, the nsp5|6 
and 6|7 sites were cleaved and the nsp4|5 junction remained uncleaved. The diagrams are 
reprinted from Ziebuhr et al. (2000) with permission. 
1a 
1ab 
A 
B 
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Fig 1.5. Transcription models illustrating the discontinuous step during nidoviral 
subgenomic mRNA synthesis. (A) ‘Leader-primed transcription’ model. Discontinuous 
transcription was proposed to occur during positive-strand RNA synthesis using the full-
length negative genomic strand as a template. The sense TRS at the 3’ end of the leader 
transcript base pairs with the antisense body TRS in the negative-strand template, after 
which the leader transcript is extended to produce a sg mRNA. (B, C) ‘Discontinuous 
negative strand extension’ model. In C, EAV is used as an example. Discontinuous 
transcription was proposed to occur during negative-strand RNA synthesis using the full-
length positive genomic strand as a template. After attenuation of the RdRp complex at a 
body TRS in the positive-strand genomic template, the nascent (-) strand is translocated 
to the leader TRS region. Following base pairing between the antisense body TRS and 
sense leader TRS, negative strand RNA synthesis resumes to add the anti-leader sequence. 
Subsequently, the sg (-) strand RNA serves as a template for sg mRNA synthesis. The 
positive- (white) and negative- (black) strand RNAs are shown. The sense leader and 
body TRS (black boxes) in positive strand RNA and antisense leader and body TRS 
(white boxes) in negative strand RNA are indicated. The diagrams A and B are modified 
from Snijder and Meulenberg (1998) and the diagram C is reprinted from van den Born et 
al. (2005) with permission.  
A 
B 
C 
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Fig 1.6. EAV sg mRNA3, -4, and -5 body TRS regions. The sequences are aligned with 
respect to the translation initiation for the corresponding structural protein. The body 
TRSs and translation initiation codon are shown in bold. The figure is reprinted from 
Pasternak et al. (2000).  
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Chapter Two 
Determination of the Permissiveness of Various Cell Lines to Equine Arteritis Virus 
Infection and Demonstration That Equine Arteritis Virus Infection Is Restricted at 
the Entry Step in Non-Permissive Cell Lines 
 
ABSTRACT 
Neither the virus attachment molecule nor the specific cell receptor has been 
identified for EAV. The early cell-EAV interactions (e.g. attachment, penetration, and 
uncoating) have not been elucidated. Although several permissive cell lines have been 
identified which support productive EAV infection, it is unknown which cell lines are 
non-permissive to EAV infection and at which steps EAV infection is blocked in these 
cell lines. In this study, a variety of cell lines of different species and tissue origin were 
tested for their permissiveness to infection with EAV strain VBS53, and the mechanisms 
that restrict EAV infection in non-permissive cell lines were investigated. The cell lines 
baby hamster kidney (BHK-21; ATCC CCL-10), rabbit kidney (RK-13; KY & ATCC 
CCL-37) and mouse muscle (C2C12; ATCC CRL-1772) were found to support 
productive infection with EAV strain VBS53 as demonstrated by infectious virus yield 
and indirect immunofluorescence assay using EAV-specific monoclonal antibodies. On 
the other hand, human cervix (Hela; ATCC CCL-2), human epidermoid larynx (Hep-2; 
ATCC CCL-23), and mouse connective tissue (L-M; ATCC CCL-1.2) cell lines exhibited 
limited susceptibility to infection with EAV strain VBS53. Interestingly, Hela cells 
became more susceptible to the virus infection after extended serial passage. The 
respective cell lines were referred to as Hela ‘High’ (passage 170-221) and Hela ‘Low’ 
(passage 95-115). While Hela ‘High’ cell line was more susceptible than Hela ‘Low’ cell 
line, it was still considerably less susceptible than BHK-21 cell line to EAV infection. 
Karyotypic analysis of Hela ‘High’ and Hela ‘Low’ cell lines using G-banding technique 
revealed chromosomal differences. Transfection of Hela ‘High’, Hela ‘Low’, Hep-2, and 
L-M cell lines with viral RNA in vitro-transcribed from a full-length EAV cDNA clone 
induced virus replication, assembly, and release. Virus levels were comparable to those in 
transfected BHK-21 cells 24 h post transfection, indicating that these cells fully support 
EAV replication when the attachment and entry steps are bypassed. Thus, interference 
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with the attachment or entry steps might account for resistance of these cells to infection 
with EAV. Attachment of EAV strain VBS53 to the cells was determined by directly 
titrating the virus bound to the cells.  It was found that EAV was able to bind to Hela 
‘High’, Hela ‘Low’, Hep-2, and L-M cell lines almost as efficiently as it did to the fully 
permissive cell line BHK-21. Attachment of EAV strain VBS53 to each cell line was 
further confirmed using a fluorescence-activated cell sorter (FACS) assay in which 
binding of biotinylated EAV was detected with streptavidin-FITC. All of the cell lines 
under study bound EAV in a dose-dependent manner and nonbiotinylated EAV 
competitively inhibited binding, indicating that the binding was specific. Virus entry 
studies showed that the efficiency of EAV strain VBS53 entry into Hela ‘High’, Hela 
‘Low’, Hep-2, and L-M cell lines was significantly lower than that of entry into BHK-21 
cells. In addition, it was observed that the entry of EAV into Hela ‘High’ cell line was 
more efficient than virus entry into Hela ‘Low’, Hep-2, and L-M cell lines. In conclusion, 
we have identified several cell lines that exhibit varying susceptibility to infection with 
EAV strain VBS53 and have found that permissiveness of a cell line to EAV is 
determined at the entry step. Results of this study would suggest that interaction of EAV 
with its attachment receptor on the cell surface may be necessary, but of itself not 
sufficient to initiate a productive infection. 
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INTRODUCTION 
Equine arteritis virus (EAV) is the prototype member of the family Arteriviridae 
which also contains porcine respiratory and reproductive syndrome virus (PRRSV), 
lactate dehydrogenase-elevating virus (LDV), and simian hemorrhagic fever virus (SHFV) 
(Snijder and Meulenberg 1998). The EAV genome is a single-stranded, positive-sense 
RNA molecule of 12.7 kb, which includes nine functional open reading frames (ORFs) 
(Snijder and Meulenberg 1998; Snijder et al. 1999). The replicase gene comprises the 5’-
terminal three-quarters of the genome and includes two ORFs (1a and 1b). ORFs 1a and 
1b are expressed directly from the genomic RNA and encode replicase proteins involved 
in viral replication and transcription (den Boon et al. 1991; 1995a; Snijder et al. 1992, 
1994; 1995; 1996; van Dinten et al. 1996; 1999; Wassenaar et al. 1997). The 3’ terminal 
one-quarter length of the genome is composed of seven ORFs (2a, 2b, and 3-7), which 
encode structural proteins E, GP2b (Gs), GP3, GP4, GP5 (GL), M, and N, respectively 
(den Boon et al. 1991; Snijder and Meulenberg 1998; Snijder et al. 1999). These 
structural proteins are expressed from 5’- and 3’-coterminal nested set of six subgenomic 
mRNAs.  
EAV virions consist of an icosahedral nucleocapsid which is surrounded by a lipid-
containing envelope with tiny surface projections (Horzinek et al. 1971). The viral 
nucleocapsid is composed of the linear viral genomic RNA and a phosphorylated 
nucleocapsid (N) protein (de Vries et al. 1992; Hyllseth 1973; Zeegers et al. 1976). The 
virion envelope contains six envelope proteins. The two major envelope proteins include 
the nonglycosylated membrane protein (M) and the relatively large envelope glycoprotein 
GP5 (de Vries et al. 1992). The M and GP5 proteins occur as disulfide-linked 
heterodimers (de Vries et al. 1995b). The unglycosylated envelope protein E is of 
intermediate abundance in the virion (Snijder et al. 1999). The three minor envelope 
proteins of EAV are glycoproteins GP2b, GP3, and GP4, which occur as heterotrimers in 
the virion (de Vries et al. 1992; 1995a; Hedges et al. 1999b; Wieringa et al. 2002; 2003a).  
The first step in virus infection is viral attachment to a specific receptor on a 
susceptible cell. In the case of EAV, neither the virus attachment molecule nor a specific 
cell receptor has yet been clearly identified. By analogy with many other animal RNA 
viruses and in view of its recognition by neutralizing antibodies, the EAV GP5 protein 
  54 
had been postulated to serve as the virus attachment protein and to mediate receptor 
recognition. However, exchange of the ectodomain of the EAV GP5 protein with that of 
PRRSV or LDV in the context of an infectious EAV cDNA clone did not alter the cell 
tropism of the virus, suggesting that the ectodomain of GP5 is not the main determinant 
of EAV tropism in cell culture (Dobbe et al., 2001). Similarly, PRRSV mutants in which 
the ectodomain of the M protein was replaced by that of EAV or LDV still retained their 
ability to infect porcine alveolar macrophages and did not acquire tropism for cells 
susceptible to the respective viruses (e.g. BHK-21 cells for EAV and mouse macrophages 
for LDV) from which the foreign ectodomains were derived (Verheije et al. 2002). This 
would suggest that, in the case of arteriviruses, the M protein is not responsible for 
receptor binding either. Recently, Wieringa et al. (2003a) have shown that minor 
structural proteins are present in EAV virions as disulfide-bonded GP2b/GP4/GP3 
heterotrimeric complexes. Also, there are indications that the E protein is noncovalently 
associated with the GP2b/GP4/GP3 trimers (Wieringa et al. 2004). It has also been 
demonstrated that the E, GP2b, GP3, and GP4 proteins are not required for the formation 
of EAV particles, although these proteins are believed essential for ensuring that the virus 
particles are infectious (Molenkamp et al. 2000; Wieringa et al. 2004). These findings 
would suggest that the GP2b/GP4/GP3/(E) complex might be involved in the EAV 
attachment/entry process. 
The cell receptor for EAV has not been identified either. Asagoe et al. (1997) 
showed that heparin can reduce EAV infection of RK-13 cells and that this inhibition was 
due to the direct interaction between heparin and EAV rather than the interaction between 
heparin and RK-13 cells. Furthermore, treatment of RK-13 cells with heparinase before 
virus inoculation decreased EAV infection of the cells (Asagoe et al. 1997). The data 
suggested that a heparin-like molecule on the surface of RK-13 cells might serve as cell 
receptor for EAV. However, heparinase treatment of cells could not completely block 
EAV infection and EAV infection could not be reduced below 13% even in the presence 
of a very high concentration of heparin (Asagoe et al. 1997), implying that other 
molecules on the cell surface might serve as EAV receptors as well. 
Identification of the receptor used by EAV for cell attachment and entry has been 
hampered by the unavailability of a known cell line that lacks the appropriate EAV 
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receptor(s). Identification of EAV non-permissive cell lines in which EAV infection is 
restricted at different steps and comparison of these non-permissive cell lines with 
permissive cell lines should help to identify the cellular factor(s) that are involved in each 
step of EAV infection. In this study, a variety of cell lines of different species and tissue 
origin were assessed for their permissiveness to infection with the strain VBS53 of EAV 
and the mechanism that restricts EAV infection in the non-permissive cell lines was 
investigated. 
 
MATERIALS AND METHODS 
Cells and viruses. The origin and morphological description of the cell lines used 
in this study are listed in Table 2.1. The RK-13 (ATCC CCL37) cell line is routinely used 
in our laboratory between passage level 192 and 204. An additional RK-13 cell line, RK-
13 (KY), is also available in the laboratory and it is routinely used between passage level 
397 and 409. The RK-13 (ATCC CCL-37) and RK-13 (KY) cell lines are 
morphologically and karyotypically distinct. Hela cells were obtained from the American 
Type Culture Collection (ATCC CCL-2) at passage level 95. Since it was found that Hela 
cells had different susceptibilities to EAV strain VBS53 infection after extensive serial 
passage, it was decided to categorize Hela cells from passage 95 to 115 as Hela ‘Low’ 
cells and these are not susceptible to EAV strain VBS53 infection. On the other hand, 
Hela cells from passage 170 to 221 were referred to as Hela ‘High’ cells and these were 
found to be partly susceptible to EAV strain VBS53 infection. All the cell lines were 
grown in Eagle’s minimum essential medium (EMEM) with 10% ferritin supplemented 
calf serum (FSCS), penicillin, streptomycin, fungizone, and sodium bicarbonate. The 
RK-13, BHK-21, Hela, Hep-2, and L-M cell lines were grown at 37ºC in an aerobic 
incubator. The C2C12 cell line was grown at 37ºC in the presence of 5% CO2. The RK-
13 cell lines were subcultured once weekly (1:5 split), whereas BHK-21, L-M, and Hep-2 
cell lines were subcultured twice weekly (1:6 split), and the C2C12 and Hela cell lines 
were subcultured once every 4 days (1:4 split) in accordance with  routine procedures. 
The origin, passage history and horse-pathogenicity of the virulent Bucyrus strain 
(VBS53) of EAV are summarized in Fig 2.1. The original isolate of EAV in 1953 was 
passaged 15 times in horses and the pleural fluid collected from the 15th inoculated horse 
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was named as the VBS53 strain of EAV, which was highly virulent for horses. The EAV 
strain VBS53 was propagated twice in BHK-21 cells to produce virus stocks which were 
used in this study. Viral infectivity was determined by plaque assay on RK-13 (KY) cells 
as previously described (McCollum et al. 1962). 
Antibodies. The development and characterization of monoclonal antibodies to the 
nucleocapsid protein (N; MAb 3E2) and the non-structural protein 1 (nsp1; MAb 12A4) 
of EAV have been previously described (MacLachlan et al. 1998; Wagner et al. 2003). 
Both MAbs 3E2 and 12A4 were kindly provided by Drs. Udeni Balasuriya and James 
MacLachlan at University of California, Davis. 
Growth of EAV in various cell lines. Growth of EAV strain VBS53 in RK-13, 
BHK-21, C2C12, Hela, Hep-2, and L-M cell lines was compared. Subconfluent 
monolayers of each cell line grown in T-25 flasks (approximately 2.2 × 106 cells/T-25 
flask) were inoculated with EAV strain VBS53 at a multiplicity of infection (m.o.i.) of 3. 
Flasks were incubated at 37°C for 1 h. The inoculum was aspirated, and cell sheets 
washed three times with PBS to remove unbound virus and the sheets overlaid with 10 ml 
of EMEM medium. This was designated time zero with respect to infection. Inoculated 
cultures were incubated at 37°C.  At 0, 12, 24, 36, 48, 60, and 72 h post infection (p.i.), 
both supernatants and cells were harvested and sonicated three times (20V, 15 sec/time) 
to fully disrupt the cells to release virus particles. Viral infectivity was determined by 
plaque assay on RK-13 (KY) cells as previously described (McCollum et al. 1962). 
Mock-infected cultures of each cell line were included in the experiment. Cell lines were 
also grown in 8-chamber slides and infected with EAV strain VBS53. At 24 h and 72 h 
post infection, cell sheets were examined by indirect immunofluorescence assay for 
expression of the viral nucleocapsid (N) protein and non-structural protein 1 (NSP1). To 
determine the effect of m.o.i. on the outcome of infection, RK-13 (KY), Hela, Hep-2, and 
L-M cell lines were infected with EAV strain VBS53 at m.o.i. of 1, 3, 10, and 50. At 0 h 
and 40 h after infection, extracellular virus (represented by culture supernatants) and cell-
associated virus (represented by cell-lysates) were titrated separately by plaque assays. 
Serial amplification of EAV in Hela ‘High’ and Hela ‘Low’ cell lines. 
Subconfluent monolayers of Hela cells (low passage P109 and high passage P200) were 
inoculated with EAV strain VBS53 at an m.o.i of 3 (using an inoculum of 0.3 ml). Mock-
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inoculated Hela cells (P109 and P200) were included. The same volume of EAV infective 
inoculum was added to 10% EMEM medium without cells and included as an additional 
control. After 1 h of incubation at 37ºC, without washing, 10 ml medium was added to 
each culture. After 4 days of incubation at 37ºC, the supernatant (P1) (10 ml) was 
harvested and centrifuged at 1900 rpm for 10 min to remove cell debris. The supernatant 
was then filtered through a 0.45 µm membrane to ensure removal of cell debris. Filtered 
supernatant (0.3 ml) from mock-inoculated Hela cells (P1 mock), EAV-inoculated Hela 
cells (P1 EAV-Hela), and EAV-inoculated medium (P1 EAV-medium) were added to 
uninfected Hela cell cultures (P110 or P201) or medium without cells, respectively, and 
incubated at 37ºC for 1 h. A 10 ml volume of medium was added and the cultures 
incubated for 4 days at 37ºC to provide ‘P2 mock’, 'P2 EAV-Hela', and 'P2 EAV-
medium', respectively. The same procedure was followed in attempting to amplify the 
virus up to P7. 
Chromosomal analysis. Karyotypic analysis of low (P98) and high (P202) passage 
Hela cells was performed using the conventional G-banding technique (ISCN 1985; 
Yunis 1976) at Department of Cytogenetics, University of Kentucky. Twenty giemsa-
banded metaphase cells from passage 98 and passage 202 Hela cells were analyzed, 
respectively. 
In vitro transcription and transfection of cells with in vitro transcribed EAV 
RNA. Viral RNA transcripts were in vitro-transcribed from the full-length infectious 
EAV cDNA clone pEAV2421/211EB which was derived from EAV strain VBS53 
(Balasuriya et al., unpublished). The in vitro transcription was carried out as previously 
described (van Dinten et al. 1997) with minor modifications. Briefly, the plasmid DNA 
was linearized with XhoI, digested with proteinase K, purified by phenol-chloroform 
extraction, precipitated with ethanol, and dissolved in water. The in vitro transcription 
was conducted in a reaction mixture of 50.0 µl: linear DNA 15.0 µl, rNTPs mix (10mM 
each, Amersham) 5.0 µl, acetylated BSA (1 mg/ml, Promega) 5.0 µl, DTT (100 mM, 
Promega) 2.5 µl, 5’ cap analog M7G(ppp)G (10 mM, New England Biolabs) 5.0 µl, RNA 
guard RNase inhibitor (Pharmacia) 2.5 µl, T7 RNA polymerase (Promega) 2.5 µl, 5x T7 
transcription buffer 10.0 µl, nuclease free water 2.5 µl. After 2 h of incubation at 37ºC, 
the RNA quality and yield were assessed by agarose gel electrophoresis and 
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spectrophotometry. RNA transcripts were introduced into BHK-21, Hela ‘High’, Hela 
‘Low’, Hep-2, and L-M cell lines by means of electroporation following previously 
described protocols (van Dinten et al. 1997) with minor modifications. Briefly, cells were 
grown to subconfluence, trypsinized, washed with PBS, and resuspended in PBS at a 
concentration of 1 x 107 cells per ml. A 15 µl aliquot of the transcripts mixture was added 
to 500 µl of the cell suspension, which was then transferred into electroporation cuvettes 
(0.4 cm electrode gap; Bio-Rad). Using a Gene Pulser II system (Bio-Rad), the cells were 
pulsed twice at 850V and 25 µF, with the pulse controller set at ‘infinite’ ohms. The cells 
were incubated at room temperature for a 10 min ‘recovery period’ after electroporation 
and then resuspended in 15 ml of culture medium which was previously warmed to room 
temperature. The cells were seeded into 8-chamber slides for immunofluorescence assays 
or into a T-25 flask to monitor virus yield at 12, 24, 48, 72, and 96 h post transfection.  
Indirect immunofluorescence assay (IFA). Mock-, EAV-infected, or EAV RNA-
transfected cells grown in 8-chamber slides were fixed with cold acetone for 10 min, and 
washed three times with PBS containing 10mM glycine. Slides were then incubated with 
MAb 3E2 (ascitic fluid) specific for EAV nucleocapsid protein, or MAb 12A4 (ascitic 
fluid) specific for EAV NSP1, followed by fluorescein-conjugated goat antimouse 
immunoglobulin (Pierce). The cell sheets were counterstained with Evans blue. The 
images were recorded using a LEICA confocal microscope.  
Measurement of virus binding to and entry into cells. EAV binding to and etnry 
into various cell lines were determined by modifying previously described asssays (de la 
Torre et al. 1988a; Vlaycheva and Chambers 2002). Subconfluent monolayers of BHK-
21, Hela ‘High’, Hela ‘Low’, Hep-2, and L-M cell lines were trypsinized and 
resuspended in culture medium at a concentration of 2 x 106 cells per ml, and cooled 
down at 4ºC for at least 30 min. In the case of each cell line, 2 x 106 PFU of EAV strain 
VBS53 (in 200 µl) was added to four replicates of 1 x 106 cells (500 µl) and held at 4ºC 
for 1 h. The cells were then washed three times with cold PBS to remove unbound virus. 
Two of the cell replicates were resuspended in 1 ml of cold culture medium. Cell 
suspensions were subjected to three cycles of freezing and thawing to release attached 
viruses, and then centrifuged for 10 min at 1900 rpm at 4ºC. Clarified supernatants were 
titrated by plaque assay on RK-13 (KY) cells as previously described (McCollum et al. 
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1962). The amount of virus attached to Hela ‘High’, Hela ‘Low’, Hep-2, and L-M cells 
was calculated as a percentage of the virus attached to BHK-21 cells. The other duplicate 
of the cells were resuspended in 1 ml of pre-warmed culture medium and incubated at 
37ºC for 1 h with agitation. After incubation for 1 h at 37ºC, the cells were treated with 
1.0 ml acid glycine (pH 3.0) to inactivate non-internalized virus. The cells were then 
washed four times with PBS and resuspended in 1 ml of culture medium. The last wash 
was saved for infectivity titration to confirm that no residual extracellular virus was 
detectable in the cell suspensions. Serial decimal dilutions of the cell suspensions were 
made in culture medium and then inoculated onto monolayers of RK-13 (KY) cells in 6-
well plates. Inoculated cultures were incubated at 37ºC for 1 h. Cell monolayers were 
overlaid with culture medium containing 0.75% carboxymethyl cellulose and incubated 
at 37ºC for 4 days. Infectious centers were counted after staining of plates with 10% 
formalin buffered crystal violet. Efficiency of virus entry into Hela ‘High’, Hela ‘Low’, 
Hep-2, and L-M cell lines was calculated as a ratio of infectious center counts in each cell 
line being evaluated to infectious center counts in BHK-21 cell line.   
Virus purification and biotinylation. Purification and biotinylation of EAV were 
carried out according to previously described assay with minor modifications (Nauwynck 
et al. 1999). The stocks of EAV strain VBS53 were pelleted by ultracentrifugation 
through a 20% (wt/wt) sucrose cushion in TNE buffer (20 mM Tris-HCl (pH 7.6), 100 
mM NaCl, 1 mM EDTA) for 5 h at 25,000 rpm (SW28 rotor) at 4°C. Virus pellets were 
resuspended in TNE buffer and further purified by ultracentrifugation using a 
discontinuous 20%-50% sucrose gradient for 16 h at 32,000 rpm (SW41 rotor) at 4ºC. 
Visible virus bands were harvested and rinsed with bicarbonate buffer (pH 8.6) by 
centrifugation for 5 h at 34,000 rpm (SW41 rotor) at 4ºC. In the final step, the purified 
virus particles were resuspended in sodium bicarbonate buffer. The infectivity titer of the 
resulting virus particles was approximately 5 × 109 pfu/ml, as determined by plaque assay 
in RK13 (KY) cells. The protein concentration was 2.0 mg/ml, as determined by the 
Bradford assay (Bio-Rad) with bovine serum albumin (BSA) as a standard. Purified EAV 
particles in suspension were biotin labeled using a protein biotinylation kit (Amersham). 
Briefly, virus particles were diluted to a concentration of 1 mg/ml in sodium bicarbonate 
buffer and 40 µl of biotinylation reagents were added per mg of virus protein. The 
  60 
mixture was shaken for 1 h at 4°C. Biotinylated virus was collected after purification on a 
Sephadex G25 column, aliquoted (0.5 ml/tube, 0.4 mg/ml), and stored at -70°C. The 
infectivity titer of the biotinylated virus was 4 × 109 pfu/ml. 
Analysis of biotinylated EAV attachment to cells by flow cytometry. 
Attachment of biotinylated EAV to various cell lines were carried out by modifying 
previously described procedures (Borrow and Oldstone 1992; Nauwynck et al. 1999). 
Subconfluent monolayers of RK-13 (KY), RK-13 (ATCC), BHK-21, Hela ‘High’, Hela 
‘Low’, Hep-2, and L-M cell lines were washed three times with cold PBS and then 
treated with non-enzymatic cell dissociation solution (Sigma) for cell detachment. 
Various amounts of biotinylated EAV [0, 2.5 µg (2.5 × 107 pfu), 5.0 µg (5.0 × 107 pfu), 
7.5 µg (7.5 × 107 pfu), 10.0 µg (1.0 × 108 pfu), 12.5 µg (1.25 × 108 pfu)] were added to 
aliquots of a suspension of each cell line containing 5 ×105 cells in a total volume of 500 
µl of PBS containing 0.2% bovine serum albumin (PBSA) and incubated at 4ºC for 1 h. 
The cells were washed three times with cold PBSA and incubated with 200 µl of a 1:100-
dilution of streptavidin-fluorescein conjugate in PBSA for 1 h at 4ºC. The cells were then 
washed three times in PBS containing 2% fetal bovine serum (FBS), followed by 
resuspension in 1.0 ml of PBS containing 2% FBS. Propidium iodide was added to the 
cell suspensions (1 µg propidium iodide per ml of cell suspension) just before analysis by 
flow cytometry. The relative fluorescence intensity of each sample was determined by 
flow cytometry and 30,000 cells were counted in each sample. Dead cells labeled with 
propidium iodide were excluded.   
The specificity of the attachment of biotinylated EAV to cells was demonstrated by 
two methods: (i) a competitive inhibition test with nonbiotinylated EAV; and (ii) binding 
experiments with biotinylated BHK-21 cellular proteins. In the first case, 5 ×105 cells 
were first incubated at 4ºC for 1 h with different amounts of nonbiotinylated EAV (0, 1 × 
108 pfu, 2.5 × 108 pfu, 5 × 108 pfu, 7.5 × 108 pfu) in a final volume of 300 µl of PBSA. 
Then, 1 × 108 pfu of biotinylated EAV was added and the total volume was increased to 
500 µl with PBSA. The cells were incubated at 4ºC for a further hour, and fluorescence 
intensities were determined in accordance with previously described protocols. Inhibition 
of attachment was calculated as follows: % inhibition = [Mean fluorescence intensity of 
cells without nonbiotinylated EAV -  Mean fluorescence intensity of cells with different 
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amounts of nonbiotinylated EAV]/[Mean fluorescence intensity of cells without 
nonbiotinylated EAV] × 100%. In the case of the second method used to confirm the 
specificity of virus attachment, biotinylated BHK-21 cellular proteins (0, 2.5 µg, 5.0 µg, 
7.5 µg, 10.0 µg, and 12.5 µg) were incubated with 5 ×105 cells of each cell line at 4ºC for 
1 h, and the fluorescence intensities determined as already described. 
 
RESULTS 
Determination of the permissiveness of various cell lines to infection with the 
VBS53 strain of EAV. In order to identify a cell line that lacks the receptor(s) for EAV 
attachment and entry, a variety of cell lines of different species and tissue origin (Table 
2.1) were tested for their permissiveness to infection with the VBS53 strain of EAV (Fig 
2.1). The first approach used to achieve this objective was to determine whether each of 
the selected cell lines supported efficient growth of the virus. In EAV-inoculated BHK-
21, RK-13 (ATCC), RK-13 (KY), and C2C12 cell lines, virus-specific cytopathic effects 
(CPE) were first visualized from 24 h p.i. with all the cell monolayers destroyed by 48 h 
p.i., confirming that EAV is very cytolytic in each of these cell lines. In contrast, virus-
specific CPE were not observed in EAV-inoculated Hela, Hep-2, and L-M cell lines even 
at 96 h after inoculation. Replication of EAV in BHK-21, RK-13 (ATCC), RK-13 (KY), 
and C2C12 cells exhibted a typical growth kinetic curve, with 4-5 log10 increases in 
infectivity titers within 24 h, followed by a gradual decline in titers after 48 h (Fig 2.2). In 
contrast, virus infectivity titers in Hela (ATCC), Hep-2, and L-M cells did not increase 
markedly (less than 2 log10 increase) during the entire observation period (Fig 2.2), 
indicating that growth of this strain of EAV in these cell lines was restricted and not 
efficient. 
To determine whether virus antigens were synthesized during infection, indirect 
immunofluorescence assays were performed. In EAV-infected BHK-21 (Fig 2.3A and B), 
RK-13 (ATCC), RK-13 (KY), and C2C12 cells (data not shown), almost 100% cells were 
positive for the structural protein N (Fig 2.3A) and for the non-structural protein nsp1 
(Fig 2.3B) by 24 h post inoculation, confirming that EAV efficiently replicated in each of 
these cell lines. However, in EAV-inoculated Hela (ATCC) and L-M cells, only a small 
number of cells were fluorescent positive for N- (Fig 2.3C and K) or nsp1 protein (Fig 
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2.3D and I) by 24 h after inoculation. The number of EAV fluorescent-positive cells in 
Hela (ATCC) and L-M cell lines was less than 2% and 6%, respectively. Even by 72 h 
post inoculation, the percentage of EAV-positive cells in Hela (ATCC) and L-M cell 
lines had not increased (Fig 2.3E, F, M, and N), indicating that the spread of virus from 
the initially infected cells to uninfected cells had not occurred. No EAV-positive cells 
were observed in the EAV-inoculated Hep-2 cell line throughout the period of 
observation (Fig 2.3O, P, Q, and R). Failure to detect expression of selected non-
structural and structural viral proteins in the majority of cells of the EAV-inoculated Hela 
(ATCC), Hep-2, and L-M cell lines would suggest that EAV infection of these cell lines 
might be restricted at steps that precede viral replication, e.g. viral attachment or entry 
steps. 
In order to determine whether increase of m.o.i. can result in productive infection of 
EAV in Hela (ATCC), Hep-2, and L-M cells, various cell lines were inoculated with 
VBS53 EAV at m.o.i. of 1, 3, 10, and 50, respectively. As shown in Table 2.2, with an 
increase of m.o.i., there was a concomitant increase in residual virus in each cell line at 0 
h post inoculation. However, with the increase in m.o.i., virus yields in RK-13 (KY) cells 
had declined by 40 h post inoculation. In Hela (ATCC), Hep-2, and L-M cell lines, on the 
other hand, an increase in m.o.i. resulted in increase in virus titer by 40 h post inoculation. 
This increase probably reflected the increase amount of virus in the inoculum. Even at a 
high m.o.i. (e.g. m.o.i. = 50), virus replication in Hela (ATCC), Hep-2, and L-M cell lines 
was not as efficient as in the fully permissive RK-13 cell line. It should be pointed out 
that in EAV-inoculated RK-13, Hep-2, and L-M cells, the percentage of extracellular 
virus to the total virus present (the sum of extracellular virus and cell-associated virus) 
was greater than 80%, while it was only around 50% in Hela (ATCC) cells (Table 2.2).  
Taken collectively, these findings confirm that RK-13, BHK-21, and C2C12 cell 
lines are fully susceptible to infection with the VBS53 strain of EAV, whereas Hela 
(ATCC), Hep-2, and L-M cell lines only have limited susceptibility to infection with this 
virus.            
Enhancement of susceptibility of Hela cells to EAV infection after extended 
serial passages. In the course of this study, it was found that the Hela cell line became 
more susceptible to infection with EAV strain VBS53 after extended serial passage. Hela 
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cells which were obtained from ATCC at passage level 95 were serially passed up to 
passage 221 as described in Materials and Methods. As indicated in Fig 2.2, the virus 
infectivity titer in EAV-inoculated Hela P176 cells was 1.5-2 log10s higher than that in 
Hela P98 cells. Using the IFA test, it was found that at 24 h post inoculation, EAV-
positive cells were approximately 12% in EAV-inoculated Hela P176 cells but less than 
2% in Hela P98 cells (Fig 2.3C, D, G, and H). Moreover, spread of the virus from the 
initially infected cells to uninfected cells was observed in Hela P176 cells as reflected by 
the increase in percentage of EAV fluorescent-positive cells from 12% at 24 h post 
inoculation to approximately 19% at 72 h post inoculation (Fig 2.3G, H, I, and J). This 
was not observed in Hela P98 cells (Fig 2.3C, D, E, and F). Furthermore, it was shown 
that Hela cells between passage level 170 and 221 have higher susceptibility to EAV 
infection than Hela cells between passage level 95 and 115, which were found to be non-
susceptible to infection. Hela cells from passage 95 to 115 were referred to as Hela ‘Low’ 
cell line and Hela cells from passage 170 to 221 as Hela ‘High’ cell line. It should be 
pointed out that the morphology and growth rate of the Hela ‘High’ cell line were 
indistinguishable from those of the Hela ‘Low’ cell line. While Hela ‘High’ cell line was 
more susceptible than Hela ‘Low’ cell line to infection with EAV strain VBS53, 
susceptibility of Hela ‘High’ cell line to infection was remarkably less than that of RK-13, 
BHK-21, and C2C12 cell lines (Fig 2.2 and Fig 2.3). Also, no apparent EAV-induced 
CPE was observed during one-step growth curve experiment of EAV in the Hela ‘High’ 
cell line. 
In order to further confirm that Hela ‘High’ cell line is more susceptible than Hela 
‘Low’ cell line to EAV infection, serial passage of EAV strain VBS53 in low (P109) and 
high (P200) passage Hela cells were carried out. As shown in Table 2.3, the VBS53 strain 
of EAV was efficiently amplified in Hela ‘High’ cell line but not in Hela ‘Low’ cell line. 
Furthermore, this strain of EAV was able to initiate persistent infection in Hela ‘High’ 
cell line but not in Hela ‘Low’ cell line (see Chapter 3), confirming that Hela cells 
evolved and acquired some new characteristics during extended subculturing. 
Chromosomal analysis of Hela ‘High’ and Hela ‘Low’ cell lines. To investigate 
the possible changes between Hela ‘High’ and Hela ‘Low’ cell lines and also to rule out 
the possibility that Hela ‘High’ cell line was contaminated by other cells during the serial 
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subculturing of Hela ‘Low’ cell line, karyotypic analyses of low (P98) and high (P202) 
passage Hela cells were performed using the conventional G-banding technique. 
Analyses of 20 Giemsa-banded metaphase cells from passage 98 and passage 202 Hela 
cells are presented in Table 2.4. It has been established that Hela cells have four typical 
marker chromosomes: one copy of marker M1, one copy of marker M2, four to five 
copies of marker M3, and two copies of marker M4. Marker M1 is the der(1;3)(q10;q10), 
marker M2 is the der(3;5)(p10;q10), marker M3 is the i(5)(p10), and marker M4 consists 
of the long arm of chromosome 11 and an arm of chromosome 19 
(http://www.atcc.org/common/catalog/numSearch/numResults.cfm?atccNum=CCL-2). 
Both Hela ‘High’ and Hela ‘Low’ cell lines were observed to contain one copy of marker 
M1, one copy of marker M2, and 3-5 copies of marker M3 (Table 2.4). Marker M4 may 
be present, because a derivative chromosome consisting of the long arm of chromosome 
11 and an arm of an unidentified chromosome was observed in both Hela ‘High’ and 
Hela ‘Low’ cell lines. This unidentified chromosome resembles the long arm of 
chromosome 20 more closely than either arm of chromosome 19 [?der(11;20)(q10;q10)] 
(Table 2.4). The fact that Hela ‘High’ cells analyzed contained typical marker 
chromosomes of Hela cells confirms that they had not been contaminated with other cells. 
Karyotypic analyses also revealed some differences between Hela ‘High’ and Hela ‘Low’ 
cell lines at chromosomal level. Hela cells at passage level 202 are karyotypically more 
heterogenous than those at passage level 98. Cells at both passage levels have a 
hyperdiploid count with modal number of 81-82 chromosomes, but the hyperdiploid 
count ranges from 78 to 94 chromosomes in passage 202 cells and from 81 to 82 in 
passage 98 cells (Table 2.4). In comparing the cells at passage level 202 to those at 
passage level 98, both gain and loss of chromosomal material appear to have occurred. 
For example, cells at passage level 202 acquired the following materials: an 
isochromosome for the short arm of chromosome 2, i(2)(p10); an isochromosome for the 
long arm of chromosome 2, i(2)(q10); an additional copy of chromosome 6 (Table 2.4). 
In contrast, a derivative chromosome der(15;15)(q10;q10) which exists in passage 98 
cells was absent in passage 202 cells (Table 2.4). In summary, karyotypical analyses 
revealed that cells at both passage level 98 and passage level 202 contain typical Hela 
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marker chromosomes. However, chromosomal changes were demonstrated in Hela cells 
between passage levels 98 and 202. 
Transfection of cells with viral RNA in vitro transcribed from an infectious 
EAV cDNA clone. As has been shown, RK-13, BHK-21, and C2C12 cell lines are fully 
susceptible to infection with EAV strain VBS53, whereas Hela ‘High’, Hela ‘Low’, Hep-
2, and L-M cell lines are of limited susceptibility to infection. In order to determine 
whether restriction of EAV infection is due to an intracellular block, viral RNA in vitro 
transcribed from an infectious EAV cDNA clone pEAV2421/211EB which was derived 
from EAV strain VBS53 (Balasuriya et al., unpublished) was transfected into BHK-21, 
Hela ‘High’, Hela ‘Low’, Hep-2, and L-M cell lines. Cytopathic effects appeared and 
progressed in BHK-21 cells 72 h after transfection. No CPE was observed in the 
transfected Hela ‘High’, Hela ‘Low’, Hep-2, and L-M cell lines even at 96 h post 
transfection. However, based on the results of virus titration and IFA testing, EAV in fact 
replicated in all of the transfected cell lines (Fig 2.4 and Fig 2.5). At 24 h post 
transfection, the percentage of EAV nsp1- and N-protein positive cells was 
approximately 20% in all transfected cell lines (Fig 2.5A, C, E, G, I and data not shown). 
Consistently, at 24 h post transfection, virus yields in transfected Hela ‘High’, Hela 
‘Low’, Hep-2, and L-M cell lines were similar (approximately 1.4 × 105 pfu/ml); these 
were even higher than the corresponding titer in transfected BHK-21 cells (approximately 
2.4 × 104 pfu/ml) (Fig 2.4). This indicated that Hela ‘High’, Hela ‘Low’, Hep-2, and L-M 
cell lines support EAV replication as efficiently as the permissive BHK-21 cell line once 
the viral RNA is released into the cytoplasm. After 24 h post transfection, virus yields in 
transfected BHK-21 cells increased to markedly higher levels than those in transfected 
Hela ‘High’, Hela ‘Low’, Hep-2, and L-M cells (Fig 2.4). This probably reflects the 
inefficiency of the released virus to initiate secondary rounds of infection in Hela, Hep-2, 
and L-M cell lines. This was corroborated by the IFA results. In transfected BHK-21 cells, 
efficient spread of the infection to nontransfected cells was observed by 48 h post 
transfection (Fig 2.5A and B), followed by the development of CPE and cell death by 72 
h post transfection. In transfected Hela ‘Low’, Hep-2, and L-M cell lines, however, 
spread of the infection from transfected cells to nontransfected cells was not observed at 
48 h (Fig 2.5C and D; G and H; I and J) or even up to 72 h (data not shown) post 
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transfection. In transfected Hela ‘High’ cells, spread of infection from transfected cells to 
nontransfected cells was not apparent (Fig 2.5E and F). Differences of virus yields in 
transfected Hela ‘High’ and Hela ‘Low’ cell lines are not as marked as those in infected 
Hela ‘High’ and Hela ‘Low’ cell lines (Fig 2.4 and Fig 2.2). Taken together, the 
transfection experiments demonstrated that Hela ‘High’, Hela ‘Low’, Hep-2, and L-M 
cell lines support EAV replication when the attachment and entry steps are bypassed, 
suggesting the absence of an intracellular block later in the virus replication cycle. Thus, 
EAV infection of these cell lines appears to be restricted at the attachment or entry steps.   
Binding assays. In order to determine whether EAV infection of Hela ‘High’, Hela 
‘Low’, Hep-2, and L-M cell lines is restricted at virus attachment step, virus binding to 
these cell lines was carried out. The first approach used to study virus attachment was to 
incubate cells with EAV strain VBS53 for 1 h at 4ºC and then the virus bound to cells 
was titrated after unattached viruses were removed through extensive washing. As shown 
in Fig 2.6, Hela ‘Low’, Hela ‘High’, and Hep-2 cell lines were able to bind EAV strain 
VBS53 almost as efficiently as the fully susceptible BHK-21 cell line. The amount of 
virus attached to L-M cell line was 25% greater than that attached to BHK-21 cell line 
(Fig 2.6).  
In order to confirm the attachment of EAV to these cell lines, another approach was 
taken using flow cytometry to examine the binding of biotinylated EAV strain VBS53 to 
each cell line. RK-13 (KY), RK-13 (ATCC), BHK-21, Hela ‘Low’, Hela ‘High’, Hep-2, 
and L-M cell lines were incubated with various amounts (0, 2.5 µg, 5.0 µg, 7.5 µg, 10.0 
µg, and 12.5 µg) of biotinylated EAV, respectively. The biotinylated EAV was found to 
bind to all of the cell lines under study and the binding level (fluorescence intensity) 
increased with the increase in the amount of biotinylated virus (Fig 2.7A, C, D, E, F, G 
and H), suggesting that EAV binds to these cells in a dose-dependent manner. However, 
using the same amount of virus, binding differences were observed between these cell 
lines. RK-13 (Fig 2.7C), BHK-21 (Fig 2.7D), Hela ‘Low’ (Fig 2.7E), Hela ‘High’ (Fig 
2.7F), and Hep-2 (Fig 2.7G) cells had similar levels of virus binding (fluorescence 
intensities), while L-M cells had a significantly higher level of virus binding (Fig 2.7H). 
Since EAV strain VBS53 was amplified in BHK-21 cells, the purified virus particles used 
for biotinylation may still have contained some BHK-21 cellular proteins. In order to 
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exclude the possibility that the binding observed was caused by BHK-21 cellular proteins, 
mock-infected BHK-21 cell supernatants which underwent the same purification 
procedure as used for EAV particles was biotinylated and various amounts of biotinylated 
BHK-21 cellular proteins (0, 2.5 µg, 5.0 µg, 7.5 µg, 10.0 µg, and 12.5 µg) equivalent to 
those of biotinylated EAV were used to perform binding assays. As shown in Fig 2.7, in 
the case of each cell line, the fluorescence intensities resulting from biotinylated BHK-21 
cellular proteins were significantly lower than those caused by biotinylated EAV. 
Moreover, unlike biotinylated EAV, an increase in the amount of biotinylated BHK-21 
cellular proteins did not remarkably increase the binding levels (fluorescence intensities). 
This indicated that fluorescence intensities observed in binding experiments mainly 
resulted from the biotinylated EAV rather than from biotinylated BHK-21 cellular 
proteins. The specificity of biotinylated EAV attachment to cells was also confirmed by 
the fact that the binding of biotinylated EAV to the various cell lines was competitively 
inhibited by nonbiotinylated EAV (Fig 2.8).  
These findings demonstrate that EAV strain VBS53 attaches to Hela ‘Low’, Hela 
‘High’, Hep-2, and L-M cell lines as efficiently as it attaches to RK-13 and BHK-21 cell 
lines, suggesting that virus attachment is not the major step in restricting EAV infection 
in Hela, Hep-2, and L-M cell lines. 
Entry assay. To determine whether infection of Hela ‘Low’, Hela ‘High’, Hep-2, 
and L-M cell lines with EAV strain VBS53 is restricted at the entry step, the virus entry 
into these cell lines was investigated. In attempting to use confocal microscopy to follow 
the attachment and entry of biotinylated EAV into BHK-21, Hela, Hep-2, and L-M cell 
lines, it was difficult to clearly distinguish attached virus from internalized virus (data not 
shown). An alternative approach was taken using a modified conventional infectious 
center assay to study EAV entry. A standardized amount of cells were incubated with a 
standardized amount of EAV strain VBS53 for 1 h at 4ºC for virus attachment. After 
extensive washing to remove unbound virus, cells were incubated at 37ºC for 1 h to allow 
for virus entry. Then, cells were treated with acid glycine (pH 3.0) to inactivate non-
internalized viruses. Subsequently, serial decimal dilutions of the cells were made and 
respective dilutions were plated onto monolayers of RK-13 (KY) cells for quantitation of 
infectious foci by plaque formation. Since it has been shown that Hela ‘High’, Hela 
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‘Low’, Hep-2, and L-M cell lines support EAV replication as efficiently as BHK-21 cells 
(Fig 2.4 and Fig 2.5) once viral RNA is introduced into the cell cytoplasm, it is 
reasonable to propose that counts of infectious centers reflect the efficiency of EAV entry 
into each cell line. As shown in Fig 2.9, the efficiency of VBS53 EAV entry into Hela 
‘Low’, Hela ‘High’, Hep-2, and L-M cell lines was significantly lower than that of virus 
entry into BHK-21 cells. In addition, it was observed that the efficiency of EAV entry 
into Hela ‘High’ cell line was approximately five-fold higher than those of virus etnry 
into Hela ‘Low’, Hep-2, and L-M cell lines (Fig 2.9). These findings indicate that 
infection with EAV strain VBS53 is restricted at the entry step in Hela, Hep-2, and L-M 
cell lines.                          
 
DISCUSSION 
Neither viral molecules nor cellular factors involved in the early events (e.g. 
attachment, penetration, uncoating) of the replication cycle of EAV have been elucidated. 
One approach to studying host requirements for EAV infection is to identify cell lines 
that are defective in their ability to support viral infection. In this study, we first 
investigated the permissiveness of various cell lines to infection with EAV strain VBS53 
and then attempted to establish the mechanism that restricts infection in non-permissive 
cell lines. It had been previously demonstrated that RK-13, BHK-21, and Vero cell lines 
are permissive to EAV infection and infection of these cell lines is highly cytocidal 
(Snijder and Meulenberg 1998). In this study the cell line C2C12, derived from the 
mouse muscle, was also found to be permissive to EAV infection with the development 
of typical EAV-induced cytopathic effects. Furthermore, it was found that EAV infection 
was restricted in Hela, Hep-2, and L-M cell lines in which no apparent CPE was observed 
during one-step growth of EAV nor was efficient virus replication demonstrated. The 
mechanism that restricts EAV infection in these cell lines was further investigated. When 
attachment and entry steps are bypassed by transfection of Hela, Hep-2, and L-M cell 
lines with viral RNA, these cell lines support EAV replication as efficiently as the 
permissive BHK-21 cell line, suggesting the absence of an intracellular block later in the 
virus replication cycle. Binding studies revealed that Hela, Hep-2, and L-M cell lines 
were able to bind the VBS53 strain of EAV efficiently. Although it has been reported to 
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use confocal microscopy to study the attachment and entry of biotinylated PRRSV into 
alveolar macrophages (Nauwynck et al. 1999), it was difficult to clearly distinguish 
attached virus from internalized virus when similar approach was used to study EAV 
entry into BHK-21, Hela, Hep-2, and L-M cell lines (data not shown). Thus, a modified 
infectious center assay was used in this study to investigate EAV entry into cells. After 
one hour incubation of virus with cells at 4ºC for virus attachment, the temperature was 
increased to 37ºC to allow for virus entry. Treatment of the cell suspensions with acid 
glycine (pH 3.0) inactivates non-internalized virus and thus only the virus that has 
successfully entered the cells can initiate subsequent replication. Since Hela, Hep-2, and 
L-M cell lines support EAV replication as efficiently as BHK-21 cells, the plaque number 
should reflect the efficiency of the virus entry into these cell lines. However, since no 
apparent CPE was observed in EAV-inoculated Hela, Hep-2, and L-M cell lines, a plaque 
assay cannot be directly performed in these cell lines. Therefore, after virus entry, the 
serial decimal dilutions of suspensions of Hela, Hep-2, L-M, and BHK-21 cells are plated 
onto monolayers of RK-13 (KY) cells which are overlaid with carboxymethyl cellulose. 
With this assay, EAV infection of Hela, Hep-2, and L-M cell lines was shown to be 
restricted at the entry step. However, there are shortcomings to this entry assay. It is 
predicated on the fact that virus entering cells must first complete a single round of 
infection in BHK-21, Hela, Hep-2, and L-M cells before infecting RK-13 cells and 
forming infectious foci. Essentially, this assay does not establish virus entry directly 
although it logically can reflect the entry efficiency. Furthermore, this assay cannot 
distinguish defects at penetration step from those at the fusion/uncoating step. A more 
direct virus entry assay will be performed to confirm these findings. For example, radio-
labeled EAV particles can be used in a virus entry assay in which radioactivity of the cell 
suspensions is measured to reflect entry efficiency after non-internalized viruses are 
inactivated by acid glycine (pH 3.0) treatment.   
In EAV-inoculated RK-13, Hep-2, and L-M cells, the percentage of extracellular 
virus to the total virus present (the sum of extracellular virus and cell-associated virus) 
was greater than 80%, while it was only around 50% in Hela cells. This would suggest 
that virus release from Hela cells might be less efficient than that from RK-13, Hep-2, 
and L-M cells.  
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Another interesting finding from this study is that Hela cells become more 
susceptible to EAV infection after extended serial passage. Hela ‘Low’ cells (P95 to P115) 
are not susceptible to infection with EAV strain VBS53 whereas Hela ‘High’ cells (P170 
to P221) are partly susceptible to infection. Increased susceptibility of Hela ‘High’ cells 
to EAV infection appears to be a stable genetic trait since 51 subsequent serial passages 
(from 170 to 221) did not result in any apparent alteration in the degree of susceptibility 
of the cells to EAV (data not shown). This would suggest that in serially subculturing of 
Hela cells up to passage 170, Hela cells acquire certain characteristics which would 
appear stable. Furthermore, EAV strain VBS53 was able to initiate persistent infection in 
Hela ‘High’ cell line but not in Hela ‘Low’ cell line (see Chapter 3), confirming that the 
Hela cell line evolved during long-term serial passage. The results of karyotypic analysis 
did not support the possibility that Hela ‘High’ cell line was contaminated by other cells. 
The Hela ‘High’ cell line still contained the marker chromosomes characteristic of the 
Hela cell line. Karyotypic analysis also revealed changes between Hela ‘Low’ and Hela 
‘High’ cell lines at chromosomal level. However, the molecular changes that are 
responsible for susceptibility differences of Hela ‘Low’ and Hela ‘High’ cell lines to 
EAV infection are not yet determined. Based on the following i) virus yields in EAV-
inoculated Hela ‘High’ cell line are significantly lower than those in EAV-inoculated 
BHK-21, RK-13, and C2C12 cell lines, ii) less than 100% of Hela ‘High’ cells are 
infected with EAV, and iii) the efficiency of EAV entry into Hela ‘High’ cell line is only 
about 10% of that with respect to BHK-21 cell line, it is postulated that Hela ‘High’ cell 
line comprises a heterogenous population of cells of which only a certain percentage of 
cells are fully permissive to EAV infection. 
The evolution of cells and emergence of cell diversity is not an unusual event. 
Normal tissues and cultured cells can exhibit a degree of heterogeneity (Ingram et al. 
1985; Schafer et al. 1987). It has been reported that BHK(TK-) cells on subculture 
spontaneously give rise to cells that are highly resistant to herpes simplex virus type-1 
infection (Roller and Roizman 1994). Clonal selections of cell lines resistant to Theiler’s 
murine encephalomyelitis virus or herpes simplex virus types 1 and 2 infections have 
been reported as well (Hertzler et al. 2000; Roller and Herold 1997). The extent of 
cellular heterogeneity is greatly increased in tumors and tumor cell heterogeneity appears 
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to result from an enhanced genetic instability of transformed cells (Cifone and Fidler 
1981; Crouch et al. 1987; Fidler et al. 1981; Lichtner et al. 1987; Nicolson 1987a, 1987b). 
Hela cells were originally derived from a cervical adenocarcinoma and perhaps retain the 
potential to evolve if they undergo extended serial passage. Cell evolution has also been 
frequently observed in cell cultures persistently infected with a virus such as mouse L cell 
evolution during persistent infection with reovirus (Ahmed et al. 1981), BHK-21 cell 
evolution during persistent infection with foot-and-mouth disease virus (de la Torre et al. 
1988a; 1989), and Hela cell and human neuroblastoma cell evolution during persistent 
infection with poliovirus (Kaplan et al. 1989; Pavio et al. 2000).       
In recent years it has become evident that viral attachment to and entry into the cell 
are frequently more complex than previously thought. A number of viruses have been 
shown to enter cells via receptor complexes rather than by an individual cell surface 
molecule. For example, human immunodeficiency virus attaches to CD4 molecule 
(Maddon et al. 1986) but requires the presence of chemokine receptors as its coreceptor 
for virus entry (Choe et al. 1996; Deng et al. 1996; Doranz et al. 1996; Dragic  et al. 1996; 
Feng et al. 1996). Adenovirus subgroups A, C, D, E, and F bind to molecule CAR 
(coxsackievirus and adenovirus receptor) (Roelvink et al. 1998) and adenovirus types 2 
and 5 bind to heparan sulfate glycosaminoglycans (Dechecchi et al. 2001), however, 
these binding molecules are insufficient for adenovirus entry which needs the 
involvement of coreceptor av–integrins (Wickham et al. 1993). Coxsackievirus A21 
(CAV21) has been shown to bind to both decay-accelerating factor (DAF) and 
intercellular adhesion molecule 1 (ICAM-1) (Shafren et al. 1997). However, DAF just 
functions as a low-affinity attachment receptor and does not initiate a productive 
infection; high-affinity binding molecule ICAM-1 is required for virus entry into cells 
(Shafren et al. 1997). Similarly, PRRSV, another arterivirus, has been shown to attach to 
heparan sulfate and porcine sialoadhesin on porcine macrophages (Delputte et al. 2002; 
Vanderheijden et al. 2003). Heparan sulfate alone is sufficient to mediate PRRSV 
attachment but not entry, whereas sialoadhesin alone is sufficient for both virus 
attachment and virus entry (Delputte et al. 2005).          
Cell receptors mediating EAV attachment and entry have not been identified. One 
previous study suggested that a heparin-like molecule on the surface of RK-13 cells 
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might serve as cell receptor for EAV (Asagoe et al. 1997). However, heparinase 
treatment of RK-13 cells could not completely block EAV infection (Asagoe et al. 1997), 
implying that other molecules on the cell might serve as EAV receptors as well. Data 
from this study indicate that Hela, Hep-2, and L-M cell lines are able to bind EAV strain 
VBS53 efficiently but cannot provide mechanism for virus entry. This would suggest that 
cell receptor(s) for attachment of EAV strain VBS53 are present on the surface of these 
cell lines, but these attachment receptor(s) are not sufficient to enable efficient virus entry. 
Additional cellular factor(s) are therefore likely to be required for entry of EAV strain 
VBS53 and these cellular factor(s) are probably absent or expressed at very low levels on 
Hela ‘Low’, Hep-2, and L-M cell lines. Compared to Hela ‘Low’ cell line, Hela ‘High’ 
cell line is more susceptible to infection with EAV strain VBS53, and this increased 
susceptibility appears to be due to increased virus entry efficiency. It would appear that 
some Hela ‘High’ cells probably have acquired the ability to express the cellular factor(s) 
which are necessary for EAV entry. RK-13, BHK-21, and C2C12 cell lines being fully 
susceptible to EAV infection presumably constitutively express the cellular factor(s) 
essential for both EAV attachment and entry. The availability of cell lines with varying 
susceptibility to EAV infection should be useful for studying post-attachment events 
involved in EAV entry. 
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Table 2.1 Source and passage level of cell lines used in study 
 
Cell line Species Tissue Morphology Source 
BHK-21 (ATCC CCL-10)  Hamster Kidney Fibroblast Dr. George Allen, University of Kentucky  
RK-13 (ATCC CCL-37) 
(passage 192-204) Rabbit Kidney Epithelial Dr. William McCollum, University of Kentucky 
RK-13 (KY) 
(passage 397-409) Rabbit Kidney Epithelial Dr. William McCollum, University of Kentucky 
C2C12 (ATCC CRL-1772)  Mouse Muscle, myoblast Fibroblast Dr. Carole Moncman, University of Kentucky 
Hela ‘Low’ (ATCC CCL-2) 
(passage 95-115) 
Human Cervical Carcinoma Epithelial American Type Culture Collection 
Hela ‘High’  
(passage 170-221) Human Cervical Carcinoma Epithelial Derived from Hela ‘Low’ cell line by the author 
Hep-2 (ATCC CCL-23)  Human Epidermoid Laryngal Carcinoma Epithelial Dr. William McCollum, University of Kentucky 
L-M (ATCC CCL-1.2) Mouse Connective tissue Fibroblast Dr. George Allen, University of Kentucky 
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Table 2.2 Effect of multiplicity of infection on outcome of infection of selected cell 
lines with EAV strain VBS53 
          
Virus Titer (pfu/ml) Virus Titer (pfu/ml) 
(0 h p.i.) (40 h p.i.) cells and 
m.o.ia cell-associated                                                                     
virusb 
extracellular                                                                                                                                      
virus 
cell-associated
virus 
extracellular                                                                                                                                              
virus 
RK-13 (KY) 
P406     
   m.o.i. = 1 1.3×101  1.1×102  1.5×106  6.1×107 (97.6)c 
   m.o.i. = 3 5.0×101 3.0×102  2.1×106 4.5×107 (95.5) 
   m.o.i. = 10 1.4×102 1.6×103  5.2×105 3.0×107 (98.3) 
   m.o.i. = 50 1.8×103 5.0×104  4.4×105 1.7×107 (97.5) 
Hela P100     
   m.o.i. = 1 3.2×101 1.6×102  1.4×103 1.7×103 (54.8) 
   m.o.i. = 3 8.0×101 6.1×102  6.3×103 7.6×103 (54.7) 
   m.o.i. = 10 5.2×102 3.1×103  2.4×104 2.3×104 (48.9) 
   m.o.i. = 50 2.2×103 3.8×104  6.5×104 7.8×104 (54.5) 
Hep-2 P454     
   m.o.i. = 1 6.7×101 1.8×102  1.6×102 6.6×102 (80.5) 
   m.o.i. = 3 1.4×102 3.3×102  8.6×102 3.2×103 (78.8) 
   m.o.i. = 10 8.7×102 1.7×104  2.3×103 1.1×104 (82.7) 
   m.o.i. = 50 3.5×103 6.7×104  8.0×103 3.9×104 (83.0) 
L-M P305     
   m.o.i. = 1 7.0×100 2.7×102  6.9×101 3.6×103 (98.1) 
   m.o.i. = 3 2.7×101 1.9×102  3.8×102 1.7×104 (97.8) 
   m.o.i. = 10 1.4×102 1.2×103  1.8×103 8.3×104 (97.9) 
   m.o.i. = 50 2.2×103 4.3×104  3.6×103 3.6×105 (99.0) 
     
a Various cells were inoculated with EAV strain VBS53 at an m.o.i. of 1, 3, 10, 50 at 37ºC for 
1 h. The inoculum was removed and the cells were washed three times with PBS. The cells 
were supplemented with 10 ml culture medium and incubated at 37ºC. This was designated 
time zero of infection. At 0 h and 40 h after infection, the extracellular virus (the supernatants) 
and cell-associated virus (the cell lysate) were harvested and titrated on RK-13 (KY) cells. 
b For harvesting cell-associated viruses, the cells were resuspended in 10 ml culture medium, 
sonicated three times (20V, 15 sec/time), and centrifuged at 1900 rpm for 10 min to remove 
cell debris. 
c The numbers in parentheses represent percentage of extracellular virus titer to the total virus 
titer. (total virus = extracellular virus + cell-associated virus)    
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Table 2.3 The outcome of serial passaging of EAV strain VBS53  
in Hela ‘Low’ and Hela ‘High’ cell lines* 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* Hela ‘Low’ (P109) and Hela ‘High’ (P200) cell lines were inoculated with EAV strain 
VBS53 at an m.o.i of 3 (using an inoculum of 0.3 ml). Mock-inoculated Hela cells were 
included. The same volume of EAV infective inoculum was added to 10% EMEM 
medium without cells and included as an additional control. After 1 h of incubation at 
37ºC, no washing, 10 ml medium was added to each culture. After 4 days of incubation at 
37ºC, the supernatant (P1) (10 ml) was harvested, centrifuged at 1900 rpm for 10 min to 
remove cell debris. The clarified supernatant was then filtered through a 0.45 µm 
membrane to ensure removal of cell debris. Filtered supernatant (0.3 ml) from mock-
inoculated Hela cells (P1 mock-Hela), EAV-inoculated Hela cells (P1 EAV-Hela), and 
EAV-inoculated medium (P1 EAV-medium) were added to uninfected Hela cell cultures 
(P110 or P201) or medium without cells, respectively, and incubated at 37ºC for 1 h. A 
10 ml volume of medium was added and the cultures incubated for 4 days at 37ºC to 
provide ‘P2 mock-Hela’, 'P2 EAV-Hela', and 'P2 EAV-medium', respectively. The same 
procedure was followed in attempting to amplify the virus up to P7. 
 
 
 
 
 
 
EAV titer (pfu/ml) Hela ‘Low’ 
P109 Mock-Hela EAV-Hela EAV-medium 
1 h p.i. 
P1 
P2 
P3 
P4 
P5 
P6 
P7 
0 
0 
0 
0 
0 
0 
0 
0 
1.55 × 105 
9.4 × 102 
0.5 
0 
0 
0 
0 
0 
1.12 ×105 
0 
0 
0 
0 
0 
0 
0 
EAV titer (pfu/ml) Hela ‘High’ 
P200 Mock-Hela EAV-Hela EAV-medium 
1 h p.i. 
P1 
P2 
P3 
P4 
P5 
P6 
P7 
0 
0 
0 
0 
0 
0 
0 
0 
1.14 × 105 
2.05 × 105 
1.65 × 104 
1.70 × 104 
3.5 × 105 
1.5 × 106 
7.2 × 106 
2.1 × 107 
1.12 × 105 
0 
0 
0 
0 
0 
0 
0 
  76 
Table 2.4 The results of karyotypic analyses of Hela ‘Low’ (P98) and Hela ‘High’ (P202) 
cell lines using G-banding technique 
 
Hela ‘Low’ (P98) 
81-82, XXX, +der(1;3)(q10;q10), der(1;9)(p10;q10), 
add(2)(q37), add(3)(q12)×1-2, +der(3;5)(p10;q10), 
add(5)(p10), +i(5)(p10)×3-5, +add(7)(p11.2), +9, +i(9)(p10), 
+10, der(10)t(10;?)(p13;?), ?der(11;20)(q10;q10), 
+der(12)t(3;12)(q21;q21.2), -13, +der(15;15)(q10;q10), +17, 
add(19)(p13.1), +20, add(22)(q13.3), +1-4mar[cp] 
chromosome pattern.  
Hela ‘High’ (P202) 
78-94, XXX, +der(1;3)(q10;q10), der(1;9)(p10;q10), 
add(2)(q37), i(2)(p10), i(2)(q10), add(3)(q12)×1-2, 
+der(3;5)(p10;q10), add(5)(p10), +i(5)(p10)×3-5, +6, 
+add(7)(p11.2), +9, +i(9)(p10), +10, 
der(10)t(10;?)(p13;?), ?der(11;20)(q10;q10), 
+der(12)t(3;12)(q21;q21.2), +17,   add(19)(p13.1), +20, 
add(22)(q13.3), +1-14mar, 0-4dmin[cp] chromosome 
pattern. 
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Fig 2.1 Passage history of the original Bucyrus virus to produce the ATCC and MLV 
vaccine strains of EAV. The EAV strain VBS53 that was used in this study is highlighted. 
 
ORIGINAL 
ISOLATE (1953) 
EAV ATCC STRAIN 
HISOTRY 
Bucyrus strain of EAV 
from the lung of an 
aborted fetus in Ohio, 
1953 
Passaged in horses 15 times 
(H15). Highly virulent in horses. 
[The EAV isolated from the 
pregnant mare (H9 EAV) was 
further passaged in horses for 6 
times. Totally 15 times in 
horses.] 
Pleural fluid of 15th horse. Also 
called Pleural Fluid of Virulent 
Bucyrus Strain (VBS53) 
Submitted to ATCC and ATCC 
made its stock by passaging in 
RK-13 cells for unknown times 
Virulent EAV ATCC strain 
(ATCC VR-796) 
MLV VACCINE 
HISTORY 
Passaged in horses 9 times 
(H9). Highly virulent in 
horses. 
[The EAV strain isolated in 
1953 was passaged in horses 8 
times (H8). H8 EAV was used 
to inoculate a pregnant mare 
The EAV from aborted fetal 
lung tissue 
Passaged in Horse Kidney 
(HK) cells 131 times and in 
Rabbit Kidney (RK-13) 
cells 111 times 
Passaged in Equine 
Dermis (ED) cells 24 
times 
ARVAC® MLV vaccine 
266 serial passages in 
cell culture (HK 131/RK 
111/ED 24) 
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Fig 2.2 Growth of the VBS53 strain of EAV in eight cell lines. Subconfluent monolayers 
of BHK-21, RK-13 (ATCC), RK-13 (KY), Hela ‘High’, Hela ‘Low’, Hep-2, and L-M 
cell lines were inoculated with EAV strain VBS53 at an m.o.i. of 3 at 37°C for 1 h and 
then washed three times with PBS to remove unbound virus. The cultures were then 
supplemented with 10 ml EMEM medium and incubated at 37°C to allow virus growth. 
This was designated time zero with respect to infection. At 0, 12, 24, 36, 48, 60, and 72 h 
p.i., both the supernatants and cells were harvested and sonicated three times (20V, 15 
sec/time) to fully disrupt the cells and release virus particles. Virus (supernatants and 
cells together) was titrated by plaque assay on RK-13 (KY) cells as previously described 
(McCollum et al. 1962). These results were confirmed in three separate experiments. 
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Fig 2.3 Indirect immunofluorescence assays on cells infected with the VBS53 strain of 
EAV. At 24 and 72 h post infection, EAV-infected cells grown in 8-chamber slides were 
fixed with cold acetone for 10 min, and then washed three times with PBS plus 10mM 
glycine. Slides were incubated with MAb 3E2 against EAV nucleocapsid protein (A, C, 
G, K, O for 24 h p.i., and E, I, M, Q for 72 h p.i.) or MAb 12A4 against EAV NSP1 (B, D, 
H, L, P for 24 h p.i., and F, J, N, R for 72 h p.i.) followed by FITC-conjugated goat 
antimouse immunoglobulin. The cells were counterstained by Evans blue. The images 
were recorded with a LEICA confocal microscope.       
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Fig 2.4 Virus yield in cells transfected with viral RNA in vitro transcribed from an 
infectious EAV cDNA clone pEAV2421/211EB. BHK-21, Hela ‘Low’, Hela ‘High’, 
Hep-2, and L-M cell lines were transfected with in vitro-transcribed viral RNA by means 
of electroporation (see Materials and Methods). At 12, 24, 48, 72, and 96 h post 
transfection, the supernatants were harvested and titrated by plaque assay on RK-13 (KY) 
cells.    
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Fig 2.5 Indirect immunofluorescence assays on cells transfected with in vitro-transcribed viral RNA. At 24 and 48 h post transfection, 
viral RNA-transfected cells grown in 8-chamber slides were fixed with cold acetone for 10 min, and then washed three times with 
PBS plus 10mM glycine. Slides were incubated with MAb 12A4 against EAV NSP1 (A-J) or MAb 3E2 against EAV nucleocapsid 
protein (data not shown) followed by FITC-conjugated goat antimouse immunoglobulin. The cells were counterstained by Evans blue. 
The images were recorded with a LEICA confocal microscope.      
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Fig 2.6 Binding of the VBS53 strain of EAV to various cell lines. Subconfluent 
monolayers of BHK-21, Hela ‘High’, Hela ‘Low’, Hep-2, and L-M cell lines were 
trypsinized and resuspended in culture medium at a concentration of 2 x 106 cells per ml, 
and cooled down at 4ºC for at least 30 min. For each cell line, 2 x 106 PFU of EAV (in 
200 µl) were added to duplicates of 1 x 106 cells (500 µl) and maintained at 4ºC for 1 h. 
The cells were washed three times with cold PBS to remove unbound virus and then 
resuspended in 1 ml of cold culture medium. The cell suspensions were subjected to three 
cycles of freezing and thawing to release attached viruses, and centrifuged for 10 min at 
1900 rpm at 4ºC. The clarified supernatants were titrated by plaque assay on RK-13 (KY) 
cells. The amount of virus attached to Hela ‘High’, Hela ‘Low’, Hep-2, and L-M cells 
was calculated as percentage of the virus attached to BHK-21 cells. Mean ± Standard 
Deviation is shown. 
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Fig 2.7 Binding of biotinylated EAV strain VBS53 to various cell lines as determined by 
flow cytometry. Suspensions of RK-13 (KY), RK-13 (ATCC), BHK-21, Hela ‘High’, 
Hela ‘Low’, Hep-2, and L-M cells were inoculated with different amounts (0, 2.5 µg, 5.0 
µg, 7.5 µg, 10.0 µg, and 12.5 µg) of biotinylated EAV or biotinylated BHK-21 cellular 
proteins (control). Following 1 h of adsorption at 4ºC, cells were washed with PBSA and 
incubated with streptavidin-fluorescein conjugate for 1 h at 4ºC. The cells were washed 
and fluorescence intensity of each sample was analyzed by flow cytometry. In the case of 
each sample, 30,000 cells were counted and dead cells were excluded through propidium 
iodide staining. Binding of biotinylated EAV or biotinylated BHK-21 cellular proteins to 
RK-13 (KY) cells were shown in (A) and (B), respectively. The binding of biotinylated 
EAV or biotinylated BHK-21 cellular proteins to other cell lines were converted to 
another format as shown in (C-H): RK-13 (ATCC) (C), BHK-21 (D), Hela ‘Low’ (E), 
Hela ‘High’ (F), Hep-2 (G), and L-M (H). In (C-H), Mean ± Standard Deviation is shown. 
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Fig 2.8 Binding of biotinylated EAV strain VBS53 to various cell lines was competitively 
inhibited by nonbiotinylated EAV. Suspensions of RK-13 (KY), Hela ‘High’, Hela ‘Low’, 
Hep-2, and L-M cells were first incubated at 4ºC for 1 h with different amounts of 
nonbiotinylated EAV (0, 1 × 108 pfu, 2.5 × 108 pfu, 5 × 108 pfu, 7.5 × 108 pfu) and then 
incubated with 1 × 108 pfu biotinylated EAV for another 1 h at 4ºC. The amount of 
biotinylated virus attached to cells was determined by flow cytometry as described above.  
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Fig 2.9 Entry of EAV strain VBS53 into various cell lines. Subconfluent monolayers of 
BHK-21, Hela ‘High’, Hela ‘Low’, Hep-2, and L-M cells were trypsinized and 
resuspended in culture medium at a concentration of 2 x 106 cells per ml, and cooled 
down at 4ºC for at least 30 min. For each cell line, 2 x 106 PFU of EAV (in 200 µl) were 
added to duplicates of 1 x 106 cells (500 µl) and maintained at 4ºC for 1 h to allow for 
virus attachment. The cells were washed three times with cold PBS to remove unbound 
virus and then resuspended in 1 ml of pre-warmed culture medium and incubated at 37ºC 
for 1 h with agitation to allow for virus entry. After 1 h of incubation at 37ºC, the cells 
were treated with 1.0 ml acid glycine (pH 3.0) to inactivate non-internalized virus. Then 
cells were washed four times with PBS and resuspended in 1 ml of culture medium. The 
last wash was saved for titration. Serial decimal dilutions of the cell suspensions were 
made in culture medium and plated onto monolayers of RK-13 (KY) cells. Inoculated 
cultures were incubated at 37ºC for 1 h. Cell monolayers were overlaid with culture 
medium containing 0.75% carboxymethyl cellulose and incubated at 37ºC for 4 days. 
Infectious centers were counted after staining of plates with 10% formalin buffered 
crystal violet. Efficiency of virus entry into Hela ‘High’, Hela ‘Low’, Hep-2, and L-M 
cells was calculated as a ratio of infectious center counts in each cell line being evaluated 
to infectious center counts in BHK-21 cells. Mean ± Standard Deviation is shown.   
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Chapter Three 
Establishment and Characterization of Persistent Equine Arteritis 
 Virus Infection in Hela Cells 
 
ABSTRACT 
It has been previously demonstrated that BHK-21, RK-13, and C2C12 cell lines are 
fully susceptible, Hela ‘High’ cell line (P170-221) is partly susceptible, and Hep-2, L-M, 
and Hela ‘Low’ (P95-115) cell lines are non-susceptible, to infection with the VBS53 
strain of EAV (Chapter 2). Furthermore, it was shown that the VBS53 strain of EAV was 
able to establish persistent infection in Hela ‘High’ cell line, but unable to establish 
persistent infection in either BHK-21, RK-13, or C2C12 cell lines in which EAV 
infection was highly cytolytic, with all the cells dead by 48 h post infection. Persistent 
infection also could not be established in Hep-2, L-M, or Hela ‘Low’ cell lines in which 
virus could no longer be detected after two passages. Similarly, transfection with in vitro-
transcribed viral RNA was capable of initiating persistent infection only in the Hela 
‘High’ cell line but not in BHK-21, Hep-2, L-M, or the Hela ‘Low’ cell lines. Persistently 
infected Hela ‘High’ cell line had the following characteristics: i) The persistently 
infected cells had been subcultured and maintained for over 3 years. ii) Persistently 
infected cell monolayers underwent recurrent episodes of partial destruction and 
subsequent recovery over the period under study. iii) Over the course of the study, the 
percentage of EAV fluorescent-positive cells in the persistently infected monolayers 
varied from 1% to 37%. In most passage levels, the percentage of virus-positive cells 
ranged between 15% and 25%. iv) Infectious virus was continuously produced 
throughout the course of persistent infection. Virus infectivity titers varied from 102 to 
106 plaque forming units (pfu) per ml but in most passage levels tested, the titer ranged 
from 104 to 106 pfu per ml. In all cases, the yield of cell-associated virus was comparable 
to that of extracellular virus. v) After cryopreservation for 3 years in liquid nitrogen, 
revived cultures still could produce infectious virus. Virus infectivity titers were similar 
before and after freezing of the cell line. vi) An attempt to clone a single cell that could 
continuously produce infectious virus was unsuccessful. vii) Addition of EAV 
neutralizing antibody-positive equine serum to the medium in which the persistently 
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infected cell line was cultivated resulted in the elimination of the persistent infection. The 
viruses recovered from the 35th passage (Hela-EAVP35) and the 80th passage (Hela-
EAVP80) of the persistently infected Hela ‘High’ cell line grew more efficiently than the 
VBS53 strain of EAV in Hela ‘Low’ and Hela ‘High’ cells. EAV strains VBS53, Hela-
EAVP35, and Hela-EAVP80 grew with the similar efficiency in BHK-21 cells. No 
significant differences were observed in the growth of EAV strains VBS53, Hela-
EAVP35, and Hela-EAVP80 in Hep-2 and L-M cell lines, respectively. Notwithstanding 
the fact that the VBS53 strain of EAV can only establish persistent infection in the Hela 
‘High’ cell line but not in the Hela ‘Low’ cell line, Hela-EAVP35 and Hela-EAVP80 
virus strains were able to establish persistent infection in both Hela ‘High’ and Hela 
‘Low’ cell lines. Neither of these strains, however, was able to establish persistent 
infection in BHK-21, Hep-2, and L-M cell lines. Entire genome sequencing of EAV 
strains VBS53, Hela-EAVP35, and Hela-EAVP80 revealed nucleotide and deduced 
amino acid changes during the course of persistent infection. The entire genome of each 
of these three EAV strains was 12,704 nucleotide (nt) in length. The nucleotide 
differences between EAV strains VBS53 and Hela-EAVP35, VBS53 and Hela-EAVP80, 
Hela-EAVP35 and Hela-EAVP80 totaled 26 nt, 34 nt, and 16 nt, respectively. The 
replicase polyprotein and the structural proteins had 15 aa, 17 aa, and 6 aa differences, 
respectively, between EAV strains VBS53 and Hela-EAVP35, VBS53 and Hela-
EAVP80, and Hela-EAVP35 and Hela-EAVP80. The majority of deduced amino acid 
changes involved EAV structural proteins E, GP2b, GP3-5 encoded by ORFs2a, 2b, and 
3-5, respectively. In conclusion, an in vitro model of EAV persistence in cell culture was 
established for the first time. Properties of the model system were characterized. The 
strain of EAV that evolved during establishment and maintenance of persistent infection 
in Hela cells was phenotypically and genetically analyzed.   
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INTRODUCTION 
Equine arteritis virus (EAV) is the prototype member of the family Arteriviridae in 
the order Nidovirales (Cavanagh 1997). The genome of equine arteritis virus is a single-
stranded, positive-sense RNA molecule of 12.7 kb, which includes nine functional open 
reading frames (ORFs) (Snijder and Meulenberg 1998; Snijder et al. 1999). The first two 
ORFs (1a and 1b) are located at the 5’-terminal three-quarters of the genome and encode 
viral replicases; the other seven ORFs (2a, 2b, and 3-7) are located at the 3’ one-quarter 
of the genome and encode structural proteins E, GP2b (Gs), GP3, GP4, GP5 (GL), M, and 
N, respectively (den Boon et al. 1991; Snijder et al. 1999). The ORF1a and ORF1b are 
translated from the genomic RNA into two replicase polyproteins which are 
proteolytically processed into 12 nonstructural proteins (nsp1-12) and multiple 
processing intermediates required for viral replication and transcription (den Boon et al. 
1991; Snijder and Meulenberg 1998; Ziebuhr et al. 2000). The structural proteins are 
expressed from 5’- and 3’-coterminal nested set of six subgenomic mRNAs (de Vries et 
al. 1990).  
EAV is the causative agent of equine viral arteritis (EVA), a globally distributed 
infectious disease of equids. Most EAV infections are subclinical in nature; occasionally 
infection results in respiratory or systemic illness, abortion/stillbirths in pregnant mares, 
and interstitial pneumonia, enteritis, or pneumonoenteritis in young foals (Glaser et al. 
1997; Timoney and McCollum 1993; 1996). After natural infection with EAV, up to 30% 
to 70% of stallions can subsequently become carriers and these constantly shed the virus 
in their semen (Timoney and McCollum 1993). Persistently infected stallions are the 
principal reservoir of EAV and are responsible for perpetuation and dissemination of 
EAV in equine populations (Balasuriya and MacLachlan 2004c; Timoney and McCollum 
1993). Carrier stallions are also thought to be a significant natural source of genetic and 
phenotypic diversity of EAV (Balasuriya et al. 1999a; 2004a; Hedges et al. 1999a). There 
is convincing evidence that establishment and maintenance of the carrier state in the 
stallion is testosterone-dependent with the detailed mechanism as yet unknown (Little et 
al. 1991; McCollum et al. 1994). What host factor(s) (except testosterone) or viral 
factor(s) contribute to the establishment and maintenance of persistent EAV infection in 
stallions remain to be determined. Geographically and temporally distinct EAV isolates 
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can vary markedly in the incidence and severity of the clinical disease they induce and in 
their abortigenic potentials (Balasuriya et al. 1998; 1999b; Balasuriya and MacLachlan 
2004c; McCollum and Timoney 1999; Timoney and McCollum 1993). The genetic 
determinants of virulence have not yet been defined for EAV. 
The ability of many viruses to establish persistent infection in cell culture has been 
documented. Such infections have been used to study virus-host cell interactions. Also, 
they are a useful tool for investigating virus and cell evolution (Ahmed et al. 1981; 
Colbere-Garapin et al. 1989; de la Torre et al. 1988a; 1989; Kaplan et al. 1989). 
Persistent infection in cell culture could possibly serve as a model system for elucidating 
mechanisms of viral persistence in vivo. In fact, genetic and phenotypic characterizations 
of virus mutants and host cell mutants during persistent infection have already greatly 
helped in the study of virus-receptor interactions (Borzakian et al. 1993; Calvez et al. 
1993; Colbere-Garapin et al. 1989; de la Torre et al. 1989; Duncan et al. 1998; Gosselin 
et al. 2003; Pavio et al. 1996; 2000; Pelletier et al. 1991; 1998a). Such studies have also 
served to define virus virulence gene (Couderc et al. 1993; 1994; Diez et al. 1990a; 
1990b), and to identify viral and host cell determinants involved in persistent viral 
infection (Benton et al. 1996; Borzakian et al. 1993; Calvez et al. 1993; Chen et al. 1996; 
Desforges et al. 2001; Dryga et al. 1997; Duncan et al. 1998; Okada et al. 1987; Pelletier 
et al. 1998a).  
EAV infection is usually highly cytolytic in cell culture, e.g. BHK-21, RK-13, and 
C2C12 (Snijder and Meulenberg 1998 and Chapter 2). Recently, it has been found that a 
Hela ‘High’ cell line (P170-221) is partly susceptible to infection with the VBS53 strain 
of EAV, whereas Hep-2, L-M, and Hela ‘Low’ (P95-115) cell lines are non-susceptible to 
this virus strain (Chapter 2). The present study further demonstrated that the VBS53 
strain of EAV was able to establish persistent infection in Hela ‘High’ cell line but not in 
Hela ‘Low’, Hep-2, or L-M cell lines. Properties of the persistent EAV infection in Hela 
‘High’ cell line were characterized. Genetic and phenotypic variations in the virus during 
the course of persistent infection were investigated. The mechanism and significance of 
persistent EAV infection in Hela cells are discussed.  
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MATERIALS AND METHODS 
Cells and viruses. The origin and conditions for the cultivation of BHK-21, RK-13, 
C2C12, Hep-2, L-M, Hela ‘Low’, and Hela ‘High’ cell lines have been described in 
Chapter 2. The origin and passage history of the VBS53 strain of EAV have been 
described in Chapter 2. The VBS53 strain of EAV was propagated twice in BHK-21 cells 
to produce virus stocks which were used in an attempt to establish persistent infection in 
vitro. Hela-EAVP35 and Hela-EAVP80 are the virus strains obtained from the 35th and 
80th passage of the persistently infected Hela ‘High’ cell line, respectively. 
Antibodies. The development and characterization of monoclonal antibodies to the 
nucleocapsid protein (N; MAb 3E2) and the non-structural protein 1 (nsp1; MAb 12A4) 
of EAV have been previously described (MacLachlan et al. 1998; Wagner et al. 2003). 
Both MAbs 3E2 and 12A4 were kindly provided by Drs. Udeni Balasuriya and James 
MacLachlan at University of California, Davis. 
Cell counting and cell viability. Before serially passaging cells, cell culture 
supernatants containing detached cells were transferred to a tube. Cells were trypsinized 
and the detached cells pooled together to provide a cell suspension. A 100 µl volume of 
cell suspension was mixed with 100 µl of 0.4% trypan blue and loaded onto a 
hemocytometer. Dead cells are stained by trypan blue. Cells were counted and cell 
viability was calculated.    
Attempt to establish persistent EAV infection. Subconfluent monolayers of 
BHK-21, RK-13 (KY), C2C12, Hela ‘High’ (P171), Hela ‘Low’ (P98), Hep-2, and L-M 
cell lines grown in T-25 flasks were inoculated with the VBS53 strain of EAV at an m.o.i. 
of 3. Following one-hour absorption at 37ºC, the cells were washed three times with PBS 
and 10 ml of fresh culture medium was added. Inoculated cultures were incubated at 37ºC. 
Cultures were microscopically monitored daily for the development of cytopathic effect 
and subcultured once every four days (1:4 split) if any cells survived. Extracellular and 
cell-associated viruses were harvested separately, and titrated by routine plaque assay in 
the RK-13 (KY) cell line. Expression of the viral nucleocapsid (N) protein and non-
structural protein 1 (NSP1) was examined using an indirect immunofluorescence assay. 
Attempts to establish persistent infection in Hela ‘Low’ (P98), Hep-2, and L-M cell lines 
with EAV strain VBS53 was repeated once. The attempt to establish persistent infection 
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in the Hela ‘High’ (P196) cell line was repeated twice. Attempts to establish persistent 
infection in BHK-21, Hela ‘Low’ (P98), Hela ‘High’ (P196), Hep-2, and L-M cell lines 
with Hela-EAVP35 or Hela-EAVP80 viruses were performed in accordance with 
protocols described above.    
RT-PCR detection of viral RNA. The aim of the study was to establish persistent 
infection in the Hela ‘High’ (P171) and Hela ‘Low’ (P98) cell lines with EAV strain 
VBS53. At selected cell culture passages, supernatants and cells were harvested and 
sonicated three times (20V, 15 sec/time) to fully disrupt the cells and release virus 
particles. Cell debris was removed by centrifugation and 140 µl of clarified supernatants 
were used for viral RNA extraction using the QIAamp viral RNA mini kit (Qiagen). The 
primers used for one-step RT-PCR were based on amplification of a conserved region of 
ORF1b (Gilbert et al. 1997): forward primer 9299P (nt position 9299-9318: 
5’CCTGAGACACTGAGTCGCGT3’) and reverse primer 9464N (nt position 9483-9464: 
5’CCTGATGCCACATGGAATGA3’). A 10 µl volume of extracted RNA was used for 
the one-step RT-PCR in a total volume of 50 µl following the instructions of the one-step 
RT-PCR kit (Qiagen). The reaction mixtures were incubated at 50ºC for 30 min and at 
95ºC for 15 min and then were cycled for 40 times as follows: 94ºC for 30 sec, 53ºC for 
30 sec, and 72ºC for 1 min. The reaction was terminated by a single extension step at 
72ºC for 10 min. A 10 µl volume of the one-step RT-PCR products were analyzed on a 
1.8% agarose gel. The predicted PCR products are 185 bp long. After addition of anti-
EAV equine serum to the medium of persistently infected cells, RT-PCR analysis of viral 
RNA at each cell passage level was carried out in accordance with the protocols 
previously described.    
Transfection of cells with in vitro transcribed EAV RNA. In vitro transcription 
of viral RNA from the full-length infectious EAV cDNA clone pEAV2421/211EB and 
transfection of BHK-21, Hela ‘High’ (P200), Hela ‘Low’ (P102), Hep-2, and L-M cell 
lines with viral RNA have been described previously (Chapter 2). After transfection, the 
cultures were microscopically monitored daily for the development of cytopathic effect 
and subcultured once every four days (1:4 split) if any cells survived. Extracellular 
viruses were harvested and titrated by routine plaque assay in RK-13 (KY) cells. 
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Expression of the viral nucleocapsid (N) protein and non-structural protein 1 (NSP1) 
were determined using an indirect immunofluorescence assay. 
Cloning of cells. Subconfluent monolayers of the 26th passage of the persistently 
infected Hela ‘High’ cell line initiated with the VBS53 strain of EAV were washed, 
trypisinized, and resuspended in fresh culture medium. After counting, the cells were 
diluted to a concentration of 10 cells per ml and then distributed into two 96-well plates 
in the amount of 0.1 ml per well. Plates were incubated at 37ºC in the presence of 5% 
CO2. Individual wells were inspected and culture medium was supplemented until the 
cell monolayer reached confluence. Supernatants from those wells which initially 
contained a single cell were titrated by plaque assay in RK-13 (KY) cells.  
Effect of anti-EAV equine serum on persistent EAV infection. EAV neutralizing 
Ab-positive equine serum used in the study was the O.I.E affirmed ‘medium positive 
reference serum standard (BL394080, produced in 1993)’. On multiple repeat testing, the 
reference serum standard had a neutralizing antibody titer of 1:32 when titrated against 
the attenuated vaccine strain of equine arteritis virus (ARVAC®, FDAH). The 81st serial 
passage of the persistently infected Hela ‘High’ cell line initiated with the VBS53 strain 
of EAV was subcultured (1:4 split ratio) and grown in Eagle’s minimum essential 
medium (EMEM) with 10% ferritin supplemented calf serum (FSCS), and EMEM with 
10% EAV-neutralizing antibody-positive equine serum, respectively. Serial 
subcultivation of the persistently infected Hela cells grown in each medium was carried 
out once every four days (1:4 split ratio). From the 88th passage, EAV Ab-positive equine 
serum was removed from the medium of one replicate of the culture which was further 
serially passed up to the 94th passage. The other replicate of the cell culture continued to 
be passed in the presence of EAV Ab-positive equine serum up to the 94th passage. At 
each passage level, extracellular and cell-associated virus containing materials were 
harvested and titrated by plaque assay. Expression of the viral nucleocapsid (N) protein 
was investigated using an indirect immunofluorescence assay. Also, RT-PCR analysis of 
viral RNA was also carried out at each passage level.  
Indirect immunofluorescence assay (IFA). The indirect immunofluorescence 
assay was performed as previously described (Chapter 2). 
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Growth of different EAV strains in various cells. Growth of EAV strains VBS53, 
Hela-EAVP35, and Hela-EAVP80 in BHK-21, Hela ‘High’ (P198), Hela ‘Low’ (P100), 
Hep-2, and L-M cell lines was compared. Subconfluent monolayers of each cell line 
grown in T-25 flasks were inoculated with the respective viruses at an m.o.i. of 3. Flasks 
were incubated at 37°C for 1 h. The inoculum was aspirated off, and cell sheets washed 
three times with PBS to remove unbound virus and the sheets then overlaid with 10 ml of 
EMEM medium. This was designated time zero with respect to infection. Inoculated 
cultures were incubated at 37°C.  At 0, 24, 48, 72, and 96 h post infection (p.i.), 
supernatants were harvested and viral infectivity was determined by plaque assay on 
cultures of the RK-13 (KY) cell line as previously described (McCollum et al. 1962).  
Isolation of viral RNA, RT-PCR amplification and sequencing. Viral RNA was 
directly isolated from EAV strains VBS53, Hela-EAVP35, and Hela-EAVP80 using the 
QIAamp viral RNA mini kit (Qiagen). The complete genomes of these three viruses were 
amplified in nine overlapping fragments (Appendix 1). Viral RNA was first reverse 
transcribed with Superscript II (Invitrogen) into cDNA following the manufacture’s 
instructions. Then, PCR amplification was performed with high-fidelity proof-reading 
PfuTurbo DNA polymerase (Stratagene) following optimized thermocycling protocols 
(Appendix 2). The PCR products were gel-purified using QIAquick gel extraction kit 
(QIAGEN). Both sense and anti-sense strands were sequenced with a total of 76 primers 
(Appendix 3) using BigDye Terminator v1.1 Cycle Sequencing Kit (Applied Biosystems) 
and Half-Dye Mix (Bioline) following the optimized cycle sequencing protocols 
(Appendix 4). After cycle sequencing, extension products were purified using the 
ethanol/EDTA precipitation method and then resuspended in template suppression 
reagent (TSR). The samples were then loaded onto ABI PRISM 310 Genetic Analyzer. 
Sequence data were analyzed with Vector NTI Suite V.7 software and summarized in 
Appendices 5 to 13.     
 
RESULTS 
The VBS53 strain of EAV is capable of establishing persistent infection in Hela 
‘High’ cell line but not in BHK-21, RK-13, C2C12, Hela ‘Low’, Hep-2 and L-M cell 
lines. It has been previously demonstrated that BHK-21, RK-13, and C2C12 cell lines are 
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fully susceptible, the Hela ‘High’ cell line (P170-221) is partly susceptible, and Hep-2, L-
M, and Hela ‘Low’ (P95-115) cell lines are non-susceptible, to infection with the VBS53 
strain of EAV (Chapter 2). EAV infection of BHK-21, RK-13, and C2C12 cell lines is 
highly cytolytic leading to the death of all cells by 48 h post infection. However, 
inoculation of Hela ‘High’, Hela ‘Low’, Hep-2, and L-M cell lines with the VBS53 strain 
of EAV did not result in any apparent cytopathic effects (CPE) throughout the course of a 
one-step growth curve up to 96 h post infection (Chapter 2). In the case of each cell line, 
inoculated cells appeared to be morphologically indistinguishable from mock-inoculated 
cells. Surprisingly, it was possible to initiate persistent infection with the VBS53 strain of 
EAV in Hela ‘High’ (P171) cells and these continuously produced infectious virus even 
after 94 serial passages (Fig 3.1). The ability of EAV strain VBS53 to establish persistent 
infection in the Hela ‘High’ cell line was confirmed in two further experiments in Hela 
P196 cells (data not shown). In contrast, after two serial passages, no infectious virus 
could be detected in Hela ‘Low’ (P98), Hep-2, and L-M cell lines inoculated with EAV 
strain VBS53 (Table 3.1), indicating that persistent infection was not established in these 
cell lines. In order to determine whether any noninfectious virus was present, the Hela 
‘Low’ (P98) cell line inoculated with EAV strain VBS53 and subsequent passages 
derived from it were examined for the presence of viral proteins and viral RNA. On IFA, 
few cells were positive for the nucleocapsid protein (Fig 3.2) and non-structural protein 1 
(nsp1) (data not shown) at the 1st passage level of EAV-inoculated Hela ‘Low’ cell line. 
No viral specific fluorescence was detected from the 2nd to 20th passage of EAV-
inoculated Hela ‘Low’ cell line. In contrast, expression of viral proteins was detected by 
IFA throughout the course of persistent infection in the Hela ‘High’ cell line (Fig 3.2), 
although the percentage of EAV fluorescent-positive cells fluctuated. On RT-PCR 
analysis for viral RNA, EAV RNA was detected throughout the course of persistent 
infection in the Hela ‘High’ cell line (Fig 3.3A), whereas viral RNA was only detected at 
the 1st and 2nd passages, and not from the 3rd to 20th passages, of the EAV-inoculated 
Hela ‘Low’ cell line (Fig 3.3B). Collectively, these findings confirm that the VBS53 
strain of EAV is able to establish persistent infection in the Hela ‘High’ cell line, but 
unable to do so either in BHK-21, RK-13, C2C12 cell lines in which all the cells 
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eventually die due to the cytolytic effects of the virus, or in the Hela ‘Low’, Hep-2, and 
L-M cell lines in which cells survive without continuous production of virus. 
Transfection with viral RNA is capable of initiating persistent infection in the 
Hela ‘High’ cell line but not in BHK-21, Hep-2, L-M, and Hela ‘Low’ cell lines. In 
order to determine whether failure to establish persistent EAV infection in Hela ‘Low’, 
Hep-2, and L-M cell lines was due to the fact that the virus cannot achieve cell entry, 
various cell lines were transfected with viral RNA in vitro-transcribed from an infectious 
EAV cDNA clone pEAV2421/211EB (Balasuriya et al., unpublished). In the case of 
transfected BHK-21 cells, cytopathic effects appeared and progressed from 72 h post 
transfection with all the cells had died by 96 h after transfection. In contrast, no CPE was 
observed in transfected Hela ‘High’, Hela ‘Low’, Hep-2, and L-M cell lines up to 96 h 
post transfection, although infectious virus production was detected in these transfected 
cells as shown in Table 3.2. Serial passaging of these transfected cell lines resulted in two 
distinct outcomes. Serial subculture of transfected Hela ‘High’ cells led to establishment 
of persistent infection in which infectious virus was produced throughout the observation 
period (from passage 1 to passage 10) (Table 3.2). Whereas no apparent CPE was 
observed from passage 1 to passage 5 in this line, cell destruction of limited extent was 
observed from passage 6 to passage 10. On the other hand, one or two more 
subcultivations of transfected Hep-2, L-M, and Hela ‘Low’ cells resulted in loss of 
infectious virus production (Table 3.2), indicating that persistent infection was not 
established in these cell lines. No cell destruction was observed in transfected Hep-2, L-
M, and Hela ‘Low’ cell lines throughout the observation period (from passage 1 to 
passage 10).  
Characterization of persistently infected Hela ‘High’ cells. Persistently infected 
Hela ‘High’ cells initiated with the VBS53 strain of EAV were characterized by the 
following properties. i) The persistently infected cells had been subcultured and 
maintained for over 3 years. ii) Persistently infected cultures underwent recurrent 
episodes of partial destruction and subsequent recovery (Table 3.3). For example, in 
passages 1 and 2, no apparent cell destruction was observed; from passage 3 to passage 5, 
a degree of cell destruction was observed; from passage 6 to passage 9, cells gradually 
recovered and the extent of cell destruction decreased compared to that observed in 
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passages 4 and 5; some cell destruction was observed again from passage 10 to passage 
14; cells again gradually recovered from passage 15 to passage 18; such recurrences of 
partial destruction and subsequent recovery of cells continued throughout the observation 
period. The percentage of dead cells (as determined by trypan blue staining) during 
periods of cell destruction was higher than that during periods of cell recovery. iii) 
During the course of persistent infection, the percentage of EAV fluorescent-positive 
cells varied from 1% to 37%. But in most passages of the persistently infected culture, 
the percentage of virus-positive cells ranged between 15% and 25% (Table 3.3). IFA 
images of persistently infected Hela ‘High’ cells at randomly selected passages are shown 
in Fig 3.2. It should be pointed out that cell death and EAV fluorescent-positive cells 
were determined randomly for some passages but not every passage of the persistently 
infected Hela ‘High’ cell line. iv) Infectious virus was continuously produced throughout 
the course of persistent infection with virus infectivity titers varying from 102 to 106 pfu 
per ml. The virus infectivity titers ranged from 104 to 106 pfu per ml in most passages of 
the persistently infected culture (Table 3.3; Fig 3.1). The yield of cell-associated virus 
was comparable (at the same log level) to that of extracellular virus at every passage level 
tested (Table 3.4). The ratio of extracellular virus to cell-associated virus fluctuated from 
30:70 to 55:45 (Table 3.4). v) After storage for 3 years in liquid nitrogen, the revived cell 
culture was still able to produce infectious virus with the virus titer similar to what it was 
prior to freezing. vi) An attempt to clone a single cell that could continuously produce 
infectious virus was unsuccessful. Cells were cloned from the 26th passage of the 
persistently infected Hela ‘High’ cell line by distributing an appropriately diluted cell 
suspension into 96-well plates. Wells were visually examined and only those wells that 
received a single cell were used. Eventually, 46 clones were obtained. However, none of 
them were found to produce infectious virus. vii) The effect of EAV neutralizing 
antibody-positive equine serum on persistently infected cells is shown in Table 3.5. The 
persistently infected Hela ‘High’ cells were treated with EAV neutralizing antibody-
positive equine serum from the 82nd passage. Before treatment with antiserum, the 
extracellular and cell-associated virus in the persistently infected Hela ‘High’ cell line 
was 5.7 × 105 pfu/ml and 9.5 × 105 pfu/ml, respectively. After two serial passages in the 
presence of antiserum, no infectious virus was detectable in either the supernatants or the 
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lysates of the culture. The cell culture treated with antiserum was maintained up to the 
94th passage during which no infectious virus could be detected. Interestingly, in the case 
of antiserum-treated cell cultures, expression of viral nucelocapsid protein was 
undetectable by the IFA test from the 83rd to the 94th cell culture passage, although viral 
RNA was still detectable by the RT-PCR from the 83rd to the 85th cell culture passage. 
This indicated that viral RNA could be present for several additional passages even when 
infectious virus and viral protein expression were no longer detectable. Following 
removal of the antiserum from the culture medium at the 88th serial passage, no renewed 
virus replication, viral antigen expression, or EAV RNA production was detected upon 7 
additional passages of Hela ‘High’ cells. This is evidence that persistently infected Hela 
‘High’ cells could be cured of EAV infection by culturing the cells in the presence of 
EAV neutralizing antibody-positive equine serum. In contrast, infectious virus, viral 
protein expression, and viral RNA were consistently detected in the mock-treated cell 
culture throughout the observation period.    
Growth kinetics of persistent viruses in various cell cultures. To determine 
whether the growth properties of the challenge strain of EAV had changed during the 
course of persistent infection, growth kinetics of the parental EAV strain VBS53 and 
viruses recovered from the 35th (Hela-EAVP35) and the 80th (Hela-EAVP80) passage of 
the persistently infected Hela ‘High’ cell line were compared in BHK-21, Hela ‘High’ 
(P198), Hela ‘Low’ (P100), Hep-2, and L-M cell lines. In BHK-21 cells (Fig 3.4A), EAV 
strains VBS53, Hela-EAVP35, and Hela-EAVP80 all caused a cytolytic infection. 
Replication of each virus strain followed a similar growth kinetic curve, with 3-4 log10 
increase in infectivity titers within 24-48 h, followed by a gradual decline in titers after 
48 h. This indicated that these three EAV strains can cause productive infections and 
grow with similar efficiency in BHK-21 cells. In both Hep-2 (Fig 3.4B) and L-M (Fig 
3.4C) cell lines, the growth of EAV strains VBS53, Hela-EAVP35, and Hela-EAVP80 
was not efficient, having similar growth kinetics for all three strains. On the other hand, 
in both Hela ‘High’ (Fig 3.4D) and Hela ‘Low’ (Fig 3.4E) cell lines, Hela-EAVP35 and 
Hela-EAVP80 strains grew better and replicated more efficiently than the VBS53 strain 
of EAV. Hela-EAVP35 and Hela-EAVP80 strains had almost the same replication 
efficiency in either Hela ‘High’ (Fig 3.4D) or Hela ‘Low’ (Fig 3.4E) cells.      
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Ability of Hela-EAVP35 and Hela-EAVP80 to establish persistent infection in 
both Hela ‘Low’ and Hela ‘High’ cell lines but not in BHK-21, Hep-2, and L-M cell 
lines. To determine whether virus recovered from persistently infected cells has acquired 
any new features in establishing persistent infection, an attempt was made to establish 
persistent infection in BHK-21, Hela ‘Low’, Hela ‘High’, Hep-2, and L-M cell lines with 
Hela-EAVP35 and Hela-EAVP80, respectively. As was the experience with the VBS53 
strain of EAV, Hela-EAVP35 and Hela-EAVP80 caused cytolytic infection in BHK-21 
cells with all the cells dead by 48 h post inoculation without the establishment of 
persistent infection. Similar to EAV strains VBS53, Hela-EAVP35 and Hela-EAVP80 
were not able to establish persistent infection in Hep-2 and L-M cell lines in which three 
serial passages led to the loss of virus production (Fig 3.5A). In contrast to the VBS53 
strain of EAV, which can only establish persistent infection in the Hela ‘High’ but not in 
the Hela ‘Low’ cell line, Hela-EAVP35 and Hela-EAVP80 were able to establish 
persistent infections in both Hela ‘High’ and Hela ‘Low’ cell lines (Fig 3.5 B and C). 
This was confirmed by IFA studies (Fig 3.6). In the persistently infected Hela ‘High’ cell 
line in which infection was initiated with Hela-EAVP35 or Hela-EAVP80, the virus 
infectivity titer on 1st passage reached 2 × 106 pfu/ml (Fig 3.5B and C). In contrast, when 
infection in persistently infected Hela ‘High’ cell line was initiated with EAV strain 
VBS53, the virus infectivity titer on 1st passage was less, only reaching 104 pfu/ml. It 
took two or three serial passages for the virus titer to reach 106 pfu/ml (Fig 3.1). This 
confirmed that Hela-EAVP35 and Hela-EAVP80 viruses grow better than EAV strain 
VBS53 in the Hela ‘High’ cell line in the course of the initial few passages in cell culture. 
In Hela ‘High’ cells persistently infected with Hela-EAVP35 or Hela-EAVP80, apparent 
cell destruction was observed from the initial passage, whereas cell destruction was not 
observed until the 6th serial passage in persistently infected Hela ‘Low’ cells. During the 
initial number of passages (1st to 5th), virus yields in Hela ‘Low’ cells were consistently 
lower than those in Hela ‘High’ cells persistently infected with the same virus strains (Fig 
3.5B and C). Virus strains Hela-EAVP35 and Hela-EAVP80 evidently grow better in 
Hela ‘High’ cells than in Hela ‘Low’ cells over the course of the initial several passages 
of infection. However, from the 6th and subsequent passages, the level of cell destruction 
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and virus yields in persistently infected Hela ‘Low’ cells approximated to those in Hela 
‘High’ cells (Fig 3.5B and C).  
Comparative nucleotide and amino acid sequence analysis of the viruses 
capable of establishing persistent infection in Hela cells. To investigate genetic 
variation of EAV during persistent infection of Hela cells, the entire genomes of EAV 
strains VBS53, Hela-EAVP35, and Hela-EAVP80 were sequenced. Sequences were 
determined by direct sequencing of RT-PCR fragments and could thus be assumed to 
reflect the consensus sequence of the virus population at the time of RNA extraction. The 
full-length nucleotide sequences and the deduced amino acid sequences of EAV strains 
VBS53, Hela-EAVP35, and Hela-EAVP80 were compared and the findings summarized 
in Table 3.6. The entire genomes of EAV strains VBS53, Hela-EAVP35, and Hela-
EAVP80 were all 12,704 nt in length, namely the same length as the published sequence 
of EAV030. The complete nucleotide (nt) differences between EAV strains VBS53 and 
Hela-EAVP35, VBS53 and Hela-EAVP80, Hela-EAVP35 and Hela-EAVP80 were 26 nt, 
34 nt, and 16 nt, respectively. All of these nucleotide changes occurred at ORFs1a, 1b, 2a, 
2b, and 3-5; no nucleotide changes were observed at the 5’ non-translated region (NTR 1-
224 including 5’ leader 1-211), nor in ORFs 6-7 and the 3’ NTR (12646-12704). The 
total number of amino acid differences in the replicase polyprotein and structural proteins 
between EAV strains VBS53 and Hela-EAVP35, VBS53 and Hela-EAVP80, Hela-
EAVP35 and Hela-EAVP80 were 15 aa, 17 aa, and 6 aa, respectively. There were 14 nt, 
20 nt, and 10 nt differences in the replicase gene, most of which were silent mutations 
which only resulted in 3 aa, 4 aa, and 1 aa changes, between EAV strains VBS53 and 
Hela-EAVP35, VBS53 and Hela-EAVP80, Hela-EAVP35 and Hela-EAVP80, 
respectively. There were 12 nt, 14 nt, and 6 nt differences in the structural protein genes 
(ORFs2a, 2b, and 3-5), respectively. Most of these were non-synonymous mutations 
which resulted in 12 aa, 13 aa, and 5 aa changes between EAV strains VBS53 and Hela-
EAVP35, VBS53 and Hela-EAVP80, Hela-EAVP35 and Hela-EAVP80, respectively. 
The majority of deduced amino acid changes involved EAV structural proteins E, GP2b, 
GP3-5 which are encoded by ORFs2a, 2b, and 3-5, respectively.  
The catalytic dyad (Cys-164 and His-230) of the nsp1 protease, the critical residues 
(Cys-270, His-332, Cys-319, Cys-349, Cys-354, Cys-344, and Cys-356) of the nsp2 
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protease, the catalytic triad (His-1103, Asp-1129 and Ser-1184) of the nsp4 protease, the 
putative substrate-binding region (Thr-1179 and His-1198) of the nsp4 protease, and 11 
cleavage sites on the replicase polyprotein 1ab were all conserved in three EAV strains 
VBS53, Hela-EAVP35, and Hela-EAVP80 (Table 3.6; Snijder and Meulenberg 1998; 
Ziebuhr et al. 2000). No potential N-glycosylation site changes were observed with 
respect to the structural proteins of these three EAV strains. 
Five ambiguous nucleotides were observed in EAV strain VBS53: 3707Y, 7021R, 
8260Y, 8290Y, and 10722Y (Y is T or C; R is A or G). Because of the existence of 
degenerate codons, however, the ambiguity of nucleotide at 3707, 7021, 8260, and 8290 
did not cause any change to the respective amino acids encoded by them. The ambiguity 
of nucleotide T or C at 10722 resulted in the ambiguity of amino acid Leu or Ser at 
position 8 of the GP4 protein. No ambiguous nucleotides were observed in either Hela-
EAVP35 or Hela-EAVP80. The degree of homology between Hela-EAVP35 and Hela-
EAVP80 (6 aa differences) was higher than that between either of these strains and the 
VBS53 strain of EAV (15 aa differences between VBS53 and Hela-EAVP35; 17 aa 
differences between VBS53 and Hela-EAVP80). This would indicate that EAV evolved 
during the course of persistent infection in the Hela ‘High’ cell line. Most of the 
mutations would appear stable. However, reversion of mutations was occasionally 
observed. For example, the amino acid at position 88 of the GP2b protein of EAV strains 
VBS53, Hela-EAVP35, and Hela-EAVP80 was Met, Val, and Met, respectively; the 
amino acid at position 246 of the GP5 protein was Arg, Lys, and Arg, respectively.   
 
DISCUSSION 
Equine arteritis virus infection is usually highly cytolytic in cultured cells, e.g. 
BHK-21, RK-13, and C2C12 ((Snijder and Meulenberg 1998 and Chapter 2). It has 
recently been found, however, that Hela ‘High’ cell line (P170-221) is partly susceptible 
to infection with the VBS53 strain of EAV, whereas Hep-2, L-M, and Hela ‘Low’ (P95-
115) cell lines are non-susceptible to this virus strain (Chapter 2). In this study the 
VBS53 strain of EAV was shown to be able to establish persistent infection in a Hela 
‘High’ cell line. To the authors’ knowledge, it is the first report of establishment of 
persistent EAV infection in cell culture.  
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Characterization of persistent viral infection in cell culture. Persistently infected 
cell cultures may or may not exhibit virus-specific cytopathic effects despite the fact that 
they continuously produce infectious virus (Frisk et al. 1999; Gercel et al. 1985; Kaplan 
et al. 1989; Moscona and Galinski 1990). In this study, it was shown that persistently 
infected Hela ‘High’ cells in which infection was initiated with EAV strain VBS53, 
underwent multiple episodes of partial destruction and subsequent recovery. During the 
course of persistent infection in the Hela ‘High’ cell line, the percentage of EAV 
fluorescent-positive cells varied from 1% to 37% but with the range falling between 15% 
and 25% in most passages. The observation that the percentage of virus-positive cells can 
show cyclic variation has also been reported for other persistent systems. For instance, in 
BHK-21 cells persistently infected with rabies virus, the percentage of cells exhibiting 
positive immunofluorescence varied from 5% to 100% in cycles of 6-8 subcultures 
(Wiktor and Clark 1972); in Hela cells persistently infected with human rhinovirus-2, the 
percentage of cells producing infectious centers varied from 0.03% to 23% (Gercel et al. 
1985). In contrast to persistent poliovirus infection in Hela cells in which freezing down 
of cells in liquid nitrogen resulted in the cells losing the ability to produce infectious 
virus (Kaplan et al. 1989), Hela cells persistently infected with EAV were still able to 
produce infectious virus after being frozen down in liquid nitrogen for 3 years, with the 
virus titer similar to what it had been prior to freezing (data not shown).  
Addition of virus-specific antibodies or anti-viral compounds to the media of 
persistently infected cells may or may not result in elimination of the persistent infection. 
It has been shown that cloning or subculture of measles virus/Hela cells in the presence 
of anti-measles serum in the culture medium led to a state in which no infectious virus 
was released, whereas the vast majority of these cells were still immunofluorescence 
positive (Rustigian 1966b), indicating the existence of viral antigen. When human 
influenza C virus/MDCK cells (Goshima and Maeno 1989) or poliovirus/human 
erythroblastoid K562 cells (Lloyd and Bovee 1993) were subcultured for several serial 
passages with growth medium containing homologous virus-neutralizing antibodies, 
extracellular virus became undetectable. However, upon further passage in the absence of 
antiserum there was a return of infectious virus yield. In contrast, it was observed that 
three serial subcultivations of human rhinovirus-2/Hela cells in the presence of antiserum 
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resulted in a cure (no extracellular virus or infectious centers or viral antigens could be 
detected) (Gercel et al. 1985). In addition, after removal of antiserum, no renewed virus 
production or viral antigen expression could be detected upon 12 further passages (Gercel 
et al. 1985), indicating that the formerly persistently infected cells were permanently 
cleared of infection. It was also found that the anti-viral compound ribavirin was able to 
eliminate foot-and-mouth disease virus (FMDV) from persistently infected BHK-21 cells 
(de la Torre et al. 1987). Addition of EAV neutralizing antibody-positive equine serum to 
the medium of persistently infected Hela ‘High’ cells resulted in the elimination of 
persistent infection. No renewed virus production or viral antigen expression or EAV 
RNA replication occurred upon 7 further passages in the absence of anti-EAV serum.  
Characteristically, persistently infected cells are resistant to superinfection with 
homologous viruses but are still susceptible to infection with heterologous viruses. For 
example, Hela cells persistently infected with human rhinovirus-2 (HRV-2) were 
resistant to superinfection with homologous viruses (HRV-2, HRV-2 TS-1 mutant, and 
HRV-4) but were susceptible to poliovirus type 2 and vesicular stomatitis virus (VSV) 
infection (Gercel et al. 1985). The virus yields in HRV-2/Hela cells superinfected with 
HRV-2, TS-1 mutant, or HRV-4 were similar to those produced in HRV-2/Hela cells 
alone (mock-superinfected) but were less than those produced in normal Hela cells 
infected with the respective virus. In contrast, virus yields in HRV-2/Hela cells 
superinfected with poliovirus type 2 or VSV were comparable to those obtained in 
normal Hela cells infected with the respective virus (Gercel et al. 1985). The question 
whether Hela ‘High’ cells persistently infected with EAV are resistant to superinfection 
with EAV was investigated in this study (Table 3.7). Virus yields in persistently infected 
Hela ‘High’ cell line which was superinfected with EAV strain VBS53 were comparable 
to those obtained in persistently infected Hela ‘High’ cells which were mock-
superinfected, but were not less than those produced in normal Hela ‘High’ cells which 
were infected with EAV strain VBS53. On the basis of this observation, it was not certain 
whether persistently infected Hela ‘High’ cells were resistant to superinfection with EAV. 
The difference between HRV-2/Hela cells and EAV/Hela ‘High’ cells is probably caused 
by the fact that normal Hela cells are fully susceptible to HRV-2 infection, whereas 
normal Hela ‘High’ cells are only partly susceptible to infection with EAV strain VBS53.  
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Virus and cell evolution during persistent infection of cell culture. Equine 
arteritis virus evolution during persistent infection of the Hela ‘High’ cell line was 
observed in this study. Hela-EAVP35 and Hela-EAVP80, isolated from the 35th and 80th 
passage of persistently infected Hela ‘High’ cell line, respectively, grew more efficiently 
than the parental EAV strain VBS53 in Hela ‘Low’ and Hela ‘High’ cell lines. Hela-
EAVP35 and Hela-EAVP80 were able to establish persistent infections in Hela ‘Low’ 
cells, whereas the parental EAV strain VBS53 was unable to do so (Table 3.8). 
Furthermore, compared to the parental EAV strain VBS53, Hela-EAVP35 and Hela-
EAVP80 had different neutralization phenotypes (Chapter 4) and exhibited potential 
changes in pathogenicity (Chapter 5). Besides these phenotypic changes, direct 
sequencing of the entire genomes of EAV strains VBS53, Hela-EAVP35, and Hela-
EAVP80 provides clearcut evidence of viral genetic evolution during persistent infection 
of Hela ‘High’ cells. It should be pointed out that the entire genome sequences of these 
three viruses are actually the predominant sequences within the viral quasispecies. In the 
replicase, amino acid mutations were only observed in nsp1, nsp2, nsp7, and nsp9. In the 
structural proteins, amino acid changes were found in E, GP2b, GP3, GP4, and GP5 
proteins but not in either M or N proteins.    
Further studies are needed to determine which amino acid(s) mutations are 
responsible for the corresponding phenotypic changes. Special attention should be paid to 
nsp2 Asp-577? Gly, nsp9 Pro-1933? Ser, E Ser-53? Cys, GP2b Leu-15? Ser, GP2b 
Trp-31? Arg, GP3 Leu-135? Pro, and GP5 Pro-98? Leu. 
It is interesting that, compared to the VBS53 strain of EAV, neither Hela-EAVP35 
nor Hela-EAVP80 exhibited apparent phenotypic differences (e.g. growth kinetics and 
the ability to establish persistent infection) in BHK-21, Hep-2, or L-M cell lines (Fig 3.4 
and Table 3.8). 
The virus-encoded RNA-dependent RNA polymerases (RdRp) are low fidelity 
enzymes with mutation rates as high as the order of 10-3 to 10-5 errors per nucleotide per 
replication cycle (Domingo and Holland 1997; Drake 1993). In addition, RNA viruses 
have very short replication times and generate very large populations during replication. 
Therefore, RNA viruses exist not as a single genotype but rather as a heterogeneous 
mixture of related genomes known as a viral quasi-species (Holland et al. 1992). The 
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quasi-species nature of RNA viruses allows viruses to adapt to environmental changes 
more rapidly and facilitates the emergence of viral variants (Castro et al. 2005). 
Therefore, it is not surprising that EAV has evolved after long-term persistence in Hela 
cells. In fact, EAV may also evolve after many passages of cytolytic infection in cell 
cultures. For example, the parent EAV strain isolated from horses did not infect primary 
hamster kidney cells; however, when the same parent EAV strain underwent 82 passages 
of cytolytic infection in horse kidney cells, the obtained virus could be able to infect 
primary hamster kidney cells (Wilson et al. 1962). Also, after many passages of cytolytic 
EAV infection in cell cultures, the virus had been observed to get attenuated (McCollum 
1969). 
Cell evolution during persistent EAV infection of Hela cells was not investigated in 
this study. Previously, it has been demonstrated that the Hela cell line becomes more 
susceptible to infection with EAV strain VBS53 after extended serial passage (Chapter 2). 
It is reasonable to postulate that cells would evolve during persistent infection of the Hela 
‘Low’ cell line initiated with Hela-EAVP35 or Hela-EAVP80. The question whether 
Hela cells cured of persistent infection with anti-EAV serum have different susceptibility 
from the corresponding passage level of normal Hela cells to EAV infection also needs to 
be investigated.    
Virus and cell evolution have also been observed in other persistent viral infection 
systems. Genetic and antigenic changes have been demonstrated in hepatitis A virus 
(HAV) variants arising during persistent infection of BS-C-1 cells (Lemon et al. 1991). 
Foot-and-mouth disease virus isolated from persistently infected BHK-21 cells was more 
cytolytic than parental FMDV for BHK-21 cells (de la Torre et al. 1988a). Further studies 
revealed amino acid substitutions of the viral capsid protein and antigenicity alteration of 
FMDV during persistence (Diez et al. 1990a). Moreover, FMDV became progressively 
less virulent for mice and cattle during the course of persistence in BHK-21 cells (Diez et 
al. 1990b). The poliovirus mutants selected from human neuroblastoma IMR-32 cells 
persistently infected with the Sabin strains could reach 1-3 log10 units higher titer in IMR-
32 cells than that in non-neural Hep-2 cells, while parental viruses had similar titers in 
both cell lines (Colbere-Garapin et al. 1989). Correlated with this modified cell tropism, 
the poliovirus mutants recovered from carrier culture could establish secondary persistent 
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infection in non-neural Hep-2 cells (Pelletier et al. 1991). Cell evolution has been 
documented in mouse L cells persistently infected with reovirus (Ahmed et al. 1981), 
BHK-21 cells persistently infected with FMDV (de la Torre et al. 1988a; 1989; Martin 
Hernandez et al. 1994), and Hela cells (Kaplan et al. 1989; Kaplan and Racaniello 1991), 
human neuroblastoma cells (Pavio et al. 2000), and Hep-2 cells (Borzakian et al. 1992) 
persistently infected with poliovirus.  
Mechanisms of persistent viral infection in cell culture. A number of studies 
have shown that various viral and host cell factors could be involved in the establishment 
and maintenance of persistent infection in cell cultures. For example, temperature-
sensitive viral mutants (Preble and Youngner 1972, 1973a, 1973b; Youngner et al. 1976), 
defective interfering viral particles (Ahmed et al. 1981; Calain et al. 1999; Holland and 
Villarreal 1974; Holland et al. 1976; Kaplan et al. 1989; Weiss et al. 1980), alteration of 
viral RNA or protein synthesis (Chen et al. 1996; Desforges et al. 2001; Dryga et al. 
1997), and specific amino acid substitutions (Borzakian et al. 1993; Calvez et al. 1993; 
Duncan et al. 1998; Matloubian et al. 1990; Pelletier et al. 1991; 1998a; 1998b) have 
been shown to be involved in different persistent infection systems. Various host factors 
such as host cell type (Hecht and Summers 1974; Poste et al. 1972; Zhang and Racaniello 
1997), host cell mutants (Kaplan et al. 1989; Kaplan and Racaniello 1991), host cell 
differentiation stage (Benton et al. 1995; 1996; Okada et al. 1987) and so on may also be 
involved in the establishment and maintenance of persistent viral infection. However, the 
detailed molecular mechanisms of persistent viral infection in cell cultures are not yet 
well understood and furthermore, the mechanisms may be unique in each system. 
The VBS53 strain of EAV is able to establish persistent infection in the Hela ‘High’ 
but not Hela ‘Low’ cell line, suggesting that some unidentified host cell factors are 
involved in persistent EAV infection. On the other hand, Hela-EAVP35 and Hela-
EAVP80 are able to establish persistent infection in the Hela ‘Low’ cell line, whereas 
EAV strain VBS53 is unable to do so. This suggests that unidentified viral factors are 
also involved in the establishment of persistent EAV infection. The fact that EAV strain 
VBS53 is able to establish persistent infection in the Hela ‘High’ cell line but not in Hela 
‘Low’ cell line is consistent with the observation that Hela ‘High’ cells are more 
susceptible than Hela ‘Low’ cells to the virus infection (Chapter 2). Correlated with the 
  107 
observation that Hela-EAVP35 and Hela-EAVP80 are able to, whereas EAV strain 
VBS53 is unable to, establish persistent infection in the Hela ‘Low’ cell line, is the fact 
that Hela-EAVP35 and Hela-EAVP80 grow more efficiently than EAV strain VBS53 in 
the Hela ‘Low’ cell line. Based on these findings, it is speculated that establishment and 
maintenance of persistent EAV infection in Hela cells is related to the susceptibility of 
the cells to EAV infection. It has been previously suggested that higher susceptibility of 
the Hela ‘High’ cell line than the Hela ‘Low’ cell line to infection with the VBS53 strain 
of EAV is because of higher efficiency of virus entry into Hela ‘High’ cells than into 
Hela ‘Low’ cells (Chapter 2). It would be interesting to investigate whether growth 
efficiencies of Hela-EAVP35 and Hela-EAVP80 in Hela ‘High’ and Hela ‘Low’ cell 
lines can be correlated with corresponding virus attachment and entry levels. Should this 
prove to be true, it would suggest that Hela-EAVP35 and Hela-EAVP80 recognize some 
new cell receptors on Hela cells. It may, thus, be postulated that establishment and 
maintenance of persistent EAV infection in Hela cells would be predicated on virus-cell 
receptor interactions. In fact, it has been suggested that interactions between poliovirus 
and its receptor may be involved in establishment and maintenance of persistent 
poliovirus infection in host cells (Borzakian et al. 1993; Calvez et al. 1993; Colbere-
Garapin et al. 1989; Duncan et al. 1998; Pavio et al. 1996; 2000; Pelletier et al. 1991; 
1998a).    
In above proposed model, cell heterogeneity is another key factor. If all of the cells 
in a cell line, such as BHK-21, RK-13, and C2C12, are susceptible to EAV infection, 
virus infection kills all of the cells and persistent infection cannot be established. If too 
few cells in a cell line, such as Hep-2 and L-M, are susceptible to EAV infection, the 
virus is not able to initiate and maintain a persistent infection. Failure to establish 
persistent infection in the Hela ‘Low’ cell line with EAV strain VBS53 may be such a 
case. However, in the case of the Hela ‘High’ cell line, a certain percentage but not 100% 
of the cells are susceptible to infection with EAV strain VBS53 or Hela-EAVP35 or 
Hela-EAVP80; infection of the Hela ‘High’ cell line with these viruses is not able to kill 
all of the cells, instead, a persistent infection may be initiated and maintained. 
Establishment of persistent infection in the Hela ‘Low’ cell line with either Hela-
EAVP35 or Hela-EAVP80 may be due to the same reason. The finding that persistently 
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infected Hela cells can be cured by treatment with anti-EAV serum would suggest that 
the persistent EAV infection is maintained by horizontal transmission of the virus 
released from infected cells to uninfected susceptible cells. It would appear that virus 
spread from cell to cell through cell fusion or virus spread from parent cells to daughter 
cells through cell division is not very likely. Failure to establish persistent infection in 
Hela ‘Low’, Hep-2, and L-M cell lines upon transfection with EAV RNA (Table 3.2) and 
failure to obtain a single clone that can continuously produce infectious EAV would 
support this hypothesis. It has been demonstrated that more than 103 cells derived from 
persistently infected BHK-21 cells are needed to reinitiate a stable, FMDV-producing 
carrier culture (de la Torre and Domingo 1988b), which would suggest that the persistent 
infection of cell culture is the result of complex interactions acting at the population level.    
In either a one-step growth curve of EAV in Hela cells (Chapter 2) or in persistently 
infected Hela cells, the percentage of extracellular virus to the total virus present (the sum 
of extracellular virus and cell-associated virus) was around or below 50%, whereas it was 
greater than 80% in a one-step growth curve of EAV in BHK-21, Hep-2, or L-M cells. 
Whether this factor is implicated to the establishment and maintenance of persistent EAV 
infection in Hela cells remains to be determined. 
Whether defective interfering particles of equine arteritis virus are involved in 
establishment and maintenance of persistent EAV infection in Hela cells also remains to 
be determined. Whether EAV infection induces production of interferon in Hela cells, 
and if yes, whether interferon plays a role in the establishment and maintenance of 
persistent EAV infection in Hela cells is unclear. 
 Significance of persistent viral infection in cell culture. Persistent viral 
infections of cell culture have been used to study virus-host cell interactions. They have 
also been shown to be a useful tool for investigating virus and cell evolutions (Ahmed et 
al. 1981; Colbere-Garapin  et al. 1989; de la Torre et al. 1988a; Kaplan et al. 1989). 
Persistent EAV infection of Hela cells provides a model system to study viral and host 
cell factors involved in viral persistence. It also provides a tool for elucidating virus-host 
cell interactions, e.g. EAV-cell receptor interactions. Furthermore, such a system can be 
used to investigate virus evolution and to study phenotypic (such as neutralization and 
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virulence) changes. Persistent EAV infection in cell culture may also assist in elucidating 
the mechanisms of EAV persistence in the carrier stallions. 
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Table 3.1 The outcome of serial passaging Hela ‘Low’ (P98), Hep-2, and L-M cell lines inoculated with EAV strain VBS53* 
 
Hela ‘Low’ cells (P98) 
Passage No. Extracellular virus  
(pfu/ml) 
Cell-associated virus  
(pfu/ml) 
L-M cells (P302) 
Extracellular virus  
(pfu/ml) 
Hep-2 cells (P460) 
Extracellular virus  
(pfu/ml) 
1 h p.i. 
P1 
P2 
P3 
P4 
P5 – P20 
3.0 × 102 
5.7 × 102 
5.0  
0 
0 
0 
5.0 × 101 
2.3 × 102 
2.0  
0 
0 
0 
5.4 × 102 
2.9 × 103 
1.2 × 101 
0 
0 
0 
4.7 × 102 
5.5 × 102 
8.0  
0 
0 
0 
 
* Selected cell lines were inoculated with the VBS53 strain of EAV at an m.o.i. of 3. Inoculated cultures were incubated at 
37ºC and subcultured once every four days (1:4 split). Extracellular and cell-associated virus was harvested and titrated by 
plaque assay on RK-13 (KY) cells. These results were confirmed in two separate experiments. 
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Table 3.2 Transfection with viral RNA established persistent infection in the Hela ‘High’ cell line 
              but not in Hela ‘Low’, Hep-2, and L-M cell lines* 
 
Passage No. 
Hela ‘Low’ cells (P102) 
Extracellular virus  
(pfu/ml) 
Hela ‘High’ cells (P200) 
Extracellular virus  
(pfu/ml) 
L-M cells (P306) 
Extracellular virus  
(pfu/ml) 
Hep-2 cells (P455) 
Extracellular virus  
(pfu/ml) 
P1 
P2 
P3 
P4 
P5 
P6 
P7 
P8 
P9 
P10 
5.2 × 104 
1.3 × 103 
1.0 × 101 
0 
0 
0 
0 
0 
0 
0 
2.1 × 105 
6.6 × 103 
4.0 × 103 
4.4 × 104 
1.2 × 105 
3.9 × 105 
1.3 × 106 
3.6 × 106 
8.6 × 105 
2.6 × 105 
6.4 × 104 
2.3 × 102 
0 
0 
0 
0 
0 
0 
0 
0 
1.4 × 104 
1.1 × 102 
0 
0 
0 
0 
0 
0 
0 
0 
 
* Selected cell lines were transfected with viral RNA in vitro-transcribed from a full-length infectious EAV cDNA 
clone. Transfected cells were incubated at 37ºC and subcultured once every four days (1:4 split). Extracellular virus 
was harvested and titrated by plaque assay on RK-13 (KY) cells. 
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Table 3.3 Some properties of persistently infected Hela ‘High’ cell line1 initiated with the VBS53 strain of EAV 
             
Passage 
level 
Extracellular 
virus titer 
(pfu/ml) 
Cell destruction 
cell 
death2  
(%)                                                                        
IFA                                           
aN3 
positive
IFA
aNSP14 
positive  
Passage 
Extracellular 
virus titer 
(pfu/ml) 
Cell destruction 
cell 
death2 
(%)                                                                                              
IFA                                                                                                
aN3 
positive
IFA
aNSP14 
positive
1 h p.i. 4.7×102 no     P27 1.2×106 cell destuction    
P1 6.0×104 no 12.5 7.8% 8.2%  P28 8.2×105 cell destuction    
P2 6.3×104 no 13.2    P29 2.0×106 cell destuction  17.8% 17.2% 
P3 2.90×105 partial destuction 16.4    P30 9.6×105 partial recovery 15.4   
P4 1.79×106 cell destuction 35.3 22.2% 24.7%  P31 2.1×104 recovery    
P5 6.00×105 cell destuction 31.2    P32 2.4×105 recovery    
P6 1.95×105 partial recovery 17.8    P33 1.5×106 partial destuction    
P7 1.0×105 partial recovery 16.2    P34 2.4×106 cell destuction 29.3 35.8% 37.4% 
P8 4.5×105 recovery 15.8    P35 4.0×106 cell destuction    
P9 5.7×105 recovery     P36 7.9×105 partial recovery    
P10 1.5×106 partial destuction     P37 7.7×105 recovery    
P11 6.8×105 partial destuction     P38 9.0×104 recovery  1.4% 2.7% 
P12 1.4×106 cell destuction     P39 1.3×105 recovery    
P13 9.1×105 cell destuction     P40 6.5×105 partial destuction    
P14 9.9×105 cell destuction     P41 1.2×106 cell destuction 37.8   
P15 2.9×105 partial recovery     P42 4.5×105 partial recovery    
P16 3.0×105 recovery     P43 6.2×105 partial recovery    
P17 1.8×105 recovery     P44 1.8×105 recovery  5.2%  
P18 1.5×105 recovery 18.1    P45 1.7×105 recovery    
P19 1.0×106 partial destuction     P46 5.1×105 recovery    
P20 6.3×105 partial destuction  11.6% 11.0%  P47 1.1×106 cell destuction    
P21 4.4×105 cell destuction     P48 1.1×104 partial recovery   2.7% 
P22 1.2×106 cell destuction     P49 1.2×104 partial recovery    
P23 2.1×104 recovery 12.3    P50 6.8×105 partial recovery    
P24 3.9×105 recovery     P51 3.1×106 cell destuction  38.4% 37.1% 
P25 1.1×106 partial destuction  17.5% 20.7%  P52 4.4×104 partial recovery    
P26 1.4×106 cell destuction     P53 2.1×104 partial recovery    
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(Table 3.3 continued) 
             
Passage 
Extracellular 
virus titer 
(pfu/ml) 
Cell destruction 
cell 
death2 
(%)                                                                                                                                                                                 
IFA                        
aN3 
positive
IFA
aNSP14 
positive  
Passage 
Extracellular 
virus titer 
(pfu/ml) 
Cell destruction 
cell 
death2 
(%)                                                                           
IFA                                                                                                
aN3 
positive
IFA
aNSP14 
positive
P54 9.3×103 partial recovery     P75 5.7×105 partial destuction    
P55 2.6×102 partial recovery  0.4% 0.9%  P76 3.8×105 recovery    
P56 5.1×102 partial recovery     P77 9.7×104 recovery    
P57 3.0×104 recovery     P78 5.0×105 recovery 12.5% 15.6% 16.8% 
P58 1.1×106 partial destuction     P79 6.9×105 recovery    
P59 2.8×106 cell destuction     P80 2.4×105 recovery    
P60 2.9×104 partial recovery     P81 5.7 ×105 partial destuction    
P61 1.4×105 recovery     P82 5.5 × 105 partial destuction    
P62 4.4×105 recovery     P83 1.4 × 105 recovery    
P63 4.9×105 partial destuction     P84 1.6 × 105 recovery    
P64 6.2×105 cell destuction     P85 2.9 × 105 recovery    
P65 6.0×105 cell destuction     P86 1.7 × 105 recovery    
P66 7.5×105 cell destuction     P87 3.7 × 105 recovery    
P67 3.5×105 partial recovery     P88 5.2 × 105 partial destuction    
P68 2.7×105 partial recovery     P89 2.8 × 105 recovery    
P69 1.8×105 partial recovery     P90 1.1 × 105 recovery    
P70 3.1×105 partial recovery     P91 1.1 × 105 recovery    
P71 1.9×105 partial recovery     P92 1.8 × 105 recovery    
P72 1.4×105 recovery     P93 7.3 × 104 recovery    
P73 3.1×105 partial destuction     P94 1.9 × 105 recovery    
P74 5.5×105 partial destuction           
 
Note: 1 Persistent infection was initiated in Hela ‘High’ (P171) cell line with the VBS53 strain of EAV.  
          2 Cell death was determined by trypan blue staining as described in Materials and Methods. 
          3 aN - monoclonal antibody 3E2 against EAV nucleocapsid protein.   
          4 aNSP1 – monoclonal antibody 12A4 against EAV non-structural protein 1.  
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Table 3.4 Ratio of extracellular to cell-associated virus at selected passage levels of the persistently infected 
 Hela ‘High’ cell line initiated with the VBS53 strain of EAV 
 
Virus titer (pfu/ml) Passage number of 
persistently infected 
Hela ‘High’ cells Extracellular virus Cell-associated virus 
Ratio of extracellular to cell- 
associated virus*  
P1 
P24 
P50 
P51 
P68 
P74 
P80 
P81 
P82 
P83 
P86 
P88 
6.0 × 104 
3.9 × 105 
6.8 × 105 
3.1 × 106 
2.7 × 105 
5.5 × 105 
2.4 × 105 
5.7 × 105 
5.5 × 105 
1.4 × 105 
1.7 × 105 
5.2 × 105 
5.0 × 104 
7.3 × 105 
9.6 × 105 
4.2 × 106 
5.3 × 105 
8.1 × 105 
5.2 × 105 
9.0 × 105 
7.6 × 105 
2.4 × 105 
2.3 × 105 
7.1 × 105 
54.5 : 45.5 
34.8 : 65.2 
41.5 : 58.5 
42.5 : 57.5 
33.8 : 66.2 
40.4 : 59.6 
31.6 : 68.4 
38.8 : 61.2 
42.0 : 58.0 
36.8 : 63.2 
42.5 : 57.5 
42.3 : 57.7 
 
* Determined 4 days after cells were subcultured. 
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Table 3.5 Effect of EAV neutralizing antibody-positive equine serum on the persistently infected  
Hela ‘High’ cell line initiated with the VBS53 strain of EAV* 
 
In EMEM with 10% FSCS  In EMEM with 10% EAV Ab-positive equine serum 
In EMEM with 10% FSCS (previously in 
EMEM with 10% EAV Ab-positive 
equine serum)     
Passage 
number 
Extracellular 
Virus 
(pfu/ml) 
Cell-
associated 
Virus 
(pfu/ml) 
IFA 
 
RT-
PCR 
result 
Extracellular 
Virus 
(pfu/ml) 
Cell-
associated 
Virus 
(pfu/ml) 
IFA 
 
RT-
PCR 
result 
Extracellular 
Virus 
(pfu/ml) 
Cell-
associated 
Virus 
(pfu/ml) 
IFA 
 
RT-
PCR 
result 
PI 81 5.7 × 105 9.0 × 105  + + 5.7 × 105 9.0 × 105 + + NA† NA NA NA 
PI 82 5.5 × 105 7.6 × 105 + + 4.0 × 100 1.2 × 103 + + NA NA NA NA 
PI 83 1.4 × 105 2.4 × 105 + + 0 2.5 × 100 -  + NA NA NA NA 
PI 84 1.6 × 105 5.6 × 105 + + 0 0 -  + NA NA NA NA 
PI 85 2.9 × 105 6.9 × 105 + + 0 0 -  + NA NA NA NA 
PI 86 1.7 × 105 2.3 × 105 ND‡ + 0 0 ND -  NA NA NA NA 
PI 87 3.7 × 105 1.2 × 106 + + 0 0 -  -  NA NA NA NA 
PI 88 5.2 × 105 7.1 × 105 + + 0 0 -  -  0 0 -  -  
PI 89 2.8 × 105 7.6 × 105 ND + 0 0 ND -  0 0 -  -  
PI 90 1.1 × 105 2.5 × 105 + + 0 0 -  -  0 0 -  -  
PI 91 1.1 × 105 2.3 × 105 ND + 0 0 ND -  0 0 -  -  
PI 92 1.8 × 105 3.4 × 105 + + 0 0 -  -  0 0 -  -  
PI 93 7.3 × 104 2.8 × 105 ND + 0 0 ND -  0 0 -  -  
PI 94 1.9 × 105 6.5 × 105 + + 0 0 -  -  0 0 -  -  
* The 81st passage of persistently infected Hela ‘High’ cells were subcultured and grown in EMEM with 10% ferritin supplemented calf serum (FSCS), and 
EMEM with 10% EAV-neutralizing Ab-positive equine serum, respectively. Serial subcultivation of the cultures grown in each kind of medium was carried 
out once every four days (1:4 split ratio). From the 88th passage, EAV Ab-positive equine serum was removed from the medium of one replicate of the culture 
which was further passed up to the 94th passage. The other replicate of the culture was passed still in the presence of EAV Ab-positive equine serum up to the 
94th passage. At each passage, extracellular and cell-associated virus was harvested and titrated by plaque assay. Expression of the viral nucleocapsid (N) 
protein was examined using IFA. RT-PCR detection of viral RNA at each passage was also carried out. 
† NA—Not applicable. ‡ ND—Not done. 
  
116
Table 3.6.  Comparison of nucleotide and amino acid sequences of VBS53 EAV, Hela-EAVP35, and Hela-EAVP80 
Nucleotide1 Modified Amino Acid2 
Leader or ORF Protein (aa length) 
Position VBS53 EAV 
Hela-
EAVP35 
Hela-
EAVP80 Position 
VBS53 
EAV 
Hela-
EAVP35 
Hela-
EAVP80 
5' NTR (1-224) N/A3 - 4 -  -  -      
5' Leader (1-211) N/A -  -  -  -      
ORF1ab (225-9751) Nonstructural proteins (nsp)         
 1ab polyprotein (3175)         
 nsp1: Met1-Gly260 (260) 658 C T T 145 Ala Val Val 
  695 C C T     
 nsp2: Gly261-Gly831 (571) 1280 C C T     
  1889 T C C     
  1954 A G G 577 Asp Gly Gly 
  1979 C T T     
  2057 C T T     
  2483 A A T     
 nsp3: Gly832-Glu1064 (233) 2898 C C T     
  3011 G G A     
 nsp4: Gly1065-Glu1268 (204) 3707 Y5 C C     
  3797 T T C     
 nsp5: Ser1269-Glu1430 (162) 4349 G A A     
 nsp6: Gly1431-Glu1452 (22) -  -  -  -  -  -  -  -  
 nsp7: Ser1453-Glu1677 (225) 4900 A G G 1559 Lys Arg Arg 
  4913 T C T     
 
nsp8/9: Gly1678-Asn1727 
(50)/Glu2370(693) 6020 C C T 1933 Pro Pro Ser 
  6752 T C C     
  7021 R5 A A     
 nsp10: Ser2371-Gln2837 (467) 8260 Y C C     
  8290 Y C C     
  8398 T T C     
 nsp11: Ser2838-Glu3056 (219) -  -  -  -  -  -  -  -  
  nsp12: Gly3057-Val3175 (119) 9727 T C T         
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(Table 3.6 continued) 
Nucleotide1 Modified Amino Acid2 
Leader or ORF Protein (aa length) 
Position VBS53 EAV 
Hela-
EAVP35 
Hela-
EAVP80 Position 
VBS53 
EAV 
Hela-
EAVP35 
Hela-
EAVP80 
 Structure proteins         
ORF2a (9751-9954) E (67) 9867 T C C     
  9907 A A T 53 Ser Ser Cys 
  9914 T C C 55 Val Ala Ala 
ORF2b (9824-10507) GP2b (227) 9867 T C C 15 Leu Ser Ser 
  9907 A A T     
  9914 T C C 31 Trp Arg Arg 
  10082 G G C 87 Val Val Leu 
  10085 A G A 88 Met Val Met 
  10157 G A A 112 Ala Thr Thr 
  10189 T C C     
ORF3 (10306-10797) GP3 (163) 10648 A G G 115 Ser Gly Gly 
  10709 T C C 135 Leu Pro Pro 
  10722 Y T T     
ORF4 10700-11158) GP4 (152) 10709 T C C 4 Tyr His His 
  10722 Y T T 8 Leu/Ser6 Leu Leu 
  11024 A A T 109 Ile Ile Phe 
ORF5 (11146-11913) GP5 (255) 11171 T C C 9 Phe Ser Ser 
  11438 C T T 98 Pro Leu Leu 
  11475 T T C     
  11704 T C C     
  11882 G A G 246 Arg Lys Arg 
ORF6 (11901-12389) M (162) -  -  -  -  -  -  -  -  
ORF7 (12313-12645) N (110) -  -  -  -  -  -  -  -  
3' NTR (12646-12704) N/A -  -  -  -            
Note:   1 Nucleotides are numbered according to the published sequence of EAV030 virus (van Dinten et. al., 1997). 
           2  Only missense mutations are shown and silent mutations are not shown. Amino acids of non-structural proteins are numbered according to their location 
              in ORF1ab polyprotein. Amino acids of structural proteins are numbered according to their locations in individual structural protein. 
            3 N/A: Not Applicable.  4 -  No nucleotide and amino acid changes occurred.  5 Y = T or C; R = A or G.  6 Leu/Ser means leucine or serine. 
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Table 3.7 Superinfection experiments with the persistently infected Hela ‘High’ (P171) 
cell line initiated with the VBS53 strain of EAV 
 
EAV Titer (pfu/ml)* 
Cell Line Infection 
1 h p.i. 48 h p.i. 96 h p.i. 
Hela P243 Mock-infection 0 0 0 
Hela P243 Infection with EAV strain VBS53 (moi = 3) 4.5 × 10
3 2.35 × 104 6.4 × 104 
PI 73 Mock-superinfection 4.65 × 103 3.55 × 105 1.65 × 105 
PI 73 Superinfection with EAV strain VBS53 (moi = 3) 1.6 × 10
4 4.45 × 105 1.4 × 105 
* Equine arteritis virus titer was determined by plaque assay on RK-13 (KY) cells. 
   pfu/ml – plaque forming unit per ml. 
 
 
 
Table 3.8 Summary of the ability of VBS53 EAV, Hela-EAVP35, and Hela-EAVP80 to 
establish persistent infection in various cell lines 
 
Cell Lines VBS53 
EAV 
Hela-EAV 
P35 
Hela-EAV 
P80 
Hela ‘High’ + + + 
Hela ‘Low’ - + + 
Hep-2 - - - 
L-M - - - 
BHK-21 - - - 
 
               Note: + Able to establish persistent infection 
                         - Unable to establish persistent infection 
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Fig 3.1 Extracellular virus produced in the persistently infected Hela ‘High’ cell line 
initiated with the VBS53 strain of EAV. Subconfluent monolayers of Hela ‘High’ (P171) 
cells grown in T-25 flasks were inoculated with EAV strain VBS53 at an m.o.i. of 3. 
Following one-hour absorption at 37ºC, the cells were washed three times with PBS and 
10 ml fresh culture medium was added. Inoculated cultures were incubated at 37ºC and 
subcultured once every four days (1:4 split ratio). Extracellular virus was harvested 
before subculturing each cell passage. Virus infectivity was titrated by plaque assay on 
RK-13 (KY) cells. Establishment of persistent infection in Hela ‘High’ cells with the 
VBS53 strain of EAV was confirmed in three separate experiments.    
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Fig 3.2 Indirect immunofluorescence assay on VBS53 EAV-inoculated Hela ‘Low’ and 
persistently infected Hela ‘High’ cell lines. At indicated passages, cells were fixed with 
cold acetone for 10 min, and then washed three times with PBS containing 10mM glycine. 
Slides were incubated with MAb 3E2 against EAV nucleocapsid protein or MAb 12A4 
against EAV NSP1 followed by FITC-conjugated goat antimouse immunoglobulin. The 
cells were counterstained by Evans blue. The images were recorded with a LEICA 
confocal microscope. The VBS53 strain of EAV failed to establish persistent infection in 
Hela ‘Low’ (P98) cells. Passage 1 and passage 2 were shown. The VBS53 strain of EAV 
initiated persistent infection in Hela ‘High’ (P171) cells. The persistently infected cells at 
the 25th (PI 25), 29th (PI 29), 44th (PI 44) and 48th (PI 48) passage were shown.     
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Fig 3.3 RT-PCR detection of viral RNA in persistently infected Hela ‘High’ cells (A) and 
VBS53 EAV-inoculated Hela ‘Low’ cells (B). In (A), the VBS53 strain of EAV 
established persistent infection in Hela ‘High’ (P171) cells. Lanes 1-9 correspond to the 
1st, 10th, 20th, 30th, 40th, 50th, 60th, 70th, and 80th passage of persistently infected Hela 
‘High’ cells, respectively. In (B), Hela ‘Low’ (P98) cells inoculated with the VBS53 
strain of EAV underwent serial subculturing. Lanes 1-8 correspond to the 1st, 2nd, 3rd, 4th, 
5th, 10th, 15th, and 20th passage, respectively. Lane 10 in (A) and lane 9 in (B) are the 
positive controls with RT-PCR amplification of the parental virus VBS53 EAV. Lane 11 
in (A) and lane 10 in (B) are the negative controls of mock-infected Hela ‘High’ and Hela 
‘Low’ cells. Lane 12 in (A) and lane 11 in (B) are negative controls with water as the 
template for RT-PCR.     
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E Fig 3.4 Growth kinetics of VBS53 EAV, 
Hela-EAVP35, and Hela-EAVP80 in 
BHK-21, Hela ‘Low’ (P100), Hela High 
(P198), Hep-2, and L-M cell lines. Each 
cell line was inoculated with respective 
virus at an m.o.i. of 3. At indicated time 
points, virus infectivity in the culture 
supernatant was titrated by plaque assay 
in RK-13 (KY) cells. 
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Fig 3.5 Attempts to establish persistent infection in Hela ‘Low’ (P98), Hela ‘High’ 
(P196), Hep-2, and L-M cell lines with Hela-EAVP35 and Hela-EAVP80. In (A), attempt 
to establish persistent infection in Hep-2 and L-M cells with Hela-EAVP35 and Hela-
EAVP80 was performed. In (B), attempt to establish persistent infection in Hela ‘Low’ 
and Hela ‘High’ cells with Hela-EAVP35 was carried out. The infectivity titers of both 
extracellular and cell-associated viruses at each passage were shown. In (C), attempt to 
establish persistent infection in Hela ‘Low’ and Hela ‘High’ cells with Hela-EAVP80 
was conducted.  
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Fig 3.6 Indirect immunofluorescence assay on persistently infected Hela ‘Low’ and Hela 
‘High’ cell lines initiated with Hela-EAVP35. At indicated passages, cells were fixed 
with cold acetone for 10 min, and then washed three times with PBS containing 10mM 
glycine. Slides were incubated with MAb 12A4 against EAV NSP1 followed by FITC-
conjugated goat antimouse immunoglobulin. The cells were counterstained by Evans blue. 
The images were recorded with a LEICA confocal microscope.  
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Chapter Four 
Genetic Characterization of Equine Arteritis Virus during Persistent Infection of 
Hela Cells and Identification of a New Neutralization Determinant 
 
ABSTRACT 
Persistent EAV infection in Hela cells has been recently established (Chapter 3). It 
has also been shown that EAV evolves during persistent infection with respect to its 
growth properties and its ability to initiate secondary persistent infection (Chapter 3). In 
this study, the viruses recovered from the persistently infected Hela cells were 
characterized for their neutralization phenotypes using EAV-specific monoclonal 
antibodies and EAV strain-specific polyclonal equine antisera. Neutralization phenotypic 
differences were observed between these viruses, indicating that viral variants with novel 
neutralization phenotypes have emerged during persistent infection in Hela cells. 
Sequencing of the entire structural protein genes (ORFs2a, 2b, and 3-7) revealed 
nucleotide and deduced amino acid changes among these viruses. In the case of EAV, 
four neutralization determinant sites have been previously identified within the 
ectodomain of the GP5 protein (site A: aa 49; site B: aa 61; site C: aa 67-90; and site D: 
aa 99-106). All of these previously identified neutralization determinants were conserved 
among the viruses recovered from persistently infected Hela cells, in spite of the fact that 
neutralization phenotypic differences were found between these viruses. This suggested 
that some as yet unidentified neutralization determinant(s) exists. An infectious EAV 
cDNA clone and reverse genetics technology were used to identify additional potential 
neutralization epitope(s). Five chimeric viruses were generated each of which contained 
the corresponding ORF5 (which encodes GP5) of the aforementioned viruses recovered 
from persistently infected Hela cells. The neutralization phenotype of each chimeric virus 
was compared to that of its parental virus from which the substituted ORF5 was derived. 
The replacement of ORF5 correlated with the neutralization phenotypic differences 
determined by most of the EAV-specific monoclonal antibodies, suggesting that the 
unidentified neutralization determinant(s) recognized by these monoclonal antibodies is 
located on the EAV GP5 protein. Site-directed mutagenesis further identified that amino 
acid 98 in the EAV GP5 protein was critical for virus neutralization. Amino acid 98 in 
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the EAV GP5 protein is a previously unrecognized and undescribed neutralization 
determinant. It is suggested that amino acid 98 be classified in neutralization site D which 
is redefined to cover amino acids 98-106. 
  
INTRODUCTION 
Equine arteritis virus (EAV) is the prototype virus in the family Arteriviridae, genus 
Arterivirus in the order Nidovirales (Cavanagh 1997). The family Arteriviridae also 
contains porcine respiratory and reproductive syndrome virus (PRRSV), lactate 
dehydrogenase-elevating virus (LDV), and simian hemorrhagic fever virus (SHFV) 
(Snijder and Meulenberg 1998). The EAV genome is a single-stranded, positive-sense 
RNA molecule of 12.7 kb, which includes nine functional open reading frames (ORFs) 
(Snijder and Meulenberg 1998; Snijder et al. 1999). The two ORFs most proximal to the 
5’ end of the virus (1a and 1b) are approximately 9.5 kb in length and encode two 
replicase polyproteins (1a and 1ab) (de Vries et al. 1997; Snijder and Meulenberg 1998). 
The remaining seven ORFs (2a, 2b, and 3-7) located at the 3’ end of the genome are 
approximately 2.9 kb in length and encode structural proteins E, GP2b, GP3, GP4, GP5, 
M, and N, respectively (den Boon et al. 1991; Snijder and Meulenberg 1998; Snijder et al. 
1999).  
There is only one serotype of EAV (Fukunaga and McCollum 1977; Golnik et al. 
1986), and all strains evaluated thus far are neutralized by polyclonal equine sera raised 
against the virulent Bucyrus strain of EAV (Balasuriya and MacLachlan 2004c). 
However, EAV strains frequently exhibit neutralization phenotypic differences; e.g., 
different EAV strains are neutralized to various degrees with different polyclonal antisera 
and monoclonal antibodies (Balasuriya et al. 1997; 2004a; 2004b; Hedges et al. 1999a). 
The EAV GP5 protein has been shown to express neutralization determinants of the virus 
(Balasuriya et al. 1993; 1995b; 1997; 2004b; Chirnside et al. 1995; Deregt et al. 1994; 
Glaser et al. 1995). The hydropathy profile of the GP5 protein predicts that amino acid 
residues 1-18 constitute the putative signal sequence, 19-116 constitute the hydrophilic 
ectodomain of the protein, while the C-terminal half consists of three membrane-
spanning domains followed by an endodomain of about 64 amino acids (de Vries et al. 
1992; Snijder et al. 2003).  Chirnside et al. (1995) has shown that horses developed 
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EAV-neutralizing antibodies after they were inoculated with either a fusion protein 
including GP5 aa 55-98 or a synthetic peptide corresponding to GP5 aa 75-97. It was 
further demonstrated that an E. coli-expressed recombinant protein comprising the entire 
ectodomain (aa 18-122) of EAV GP5 protein induced high neutralizing antibodies in 
ponies (Castillo-Olivares et al. 2001). These data support the hypothesis that the 
ectodomain (aa 19-116) of EAV GP5 protein is immunodominant. By comparing the 
sequences of neutralization-sensitive EAV and neutralization-resistant viruses (escape 
mutants, EM), Glaser et al. (1995) identified that amino acid residues at 99 and 100 are 
critical for virus neutralization. After extensive comparison of GP5 amino acid sequences 
and neutralization phenotypes of a large number of field and laboratory EAV strains 
using both neutralizing monoclonal antibodies and EAV strain-specific polyclonal equine 
antisera, Balasuriya et al. (1993; 1995b; 1997) identified four distinct neutralization sites. 
These sites include amino acids 49 (site A), 61 (site B), 67-90 (site C), and 99-106 (site D) 
in the GP5 protein. In a recent study, the ORF5 of an infectious EAV clone was replaced 
with that of different laboratory, field, and vaccine strains of EAV, thus generating 
various chimeric viruses (Balasuriya et al. 2004b). The comparative characterization of 
the neutralization phenotypes of chimeric viruses and parental viruses has further 
confirmed the importance of the aforementioned four neutralization sites in the GP5 
protein. Taken together, these studies demonstrated that the ectodomain of the GP5 
protein contains EAV neutralization determinants. Site D includes several overlapping 
linear epitopes. The four neutralization sites (A-D) are conformationally interactive 
(Balasuriya et al. 1997; 2004b). 
An in vitro model of viral persistence involving Hela cell cultures infected with 
EAV has been recently developed (Chapter 3). In this study, it was shown that viral 
variants with novel neutralization phenotypes emerged during persistent infection of Hela 
cells. Sequencing of the entire structural protein genes (ORFs2a, 2b, and 3-7) revealed 
nucleotide and deduced amino acid changes among these viruses. However, all of the 
previously identified neutralization determinants (sites A to D) were conserved among 
the viruses recovered from persistently infected Hela cells, in spite of the fact that 
neutralization phenotypic differences were found between these viruses. This suggested 
that some as yet unidentified neutralization determinant(s) exists. An infectious EAV 
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cDNA clone and reverse genetics technology were used to identify additional potential 
neutralization epitope(s).  
 
MATERIALS AND METHODS 
Cells and viruses. Rabbit kidney (RK-13, KY) and baby hamster kidney (BHK-21) 
cells were maintained in Eagle’s medium (EMEM) with 10% ferritin supplemented calf 
serum (FSCS), penicillin, streptomycin, fungizone, and sodium bicarbonate. The VBS53 
strain of EAV was propagated twice in BHK-21 cells to produce virus stocks which were 
used to establish persistent infection in the Hela ‘High’ cell line. Hela-EAVP10, Hela-
EAVP35, Hela-EAVP60, and Hela-EAVP80 are the viruses isolated from the 10th, 35th, 
60th, and 80th passage levels of the persistently infected Hela ‘High’ cell line, respectively.  
Monoclonal antibodies and polyclonal anti-sera. The development and 
characterization of a panel of 12 neutralizing monoclonal antibodies to GP5 (MAbs 5G11, 
6D10, 7E5, 9F2, 10F11, 10H4, 1H7, 1H9, 5E8, 6A2, 7D4, and 10B4) and non-
neutralizing monoclonal antibodies to the nucleocapsid protein (N; MAb 3E2) and 
nonstructural protein 1 (nsp1; MAb 12A4) of EAV have been previously described 
(Table 4.1; Balasuriya et al. 1993; 1995b; 1997; 2004b; MacLachlan et al. 1998; Wagner 
et al. 2003). The source of EAV strain-specific polyclonal equine antisera (anti-GP5/M, 
anti-KY53, anti-KY84, anti-KY53+KY84, anti-CA95, anti-ARVAC, anti-NVSL, and 
anti-EAV030H) and negative control sera (control sera NVSL and OAT PB) have also 
been previously described (Table 4.1; Balasuriya et al. 2002; 2004b; MacLachlan et al. 
1998; Wagner et al. 2003).  
Sequencing of structural protein genes of Hela-EAVP10 and Hela-EAVP60. 
The entire genomes of EAV strain VBS53, Hela-EAVP35, and Hela-EAVP80 have been 
sequenced (Chapter 3). The structural protein genes (ORFs2a, 2b, and 3-7) of Hela-
EAVP10 and Hela-EAVP60 were sequenced following the procedures described for 
sequencing Hela-EAVP35 and Hela-EAVP80 (Chapter 2). The sequence data and 
alignments results are summarized in Appendices 5, and 7 to 13.  
Construction of chimeric full-length EAV cDNA clones containing ORF5 from 
EAV strains VBS53, Hela-EAVP10, Hela-EAVP35, Hela-EAVP60, and Hela-
EAVP80. EAV infectious cDNA clone pA45 (de Vries et al. 2000; Dobbe et al. 2001) 
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served as the backbone for all chimeric constructs used in this study. In the construct 
pA45, the naturally overlapping ORFs 4 and 5 were separated by a newly introduced 24-
nucleotide sequence containing a unique AflII restriction site (Fig 4.1B). The separation 
did not change the amino acids encoded by ORFs 4 and 5, and did not interfere with virus 
replication. The progeny viruses stably maintained the mutations that were introduced (de 
Vries et al. 2000). A shuttle vector (pS45) containing a BglII (10704)- XhoI (12869) 
fragment of the pA45 plasmid was used for cloning of ORF5 from individual EAV 
strains. To facilitate cloning, a NotI restriction site was inserted downstream of the AflII 
site in the sequence separating ORFs 4 and 5 (Fig 4.1A; Dobbe et al. 2001). Both the 
infectious cDNA clone pA45 and the shuttle vector pS45 were kindly provided by Dr. 
Eric Snijder, Leiden University, the Netherlands. 
The ORF5 sequences were RT-PCR-amplified from EAV strains VBS53, Hela-
EAVP10, Hela-EAVP35, Hela-EAVP60, and Hela-EAVP80 using a forward primer 
11152SD which contains a NotI site upstream of the ORF5 translation initiation codon 
and a reverse primer 11960N which contains a natural XbaI site just downstream of the 
ORF5 sequence (Table 4.5). The PCR products were digested with restriction enzymes 
(NotI and XbaI), and ligated into the pS45 shuttle vector which had been digested with 
the same restriction enzymes (Fig 4.1). The ligation mixture was transformed into Ecoli 
DH5a cells. The colonies were digested with restriction enzymes for screening positive 
clones. The RT-PCR-derived insert was sequenced to confirm that recombinant shuttles 
(pS45VBS53, pS45Hela-EAVP10, pS45Hela-EAVP35, pS45Hela-EAVP60, and 
pS45Hela-EAVP80) contained the correct insert sequences. The BglII-XhoI fragments 
corresponding to ORFs 4-7 and the genomic 3’ end were subcloned from recombinant 
shuttle vectors into the pA45 plasmid to obtain full-length chimeric EAV cDNA clones 
containing ORF5 from individual EAV strains (Fig 4.1). The authenticity of the ORF5 
inserts in full-length chimeric EAV cDNA clones (5rVBS53, 5rHela-EAVP10, 5rHela-
EAVP35, 5rHela-EAVP60, and 5rHela-EAVP80 clones) was confirmed by sequencing. 
Site-directed mutagenesis. The site-specific nucleotide substitution of ORF5 
11438C? T (which results in GP5 98Pro? Leu) in EAV strain VBS53 was carried out at 
the PCR step (Fig 4.2). The first-step PCR was performed with positive primer 
C211156P and negative mutagenic primer 11443N (Table 4.5) using the recombinant 
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shuttle pS45VBS53 as template. The second-step PCR was performed using the mixture 
of the 1st mutagenesis PCR product and the template pS45VBS53 together with negative 
primer 11515N in which the 1st mutagenesis PCR product acted as the positive primer. 
The 2nd mutagenesis PCR product was the desired fragment containing the site-specific 
nucleotide substitution (Fig 4.2). The thermacycling conditions for site-directed 
mutagenesis PCR reactions are shown in Appendix 14. The 2nd mutagenesis PCR 
products were digested with restriction enzymes (NotI and EcoRI) and cloned into the 
shuttle pS45VBS53 to obtain site-mutated shuttle pS45VBS53P98L from which the 
BglII-XhoI fragment was subcloned into the plasmid pA45, thus generating the site-
mutated chimeric EAV cDNA clone 5rVBS53P98L. On completion of each cloning step, 
authenticity of the inserts was confirmed by sequencing. 
In vitro transcription and generation of chimeric viruses. Viral RNA transcripts 
were generated in vitro from each chimeric/mutant infectious cDNA clone as previously 
described (Chapter 2; van Dinten et al. 1997). Full-length RNA transcripts were 
transfected into BHK-21 cells by electroporation in accordance with previously described 
protocols (Chapter 2; Balasuriya et al. 2004b; van Dinten et al. 1997). The cells were 
incubated at room temperature for a 10 min ‘recovery period’ after electroporation and 
then resuspended in 15 ml of culture medium which was previously warmed to room 
temperature. The cells were seeded into T-25 flasks and incubated at 37ºC until 
cytopathic effects were evident. Meanwhile, an aliquot of electroporated cells was seeded 
into 8-chamber slides, incubated at 37ºC for 24 h, and then examined by indirect 
immunofluorescence assay (IFA). Monoclonal antibodies 12A4 and 3E2 specific for 
EAV nonstructural protein 1 and the nucleocapsid protein (N), respectively, were used to 
detect virus replication and protein expression according to previously described 
protocols (Chapter 2). When cytopathic effects were evident (usually 72 h post 
transfection), tissue culture fluids were harvested from T-25 flasks and centrifuged at 
1900 rpm for 10 min at 4ºC.  Infectivity titers of chimeric/mutant viruses (5rVBS53, 
5rVBS53P98L, 5rHela-EAVP10, 5rHela-EAVP35, 5rHela-EAVP60, and 5rHela-
EAVP80) were determined as tissue culture infectious doses (TCID50) using RK-13 (KY) 
cells as the indicator cells. The infectivity titers of these viruses ranged from 104.5 to 105 
TCID50 units per 50 µl. The authenticity of the ORF5 insert in each chimeric/mutant virus 
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was confirmed by RT-PCR amplification and sequencing as previously described 
(Chapter 3).  
Microneutralization assay. Neutralization titers of various monoclonal antibodies 
and polyclonal antisera (Table 4.1) against each virus strain were determined by 
microneutralization assay as previously described (Balasuriya et al. 1995b; 1997; 2004b). 
Briefly, two-fold dilutions of heat-inactivated monoclonal antibodies and polyclonal 
equine antisera were made in EMEM, with the lowest dilution of 1:32 and 1:8, 
respectively. Serially diluted monoclonal antibodies (from 1:32 to 1:4096) and polyclonal 
antisera (from 1:8 to 1:1024) were added to 96-well plates in duplicate for each antibody. 
Then approximately 200 TCID50 of each virus strain was added and mixed with 
monoclonal antibodies or polyclonal antisera. The plates were incubated at 37ºC for 30 
min. A suspension of RK-13 (KY) cells was then added, and cultures were incubated at 
37ºC for 60-72 h until cytopathic effect had fully developed in the control wells. 
Neutralization titers of each antibody against each virus were recorded as the reciprocal 
of the highest final dilution that provided at least 50% protection of the RK-13 (KY) cell 
monolayers. 
 
RESULTS AND DISCUSSION 
Emergence of viral variants with novel neutralization phenotypes during 
persistent EAV infection of Hela cells. Persistent EAV infection in Hela cells has been 
recently established (Chapter 3). It has been shown that EAV evolves during persistent 
infection of cultured cells with respect to its growth properties and its ability to initiate 
secondary persistent infection (Chapter 3). In order to determine whether EAV had 
undergone neutralization phenotypic changes during persistent infection of Hela cells, the 
parental EAV strain VBS53 and the viruses recovered from the 10th (Hela-EAVP10), 35th 
(Hela-EAVP35), 60th (Hela-EAVP60), and 80th (Hela-EAVP80) passage levels of the 
persistently infected Hela ‘High’ cell line were characterized in term of their 
neutralization phenotypes using EAV-specific monoclonal antibodies and EAV strain-
specific polyclonal equine antisera (Table 4.1). Neutralization phenotypic differences 
were observed in these viruses. For example, EAV strains VBS53 and Hela-EAVP10 
were neutralized by monoclonal antibodies (MAbs) 5G11, 6D10, 7E5, 9F2, 10F11, 10H4, 
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and 6A2, whereas Hela-EAVP35, Hela-EAVP60, and Hela-EAVP80 were not 
neutralized by any of these MAbs (Table 4.2). On the other hand, EAV strains VBS53 
and Hela-EAVP10 were resistant to neutralization by MAb 1H7, whereas Hela-EAVP35, 
Hela-EAVP60, and Hela-EAVP80 were neutralized by this MAb (Table 4.2). Similarly, 
some of the EAV strain-specific polyclonal equine antisera (e.g. anti-GP5/M and anti-
EAV030H) neutralized Hela-EAVP80 to a significantly higher titer than EAV strain 
VBS53 (Table 4.3). These findings indicate that viral variants with novel neutralization 
phenotypes emerged during persistent EAV infection in Hela cells. In vivo, it has also 
been repeatedly demonstrated that viruses of different neutralization phenotypes emerge 
during persistent EAV infection of stallions (Balasuriya et al. 1999a; 2001; 2004a; 
Hedges et al. 1999a).  
Comparison of the structural protein genes of EAV strains VBS53, Hela-
EAVP10, Hela-EAVP35, Hela-EAVP60, and Hela-EAVP80. In order to further 
characterize the relationship between EAV structural protein sequences and 
neutralization phenotypes, EAV strains VBS53, Hela-EAVP10, Hela-EAVP35, Hela-
EAVP60, and Hela-EAVP80 were compared for their nucleotide and deduced amino acid 
sequences of the structural protein genes (ORFs 2a, 2b, and 3-7). The entire genomes of 
EAV strains VBS53, Hela-EAVP35, and Hela-EAVP80 have been sequenced previously 
(Chapter 3). In this study, the structural protein genes (ORFs 2a, 2b, and 3-7) of Hela-
EAVP10 and Hela-EAVP60 were sequenced. As shown in Table 4.4, nucleotide and 
amino acid changes were observed in the structural proteins E, GP2b, GP3, GP4, and 
GP5, but not in M and N proteins. The amino acid sequences of structural proteins were 
100% identical between EAV strains VBS53 and Hela-EAVP10 except that the amino 
acid at position 8 of the GP4 protein was Leucine or Serine for VBS53 while Leucine for 
Hela-EAVP10 (Table 4.4). The degree of amino acid identity among Hela-EAVP35, 
Hela-EAVP60, and Hela-EAVP80 was higher than that between any of these strains and 
VBS53 or Hela-EAVP10 (Table 4.4).  
The EAV GP5 protein has been shown to express neutralization determinants of the 
virus (Balasuriya et al. 1993; 1995b; 1997; 2004b; Chirnside et al. 1995; Deregt et al. 
1994; Glaser et al. 1995). To date, four neutralization sites  have been identified for EAV 
and all of them are located within the N-terminal ectodomain of the GP5 protein (site A: 
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amino acid 49; site B: amino acid 61; site C: amino acids 67-90; and site D: amino acids 
99-106) (Balasuriya et al. 1993; 1995b; 1997; 2004b). All of these four neutralization 
sites were conserved among EAV strains VBS53, Hela-EAVP10, Hela-EAVP35, Hela-
EAVP60, and Hela-EAVP80 (Table 4.4), although neutralization phenotypic differences 
were observed among these viruses (Table 4.2). This suggested that some as yet 
unidentified neutralization determinant(s) exists. Since all of the EAV-neutralizing 
monoclonal antibodies that have been characterized thus far recognize the GP5 protein as 
shown by Western blot and/or immunoprecipitation assays (Balasuriya et al. 1993; 1995b; 
1997; Deregt et al. 1994; Glaser et al. 1995), it is suspected that the potential 
neutralization determinant(s) responsible for the neutralization phenotypic differences 
among EAV strains VBS53, Hela-EAVP10, Hela-EAVP35, Hela-EAVP60, and Hela-
EAVP80 is also located on the GP5 protein.   
Generation of GP5 chimeric viruses and neutralization phenotypes of these 
chimeric viruses. To confirm that the potential neutralization determinant(s) responsible 
for the neutralization phenotypic differences among viruses recovered from persistently 
infected Hela cells is located on the GP5 protein, the ORF5 of the infectious EAV cDNA 
clone pA45 was replaced with the respective ORF5 of EAV strains VBS53, Hela-
EAVP10, Hela-EAVP35, Hela-EAVP60, and Hela-EAVP80 (Fig 4.2). The neutralization 
phenotypes of chimeric viruses (5rVBS53, 5rHela-EAVP10, 5rHela-EAVP35, 5rHela-
EAVP60, and 5rHela-EAVP80) were determined with EAV-specific MAbs and EAV-
strain specific polyclonal equine antisera, and compared to those of the parental viruses 
from which the substituted ORF5 was derived (Table 4.2 and 4.3). As shown in Table 4.2, 
chimeric viruses 5rVBS53 and 5rHela-EAVP10 were neutralized by MAbs 5G11, 6D10, 
7E5, 9F2, 10F11, 10H4, and 6A2, whereas none of 5rHela-EAVP35, 5rHela-EAVP60, 
and 5rHela-EAVP80 viruses was neutralized by any of these MAbs. This is consistent 
with the neutralization results of their respective parental viruses with the same MAbs 
(Table 4.2). All of the chimeric viruses 5rVBS53, 5rHela-EAVP10, 5rHela-EAVP35, 
5rHela-EAVP60, and 5rHela-EAVP80 shared the same backbone as the pA45 virus and 
the only differences among them were ORF5 sequences. This would suggest that the 
neutralization phenotypic differences among chimeric viruses detected by above MAbs 
result from differences in the GP5 proteins. The potential neutralization determinant(s) 
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recognized by MAbs 5G11, 6D10, 7E5, 9F2, 10F11, 10H4, and 6A2 are located on the 
EAV GP5 proteins. On the other hand, it was observed that chimeric viruses 5rHela-
EAVP35, 5rHela-EAVP60, and 5rHela-EAVP80 were resistant to neutralization by MAb 
1H7, whereas their parental viruses Hela-EAVP35, Hela-EAVP60, and Hela-EAVP80 
were neutralized by this MAb (Table 4.2). These three chimeric viruses have the same 
ORF5 sequences as their respective parental viruses. This would suggest that 
neutralization of Hela-EAVP35, Hela-EAVP60, and Hela-EAVP80 by MAb 1H7 may 
involve some other structural proteins. Since the M and N proteins of these viruses did 
not show any sequence differences (Table 4.4), it is probable that one or some of 
structural proteins E, GP2b, GP3, and GP4 are involved in neutralization by MAb 1H7. It 
has been previously demonstrated that MAb 1H7 recognizes amino acid 49 of EAV GP5 
protein (Balasuriya et al. 1997; 2004b). Furthermore, individual neutralization sites (A-D) 
interact with one another to form conformation-dependent epitopes (Balasuriya et al. 
1995b; 1997; 2004b). Therefore, it would appear that the neutralization sites are 
conformationally dependent and they not only interact with each other but also may 
interact with other structural proteins.  
Generation of mutant virus with site-specific substitution in the GP5 protein 
and its neutralization phenotype. As has been shown, the potential neutralization 
determinant(s) recognized by MAbs 5G11, 6D10, 7E5, 9F2, 10F11, 10H4, and 6A2 are 
located on the EAV GP5 proteins. Comparison of the GP5 protein sequences revealed 
that there were four amino acid changes (amino acids 9, 98, 202, and 246) among these 
viruses (Fig 4.3). At position 202, only Hela-EAVP60 and 5rHela-EAVP60 were 
different from the other viruses; at position 246, only Hela-EAVP35 and 5rHela-EAVP35 
were different from the other viruses. Based on the fact that EAV strains VBS53, Hela-
EAVP10 and their respective GP5 chimeric viruses were neutralized by MAbs 5G11, 
6D10, 7E5, 9F2, 10F11, 10H4, and 6A2, whereas Hela-EAVP35, Hela-EAVP60, Hela-
EAVP80 and their respective GP5 chimeric viruses were not neutralized by these MAbs, 
amino acids 202 and 246 do not appear to be the potential neutralization determinant(s) 
responsible for neutralization phenotypic differences detected by these MAbs. In contrast, 
amino acids 9 and 98 would appear to be the possible potential neutralization 
determinant(s). Since amino acids 1-18 of the GP5 protein are the putative signal 
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sequence which is cleaved off during transport through the endoplasmic reticulum (de 
Vries et al. 1992; Snijder et al. 2003), amino acid 9 is unlikely to be the potential 
neutralization determinant(s). By exclusion, therefore, amino acid 98 would appear to be 
the potential neutralization determinant. To unequivocally demonstrate this, amino acid 
98 on the GP5 protein of the virus 5rVBS53 was site-specifically mutated from Proline to 
Leucine (Fig 4.2). The neutralization phenotypes of the mutant virus 5rVBS53P98L were 
determined and compared to those of the other viruses (Table 4.2 and 4.3). It was shown 
that 5rVBS53 EAV was neutralized by MAbs 5G11, 6D10, 7E5, 9F2, 10F11, 10H4, and 
6A2, whereas the mutant virus 5rVBS53P98L was resistant to neutralization by these 
MAbs (Table 4.2). This clearly demonstrated that the neutralization phenotypic 
differences were caused by the exchange of Proline to Leucine in amino acid 98. The 
neutralization phenotypes of parental EAV strains and chimeric viruses and their 
respective amino acids at 98 of the GP5 protein are consistent with this finding (Table 4.2 
and Fig 4.3). It has been previously demonstrated that MAb 6A2 recognizes amino acid 
69 of the EAV GP5 protein (Balasuriya et al. 1997; 2004b). This study showed that MAb 
6A2 may also recognize amino acid 98 of the EAV GP5 protein, confirming that 
neutralization epitopes may interact with each other and are conformationally dependent. 
On the other hand, exchange of Proline to Leucine in amino acid 98 did not result in 
VBS53 EAV becoming susceptible to neutralization by MAb 1H7, confirming that the 
neutralization phenotypic differences detected by MAb 1H7 among EAV strains VBS53, 
Hela-EAVP10, Hela-EAVP35, Hela-EAVP60, and Hela-EAVP80 were not caused by 
this site-specific substitution.  
In summary, this study demonstrated that viral variants with novel neutralization 
phenotypes emerged during persistent EAV infection in Hela cells. Previously identified 
four neutralization sites (A-D) were all conserved among viruses recovered from 
persistently infected Hela cells, suggesting the existence of some as yet unidentified 
neutralization determinant(s). Using an infectious EAV cDNA clone and reverse genetics 
technology, it was identified that amino acid 98 on the EAV GP5 protein is a new 
neutralization determinant. It is suggested that amino acid 98 be classified in 
neutralization site D which covers amino acids 98-106.  
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Table 4.1 Monoclonal antibodies and polyclonal antisera to equine arteritis virus 
Antibody Antibody specificity/epitope location (amino acid position and [site])                               recognized by the antibody Reference 
Monoclonal antibodies 
5G11 GP5/99 and 102; [D] Balasuriya et al. 1993; 1995b 
6D10 GP5/99 and 102; [D] Balasuriya et al. 1993; 1995b 
7E5 GP5/99 and 102; [D] Balasuriya et al. 1993; 1995b 
9F2 GP5/99 and 102; [D] Balasuriya et al. 1993; 1995b 
10F11 GP5/99 and 102; [D] Balasuriya et al. 1993; 1995b 
10H4 GP5/99, 102, and 103; [D] Balasuriya et al. 1993; 1995b 
1H7 GP5/49; [A] Balasuriya et al. 1997 
1H9 GP5/69; [C] Balasuriya et al. 1997 
5E8 GP5/61; [B] Balasuriya et al. 1997 
6A2 GP5/69; [C] Balasuriya et al. 1997 
7D4 GP5/69; [C] Balasuriya et al. 1997 
10B4 GP5/99, 102, and 103; [D] Balasuriya et al. 1997 
3E2 N MacLachlan et al. 1998 
12A4 nsp1 Wagner et al. 2003 
   
polyclonal equine antisera  
anti-GP5/M GP5 and M proteins Balasuriya et al. 2002 
anti-KY53 polyclonal MacLachlan et al. 1998 
anti-KY84 polyclonal MacLachlan et al. 1998 
anti-KY53+KY84 polyclonal  
anti-CA95 polyclonal  
anti-ARVAC polyclonal MacLachlan et al. 1998 
anti-NVSL polyclonal Wagner et al. 2003 
anti-EAV030H polyclonal Commercial serum from National Veterinary Services Laboratory 
control serum NVSL Not applicable Commercial serum from National Veterinary Services Laboratory 
control serum  
OAT PB Not applicable  
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Table 4.2 Neutralization titersa of monoclonal antibodies against parental and chimeric equine arteritis viruses 
Monoclonal antibodies  
Virus strain 
  5G11 6D10 7E5 9F2 10F11 10H4 1H7 1H9 5E8 6A2 7D4 10B4 3E2c 12A4d 
VBS53 EAV  4096 >4096 1024 512 >4096 >4096 <32 <32 <32 64 <32 <32 <32 <32 
5rVBS53 EAV >4096 >4096 >4096 >4096 >4096 >4096 32 <32 <32 128 <32 <32 <32 <32 
5rVBS53P98L <32 <32 <32 <32 <32 <32 <32 <32 <32 <32 <32 <32 <32 <32 
Hela-EAVP10 4096 >4096 2048 1024 >4096 >4096 <32 <32 <32 512 <32 <32 <32 <32 
5rHela-EAVP10 4096 >4096 2048 2048 >4096 >4096 <32 <32 <32 512 <32 <32 <32 <32 
Hela-EAVP35  <32 <32 <32 <32 <32 <32 2048 <32 <32 <32 <32 <32 <32 <32 
5rHela-EAVP35  <32 <32 <32 <32 <32 <32 <32 <32 <32 <32 <32 <32 <32 <32 
Hela-EAVP60b <32 <32 <32 <32 <32 <32 2048 <32 <32 <32 <32 <32 <32 <32 
5rHela-EAVP60b <32 <32 <32 <32 <32 <32 <32 <32 <32 <32 <32 <32 <32 <32 
Hela-EAVP80  <32 <32 <32 <32 <32 <32 >4096 <32 <32 <32 <32 <32 <32 <32 
5rHela-EAVP80  <32 <32 <32 <32 <32 <32 <32 <32 <32 <32 <32 <32 <32 <32 
a Neutralization titers are expressed as the inverse of the antibody dilution providing 50% protection of RK-13 (KY) cell monolayers against 200 TCID50 of virus 
b Neutralization titers are expressed as the inverse of the antibody dilution providing 50% protection of RK-13 (KY) cell monolayers against 100 TCID50 of virus 
c control MAb to N protein of EAV 
d control Mab to nsp1 of EAV 
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Table 4.3 Neutralization titersa of polyclonal equine antisera against parental and chimeric equine arteritis viruses 
Polyclonal equine antisera 
Virus strain 
 Anti-
GP5/M 
Anti-
KY53+KY84 
Anti-
KY84 
Anti-
CA95 
Anti-
ARVAC 
Anti-
EAVNVSL 
Anti-
EAV030H 
Anti-
KY53 
NVSL 
NEGc OAT PB
d 
VBS53 EAV  8 >1024 256 512 8 64 64 256 <8 <8 
5rVBS53 EAV 64 >1024 1024 >1024 32 256 512 >1024 <8 <8 
5rVBS53P98L 128 >1024 >1024 >1024 32 256 1024 >1024 <8 <8 
Hela-EAVP10 16 >1024 256 512 <8 128 256 1024 <8 <8 
5rHela-EAVP10 128 >1024 1024 1024 64 128 256 1024 <8 <8 
Hela-EAVP35  64 >1024 512 1024 16 256 128 512 <8 <8 
5rHela-EAVP35  256 >1024 1024 1024 16 512 256 1024 <8 <8 
Hela-EAVP60b 128 >1024 512 1024 16 512 256 512 <8 <8 
5rHela-EAVP60b 256 >1024 >1024 >1024 32 256 512 >1024 <8 <8 
Hela-EAVP80  1024 >1024 >1024 >1024 32 512 1024 1024 <8 <8 
5rHela-EAVP80 128 >1024 >1024 >1024 32 128 1024 1024 <8 <8 
a Neutralization titers are expressed as the inverse of the antibody dilution providing 50% protection of RK-13 (KY) cell monolayers against 200 TCID50 of virus 
b Neutralization titers are expressed as the inverse of the antibody dilution providing 50% protection of RK-13 (KY) cell monolayers against 100 TCID50 of virus 
c,d Negative control equine serum 
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Table 4.4 Comparison of structural protein genes of EAV strains VBS53, Hela-EAVP10, -P35, -P60, and -P80 
Leader or ORF Protein (aa length) Nucleotide location1 
Amino acid 
location2 VBS53 EAV 
Hela-
EAVP10 
Hela-
EAVP35 
Hela-
EAVP60 
Hela-
EAVP80 
ORF2a (9751-9954) E (67) 9867 39 T (Val)3 C (Val) C (Val) C (Val) C(Val) 
  9907 53 A (Ser) A (Ser) A (Ser) T (Cys) T (Cys) 
  9914 55 T (Val) T (Val) C (Ala) C (Ala) C (Ala) 
         
ORF2b (9824-10507) GP2b (227) 9867 15 T (Leu) T (Leu) C (Ser) C (Ser) C (Ser) 
  9907 28 A (Ala) A (Ala) A (Ala) T (Ala) T (Ala) 
  9914 31 T (Trp) T (Trp) C (Arg) C (Arg) C (Arg) 
  10082 87 G (Val) G (Val) G (Val) C (Leu) C (Leu) 
  10085 88 A (Met) A (Met) G (Val) A (Met) A (Met) 
  10157 112 G (Ala) G (Ala) A (Thr) A (Thr) A (Thr) 
  10189 122 T (Ile) C (Ile) C (Ile) C (Ile) C (Ile) 
  10267 148 T (Tyr) T (Tyr) T (Tyr) C (Tyr) T (Tyr) 
         
ORF3 (10306-10797) GP3 (163) 10648 115 A (Ser) A (Ser) G (Gly) G (Gly) G (Gly) 
  10709 135 T (Leu) T (Leu) C (Pro) C (Pro) C (Pro) 
  10722 139 Y (Ile) T (Ile) T (Ile) T (Ile) T (Ile) 
         
ORF4 (10700-11158) GP4 (152) 10709 4 T (Tyr) T (Tyr) C (His) C (His) C (His) 
  10722 8 Y (Leu/Ser)4 T (Leu) T (Leu) T (Leu) T (Leu) 
  11024 109 A (Ile) A (Ile) A (Ile) T (Phe) T (Phe) 
         
ORF5 (11146-11913) GP5 (255) 11171 9 T (Phe) T (Phe) C (Ser) C (Ser) C (Ser) 
  11438 98 C (Pro) C (Pro) T (Leu) T (Leu) T (Leu) 
  11475 110 T (Ile) T (Ile) T (Ile) C (Ile) C (Ile) 
  11704 187 T (Leu) T (Leu) C (Leu) C (Leu) C (Leu) 
  11749 202 A (Ile) A (Ile) A (Ile) G (Val) A (Ile) 
  11882 246 G (Arg) G (Arg) A (Lys) G (Arg) G (Arg) 
         
ORF6 (11901-12389) M (162) - 5 -  -  -  -  -  -  
ORF7 (12313-12645) N (110) -  -  -  -  -  -  -  
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Notes to Table 4.4:    
1 Nucleotides are numbered according to the published sequence of EAV030 virus (van Dinten et al. 1997). 
2 Amino acids of structural proteins are numbered according to their locations in individual structural protein. 
3 Nucleotide and amino acid changes are shown. Amino acid is shown by three-letter symbols in parenthesis. Missense mutations are shown in bold. 
4 Leu/Ser means leucine or serine. 
5 -  No nucleotide and amino acid changes occurred. 
 
 
Table 4.5 Oligonucleotide primers used for RT-PCR amplification 
Primer ID Polarity Sequence (5'-3') Position (nt) 
Primers for cloning entire ORF5 from EAV strains VBS53, Hela-EAVP10, -P35, -P60, and -P80                                                  
into the shuttle vector pS45  
11152SD Positive TCT GTG AAC TTA AGG CGG CCG CAG CAT GTT ATC TAT GAT TG 11152-11176a/11146-11161b 
11960N Negative AAA GTA ATC TAG ATA CTC ACC TAA AAT CCC GTC ACC ACA AAA TGA ATC TA 11960-11911b 
    
Primers for site-directed mutagenesis  
C211156P Positive GGC TCA ACG CTG TTA TCT GTG AAC 11137-11160a 
11443Nc Negative TGT ACA GTC CAT GCG CCT GTT CCA 
11443-11420b                                                     
(nt change at positive sense 
strand: 11438 C? T; aa 
change GP5 98 Pro? Leu);  
mutagenesis of ORF5 from 
VBS53 EAV  
11515N Negative ACA CAT CCA ACA CAA CTA TGC C 11515-11494b 
a Nucleotide sequence from the plasmid pS45 and numbered accordingly.                                                                                                                                                                                     
b EAV sequence numbered according to the pEAV030 sequence and the NotI site in the primer 11152SD is underlined; natural XbaI site in the primer 11960N 
is underlined and italicized.                                                                                                                                                                                                                                                        
c Mutagenesis primer and the mutated nucleotide is underlined and in bold. 
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BglII 
(10704) 
XhoI 
(12869) 
ORF4
ORF6
ORF7ORF5 AAAAAn 35 
CGCTGTTATCTGTGAacttaaggcggccgcagcatgctgtccatgaTT
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▲ 
ORF4 stop codon 
▲ 
ORF5 start codon 
XbaI 
pS45 shuttle vector  
containing BglII  XhoI fragment  
1a
1b 2b
2a
4
3
75
6
AAAAAn 3 
BglII 
(10704)
XhoI 
(12869)
CGCTGTTATCTGTGAacttaagcaacatgctgtccatgaTT
AflII ▲ 
ORF4 stop codon 
▲ 
ORF5 start codon 
5 
pA45 plasmid 
A 
B 
AflII 
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Fig 4.1 Flow diagram outlining construction of the full-length chimeric clone which contains ORF5 from different strains of EAV 
using the backbone of the infectious cDNA clone pA45 (de Vries et al. 2000; Dobbe et al. 2001) and generation of chimeric viruses. 
In A and B, the nucleotides that were inserted to separate ORFs 4 and 5 are shown in lowercase. See Materials and Methods for details. 
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Fig 4.2 Flow diagram outlining the site-directed mutagenesis of EAV ORF5 11438C? T 
in plasmid pS45VBS53. In step 1, the mutation was introduced to the DNA by 
performing PCR with positive primer C211156P and negative mutagenic primer 11443N 
using the template pS45VBS53. In step 2, the 1st mutagenesis PCR product was mixed 
with the template pS45VBS53 and PCR was performed with positive primer (the 1st 
mutagenesis PCR product acting as positive primer) and negative primer 11515N. The 
2nd mutagenesis PCR product is the desired fragment containing site-specific nucleotide 
substitution.  
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                1                                               50                                               100 
VBS53EAV        MLSMIVLLFLLWGAPSHAYFSYYTAQRFTDFTLCMLTDRGVIANLLRYDEHTALYNCSASKTCWYCTFLDEQIITFGTDCNDTYAVPVAEVLEQAHGPYS 
5rVBS53         ........F........................................................................................P.. 
5rVBS53P98L     ........F........................................................................................L.. 
Hela-EAVP10     ........F........................................................................................P.. 
5rHela-EAVP10   ........F........................................................................................P.. 
Hela-EAVP35     ........S........................................................................................L.. 
5rHela-EAVP35   ........S........................................................................................L.. 
Hela-EAVP60     ........S........................................................................................L.. 
5rHela-EAVP60   ........S........................................................................................L.. 
Hela-EAVP80     ........S........................................................................................L.. 
5rHela-EAVP80   ........S........................................................................................L.. 
                
                101                                            150                                               200 
VBS53EAV        VLFDDMPPFIYYGREFGIVVLDVFMFYPVLVLFFLSVLPYATLILEMCVSILFIIYGIYSGAYLAMGIFAATLAIHSIVVLRQLLWLCLAWRYRCTLHAS 
5rVBS53         .................................................................................................... 
5rVBS53P98L     .................................................................................................... 
Hela-EAVP10     .................................................................................................... 
5rHela-EAVP10   .................................................................................................... 
Hela-EAVP35     .................................................................................................... 
5rHela-EAVP35   .................................................................................................... 
Hela-EAVP60     .................................................................................................... 
5rHela-EAVP60   .................................................................................................... 
Hela-EAVP80     .................................................................................................... 
5rHela-EAVP80   .................................................................................................... 
                
                201                                            250 
VBS53EAV        FISAEGKVYPVDPGLPVAAAGNRLLVPGRPTIDYAVAYGSKVNLVRLGAAEVWEP- 
5rVBS53         .I...........................................R.........- 
5rVBS53P98L     .I...........................................R.........- 
Hela-EAVP10     .I...........................................R.........- 
5rHela-EAVP10   .I...........................................R.........- 
Hela-EAVP35     .I...........................................K.........- 
5rHela-EAVP35   .I...........................................K.........- 
Hela-EAVP60     .V...........................................R.........- 
5rHela-EAVP60   .V...........................................R.........- 
Hela-EAVP80     .I...........................................R.........- 
5rHelaEAVP80    .I...........................................R.........-                
 
Fig 4.3 Aligned deduced amino acid sequence of the GP5 proteins of parental and chimeric equine arteritis viruses. 
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Chapter Five 
Potential Changes in Pathogenicity of Equine Arteritis Virus 
During Persistent Infection of Hela Cells 
 
ABSTRACT 
A previously described in vitro assay has shown that the growth characteristics of 
different EAV strains in equine endothelial cells can generally be related to the 
pathogenicity of individual strains of the virus for horses [Moore et al. (2002) Virology 
298, 39-44; Moore et al. (2003) Am J Vet Res 64, 779-84]. Virulent strains of EAV 
usually replicated more quickly, caused larger plaques, and gave rise to more rapid cell 
lysis in equine endothelial cells than did avirulent strains of the virus. In the present study, 
this in vitro assay was used to investigate whether virus recovered from Hela cells 
persistently infected with EAV differed in characteristics from the original strain of EAV 
used to initiate infection. It was found that viruses recovered from persistently infected 
Hela cells over time progressively caused smaller and smaller plaques in equine 
endothelial cells, suggesting that EAV probably became less virulent during the course of 
persistent infection in Hela cells. Since the actual virulence of different EAV strains can 
only be definitely determined in horses, the potential changes in pathogenicity of EAV 
during persistent infection of Hela cells need to be verified by challenge studies in horses. 
 
INTRODUCTION 
Equine arteritis virus (EAV) is the causative agent of equine viral arteritis (EVA), a 
globally distributed infectious disease of equids (Timoney and McCollum 1993). EAV is 
a single-stranded, positive sense RNA virus and the prototype member of the family 
Arteriviridae in the order Nidovirales (Cavanagh 1997). Only one serotype of EAV has 
been recognized (Fukunaga and McCollum 1977; Golnik et al. 1986), and all strains 
evaluated thus far are neutralized by polyclonal equine sera raised against the virulent 
Bucyrus strain of EAV (Balasuriya and MacLachlan 2004c). However, geographically 
and temporally distinct EAV isolates vary not only antigenically but also in the severity 
of the clinical disease they induce and in their abortigenic potential (Balasuriya et al. 
1998; 1999b; Balasuriya and MacLachlan 2004c; McCollum and Timoney 1999; 
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Timoney and McCollum 1993). While the majority of field strains of EAV cause 
subclinical infection in horses, some strains can cause the clinical manifestations of EVA. 
For example, the virulence of certain EAV strains for horses has been defined: highly 
virulent (VBS53 and ATCC EAV), moderately virulent (KY84, CAN86, AZ87, and 
IL93), mildly virulent (SWZ64, AUT68, IL94, and CA97), and putatively avirulent 
(KY63, PA76, KY77, CA95G, and ARVAC vaccine) strains of EAV (MacLachlan et al. 
1996; McCollum 1981; McCollum and Timoney 1984; McCollum et al. 1995; McCollum 
and Timoney 1999; Moore et al. 2003b; Patton et al. 1999; Timoney and McCollum 
1993).  
EAV has a particular tropism for macrophages and vascular endothelium in infected 
horses, and the clinical manifestations of EVA reflect endothelial injury (Crawford and 
Henson 1973; Del Piero 2000; Estes and Cheville 1970; MacLachlan et al. 1996; 
McCollum 1981). An in vitro assay has recently been developed (Moore et al. 2002; 
2003b) which has been used to investigate the virulence of various strains of EAV in 
horses. Comparison of growth characteristics in equine endothelial cells (EECs) of 
various EAV strains whose virulence had been previously determined in horses revealed 
that virulent strains of EAV generally replicated more quickly, caused larger plaques, and 
led to more rapid cell lysis in cultured EECs than the avirulent strains did. However, 
there was one notable exception. The highly attenuated modified live vaccine strain of 
EAV caused larger plaques in equine endothelial cells than known virulent strains of the 
virus (Moore et al. 2003b). Based on the findings of the studies, it was concluded that 
primary equine endothelial cells can serve as a very useful in vitro model for 
characterizing the virulence of EAV (Moore et al. 2002; 2003b). It was found that 
virulent and avirulent strains of EAV induced different quantities of proinflammatory 
cytokines in alveolar and blood-derived equine macrophages (Moore et al. 2003a). 
Persistent infection of Hela cells with EAV has been recently established (Chapter 
3). It has been shown that EAV evolves during persistent infection with respect to its 
growth properties, ability to initiate secondary persistent infection (Chapter 3), and its 
genetic and neutralization phenotypic characteristics (Chapter 4). The objective of the 
present study was to investigate whether the pathogenicity of EAV had changed in the 
course of persistent infection in Hela cells. To achieve this goal, the in vitro assay 
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described by Moore et al. (2002; 2003b) was used to investigate and estimate the 
virulence of viruses recovered from persistently infected Hela cells. The actual 
pathogenicity of these viruses will require challenge studies in horses.   
 
MATERIALS AND METHODS 
Cells and viruses. Rabbit kidney (RK-13, KY) cells and baby hamster kidney 
(BHK-21) cells were maintained in Eagle’s medium (EMEM) with 10% ferritin 
supplemented calf serum (FSCS), penicillin, streptomycin, fungizone, and sodium 
bicarbonate. The isolation and purification of primary equine endothelial cells (EEC) has 
been previously described in detail (Hedges et al. 2001; Moore et al. 2003b). Equine 
endothelial cells were kindly provided by Drs. Udeni Balasuriya and James MacLachlan 
at University of California, Davis. Equine endothelial cells were maintained in 
Dulbecco’s modified essential medium (DMEM) with sodium pyruvate, 10% fetal bovine 
serum, penicillin, streptomycin, non-essential amino acids, and L-glutamine. All 
experiments were performed on EECs between passages 10 and 15. The VBS53 strain of 
EAV was propagated twice in BHK-21 cells to produce virus stocks which were used to 
establish persistent infection in the Hela ‘High’ cell line. Hela-EAVP10, Hela-EAVP20, 
Hela-EAVP35, Hela-EAVP50, Hela-EAVP60, and Hela-EAVP80 are the viruses isolated 
from the 10th, 20th, 35th, 50th, 60th, and 80th passage levels of the persistently infected Hela 
‘High’ cell line, respectively.  
Growth of various EAV strains in EECs and RK-13 cells. Each virus (VBS53, 
Hela-EAVP10, Hela-EAVP20, Hela-EAVP35, Hela-EAVP50, Hela-EAVP60, and Hela-
EAVP80) was diluted to approximately 100 pfu per ml and inoculated onto confluent 
monolayers of EECs or RK-13 cells. Each virus strain was inoculated into six T-25 flasks 
with an inoculum of 1 ml of diluted virus per flask. After one hour’s incubation at 37ºC, 
cell monolayers were overlaid with EMEM containing 0.75% carboxymethyl cellulose. 
Inoculated cultures were incubated at 37ºC, and cytopathic effects were checked daily. At 
each of the following time points, 48, 72, and 87 h post inoculation, duplicates of the 
inoculated cell cultures were stained with 10% formalin buffered crystal violet. Of the 
cultures stained at 87 h post inoculation, at least 50 plaques were measured to determine 
mean plaque size. 
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RESULTS AND DISCUSSION 
Genetic variation and divergent phenotypic properties (e.g. neutralization and 
virulence) have been repeatedly demonstrated among field isolates and laboratory 
adapted strains of EAV. Persistently infected stallions (carrier stallions) are thought to be 
a natural source of genetic and phenotypic diversity of EAV (Balasuriya et al. 2004a; 
Balasuriya and MacLachlan 2004c; Hedges et al. 1999a). An in vitro model of EAV 
persistence in Hela cells has been recently established (Chapter 3) to help characterize 
virus evolution during persistent infection. It has been shown that EAV evolves during 
persistent infection in cell culture with respect to its growth properties, ability to initiate 
secondary persistent infection (Chapter 3), and genetic and neutralization phenotypic 
characteristics (Chapter 4). In order to determine whether the pathogenicity of EAV had 
changed during persistent infection of Hela cells, an in vitro assay described by Moore et 
al. (2002; 2003b) was used to investigate the virulence of viruses recovered from 
persistently infected Hela cells. All of the EAV strains (VBS53, Hela-EAVP10, Hela-
EAVP20, Hela-EAVP35, Hela-EAVP50, Hela-EAVP60, and Hela-EAVP80) caused lytic 
infections in both RK-13 and primary equine endothelial cells. However, the onset of 
cytopathic effect (CPE) differed in RK-13 and EECs. In EEC cells, CPE became evident 
at 48 h post inoculation, and typical plaques could be observed after cells were stained. 
However, in RK-13 cells, CPE was not apparent even at 72 h post inoculation, and 
plaques were not clear after cells were stained at either 48 h or 72 h post inoculation. At 
87 h post inoculation, CPE in both EECs and RK-13 cells was evident and plaques were 
clearcut and readily measurable after staining. Therefore, it was decided to determine and 
compare plaque size of each virus in RK-13 and EECs at 87 h post inoculation. 
As shown in Table 5.1 and Fig 5.1, EAV strain VBS53 produced significantly 
larger plaques in EECs than all of the other EAV strains evaluated (Hela-EAVP10, -P20, 
-P35, -P50, -P60, and -P80; P < 0.002 between VBS53 EAV and Hela-EAVP10; P < 
0.001 between VBS53 EAV and any other EAV strains); Hela-EAVP10 produced 
significantly larger plaques in EECs than Hela-EAVP20, -P35, -P50, -P60, and -P80 did 
(P < 0.001); Hela-EAVP20 produced significantly larger plaques in EECs than Hela-
EAVP35, -P50, -P60, and -P80 did (P < 0.001); Hela-EAVP35 produced significantly 
larger plaques in EECs than did Hela-EAVP50 (P < 0.001), -P60 (P < 0.002), and -P80 (P 
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<0.001); there was no significant difference in plaque size among Hela-EAVP50, -P60, 
and -P80 strains (P > 0.1). In contrast, there was no significant difference in the size of 
plaques produced by all seven of these EAV strains in RK-13 cells. If the size of plaques 
produced by EAV in EECs truly reflects the virulence of a virus strain for horses, these 
findings would suggest that EAV became progressively less virulent during the course of 
persistent infection in Hela cells up to the 50th passage in cell culture after which there 
did not appear to be any further reduction in viral virulence.  
However, the actual pathogenicity of these EAV strains needs to be definitively 
determined by challenge studies in horses. Determination of the pathogenicity of these 
viruses recovered from persistently infected Hela cells for horses is currently in progress. 
If EAV, by serial passage in persistently infected Hela cells, should prove to become 
progressively less virulent for the horse, that is not without precedent. It has been 
previously demonstrated that foot-and-mouth disease virus became progressively less 
virulent for mice and cattle during the course of persistence in BHK-21 cells (Diez et al. 
1990b). So far, the genetic determinants of EAV virulence have not been defined. 
Alignment of available nucleotide and amino acid sequences of a variety of EAV strains 
with varying virulence (e.g. EAV strains VBS53, KY84, CAN86, AZ87, IL93, SWZ64, 
AUT68, IL94, CA97, KY63, PA76, KY77, CA95G, and ARVAC vaccine) failed to 
identify a unique mutation that could possibly distinguish virulent strains from avirulent 
strains (data not shown). It would suggest that virulence differences between EAV strains 
are probably determined by a combination of multiple mutations or by mutation(s) 
present in the fragment of the genome whose sequences are not available yet for most of 
the aforementioned EAV strains. Therefore, comparison of the entire genomes of EAV 
strains that differ in virulence for horses may be the appropriate way to identify the target 
gene(s) responsible for EAV virulence. At this time, entire genome sequences are only 
available for a few EAV strains, e.g. the VBS53 strain (Chapter 3), ARVAC vaccine 
strain (Balasuriya et al., unpublished), EAV030 virus generated from the infectious 
cDNA clone EAV030 (Balasuriya et al. 1999b; van Dinten et al. 1997), Hela-EAVP35 
and Hela-EAVP80 (Chapter 3). Among these strains, VBS53 EAV has demonstrated 
virulent properties (MacLachlan et al. 1996; McCollum et al. 1971); the ARVAC vaccine 
strain and EAV030 virus have been demonstrated avirulent (Balasuriya et al. 1999b; 
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McCollum 1986); the virulence of Hela-EAVP35 and Hela-EAVP80 for horses has not 
been established. Determination of the in vivo virulence of Hela-EAVP35 and Hela-
EAVP80 should help to identify the genetic determinants of EAV virulence. 
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Table 5.1 Plaque size of different EAV strains in RK-13 (KY) and EEC cells 
          
 
Virus Number of  plaques measured 
Plaque diameter (mm) 
Mean ± SE 
  RK-13 (KY) EEC RK-13 (KY) EEC 
     
VBS53 EAV 81 59 2.12 ± 0.06 6.17 ± 0.13 
     
Hela-EAVP10 79 63 2.03 ± 0.06 5.67 ± 0.09  
     
Hela-EAVP20 85 60 1.99 ± 0.04 4.88 ± 0.12  
     
Hela-EAVP35  95 98 2.07 ± 0.04 3.92 ± 0.07  
     
Hela-EAVP50 85 83 2.16 ± 0.04 3.33 ± 0.08 
     
Hela-EAVP60 90 55 2.05 ± 0.04 3.53 ± 0.09 
     
Hela-EAVP80 90 58 2.00 ± 0.04 3.36 ± 0.11 
     
  RK-13 (KY) = Rabbit Kidney cells (KY); EEC = Equine endothelial cells;                 
SE = Standard error of the Mean.    
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Fig 5.1 Size of plaques produced by EAV strains VBS53, Hela-EAVP10, Hela-EAVP20, 
Hela-EAVP35, Hela-EAVP50, Hela-EAVP60, and Hela-EAVP80 in equine endothelial 
cells (EECs) and rabbit kidney (RK-13 KY) cells. Mean ± Standard Error is shown in (A). 
In (B), pictures of plaques formed by three EAV strains VBS53, Hela-EAVP35, and 
Hela-EAVP80 in EECs and RK-13 cells are shown.    
 VBS53 EAV   Hela-EAVP35   Hela-EAVP80                              
EEC 
RK-13 
B 
A 
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SUMMARY 
 
Chapter 1 of this dissertation presents an overview of current knowledge of the 
molecular biology of equine arteritis virus; EAV infection and persistently infected 
stallions were briefly described; and persistent infection of cell cultures with RNA 
viruses were reviewed.  
Neither a virus attachment molecule nor a specific cell receptor has yet been 
identified for equine arteritis virus. Identification of the receptor used by EAV for cell 
attachment and entry has been hampered by the unavailability of a known cell line that 
lacks the appropriate EAV receptor(s). In Chapter 2, a variety of cell lines of different 
species and tissue origin were assessed for their permissiveness to infection with the 
strain VBS53 of EAV and the mechanism that restricts EAV infection in the non-
permissive cell lines was investigated. The cell lines BHK-21, RK-13, and C2C12 were 
found to support productive infection with EAV strain VBS53, whereas Hela, Hep-2, and 
L-M cell lines exhibited limited susceptibility to infection with the virus. In the course of 
the study, it was found that the Hela cell line became more susceptible to infection with 
EAV strain VBS53 after extended serial passage. The respective cell lines were referred 
to as Hela ‘High’ (passage 170-221) and Hela ‘Low’ (passage 95-115) lines. While the 
Hela ‘High’ cell line was more susceptible than the Hela ‘Low’ cell line, it was still 
considerably less susceptible than the BHK-21 cell line to EAV infection. Subsequent 
studies demonstrated that infection with EAV strain VBS53 was restricted at the entry 
step in Hela, Hep-2, and L-M cell lines. The availability of cells with varying 
susceptibility to EAV infection should help to identify the cellular factor(s) involved in 
EAV attachment and entry. 
Up to 30% to 70% of stallions can subsequently become persistently infected 
following natural infection with EAV. The detailed mechanism by which EAV 
establishes persistent infection in stallions is unknown. Carrier stallions are not only a 
natural reservoir of EAV responsible for maintenance and dissemination of EAV in 
equine populations, but also a natural source of genetic and phenotypic diversity of EAV. 
Persistent viral infections in cell culture have been demonstrated as a valuable tool to 
study virus-host cell interactions, virus and host cell evolutions, and to elucidate the 
mechanisms of viral persistence. In Chapter 3, an in vitro model of EAV persistence, 
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namely persistently infected cultures of Hela cells, was established and characterized. 
Virus evolution with respect to virus growth characteristics, ability of the virus to initiate 
secondary persistent infection, and genetic changes during persistent EAV infection in 
Hela cells was investigated. In Chapter 4, neutralization phenotypic changes of viruses 
were observed during the course of persistent EAV infection in Hela cells. Subsequent 
reverse genetics studies identified that amino acid 98 of the GP5 protein is a new 
neutralization determinant of EAV. In Chapter 5, using an in vitro assay, it was found 
that EAV probably became progressively less virulent during the course of persistent 
infection in Hela cells. The potential changes in pathogenicity of EAV during persistent 
infection of Hela cells need to be verified by inoculation of horses. The results in 
Chapters 3, 4, and 5 have demonstrated that persistent EAV infection of Hela cells 
provides a system to characterize genetic and phenotypic evolution of the virus. 
Persistent EAV infection of Hela cells may also be a useful tool for investigating viral 
and host cell factors involved in viral persistence and for elucidating virus-host cell 
interactions, e.g. EAV-cell receptor interactions.   
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Appendix 1. Primers used for RT-PCR amplification of the genome of EAV 
      
Fragment Primer ID Polarity Nt position Nucleotide sequence (5' to 3') Primer Size  (bp) 
      
1P + 1-30 GCT CGA AGT GTG TAT GGT GCC ATA TAC GGC 30 Frag 1 
(1559 bp) 1540N - 1540-1559 TTG AAG TCG CGT GCG CGG TG 20 
      
947P + 947-966 CTA CGT TTG TGA CAT CTC TG 20 Frag 2 
(2191 bp) 3118N - 3118-3137 GAA CAG ATT CAC AAA AAG CG 20 
      
2610P + 2610-2629 GAC CAT GCT CTT TAC AAC CG 20 Frag 3 
(2010 bp) 4600N - 4600-4619 GTC ATC ATC AGT GAG GGC AG 20 
      
4357P + 4357-4376 TCC TAG TGT ACC AGT TCC CC 20 Frag 4 
(2240 bp) 6577N - 6577-6596 TCT CCA GGT CTG TTT CAA GG 20 
      
5802P + 5802-5821 ACG CTT TTC AAG GGT TCC AC 20 Frag 5 
(949 bp) 6731N - 6731-6750 CCC CCG CGT TTG GTG AAT GC 20 
      
6587P + 6587-6606 GAC CTG GAG AGT TGT GAT CG 20 Frag 6 
(3284 bp) 9850N - 9850-9870 AGT AAC AAC AGC CAA TGC AAG 21 
      
7391P + 7391-7411 TGG TTC TGT GGC AAT TGT GTC 21 Frag 7 
(2480 bp) 9850N - 9850-9870 AGT AAC AAC AGC CAA TGC AAG 21 
      
9745P + 9745-9767 CGT GTG ATG GGC TTA GTG TGG TC 23 Frag 8 
(1718 bp) 11442N - 11442-11462 ATG TCA TCA AAC AGC GCA CTG 21 
      
11097P + 11097-11117 TTG TGG CTA TAG TTT ATG TTC 21 Frag 9 
(1608 bp) 12681N - 12681-12704 GGT TCC TGG GTG GCT AAT AAC TAC 24 
      
Note: Nucleotides are numbered according to the published sequence of EAV030 virus (van Dinten et al., 1997).   
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Appendix 2. Optimized thermacycling protocols for PCR amplification of EAV 
genome 
          
Thermacycling Conditions 
Fragment Primer 
VBS53 EAV Hela-EAVP35 Hela-EAVP80 
     
 1P 95ºC  30 sec 95ºC  30 sec 95ºC  30 sec 
Frag 1  55ºC  30 sec 55ºC  30 sec 55ºC  30 sec 
 1540N 72ºC   2 min 72ºC   2 min 72ºC   2 min 
     
 947P 95ºC  30 sec 95ºC  30 sec 95ºC  30 sec 
Frag 2  42ºC  30 sec 42ºC  30 sec 40ºC  30 sec 
 3118N 72ºC   3 min 72ºC   3 min 72ºC   3 min 
     
 2610P 95ºC  30 sec 95ºC  30 sec 95ºC  30 sec 
Frag 3  46ºC  30 sec 46ºC  30 sec 46ºC  30 sec 
 4600N 72ºC   3 min 72ºC   3 min 72ºC   3 min 
     
 4357P 95ºC  30 sec 95ºC  30 sec 95ºC  30 sec 
Frag 4  46ºC  30 sec 46ºC  30 sec 46ºC  30 sec 
 6577N 72ºC   3 min 72ºC   3 min 72ºC   3 min 
     
 5802P 95ºC  30 sec 95ºC  30 sec 95ºC  30 sec 
Frag 5  49ºC  30 sec 49ºC  30 sec 47ºC  30 sec 
 6731N 72ºC   2 min 72ºC   2 min 72ºC   2 min 
     
 6587P 95ºC  30 sec 95ºC  30 sec 95ºC  30 sec 
Frag 6  46ºC  30 sec 46ºC  30 sec 46ºC  30 sec 
 9850N 72ºC   3 min 72ºC   3 min 72ºC   3 min 
     
 7391P 95ºC  30 sec 95ºC  30 sec 95ºC  30 sec 
Frag 7  46ºC  30 sec 46ºC  30 sec 46ºC  30 sec 
 9850N 72ºC   3 min 72ºC   3 min 72ºC   3 min 
     
 9745P 95ºC  30 sec 95ºC  30 sec 95ºC  30 sec 
Frag 8  47ºC  30 sec 45ºC  30 sec 45ºC  30 sec 
 11442N 72ºC   3 min 72ºC   3 min 72ºC   3 min 
     
 11097P 95ºC  30 sec 95ºC  30 sec 95ºC  30 sec 
Frag 9  42ºC  30 sec 45ºC  30 sec 45ºC  30 sec 
  12681N 72ºC   3 min 72ºC   3 min 72ºC   3 min 
     
Note:  
1. PCR amplification of each fragment of each strain follows: 95ºC 2 min; 35 cycles 
of amplification; 72ºC 10 min; 4ºC forever. Above table only shows the 
thermacycling conditions for 35 cycles of amplification.  
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Appendix 3. EAV sequencing primers list 
    
Note: Nucleotides are numbered according to the published sequence of EAV030 virus 
(van Dinten et al., 1997) 
     
     
Fragment 1 Positve                      Sequence (5'-3') Nt Position Size (bp) 
(1-1559) 1P 
GCT CGA AGT GTG TAT GGT GCC ATA 
TAC GGC  1--30 30 
 457P GGT ATC GAG CTG CCA AAG TC 457--476 20 
 833P AGA CCT GGG TTT GGG CAT CA 833--852 20 
 947P CTA CGT TTG TGA CAT CTC TG 947--966 20 
     
 Negative                      Sequence (5'-3') Nt Position Size (bp) 
 233N CAA ATC CAG TAG CGG AGA AG 233--252 20 
 548N CTT GCC TCT TCA ATG GCT AAC 548--568 21 
 880N AGG CGA ACC CCT CAT AAT GT 880-899 20 
 1270N ATT GCA GAT GCC CCT GAA AC 1270--1289 20 
 1540N TTG AAG TCG CGT GCG CGG TG 1540--1559 20 
     
     
Fragment 2 Positive                      Sequence (5'-3') Nt Position Size (bp) 
(947-3137) 1524P CAG GCG CCC ATC CCA GCA CC 1524--1543 20 
 1891P TGG GCA ATA ATG TTG TTC TG 1891--1910 20 
 2296P TCG ATG TTG TGG GCA TGG C 2296--2314 19 
 2610P GAC CAT GCT CTT TAC AAC CG 2610--2629 20 
     
 Negative                      Sequence (5'-3') Nt Position Size (bp) 
 1540N TTG AAG TCG CGT GCG CGG TG 1540--1559 20 
 1836N AAA GCA AGA GAT GGC CAT AT 1836--1855 20 
 2106N ACA GTG CAA GGA ACA TAA GC 2106--2125 20 
 2508N TCA CAA CAG CTC CTG TTT GTT C 2508--2529 22 
 3118N GAA CAG ATT CAC AAA AAG CG 3118-3137 20 
     
     
Fragment 3 Positive                      Sequence (5'-3') Nt Position Size (bp) 
(2610-4619) 2963P GAT CTT GTT GGT CTG CCA CC  2963--2982 20 
 3331P ATT CAC TGC TTG GAG TGG CT 3331-3350 20 
 3668P TTT CGC CCA ACC AAC AAC CG 3668--3687 20 
 4002P CTG ATT GAT GGC TTA TCC AA 4002--4021 20 
 4357P TCC TAG TGT ACC AGT TCC CC 4357--4376 20 
     
 Negative                      Sequence (5'-3') Nt Position Size (bp) 
 3485N TGT TCC TGG TCC ACA CTG AC 3485--3504 20 
 3832N CAC GTA GGC AAC ACC ACT TG 3832--3851 20 
 4472N AAG TCC TGT CAA AGC GAC CT  4472--4491 20 
 4600N GTC ATC ATC AGT GAG GGC AG 4600--4619 20 
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Fragment 4 Positive                      Sequence (5'-3') Nt Position Size (bp) 
(4357-6596) 4357P TCC TAG TGT ACC AGT TCC CC 4357--4376 20 
 4718P CAT CCT TAA TGC ATC CTT GC 4718--4737 20 
 5072P TGC GGT CTC GAA TGA TTA TG  5072--5091 20 
 5436P TGG GGC GTC GGA CCT TTG CT  5436--5455 20 
 5802P ACG CTT TTC AAG GGT TCC AC 5802--5821 20 
 6198P GGG CGT ACT TAA AAG AGG AG 6198--6217 20 
     
 Negative                      Sequence (5'-3') Nt Position Size (bp) 
 4828N CAG ACC GTC GAT AAC CAC AA  4828--4847 20 
 5198N CTT CCT GAT GCT CCA CGT AA  5198--5217 20 
 5569N ACC CAA GCA GTG TGT CTT TT  5569--5588 20 
 5969N GTA ACG GCC TCA CAT CCA GC  5969--5988 20 
 6363N CAT GGT GGC GGT TTG TAG AT 6363--6382 20 
 6577N TCT CCA GGT CTG TTT CAA GG 6577--6596 20 
     
     
Fragment 5 Positive                      Sequence (5'-3') Nt Position Size (bp) 
(5802-6750) 6449P ATT GGC CTA GGT TTG CGT GCC TGC 6449--6472 24 
     
 Negative                      Sequence (5'-3') Nt Position Size (bp) 
 6731N CCC CCG CGT TTG GTG AAT GC 6731--6750 20 
     
     
Fragment 6 Positive                      Sequence (5'-3') Nt Position Size (bp) 
(6587-9870) 6587P GAC CTG GAG AGT TGT GAT CG 6587--6606 20 
 6950P ACA CCC AAC CAG CAT TAC GC  6950--6969 20 
 7391P TGG TTC TGT GGC AAT TGT GT 7391--7411 21 
     
 Negative                      Sequence (5'-3') Nt Position Size (bp) 
 7111N GTG TAA CGC GGT CCT GAA GA  7111--7130 20 
 7468N AAG TGG AGC GGT ACA TGA TG 7468--7487 20 
     
     
Fragment 7 Positive                      Sequence (5'-3') Nt Position Size (bp) 
(7391-9870) 7720P CAT CGC AGT ACC ACT TCA GG 7720--7739 20 
 8107P AGT CAA GGG TTA CGG TGA TT  8107--8126 20 
 8493P ACA TCT ACG ACC CCT TTG AT 8493--8512 20 
 8842P GCC CGT AGT GTC CAA TGA TA 8842--8861 20 
 9206P GCC CTG GTA GGT GCT TCA TT  9206--9225 20 
 9570P CAC CTG CTG GTT ATG CGA TC 9570--9589 20 
     
 Negative                      Sequence (5'-3') Nt Position Size (bp) 
 7831N GCA CAT CTT TGA CCA GGT GA  7831--7850 20 
 8177N AGG CTG ACA AAA TGT CGG AG  8177--8196 20 
 8543N AAG TCC TGC GCC TCT GCT TC 8543--8562 20 
 8907N CGC TGA GCA CGG TTT ACT GA  8907--8926 20 
 9299N ACG CGA CTC AGT GTC TCA GG 9299--9318 20 
 9614N ACT TCT GTT GAG CTG AGG AG 9614--9633 20 
 9850N AGT AAC AAC AGC CAA TGC AAG 9850--9870 21 
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Fragment 8 Positive                      Sequence (5'-3') Nt Position Size (bp) 
9745P-11442N 9745P CGT GTG ATG GGC TTA GTG TGG TC 9745--9767 23 
 10142P GAG TCT TCT AGC TAT GCT CC 10142--10161 20 
 10511P ACA CGG GTT ATG AAT ATG CC 10511--10530 20 
 10845P GGT GTA GGA ATT TTA TTA ATG 10845--10865 21 
 11097P TTG TGG CTA TAG TTT ATG TTC 11097--11117 21 
     
 Negative                      Sequence (5'-3') Nt Position Size (bp) 
 10128N AAG ACT CCA GAT GGT CAA AGC 10128--10148 21 
 10517N GAC CCC GGC ATA TTC ATA AC 10517--10536 20 
 10780N TAA AAT TAC GAG CCT CTG CAG CG 10780--10802 23 
 11235N CGT CAG CAT ACA CAA GGT GAA G 11235--11256 22 
     
     
Fragment 9 Positive                      Sequence (5'-3') Nt Position Size (bp) 
11097P-12681N 11272P GCC AAT TTG CTG CGA TAT GAT G 11272--11293 22 
 11557P CTA CCC TAT GCT ACG CTT ATT C 11557--11578 22 
 11850P AGT GGC CTA CGG CAG CAA AGT C  11850--11871 22 
 12069P TTT GTT ATA GTT GGA AGA GC 12069--12088 20 
 12481P GAT TTA AAT CAA CAG GAG CG 12481--12500 20 
     
 Negative                      Sequence (5'-3') Nt Position Size (bp) 
 11442N ATG TCA TCA AAC AGC GCA CTG 11442--11462 21 
 11691N CAG GCA TAA CCA CAG TAA TTG G 11691--11712 22 
 11995N CTA ACC CAG ATG CTA CAT ACC 11995--12015 21 
 12370N TCA TTG TAG CTT GTA GGC TG 12370--12389 20 
 12681N GGT TCC TGG GTG GCT AAT AAC TAC 12681--12704 24 
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Appendix 4. Protocols of cycle sequencing 
 
Reagent Volume Needed 
BigDye Ready Reaction Mix (2.5X) 1.5 µl 
Half-Dye mix 1.5 µl 
EAV Sequencing Primer 
 (3.2 pmol/µl) 
1 µl 
Template Variable, depends on template size 
Nuclease-free water Variable 
Final Volume 15 µl 
 
 
Note:  Perform cycle sequencing following the program below:  
(1) Place the tubes in a thermal cycler and set to the correct volume. 
(2) Perform an initial denaturation. 
a. Rapid thermal ramp (1°C/second)  to 96°C 
b. 96°C for 1 min 
(3) Repeat the following for 25 cycles: 
· Rapid thermal ramp to 96°C 
· 96°C for 10 seconds. 
· Rapid thermal ramp to 50°C 
· 50°C for 5 seconds. 
· Rapid thermal ramp to 60°C 
· 60°C for 4 minutes. 
(4) Rapid thermal ramp to 4°C and hold until ready to purify. 
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Appendix 5. Alignment of nucleotide sequences of VBS53 EAV (entire genome), Hela-EAVP10 (ORFs 2-7), 
 Hela-EAVP35 (entire genome), Hela-EAVP60 (ORFs 2-7) and Hela-EAVP80 (entire genome) 
 
             1                                               50                                               100 
VBS53 EAV    GCTCGAAGTGTGTATGGTGCCATATACGGCTCACCACCATATACACTGCAAGAATTACTATTCTTGTGGGCCCCTCTCGGTAAATCCTAGAGGGCTTTCC 
Hela-EAVP10  
Hela-EAVP35  .................................................................................................... 
Hela-EAVP60  
Hela-EAVP80  .................................................................................................... 
            
             101                                            150                                               200 
VBS53 EAV    TCTCGTTATTGCGAGATTCGTCGTTAGATAACGGCAAGTTCCCTTTCTTACTATCCTATTTTCATCTTGTGGCTTGACGGGTCACTGCCATCGTCGTCGA 
Hela-EAVP10  
Hela-EAVP35  .................................................................................................... 
Hela-EAVP60  
Hela-EAVP80  .................................................................................................... 
 
             201                                            250                                               300 
VBS53 EAV    TCTCTATCAACTACCCTTGCGACTATGGCAACCTTCTCCGCTACTGGATTTGGAGGGAGTTTTGTTAGGGACTGGTCCCTGGACTTACCCGACGCTTGTG 
Hela-EAVP10  
Hela-EAVP35  .................................................................................................... 
Hela-EAVP60  
Hela-EAVP80  .................................................................................................... 
            
             301                                            350                                               400 
VBS53 EAV    AGCATGGCGCGGGATTGTGCTGTGAAGTGGACGGCTCCACCTTATGCGCCGAGTGTTTTCGCGGTTGCGAAGGAGTGGAGCAATGTCCTGGCTTGTTCAT 
Hela-EAVP10  
Hela-EAVP35  .................................................................................................... 
Hela-EAVP60  
Hela-EAVP80  .................................................................................................... 
            
             401                                            450                                               500 
VBS53 EAV    GGGACTGTTAAAACTGGCTTCGCCAGTTCCAGTGGGACATAAGTTCCTGATTGGTTGGTATCGAGCTGCCAAAGTCACCGGGCGTTACAATTTCCTTGAG 
Hela-EAVP10  
Hela-EAVP35  .................................................................................................... 
Hela-EAVP60  
Hela-EAVP80  .................................................................................................... 
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             501                                            550                                               600 
VBS53 EAV    CTGTTGCAACACCCTGCTTTCGCCCAGCTGCGTGTGGTTGATGCTAGGTTAGCCATTGAAGAGGCAAGTGTGTTTATTTCCACTGACCACGCGTCTGCTA 
Hela-EAVP10  
Hela-EAVP35  .................................................................................................... 
Hela-EAVP60  
Hela-EAVP80  .................................................................................................... 
            
             601                                            650                                               700 
VBS53 EAV    AGCGTTTCCCTGGCGCTAGATTTGCGCTGACACCGGTGTATGCTAGCGCTTGGGTTGCGAGCCCGGCTGCTAACAGTTTGATAGTGACCATTGACCAGGA 
Hela-EAVP10  
Hela-EAVP35  .........................................................T....................................C..... 
Hela-EAVP60  
Hela-EAVP80  .........................................................T....................................T..... 
            
             701                                            750                                               800 
VBS53 EAV    ACAAGATGGGTTCTGCTGGTTAAAACTTTTGCCACCTGACCGCCGTGAGGCTGGTTTGCGGTTGTATTACAACCATTACCGCGAACAAAGGACCGGGTGG 
Hela-EAVP10  
Hela-EAVP35  .................................................................................................... 
Hela-EAVP60  
Hela-EAVP80  .................................................................................................... 
            
             801                                            850                                               900 
VBS53 EAV    CTGTCTAAAACAGGACTTCGCTTATGGCTTGGAGACCTGGGTTTGGGCATCAATGCGAGCTCTGGAGGGCTGAAATTCCACATTATGAGGGGTTCGCCTC 
Hela-EAVP10  
Hela-EAVP35  .................................................................................................... 
Hela-EAVP60  
Hela-EAVP80  .................................................................................................... 
                             
             901                                            950                                              1000 
VBS53 EAV    AGCGAGCTTGGCATATCACAACACGCAGCTGCAAGCTGAAGAGCTACTACGTTTGTGACATCTCTGAAGCAGACTGGTCCTGTTTGCCTGCTGGCAACTA 
Hela-EAVP10  
Hela-EAVP35  .................................................................................................... 
Hela-EAVP60  
Hela-EAVP80  .................................................................................................... 
            
 
 
 
 
 
  
164
1001 1050                                              1100 
VBS53 EAV    CGGCGGCTACAATCCACCAGGGGACGGAGCTTGCGGTTACAGGTGCTTGGCCTTCATGAATGGCGCCACTGTTGTGTCGGCTGGTTGCAGTTCTGACTTG 
Hela-EAVP10  
Hela-EAVP35  .................................................................................................... 
Hela-EAVP60  
Hela-EAVP80  .................................................................................................... 
            
             1101                                          1150                                              1200 
VBS53 EAV    TGGTGTGATGATGAGTTGGCTTATCGAGTCTTTCAATTGTCACCCACGTTCACGGTTACCATCCCAGGTGGGCGAGTTTGTCCGAATGCCAAGTACGCAA 
Hela-EAVP10  
Hela-EAVP35  .................................................................................................... 
Hela-EAVP60  
Hela-EAVP80  .................................................................................................... 
            
             1201                                          1250                                              1300 
VBS53 EAV    TGATTTGTGACAAGCAGCACTGGCGCGTCAAACGTGCAAAGGGCGTCGGCCTGTGTCTCGATGAAAGCTGTTTCAGGGGCACCTGCAATTGCCAACGCAT 
Hela-EAVP10  
Hela-EAVP35  ...............................................................................C.................... 
Hela-EAVP60  
Hela-EAVP80  ...............................................................................T.................... 
            
             1301                                          1350                                              1400 
VBS53 EAV    GAGTGGACCACCACCTGCACCCGTGTCAGCCGCCGTGTTAGATCACATACTGGAGGCGGCGACGTTTGGCAACGTTCGCGTGGTTACACCTGAAGGGCAG 
Hela-EAVP10  
Hela-EAVP35  .................................................................................................... 
Hela-EAVP60  
Hela-EAVP80  .................................................................................................... 
            
             1401                                          1450                                              1500 
VBS53 EAV    CCACGCCCCGTACCAGCGCCGCGAGTTCGTCCCAGCGCCAACTCTTCTGGAGATGTCAAAGATCCGGCGCCCGTTCCGCCAGTACCAAAACCAAGGACCA 
Hela-EAVP10  
Hela-EAVP35  .................................................................................................... 
Hela-EAVP60  
Hela-EAVP80  .................................................................................................... 
            
 
 
 
 
 
  
165
             1501                                          1550                                              1600 
VBS53 EAV    AGCTTGCCAAACCGAACCCAACTCAGGCGCCCATCCCAGCACCGCGCACGCGACTTCAAGGGGCCTCAACACAGGAGCCACTGGCGAGTGCAGGAGTTGC 
Hela-EAVP10  
Hela-EAVP35  .................................................................................................... 
Hela-EAVP60  
Hela-EAVP80  .................................................................................................... 
            
             1601                                          1650                                              1700 
VBS53 EAV    TTCTGACTCGGCACCTAAATGGCGTGTGGCCAAAACTGTGTACAGCTCCGCGGAGCGCTTTCGGACCGAACTGGTACAACGTGCTCGGTCCGTTGGGGAC 
Hela-EAVP10  
Hela-EAVP35 .................................................................................................... 
Hela-EAVP60  
Hela-EAVP80  .................................................................................................... 
            
             1701                                          1750                                              1800 
VBS53 EAV    GTTCTTGTTCAAGCGCTACCGCTCAAAACCCCAGCAGTGCAGCGGTATACCATGACTCTGAAGATGATGCGTTCACGCTTCAGTTGGCACTGCGACGTGT 
Hela-EAVP10  
Hela-EAVP35  .................................................................................................... 
Hela-EAVP60  
Hela-EAVP80  .................................................................................................... 
            
             1801                                          1850                                              1900 
VBS53 EAV    GGTACCCTTTGGCTGTAATCGCTTGTTTGCTCCCTATATGGCCATCTCTTGCTTTGCTCCTTAGCTTTGCCATTGGGTTGATACCCAGTGTGGGCAATAA 
Hela-EAVP10  
Hela-EAVP35  ........................................................................................C........... 
Hela-EAVP60  
Hela-EAVP80  ........................................................................................C........... 
 
             1901                                          1950                                              2000 
VBS53 EAV    TGTTGTTCTGACAGCGCTTCTGGTTTCATCAGCTAATTATGTTGCGTCAATGGACCATCAATGTGAAGGTGCGGCTTGCTTAGCCTTGCTGGAAGAAGAA 
Hela-EAVP10  
Hela-EAVP35  .....................................................G........................T..................... 
Hela-EAVP60  
Hela-EAVP80  .....................................................G........................T..................... 
            
 
 
 
 
 
  
166
             2001                                          2050                                              2100 
VBS53 EAV    CACTATTATAGAGCGGTCCGTTGGCGCCCGATTACAGGCGCGCTGTCGCTTGTGCTCAATTTACTGGGGCAGGTAGGCTATGTAGCTCGTTCCACCTTTG 
Hela-EAVP10  
Hela-EAVP35  ........................................................T........................................... 
Hela-EAVP60  
Hela-EAVP80  ........................................................T........................................... 
            
             2101                                          2150                                              2200 
VBS53 EAV    ATGCAGCTTATGTTCCTTGCACTGTGTTCGATCTTTGCAGCTTTGCTATTCTGTACCTCTGCCGCAATCGTTGCTGGAGATGCTTCGGACGCTGTGTGCG 
Hela-EAVP10  
Hela-EAVP35  .................................................................................................... 
Hela-EAVP60  
Hela-EAVP80  .................................................................................................... 
            
             2201                                          2250                                              2300 
VBS53 EAV    AGTTGGGCCTGCCACGCATGTTTTGGGTTCCACCGGGCAACGAGTTTCCAAACTGGCGCTCATTGATTTGTGTGACCACTTTTCAAAGCCCACCATCGAT 
Hela-EAVP10  
Hela-EAVP35  .................................................................................................... 
Hela-EAVP60  
Hela-EAVP80  .................................................................................................... 
            
             2301                                          2350                                              2400 
VBS53 EAV    GTTGTGGGCATGGCAACTGGTTGGAGCGGATGTTACACAGGAACCGCCGCAATGGAGCGTCAGTGTGCCTCTACGGTGGACCCTCACTCGTTCGACCAGA 
Hela-EAVP10  
Hela-EAVP35  .................................................................................................... 
Hela-EAVP60  
Hela-EAVP80  .................................................................................................... 
            
             2401                                          2450                                              2500 
VBS53 EAV    AGAAGGCAGGAGCGATTGTTTACCTCACCCCCCCTGTCAACAGCGGGTCAGCGCTGCAGTGCCTCAATGTCATGTGGAAGCGACCAATTGGGTCCACTGT 
Hela-EAVP10  
Hela-EAVP35  ..................................................................................A................. 
Hela-EAVP60  
Hela-EAVP80  ..................................................................................T................. 
            
 
 
 
 
 
  
167
             2501                                          2550                                              2600 
VBS53 EAV    CCTTGGGGAACAAACAGGAGCTGTTGTGACGGCGGTCAAGAGTATCTCTTTCTCACCTCCCTGCTGCGTCTCTACCACTTTGCCCACCCGACCCGGTGTG 
Hela-EAVP10  
Hela-EAVP35  .................................................................................................... 
Hela-EAVP60  
Hela-EAVP80  .................................................................................................... 
            
             2601                                          2650                                              2700 
VBS53 EAV    ACCGTTGTCGACCATGCTCTTTACAACCGGTTGACTGCTTCAGGGGTCGATCCCGCTTTATTGCGTGTTGGGCAAGGTGATTTTCTAAAACTTAATCCGG 
Hela-EAVP10  
Hela-EAVP35  .................................................................................................... 
Hela-EAVP60  
Hela-EAVP80  .................................................................................................... 
            
             2701                                          2750                                              2800 
VBS53 EAV    GGTTCCGGCTGATAGGTGGATGGATTTATGGGATATGCTATTTTGTGTTGGTGGTTGTGTCAACTTTTACCTGCTTACCTATCAAATGTGGCATTGGCAC 
Hela-EAVP10  
Hela-EAVP35 .................................................................................................... 
Hela-EAVP60  
Hela-EAVP80 .................................................................................................... 
            
             2801                                          2850                                              2900 
VBS53 EAV    CCGCGACCCTTTCTGCCGCAGAGTGTTTTCTGTACCCGTCACCAAGACCCAAGAGCACTGCCATGCTGGAATGTGTGCTAGCGCTGAAGGCATCTCTCTG 
Hela-EAVP10  
Hela-EAVP35  .................................................................................................C.. 
Hela-EAVP60  
Hela-EAVP80  .................................................................................................T.. 
            
             2901                                          2950                                              3000 
VBS53 EAV    GACTCTCTGGGGTTAACTCAGTTACAAAGTTACTGGATCGCTGCCGTCACTAGCGGATTAGTGATCTTGTTGGTCTGCCACCGCCTGGCCATCAGCGCCT 
Hela-EAVP10  
Hela-EAVP35  .................................................................................................... 
Hela-EAVP60  
Hela-EAVP80  .................................................................................................... 
            
 
 
 
 
 
  
168
             3001                                          3050                                              3100 
VBS53 EAV    TGGACTTGTTGACTCTAGCTTCCCCTTTAGTGTTGCTTGTGTTCCCTTGGGCATCTGTGGGGCTTTTACTTGCTTGCAGTCTCGCTGGTGCTGCTGTGAA 
Hela-EAVP10  
Hela-EAVP35  ..........G......................................................................................... 
Hela-EAVP60  
Hela-EAVP80  ..........A......................................................................................... 
            
             3101                                          3150                                              3200 
VBS53 EAV    AATACAGTTGTTGGCGACGCTTTTTGTGAATCTGTTCTTTCCCCAAGCTACCCTTGTCACTATGGGATACTGGGCGTGCGTGGCGGCTTTGGCCGTTTAC 
Hela-EAVP10  
Hela-EAVP35  .................................................................................................... 
Hela-EAVP60  
Hela-EAVP80  .................................................................................................... 
            
             3201                                          3250                                              3300 
VBS53 EAV    AGTTTGATGGGCTTGCGAGTGAAAGTGAATGTGCCCATGTGTGTGACACCTGCCCATTTTCTGCTGCTGGCGAGGTCAGCTGGACAGTCAAGAGAGCAGA 
Hela-EAVP10  
Hela-EAVP35  .................................................................................................... 
Hela-EAVP60  
Hela-EAVP80  .................................................................................................... 
            
             3301                                          3350                                              3400 
VBS53 EAV    TGCTCCGGGTCAGCGCTGCTGCCCCCACCAATTCACTGCTTGGAGTGGCTCGTGATTGTTATGTCACAGGCACAACTCGGCTGTACATACCCAAGGAAGG 
Hela-EAVP10  
Hela-EAVP35  .................................................................................................... 
Hela-EAVP60  
Hela-EAVP80  .................................................................................................... 
            
             3401                                          3450                                              3500 
VBS53 EAV    CGGGATGGTGTTTGAAGGGCTATTCAGGTCACCGAAGGCGCGCGGCAACGTCGGCTTCGTGGCTGGTAGCAGCTACGGCACAGGGTCAGTGTGGACCAGG 
Hela-EAVP10  
Hela-EAVP35  .................................................................................................... 
Hela-EAVP60  
Hela-EAVP80  .................................................................................................... 
            
 
 
 
 
 
  
169
             3501                                          3550                                              3600 
VBS53 EAV    AACAACGAGGTCGTCGTACTGACAGCGTCACACGTGGTTGGCCGCGCTAACATGGCCACTCTGAAGATCGGTGACGCAATGCTGACTCTGACTTTCAAAA 
Hela-EAVP10  
Hela-EAVP35  .................................................................................................... 
Hela-EAVP60  
Hela-EAVP80  .................................................................................................... 
            
             3601                                          3650                                              3700 
VBS53 EAV    AGAATGGCGACTTCGCCGAGGCAGTGACGACACAGTCCGAGCTCCCAGGCAATTGGCCACAGTTGCATTTCGCCCAACCAACAACCGGGCCCGCTTCATG 
Hela-EAVP10  
Hela-EAVP35  .................................................................................................... 
Hela-EAVP60  
Hela-EAVP80  .................................................................................................... 
            
             3701                                          3750                                              3800 
VBS53 EAV    GTGCACYGCCACAGGAGATGAAGAAGGCTTGCTCAGTGGCGAGGTTTGTCTGGCGTGGACTACTAGTGGCGACTCTGGATCAGCAGTGGTTCAGGGTGAC 
Hela-EAVP10  
Hela-EAVP35  ......C.........................................................................................T... 
Hela-EAVP60  
Hela-EAVP80  ......C.........................................................................................C... 
            
             3801                                          3850                                              3900 
VBS53 EAV    GCTGTGGTAGGGGTCCACACCGGTTCGAACACAAGTGGTGTTGCCTACGTGACCACCCCAAGCGGAAAACTCCTTGGCGCCGACACCGTGACTTTGTCAT 
Hela-EAVP10  
Hela-EAVP35  .................................................................................................... 
Hela-EAVP60  
Hela-EAVP80  .................................................................................................... 
            
             3901                                          3950                                              4000 
VBS53 EAV    CACTGTCAAAGCATTTCACAGGCCCTTTGACATCAATCCCGAAGGACATCCCTGACAACATCATTGCCGATGTTGATGCTGTTCCTCGTTCTCTGGCCAT 
Hela-EAVP10  
Hela-EAVP35  .................................................................................................... 
Hela-EAVP60  
Hela-EAVP80  .................................................................................................... 
            
 
 
 
 
 
  
170
             4001                                          4050                                              4100 
VBS53 EAV    GCTGATTGATGGCTTATCCAATAGAGAGAGCAGCCTTTCTGGACCTCAGTTGTTGTTAATTGCTTGTTTTATGTGGTCTTATCTTAACCAACCTGCTTAC 
Hela-EAVP10  
Hela-EAVP35  .................................................................................................... 
Hela-EAVP60  
Hela-EAVP80  .................................................................................................... 
  
             4101                                          4150                                              4200 
VBS53 EAV    TTGCCTTATGTGCTGGGCTTCTTTGCCGCTAACTTCTTCCTGCCAAAAAGTGTTGGCCGCCCTGTGGTCACTGGGCTTCTATGGTTGTGCTGCCTCTTCA 
Hela-EAVP10  
Hela-EAVP35  .................................................................................................... 
Hela-EAVP60  
Hela-EAVP80  .................................................................................................... 
            
             4201                                          4250                                              4300 
VBS53 EAV    CACCGCTTTCCATGCGCTTGTGCTTGTTCCATCTGGTCTGTGCTACCGTCACGGGAAACGTGATATCTTTGTGGTTCTACATCACTGCCGCTGGCACGTC 
Hela-EAVP10  
Hela-EAVP35  .................................................................................................... 
Hela-EAVP60  
Hela-EAVP80  .................................................................................................... 
            
             4301                                          4350                                              4400 
VBS53 EAV    TTACCTTTCTGAGATGTGGTTCGGAGGCTATCCCACCATGTTGTTTGTGCCACGGTTCCTAGTGTACCAGTTCCCCGGCTGGGCTATTGGCACAGTACTA 
Hela-EAVP10  
Hela-EAVP35  ................................................A................................................... 
Hela-EAVP60  
Hela-EAVP80  ................................................A................................................... 
            
             4401                                          4450                                              4500 
VBS53 EAV    GCGGTATGCAGCATCACCATGCTGGCTGCTGCCCTCGGTCACACCCTGTTACTGGATGTGTTCTCCGCCTCAGGTCGCTTTGACAGGACTTTCATGATGA 
Hela-EAVP10  
Hela-EAVP35  .................................................................................................... 
Hela-EAVP60  
Hela-EAVP80  .................................................................................................... 
            
 
 
 
 
 
  
171
             4501                                          4550                                              4600 
VBS53 EAV    AATACTTCCTGGAGGGAGGAGTGAAAGAGAGTGTCACCGCCTCAGTCACCCGCGCTTATGGCAAACCAATTACCCAGGAGAGTCTCACTGCAACATTGGC 
Hela-EAVP10  
Hela-EAVP35  .................................................................................................... 
Hela-EAVP60  
Hela-EAVP80  .................................................................................................... 
            
             4601                                          4650                                              4700 
VBS53 EAV    TGCCCTCACTGATGATGACTTCCAATTCCTCTCTGATGTGCTTGACTGTCGGGCCGTCCGATCGGCAATGAATCTGCGTGCCGCTCTCACAAGTTTTCAA 
Hela-EAVP10  
Hela-EAVP35  .................................................................................................... 
Hela-EAVP60  
Hela-EAVP80  .................................................................................................... 
            
             4701                                          4750                                              4800 
VBS53 EAV    GTGGCGCAGTATCGTAACATCCTTAATGCATCCTTGCAAGTCGATCGTGACGCTGCTCGTAGTCGCAGACTAATGGCAAAACTGGCTGATTTTGCGGTTG 
Hela-EAVP10  
Hela-EAVP35  .................................................................................................... 
Hela-EAVP60  
Hela-EAVP80  .................................................................................................... 
            
             4801                                          4850                                              4900 
VBS53 EAV    AACAAGAAGTAACAGCTGGAGACCGTGTTGTGGTTATCGACGGTCTGGACCGCATGGCTCACTTCAAAGACGATTTGGTGCTGGTTCCTTTGACCACCAA 
Hela-EAVP10  
Hela-EAVP35  ...................................................................................................G 
Hela-EAVP60  
Hela-EAVP80  ...................................................................................................G 
            
             4901                                          4950                                              5000 
VBS53 EAV    AGTAGTAGGCGGTTCTAGGTGCACCATTTGTGACGTCGTTAAGGAAGAAGCCAATGACACCCCAGTTAAGCCAATGCCCAGCAGGAGACGCCGCAAGGGC 
Hela-EAVP10  
Hela-EAVP35  ............C....................................................................................... 
Hela-EAVP60  
Hela-EAVP80  ............T....................................................................................... 
            
 
 
 
 
 
  
172
             5001                                          5050                                              5100 
VBS53 EAV    CTGCCTAAAGGTGCTCAGTTGGAGTGGGACCGTCACCAGGAAGAGAAGAGGAACGCCGGTGATGATGATTTTGCGGTCTCGAATGATTATGTCAAGAGAG 
Hela-EAVP10  
Hela-EAVP35  .................................................................................................... 
Hela-EAVP60  
Hela-EAVP80  .................................................................................................... 
            
             5101                                          5150                                              5200 
VBS53 EAV    TGCCAAAGTACTGGGATCCCAGCGACACCCGAGGCACGACAGTGAAAATCGCCGGCACTACCTATCAGAAAGTGGTTGACTATTCAGGCAATGTGCATTA 
Hela-EAVP10  
Hela-EAVP35  .................................................................................................... 
Hela-EAVP60  
Hela-EAVP80  .................................................................................................... 
 
             5201                                          5250                                              5300 
VBS53 EAV    CGTGGAGCATCAGGAAGATCTGCTAGACTACGTGCTGGGCAAGGGGAGCTATGAAGGCCTAGATCAGGACAAAGTGTTGGACCTCACAAACATGCTTAAA 
Hela-EAVP10  
Hela-EAVP35  .................................................................................................... 
Hela-EAVP60  
Hela-EAVP80  .................................................................................................... 
            
             5301                                          5350                                              5400 
VBS53 EAV    GTGGACCCCACGGAGCTCTCCTCCAAAGACAAAGCCAAGGCGCGTCAGCTTGCTCATCTGCTGTTGGATCTGGCTAACCCAGTTGAGGCAGTGAATCAGT 
Hela-EAVP10  
Hela-EAVP35  .................................................................................................... 
Hela-EAVP60  
Hela-EAVP80  .................................................................................................... 
            
             5401                                          5450                                              5500 
VBS53 EAV    TAAACTGAGAGCGCCCCACATCTTTCCCGGCGATGTGGGGCGTCGGACCTTTGCTGACTCTAAAGACAAGGGTTTCGTGGCTCTACACAGTCGCACAATG 
Hela-EAVP10  
Hela-EAVP35  .................................................................................................... 
Hela-EAVP60  
Hela-EAVP80  .................................................................................................... 
            
 
 
 
 
 
  
173
             5501                                          5550                                              5600 
VBS53 EAV    TTTTTAGCTGCCCGGGACTTTTTATTTAACATCAAATTTGTGTGCGACGAAGAGTTCACAAAGACCCCAAAAGACACACTGCTTGGGTACGTACGCGCCT 
Hela-EAVP10  
Hela-EAVP35  .................................................................................................... 
Hela-EAVP60  
Hela-EAVP80  .................................................................................................... 
            
             5601                                          5650                                              5700 
VBS53 EAV    GCCCTGGTTACTGGTTTATTTTCCGTCGTACGCACCGGTCGCTGATTGATGCATACTGGGACAGTATGGAGTGCGTTTACGCGCTTCCCACCATATCTGA 
Hela-EAVP10  
Hela-EAVP35  .................................................................................................... 
Hela-EAVP60  
Hela-EAVP80  .................................................................................................... 
            
             5701                                          5750                                              5800 
VBS53 EAV    TTTTGATGTGAGCCCAGGTGACGTCGCAGTGACGGGTGAGCGATGGGATTTTGAATCTCCCGGAGGAGGCCGTGCAAAACGTCTCACAGCTGATCTGGTG 
Hela-EAVP10  
Hela-EAVP35  .................................................................................................... 
Hela-EAVP60  
Hela-EAVP80  .................................................................................................... 
            
             5801                                          5850                                              5900 
VBS53 EAV    CACGCTTTTCAAGGGTTCCACGGAGCCTCTTATTCCTATGATGACAAGGTGGCAGCTGCTGTCAGTGGTGACCCGTATCGGTCGGACGGCGTCTTGTATA 
Hela-EAVP10  
Hela-EAVP35  .................................................................................................... 
Hela-EAVP60  
Hela-EAVP80  .................................................................................................... 
            
             5901                                          5950                                              6000 
VBS53 EAV    ACACCCGTTGGGGCAACATTCCATATTCTGTCCCAACCAATGCTTTGGAAGCCACAGCTTGCTACCGTGCTGGATGTGAGGCCGTTACCGACGGGACCAA 
Hela-EAVP10  
Hela-EAVP35  .................................................................................................... 
Hela-EAVP60  
Hela-EAVP80  .................................................................................................... 
            
 
 
 
 
 
  
174
             6001                                          6050                                              6100 
VBS53 EAV    CGTCATCGCAACAATTGGGCCCTTCCCGGAGCAACAACCCATACCGGACATCCCAAAAAGCGTGCTTGACAACTGCGCTGACATCAGCTGTGACGCTTTC 
Hela-EAVP10  
Hela-EAVP35  ...................C................................................................................ 
Hela-EAVP60  
Hela-EAVP80  ...................T................................................................................ 
            
             6101                                          6150                                              6200 
VBS53 EAV    ATAGCGCCCGCTGCAGAGACAGCCCTGTGTGATGATTTAGAGAAATACAACCTATCCACGCAGGGTTTTGTGTTGCCTAGTGTTTTCTCCATGGTGCGGG 
Hela-EAVP10  
Hela-EAVP35  .................................................................................................... 
Hela-EAVP60  
Hela-EAVP80  .................................................................................................... 
              
             6201                                          6250                                              6300 
VBS53 EAV    CGTACTTAAAAGAGGAGATTGGAGACGCTCCACCACTCTACTTGCCATCTACTGTACCATCTAAAAATTCACAAGCCGGAATTAACGGCGCTGAGTTTCC 
Hela-EAVP10  
Hela-EAVP35  .................................................................................................... 
Hela-EAVP60  
Hela-EAVP80  .................................................................................................... 
            
             6301                                          6350                                              6400 
VBS53 EAV    TACAAAGTCTTTACAGAGCTACTGTTTGATTGATGACATGGTGTCACAGTCCATGAAAAGCAATCTACAAACCGCCACCATGGCGACTTGTAAACGGCAG 
Hela-EAVP10  
Hela-EAVP35  .................................................................................................... 
Hela-EAVP60  
Hela-EAVP80  .................................................................................................... 
            
             6401                                          6450                                              6500 
VBS53 EAV    TACTGTTCCAAATACAAGATTAGGAGCATTCTGGGCACCAACAATTACATTGGCCTAGGTTTGCGTGCCTGCCTTTCGGGGGTTACGGCCGCATTCCAAA 
Hela-EAVP10  
Hela-EAVP35  .................................................................................................... 
Hela-EAVP60  
Hela-EAVP80  .................................................................................................... 
            
 
 
 
 
 
  
175
             6501                                          6550                                              6600 
VBS53 EAV    AAGCTGGAAAGGATGGGTCACCGATTTATTTGGGCAAGTCAAAATTCGACCCGATACCAGCTCCTGACAAGTACTGCCTTGAAACAGACCTGGAGAGTTG 
Hela-EAVP10  
Hela-EAVP35  .................................................................................................... 
Hela-EAVP60  
Hela-EAVP80  .................................................................................................... 
            
             6601                                          6650                                              6700 
VBS53 EAV    TGATCGCTCCACCCCGGCTTTGGTGCGTTGGTTCGCTACTAATCTTATTTTTGAGCTAGCTGGCCAGCCCGAGTTGGTGCACAGCTACGTGTTGAATTGC 
Hela-EAVP10  
Hela-EAVP35  .................................................................................................... 
Hela-EAVP60  
Hela-EAVP80  .................................................................................................... 
            
             6701                                          6750                                              6800 
VBS53 EAV    TGTCACGATCTAGTTGTGGCGGGTAGTGTAGCATTCACCAAACGCGGGGGTTTGTCATCTGGAGACCCTATCACTTCCATTTCCAATACCATCTATTCAT 
Hela-EAVP10  
Hela-EAVP35  ...................................................C................................................ 
Hela-EAVP60  
Hela-EAVP80  ...................................................C................................................ 
            
             6801                                          6850                                              6900 
VBS53 EAV    TGGTGCTGTACACCCAGCACATGTTGCTATGTGGACTTGAAGGCTATTTCCCAGAGATTGCAGAAAAATATCTTGATGGCAGCCTGGAGCTGCGGGACAT 
Hela-EAVP10  
Hela-EAVP35  .................................................................................................... 
Hela-EAVP60  
Hela-EAVP80  .................................................................................................... 
            
             6901                                          6950                                              7000 
VBS53 EAV    GTTCAAGTACGTTCGAGTGTACATCTACTCGGACGATGTGGTTCTAACCACACCCAACCAGCATTACGCGGCCAGCTTTGACCGCTGGGTCCCCCACCTG 
Hela-EAVP10  
Hela-EAVP35  .................................................................................................... 
Hela-EAVP60  
Hela-EAVP80  .................................................................................................... 
            
 
 
 
 
 
  
176
             7001                                          7050                                              7100 
VBS53 EAV    CAGGCGCTGCTAGGTTTCAARGTTGACCCAAAGAAAACTGTGAACACCAGCTCCCCTTCCTTTTTGGGCTGCCGGTTCAAGCAAGTGGACGGCAAGTGTT 
Hela-EAVP10  
Hela-EAVP35  ....................A............................................................................... 
Hela-EAVP60  
Hela-EAVP80  ....................A............................................................................... 
            
             7101                                          7150                                              7200 
VBS53 EAV    ATCTAGCCAGTCTTCAGGACCGTGTTACACGCTCTCTGTTATACCACATTGGTGCAAAGAATCCCTCAGAGTACTATGAAGCTGCTGTTTCCATCTTTAA 
Hela-EAVP10  
Hela-EAVP35  .................................................................................................... 
Hela-EAVP60  
Hela-EAVP80  .................................................................................................... 
            
             7201                                          7250                                              7300 
VBS53 EAV    GGACTCCATTATCTGCTGTGATGAAGACTGGTGGACGGACCTCCATCGACGTATCAGTGGCGCTGCGCGTACTGACGGAGTTGAGTTCCCCACCATTGAA 
Hela-EAVP10  
Hela-EAVP35  .................................................................................................... 
Hela-EAVP60  
Hela-EAVP80  .................................................................................................... 
            
             7301                                          7350                                              7400 
VBS53 EAV    ATGTTAACATCCTTCCGCACCAAGCAGTATGAGAGTGCCGTGTGCACAGTTTGTGGGGCCGCCCCCGTGGCCAAGTCTGCTTGTGGAGGGTGGTTCTGTG 
Hela-EAVP10  
Hela-EAVP35  .................................................................................................... 
Hela-EAVP60  
Hela-EAVP80  .................................................................................................... 
 
             7401                                          7450                                              7500 
VBS53 EAV    GCAATTGTGTCCCGTACCACGTGGGTCATTGTCACACAACCTCGCTCTTCGCCAACTGCGGGCACGACATCATGTACCGCTCCACTTACTGCACAATGTG 
Hela-EAVP10  
Hela-EAVP35  .................................................................................................... 
Hela-EAVP60  
Hela-EAVP80  .................................................................................................... 
            
 
 
 
 
 
  
177
             7501                                          7550                                              7600 
VBS53 EAV    TGAGGGTTCCCCAAAACAGATGGTACCAAAAGTGCCTCACCCGATCCTGGATCATTTGCTGTGCCACATTGATTACGGCAGTAAAGAGGAACTAACTCTG 
Hela-EAVP10  
Hela-EAVP35  .................................................................................................... 
Hela-EAVP60  
Hela-EAVP80  .................................................................................................... 
            
             7601                                          7650                                              7700 
VBS53 EAV    GTAGTGGCGGATGGTCGAACAACATCACCGCCCGGGCGCTACAAAGTGGGTCACAAGGTAGTCGCCGTGGTTGCAGATGTGGGAGGCAACATTGTGTTTG 
Hela-EAVP10  
Hela-EAVP35  .................................................................................................... 
Hela-EAVP60  
Hela-EAVP80  .................................................................................................... 
 
             7701                                          7750                                              7800 
VBS53 EAV    GGTGCGGTCCTGGATCACACATCGCAGTACCACTTCAGGATACGCTCAAGGGCGTGGTGGTGAATAAAGCTCTGAAGAACGCCGCCGCCTCTGAGTACGT 
Hela-EAVP10  
Hela-EAVP35  .................................................................................................... 
Hela-EAVP60  
Hela-EAVP80  .................................................................................................... 
            
             7801                                          7850                                              7900 
VBS53 EAV    GGAAGGACCCCCTGGGAGTGGGAAGACTTTTCACCTGGTCAAAGATGTGCTAGCCGTGGTCGGTAGCGCGACCTTGGTTGTGCCCACCCACGCGTCCATG 
Hela-EAVP10  
Hela-EAVP35  .................................................................................................... 
Hela-EAVP60  
Hela-EAVP80  .................................................................................................... 
            
             7901                                          7950                                              8000 
VBS53 EAV    CTGGACTGCATCAACAAGCTCAAACAAGCGGGCGCCGATCCATACTTTGTGGTGCCCAAGTATACAGTTCTTGACTTTCCCCGGCCTGGCAGTGGAAACA 
Hela-EAVP10  
Hela-EAVP35  .................................................................................................... 
Hela-EAVP60  
Hela-EAVP80  .................................................................................................... 
            
 
 
 
 
 
  
178
             8001                                          8050                                              8100 
VBS53 EAV    TCACAGTGCGACTGCCACAGGTCGGAACCAGTGAGGGAGAAACCTTTGTGGATGAGGTGGCCTACTTCTCACCAGTGGATCTGGCGCGCATTTTAACCCA 
Hela-EAVP10  
Hela-EAVP35  .................................................................................................... 
Hela-EAVP60  
Hela-EAVP80  .................................................................................................... 
            
             8101                                          8150                                              8200 
VBS53 EAV    GGGTCGAGTCAAGGGTTACGGTGATTTAAATCAGCTCGGGTGTGTCGGACCCGCGAGCGTGCCACGTAACCTTTGGCTCCGACATTTTGTCAGCCTGGAG 
Hela-EAVP10  
Hela-EAVP35  .................................................................................................... 
Hela-EAVP60  
Hela-EAVP80  .................................................................................................... 
            
             8201                                          8250                                              8300 
VBS53 EAV    CCCTTGCGAGTGTGCCATCGATTCGGCGCTGCTGTGTGTGATTTGATCAAGGGCATTTAYCCTTATTATGAGCCAGCTCCACATACCACYAAAGTGGTGT 
Hela-EAVP10  
Hela-EAVP35  ...........................................................C.............................C.......... 
Hela-EAVP60  
Hela-EAVP80  ...........................................................C.............................C.......... 
            
             8301                                          8350                                              8400 
VBS53 EAV    TTGTGCCAAATCCAGACTTTGAGAAAGGTGTAGTCATCACCGCCTACCACAAAGATCGCGGTCTTGGTCACCGCACAATTGATTCAATTCAAGGCTGTAC 
Hela-EAVP10  
Hela-EAVP35  .................................................................................................T.. 
Hela-EAVP60  
Hela-EAVP80  .................................................................................................C.. 
            
             8401                                          8450                                              8500 
VBS53 EAV    ATTCCCTGTTGTGACTCTTCGACTGCCCACACCCCAATCACTGACGCGCCCGCGCGCAGTTGTGGCGGTTACTAGGGCGTCTCAGGAATTATACATCTAC 
Hela-EAVP10  
Hela-EAVP35  .................................................................................................... 
Hela-EAVP60  
Hela-EAVP80  .................................................................................................... 
            
 
 
 
 
 
  
179
             8501                                          8550                                              8600 
VBS53 EAV    GACCCCTTTGATCAGCTTAGCGGGTTGTTGAAGTTCACCAAGGAAGCAGAGGCGCAGGACTTGATCCATGGCCCACCTACAGCATGCCACCTGGGCCAAG 
Hela-EAVP10  
Hela-EAVP35  .................................................................................................... 
Hela-EAVP60  
Hela-EAVP80  .................................................................................................... 
            
             8601                                          8650                                              8700 
VBS53 EAV    AAATTGACCTTTGGTCCAATGAGGGCCTCGAATATTACAAGGAAGTCAACCTGCTGTACACACACGTCCCCATCAAGGATGGTGTAATACACAGTTACCC 
Hela-EAVP10  
Hela-EAVP35  .................................................................................................... 
Hela-EAVP60  
Hela-EAVP80  .................................................................................................... 
            
             8701                                          8750                                              8800 
VBS53 EAV    TAATTGTGGCCCTGCCTGTGGCTGGGAAAAGCAATCCAACAAAATTTCGTGCCTCCCGAGAGTGGCACAAAATTTGGGCTACCACTATTCCCCAGACTTA 
Hela-EAVP10  
Hela-EAVP35  .................................................................................................... 
Hela-EAVP60  
Hela-EAVP80  .................................................................................................... 
            
             8801                                          8850                                              8900 
VBS53 EAV    CCAGGATTTTGCCCCATACCAAAAGAACTCGCTGAGCATTGGCCCGTAGTGTCCAATGATAGGTACCCGAATTGCTTGCAAATCACCTTACAGCAAGTAT 
Hela-EAVP10  
Hela-EAVP35  .................................................................................................... 
Hela-EAVP60  
Hela-EAVP80  .................................................................................................... 
            
             8901                                          8950                                              9000 
VBS53 EAV    GTGAACTCAGTAAACCGTGCTCAGCGGGCTATATGGTTGGACAATCTGTTTTCGTGCAGACGCCTGGTGTGACATCTTACTGGCTTACTGAATGGGTCGA 
Hela-EAVP10  
Hela-EAVP35  .................................................................................................... 
Hela-EAVP60  
Hela-EAVP80  .................................................................................................... 
            
 
 
 
 
 
  
180
             9001                                          9050                                              9100 
VBS53 EAV    CGGCAAAGCGCGTGCTCTACCAGATTCCTTATTCTCGTCCGGTAGGTTCGAGACTAACAGCCGCGCTTTCCTCGATGAAGCCGAGGAAAAGTTTGCCGCC 
Hela-EAVP10  
Hela-EAVP35  .................................................................................................... 
Hela-EAVP60  
Hela-EAVP80  .................................................................................................... 
            
             9101                                          9150                                              9200 
VBS53 EAV    GCTCACCCTCATGCCTGTTTGGGAGAAATTAATAAGTCCACCGTGGGAGGATCCCACTTCATCTTTTCCCAATATTTACCACCATTGCTACCCGCAGACG 
Hela-EAVP10  
Hela-EAVP35  .................................................................................................... 
Hela-EAVP60  
Hela-EAVP80  .................................................................................................... 
            
             9201                                          9250                                              9300 
VBS53 EAV    CTGTTGCCCTGGTAGGTGCTTCATTGGCTGGGAAAGCTGCTAAAGCTGCTTGCAGCGTCGTTGACGTCTATGCTCCATCATTTGAACCTTATCTGCACCC 
Hela-EAVP10  
Hela-EAVP35  .................................................................................................... 
Hela-EAVP60  
Hela-EAVP80  .................................................................................................... 
            
             9301                                          9350                                              9400 
VBS53 EAV    TGAGACACTGAGTCGCGTGTACAAGATTATGATCGATTTCAAGCCGTGTAGGCTTATGGTGTGGAGAAACGCGACCTTTTATGTCCAAGAGGGTGTTGAT 
Hela-EAVP10  
Hela-EAVP35  .................................................................................................... 
Hela-EAVP60  
Hela-EAVP80  .................................................................................................... 
            
             9401                                          9450                                              9500 
VBS53 EAV    GCAGTTACATCAGCACTAGCAGCTGTGTCCAAACTCATCAAAGTGCCGGCCAATGAGCCTGTTTCATTCCATGTGGCATCAGGGTACAGAACCAACGCGC 
Hela-EAVP10  
Hela-EAVP35  .................................................................................................... 
Hela-EAVP60  
Hela-EAVP80  .................................................................................................... 
            
 
 
 
 
 
  
181
             9501                                          9550                                              9600 
VBS53 EAV    TGGTAGCGCCCCAGGCTAAAATTTCGATTGGAGCCTACGCCGCCGAGTGGGCACTGTCAACTGAACCGCCACCGGCTGGTTATGCGATCGTGCGGCGATA 
Hela-EAVP10  
Hela-EAVP35  .................................................................................................... 
Hela-EAVP60  
Hela-EAVP80  .................................................................................................... 
            
             9601                                          9650                                              9700 
VBS53 EAV    TATTGTAAAGAGGCTCCTCAGCTCAACAGAAGTGTTCTTGTGCCGCAGGGGTGTTGTGTCTTCCACCTCAGTGCAGACCATTTGTGCACTAGAGGGATGT 
Hela-EAVP10  
Hela-EAVP35  .................................................................................................... 
Hela-EAVP60  
Hela-EAVP80  .................................................................................................... 
            
             9701                                          9750                                              9800 
VBS53 EAV    AAACCTCTGTTCAACTTCTTACAAATTGGTTCAGTCATTGGGCCCGTGTGATGGGCTTAGTGTGGTCACTGATTTCAAATTCTATTCAGACTATTATTGC 
Hela-EAVP10                                                   .................................................. 
Hela-EAVP35  ..........................C......................................................................... 
Hela-EAVP60                                                   .................................................. 
Hela-EAVP80  ..........................T......................................................................... 
            
             9801                                          9850                                              9900 
VBS53 EAV    TGATTTTGCTATTTCTGTGATTGATGCAGCGCTTTTCTTTCTCATGCTACTTGCATTGGCTGTTGTTACTGTGTTTCTTTTCTGGCTCATTGTTGCCATC 
Hela-EAVP10  ..................................................................T................................. 
Hela-EAVP35  ..................................................................C................................. 
Hela-EAVP60  ..................................................................C................................. 
Hela-EAVP80  ..................................................................C................................. 
 
             9901                                          9950                                             10000 
VBS53 EAV    GGCCGCAGCTTGGTGGCGCGGTGTTCACGAGGTGCGCGTTACAGACCTGTTTAAGGATTTGCAGTGCGACAACCTGCGCGCGAAAGATGCCTTCCCGAGT 
Hela-EAVP10  ......A......T...................................................................................... 
Hela-EAVP35  ......A......C...................................................................................... 
Hela-EAVP60  ......T......C...................................................................................... 
Hela-EAVP80  ......T......C...................................................................................... 
            
 
 
 
 
 
  
182
             10001                                        10050                                             10100 
VBS53 EAV    CTGGGATATGCTCTGTCGATTGGCCAGTCGAGGCTATCGTATATGCTGCAGGATTGGTTGCTTGCTGCGCACCGCAAGGAAGTTATGCCCTCCAATATCA 
Hela-EAVP10  .................................................................................G..A............... 
Hela-EAVP35  .................................................................................G..G............... 
Hela-EAVP60  .................................................................................C..A............... 
Hela-EAVP80  .................................................................................C..A............... 
            
             10101                                        10150                                             10200 
VBS53 EAV    TGCCTATGCCCGGTCTTACTCCTGATTGCTTTGACCATCTGGAGTCTTCTAGCTATGCTCCATTTATCAATGCCTATCGGCAGGCAATTTTGAGTCAATA 
Hela-EAVP10  ........................................................G...............................C........... 
Hela-EAVP35  ........................................................A...............................C........... 
Hela-EAVP60  ........................................................A...............................C........... 
Hela-EAVP80  ........................................................A...............................C........... 
            
             10201                                        10250                                             10300 
VBS53 EAV    CTCACAAGAGCTCCTGCTCGAAGCCATCAACTGTAAATTGCTTGCTGTGGTTGCACCGGCATTGTATCATAATTACCATCTAGCCAATTTGACCGGACCG 
Hela-EAVP10  ..................................................................T................................. 
Hela-EAVP35  ..................................................................T................................. 
Hela-EAVP60  ..................................................................C................................. 
Hela-EAVP80  ..................................................................T................................. 
 
             10301                                        10350                                             10400 
VBS53 EAV    GCCACATGGGTCGTGCCTACAGTGGGCCAGTTGCACTATTATGCTTCTTCCTCTATTTTTGCTTCATCTGTGGAAGTGTTGGCAGCAATAATACTACTAT 
Hela-EAVP10  .................................................................................................... 
Hela-EAVP35  .................................................................................................... 
Hela-EAVP60  .................................................................................................... 
Hela-EAVP80  .................................................................................................... 
 
             10401                                        10450                                             10500 
VBS53 EAV    TTGCATGCATACCACTAGTGACACGAGTGTACATCTCTTTTACGCGGCTAATGTCACCTTCCCGTCGCACTTCCAGCGGCACTTTGCCGCGGCGCAAGAT 
Hela-EAVP10  .................................................................................................... 
Hela-EAVP35  .................................................................................................... 
Hela-EAVP60  .................................................................................................... 
Hela-EAVP80  .................................................................................................... 
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             10501                                        10550                                             10600 
VBS53 EAV    TTTGTAGTGCACACGGGTTATGAATATGCCGGGGTCACTATGTTAGTGCACTTGTTTGCCAACTTGGTTCTGACATTTCCGAGCTTAGTTAATTGTTCCC 
Hela-EAVP10  .................................................................................................... 
Hela-EAVP35  .................................................................................................... 
Hela-EAVP60  .................................................................................................... 
Hela-EAVP80  .................................................................................................... 
            
             10601                                        10650                                             10700 
VBS53 EAV    GCCCTGTGAATGTCTTTGCTAATGCTTCTTGCGTGCAAGTGGTTTGTAGTCATACCAACTCAACTACTGGCTTGGGTCAACTTTCTTTTTCCTTTGTAGA 
Hela-EAVP10  ...............................................A.................................................... 
Hela-EAVP35  ...............................................G.................................................... 
Hela-EAVP60  ...............................................G.................................................... 
Hela-EAVP80  ...............................................G....................................................           
               
             10701                                        10750                                             10800 
VBS53 EAV    TGAAGATCTACGGCTGCATATYAGGCCTACTCTTATTTGTTGGTTTGCCTTGTTGTTGGTGCACTTTCTACCCATGCCACGCTGCAGAGGCTCGTAATTT 
Hela-EAVP10  ........T............T.............................................................................. 
Hela-EAVP35  ........C............T.............................................................................. 
Hela-EAVP60  ........C............T.............................................................................. 
Hela-EAVP80  ........C............T.............................................................................. 
            
             10801                                        10850                                             10900 
VBS53 EAV    TACTTACATTAGTCATGGATTGGGCCACGTGCACGGTCATGAGGGGTGTAGGAATTTTATTAATGTCACTCATTCTGCATTTCTTTATCTTAATCCCACC 
Hela-EAVP10  .................................................................................................... 
Hela-EAVP35  .................................................................................................... 
Hela-EAVP60  .................................................................................................... 
Hela-EAVP80  .................................................................................................... 
            
             10901                                        10950                                             11000 
VBS53 EAV    ACTCTCACTGCGCCGGCTATAACTCATTGTTTACTTCTGGTTCTGGCAGCCAAAATGGAACACCCAAACGCTACTATCTGGCTGCAGCTGCAGCCGTTTG 
Hela-EAVP10  .................................................................................................... 
Hela-EAVP35  .................................................................................................... 
Hela-EAVP60  .................................................................................................... 
Hela-EAVP80  .................................................................................................... 
 
 
 
 
 
 
  
184
             11001                                        11050                                             11100 
VBS53 EAV    GGTATCATGTGGCTGGCGATGTCATTGTCAACTTGGAAGAGAATAAGAGGCATCCTTACTTTAAACTTTTGAGAGCGCCGGCTTTACCGCTTGGTTTTGT 
Hela-EAVP10  .......................A............................................................................ 
Hela-EAVP35  .......................A............................................................................ 
Hela-EAVP60  .......................T............................................................................ 
Hela-EAVP80  .......................T............................................................................ 
 
             11101                                        11150                                             11200 
VBS53 EAV    GGCTATAGTTTATGTTCTTTTACGACTGGTACGTTGGGCTCAACAATGTTATCTATGATTGTATTGCTATTCTTGCTTTGGGGTGCGCCATCACATGCTT 
Hela-EAVP10  ......................................................................T............................. 
Hela-EAVP35  ......................................................................C............................. 
Hela-EAVP60  ......................................................................C............................. 
Hela-EAVP80  ......................................................................C............................. 
            
             11201                                        11250                                             11300 
VBS53 EAV    ACTTCTCATACTACACCGCTCAGCGCTTCACAGACTTCACCTTGTGTATGCTGACGGATCGCGGCGTTATTGCCAATTTGCTGCGATATGATGAGCACAC 
Hela-EAVP10  .................................................................................................... 
Hela-EAVP35  .................................................................................................... 
Hela-EAVP60  .................................................................................................... 
Hela-EAVP80  .................................................................................................... 
            
             11301                                        11350                                             11400 
VBS53 EAV    TGCTTTGTACAATTGTTCCGCCAGTAAAACCTGTTGGTATTGCACATTCCTGGACGAACAGATTATCACGTTTGGAACCGATTGTAATGACACCTACGCG 
Hela-EAVP10  .................................................................................................... 
Hela-EAVP35  .................................................................................................... 
Hela-EAVP60  .................................................................................................... 
Hela-EAVP80  .................................................................................................... 
            
             11401                                        11450                                             11500 
VBS53 EAV    GTCCCAGTTGCTGAGGTCCTGGAACAGGCGCATGGACCGTACAGTGTGCTGTTTGATGACATGCCCCCTTTTATTTACTATGGCCGTGAATTCGGCATAG 
Hela-EAVP10  .....................................C....................................T......................... 
Hela-EAVP35  .....................................T....................................T......................... 
Hela-EAVP60  .....................................T....................................C......................... 
Hela-EAVP80  .....................................T....................................C......................... 
            
 
 
 
 
 
  
185
             11501                                        11550                                             11600 
VBS53 EAV    TTGTGTTGGATGTGTTTATGTTCTATCCCGTTTTAGTTCTGTTTTTCTTATCAGTACTACCCTATGCTACGCTTATTCTTGAAATGTGTGTATCTATTCT 
Hela-EAVP10  .................................................................................................... 
Hela-EAVP35  .................................................................................................... 
Hela-EAVP60  .................................................................................................... 
Hela-EAVP80  .................................................................................................... 
            
             11601                                        11650                                             11700 
VBS53 EAV    GTTTATAATCTATGGCATTTACAGCGGGGCCTACTTGGCCATGGGCATATTTGCGGCCACGCTTGCTATACATTCAATTGTGGTCCTCCGCCAATTACTG 
Hela-EAVP10  .................................................................................................... 
Hela-EAVP35  .................................................................................................... 
Hela-EAVP60  .................................................................................................... 
Hela-EAVP80  .................................................................................................... 
            
             11701                                        11750                                             11800 
VBS53 EAV    TGGTTATGCCTGGCTTGGCGATACCGCTGTACGCTTCACGCGTCCTTTATATCAGCTGAGGGGAAAGTGTACCCCGTAGACCCCGGACTCCCGGTTGCCG 
Hela-EAVP10  ...T............................................A................................................... 
Hela-EAVP35  ...C............................................A................................................... 
Hela-EAVP60  ...C............................................G................................................... 
Hela-EAVP80  ...C............................................A................................................... 
 
             11801                                        11850                                             11900 
VBS53 EAV    CCGCGGGCAATCGGTTGTTAGTCCCAGGTAGGCCCACTATCGATTATGCAGTGGCCTACGGCAGCAAAGTCAACCTTGTGAGGTTGGGGGCAGCTGAGGT 
Hela-EAVP10  .................................................................................G.................. 
Hela-EAVP35  .................................................................................A.................. 
Hela-EAVP60  .................................................................................G.................. 
Hela-EAVP80  .................................................................................G.................. 
            
             11901                                        11950                                             12000 
VBS53 EAV    ATGGGAGCCATAGATTCATTTTGTGGTGACGGGATTTTAGGTGAGTATCTAGATTACTTTATTCTGTCCGTCCCACTCTTGCTGTTGCTTACTAGGTATG 
Hela-EAVP10  .................................................................................................... 
Hela-EAVP35  .................................................................................................... 
Hela-EAVP60  .................................................................................................... 
Hela-EAVP80  .................................................................................................... 
            
 
 
 
 
 
  
186
             12001                                        12050                                             12100 
VBS53 EAV    TAGCATCTGGGTTAGTGTATGTTTTGACTGCCTTGTTCTATTCCTTTGTATTAGCAGCTTATATTTGGTTTGTTATAGTTGGAAGAGCCTTTTCTACTGC 
Hela-EAVP10  .................................................................................................... 
Hela-EAVP35  .................................................................................................... 
Hela-EAVP60  .................................................................................................... 
Hela-EAVP80  .................................................................................................... 
            
             12101                                        12150                                             12200 
VBS53 EAV    TTATGCTTTTGTGCTTTTGGCTGCTTTTCTGTTATTAGTAATGAGGATGATTGTAGGTATGATGCCTCGTCTTCGGTCCATTTTCAACCATCGCCAACTG 
Hela-EAVP10  .................................................................................................... 
Hela-EAVP35  .................................................................................................... 
Hela-EAVP60  .................................................................................................... 
Hela-EAVP80  .................................................................................................... 
            
             12201                                        12250                                             12300 
VBS53 EAV    GTGGTAGCTGATTTTGTGGACACACCTAGTGGACCTGTTCCCATCCCCCGCTCAACTACTCAGATAGTGGTTCGCGGCAACGGGTACACCGCAGTTGGTA 
Hela-EAVP10  .................................................................................................... 
Hela-EAVP35  .................................................................................................... 
Hela-EAVP60  .................................................................................................... 
Hela-EAVP80  .................................................................................................... 
            
             12301                                        12350                                             12400 
VBS53 EAV    ACAAGCTTGTCGATGGCGTCAAGACGATCACGTCCGCAGGCCGCCTCTTTTCGAAACGGGCGGCGGCGACAGCCTACAAGCTACAATGACCTACTGCGTA 
Hela-EAVP10  .................................................................................................... 
Hela-EAVP35  .................................................................................................... 
Hela-EAVP60  .................................................................................................... 
Hela-EAVP80  .................................................................................................... 
            
             12401                                        12450                                             12500 
VBS53 EAV    TGTTTGGTCAGATGCGGGTCCGCAAACCGCCCGCGCAACCCACTCAGGCTATCATTGCAGAGCCTGGAGACCTTAGGCATGATTTAAATCAACAGGAGCG 
Hela-EAVP10  .................................................................................................... 
Hela-EAVP35  .................................................................................................... 
Hela-EAVP60  .................................................................................................... 
Hela-EAVP80  .................................................................................................... 
 
 
 
 
 
 
  
187
             12501                                        12550                                             12600 
VBS53 EAV    CGCCACCCTTTCGTCGAACGTACAACGGTTCTTCATGATTGGGCATGGTTCACTCACTGCAGATGCCGGAGGACTCACGTACACCGTCAGTTGGGTTCCT 
Hela-EAVP10  .................................................................................................... 
Hela-EAVP35  .................................................................................................... 
Hela-EAVP60  .................................................................................................... 
Hela-EAVP80  .................................................................................................... 
            
             12601                                        12650                                             12700 
VBS53 EAV    ACCAAACAAATCCAGCGCAAAGTTGCGCCTCCAGCAGGGCCGTAAGACGTGGATATTCTCCTGTGTGGCGTCATGTTGAAGTAGTTATTAGCCACCCAGG 
Hela-EAVP10  .................................................................................................... 
Hela-EAVP35  .................................................................................................... 
Hela-EAVP60  .................................................................................................... 
Hela-EAVP80  .................................................................................................... 
    
             12701 
VBS53 EAV    AACC 
Hela-EAVP10  .... 
Hela-EAVP35  .... 
Hela-EAVP60  .... 
Hela-EAVP80  .... 
 
 
Note:  
1. The entire genome sequences (1-12704) of VBS53 EAV, Hela-EAVP35, and Hela-EAVP80 were shown. The nucleotide 
sequences (9751-12704, corresponding to ORFs 2-7 plus 3’ non-translated region) of Hela-EAVP10 and Hela-EAVP60 were 
shown. 
2.  Y = T or C; R = A or G. 
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Appendix 6. Alignment of amino acid sequences of polyprotein 1ab of VBS53 EAV, Hela-EAVP35, and Hela-EAVP80 
 
             1                                               50                                               100 
VBS53 EAV    MATFSATGFGGSFVRDWSLDLPDACEHGAGLCCEVDGSTLCAECFRGCEGVEQCPGLFMGLLKLASPVPVGHKFLIGWYRAAKVTGRYNFLELLQHPAFA 
Hela-EAVP35  .................................................................................................... 
Hela-EAVP80  .................................................................................................... 
    
             101                                            150                                               200 
VBS53 EAV    QLRVVDARLAIEEASVFISTDHASAKRFPGARFALTPVYASAWVASPAANSLIVTIDQEQDGFCWLKLLPPDRREAGLRLYYNHYREQRTGWLSKTGLRL 
Hela-EAVP35  ............................................V....................................................... 
Hela-EAVP80  ............................................V....................................................... 
    
             201                                            250                                               300 
VBS53 EAV    WLGDLGLGINASSGGLKFHIMRGSPQRAWHITTRSCKLKSYYVCDISEADWSCLPAGNYGGYNPPGDGACGYRCLAFMNGATVVSAGCSSDLWCDDELAY 
Hela-EAVP35  .................................................................................................... 
Hela-EAVP80  .................................................................................................... 
    
             301                                            350                                               400 
VBS53 EAV    RVFQLSPTFTVTIPGGRVCPNAKYAMICDKQHWRVKRAKGVGLCLDESCFRGTCNCQRMSGPPPAPVSAAVLDHILEAATFGNVRVVTPEGQPRPVPAPR 
Hela-EAVP35  .................................................................................................... 
Hela-EAVP80  .................................................................................................... 
    
             401                                            450                                               500 
VBS53 EAV    VRPSANSSGDVKDPAPVPPVPKPRTKLAKPNPTQAPIPAPRTRLQGASTQEPLASAGVASDSAPKWRVAKTVYSSAERFRTELVQRARSVGDVLVQALPL 
Hela-EAVP35  .................................................................................................... 
Hela-EAVP80  .................................................................................................... 
    
             501                                            550                                               600 
VBS53 EAV    KTPAVQRYTMTLKMMRSRFSWHCDVWYPLAVIACLLPIWPSLALLLSFAIGLIPSVGNNVVLTALLVSSANYVASMDHQCEGAACLALLEEEHYYRAVRW 
Hela-EAVP35  ............................................................................G....................... 
Hela-EAVP80  ............................................................................G....................... 
    
             601                                            650                                               700 
VBS53 EAV    RPITGALSLVLNLLGQVGYVARSTFDAAYVPCTVFDLCSFAILYLCRNRCWRCFGRCVRVGPATHVLGSTGQRVSKLALIDLCDHFSKPTIDVVGMATGW 
Hela-EAVP35  .................................................................................................... 
Hela-EAVP80  .................................................................................................... 
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             701                                            750                                               800 
VBS53 EAV    SGCYTGTAAMERQCASTVDPHSFDQKKAGAIVYLTPPVNSGSALQCLNVMWKRPIGSTVLGEQTGAVVTAVKSISFSPPCCVSTTLPTRPGVTVVDHALY 
Hela-EAVP35  .................................................................................................... 
Hela-EAVP80  .................................................................................................... 
    
             801                                            850                                               900 
VBS53 EAV    NRLTASGVDPALLRVGQGDFLKLNPGFRLIGGWIYGICYFVLVVVSTFTCLPIKCGIGTRDPFCRRVFSVPVTKTQEHCHAGMCASAEGISLDSLGLTQL 
Hela-EAVP35  .................................................................................................... 
Hela-EAVP80  .................................................................................................... 
    
             901                                            950                                              1000 
VBS53 EAV    QSYWIAAVTSGLVILLVCHRLAISALDLLTLASPLVLLVFPWASVGLLLACSLAGAAVKIQLLATLFVNLFFPQATLVTMGYWACVAALAVYSLMGLRVK 
Hela-EAVP35  .................................................................................................... 
Hela-EAVP80  .................................................................................................... 
    
             1001                                          1050                                              1100 
VBS53 EAV    VNVPMCVTPAHFLLLARSAGQSREQMLRVSAAAPTNSLLGVARDCYVTGTTRLYIPKEGGMVFEGLFRSPKARGNVGFVAGSSYGTGSVWTRNNEVVVLT 
Hela-EAVP35  .................................................................................................... 
Hela-EAVP80  .................................................................................................... 
    
             1101                                          1150                                              1200 
VBS53 EAV    ASHVVGRANMATLKIGDAMLTLTFKKNGDFAEAVTTQSELPGNWPQLHFAQPTTGPASWCTATGDEEGLLSGEVCLAWTTSGDSGSAVVQGDAVVGVHTG 
Hela-EAVP35  .................................................................................................... 
Hela-EAVP80  .................................................................................................... 
    
             1201                                          1250                                              1300 
VBS53 EAV    SNTSGVAYVTTPSGKLLGADTVTLSSLSKHFTGPLTSIPKDIPDNIIADVDAVPRSLAMLIDGLSNRESSLSGPQLLLIACFMWSYLNQPAYLPYVLGFF 
Hela-EAVP35  .................................................................................................... 
Hela-EAVP80  .................................................................................................... 
    
             1301                                          1350                                              1400 
VBS53 EAV    AANFFLPKSVGRPVVTGLLWLCCLFTPLSMRLCLFHLVCATVTGNVISLWFYITAAGTSYLSEMWFGGYPTMLFVPRFLVYQFPGWAIGTVLAVCSITML 
Hela-EAVP35  .................................................................................................... 
Hela-EAVP80  .................................................................................................... 
    
             1401                                          1450                                              1500 
VBS53 EAV    AAALGHTLLLDVFSASGRFDRTFMMKYFLEGGVKESVTASVTRAYGKPITQESLTATLAALTDDDFQFLSDVLDCRAVRSAMNLRAALTSFQVAQYRNIL 
Hela-EAVP35  .................................................................................................... 
Hela-EAVP80  .................................................................................................... 
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             1501                                          1550                                              1600 
VBS53 EAV    NASLQVDRDAARSRRLMAKLADFAVEQEVTAGDRVVVIDGLDRMAHFKDDLVLVPLTTKVVGGSRCTICDVVKEEANDTPVKPMPSRRRRKGLPKGAQLE 
Hela-EAVP35  ..........................................................R......................................... 
Hela-EAVP80  ..........................................................R......................................... 
    
             1601                                          1650                                              1700 
VBS53 EAV    WDRHQEEKRNAGDDDFAVSNDYVKRVPKYWDPSDTRGTTVKIAGTTYQKVVDYSGNVHYVEHQEDLLDYVLGKGSYEGLDQDKVLDLTNMLKVDPTELSS 
Hela-EAVP35  .................................................................................................... 
Hela-EAVP80  .................................................................................................... 
    
             1701                                          1750                                              1800 
VBS53 EAV    KDKAKARQLAHLLLDLANPVEAVNQLNLRAPHIFPGDVGRRTFADSKDKGFVALHSRTMFLAARDFLFNIKFVCDEEFTKTPKDTLLGYVRACPGYWFIF 
Hela-EAVP35  .................................................................................................... 
Hela-EAVP80  .................................................................................................... 
    
             1801                                          1850                                              1900 
VBS53 EAV    RRTHRSLIDAYWDSMECVYALPTISDFDVSPGDVAVTGERWDFESPGGGRAKRLTADLVHAFQGFHGASYSYDDKVAAAVSGDPYRSDGVLYNTRWGNIP 
Hela-EAVP35  .................................................................................................... 
Hela-EAVP80  .................................................................................................... 
    
             1901                                          1950                                              2000 
VBS53 EAV    YSVPTNALEATACYRAGCEAVTDGTNVIATIGPFPEQQPIPDIPKSVLDNCADISCDAFIAPAAETALCDDLEKYNLSTQGFVLPSVFSMVRAYLKEEIG 
Hela-EAVP35  ................................P................................................................... 
Hela-EAVP80  ................................S................................................................... 
    
             2001                                          2050                                              2100 
VBS53 EAV    DAPPLYLPSTVPSKNSQAGINGAEFPTKSLQSYCLIDDMVSQSMKSNLQTATMATCKRQYCSKYKIRSILGTNNYIGLGLRACLSGVTAAFQKAGKDGSP 
Hela-EAVP35  .................................................................................................... 
Hela-EAVP80  .................................................................................................... 
    
             2101                                          2150                                              2200 
VBS53 EAV    IYLGKSKFDPIPAPDKYCLETDLESCDRSTPALVRWFATNLIFELAGQPELVHSYVLNCCHDLVVAGSVAFTKRGGLSSGDPITSISNTIYSLVLYTQHM 
Hela-EAVP35  .................................................................................................... 
Hela-EAVP80  .................................................................................................... 
    
             2201                                          2250                                              2300 
VBS53 EAV    LLCGLEGYFPEIAEKYLDGSLELRDMFKYVRVYIYSDDVVLTTPNQHYAASFDRWVPHLQALLGFKVDPKKTVNTSSPSFLGCRFKQVDGKCYLASLQDR 
Hela-EAVP35  .................................................................................................... 
Hela-EAVP80  .................................................................................................... 
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             2301                                          2350                                              2400 
VBS53 EAV    VTRSLLYHIGAKNPSEYYEAAVSIFKDSIICCDEDWWTDLHRRISGAARTDGVEFPTIEMLTSFRTKQYESAVCTVCGAAPVAKSACGGWFCGNCVPYHV 
Hela-EAVP35  .................................................................................................... 
Hela-EAVP80  .................................................................................................... 
 
             2401                                          2450                                              2500 
VBS53 EAV    GHCHTTSLFANCGHDIMYRSTYCTMCEGSPKQMVPKVPHPILDHLLCHIDYGSKEELTLVVADGRTTSPPGRYKVGHKVVAVVADVGGNIVFGCGPGSHI 
Hela-EAVP35  .................................................................................................... 
Hela-EAVP80  .................................................................................................... 
    
             2501                                          2550                                              2600 
VBS53 EAV    AVPLQDTLKGVVVNKALKNAAASEYVEGPPGSGKTFHLVKDVLAVVGSATLVVPTHASMLDCINKLKQAGADPYFVVPKYTVLDFPRPGSGNITVRLPQV 
Hela-EAVP35  .................................................................................................... 
Hela-EAVP80  .................................................................................................... 
    
             2601                                          2650                                              2700 
VBS53 EAV    GTSEGETFVDEVAYFSPVDLARILTQGRVKGYGDLNQLGCVGPASVPRNLWLRHFVSLEPLRVCHRFGAAVCDLIKGIYPYYEPAPHTTKVVFVPNPDFE 
Hela-EAVP35  .................................................................................................... 
Hela-EAVP80  .................................................................................................... 
 
             2701                                          2750                                              2800 
VBS53 EAV    KGVVITAYHKDRGLGHRTIDSIQGCTFPVVTLRLPTPQSLTRPRAVVAVTRASQELYIYDPFDQLSGLLKFTKEAEAQDLIHGPPTACHLGQEIDLWSNE 
Hela-EAVP35  .................................................................................................... 
Hela-EAVP80  .................................................................................................... 
    
             2801                                          2850                                              2900 
VBS53 EAV    GLEYYKEVNLLYTHVPIKDGVIHSYPNCGPACGWEKQSNKISCLPRVAQNLGYHYSPDLPGFCPIPKELAEHWPVVSNDRYPNCLQITLQQVCELSKPCS 
Hela-EAVP35  .................................................................................................... 
Hela-EAVP80  .................................................................................................... 
    
             2901                                          2950                                              3000 
VBS53 EAV    AGYMVGQSVFVQTPGVTSYWLTEWVDGKARALPDSLFSSGRFETNSRAFLDEAEEKFAAAHPHACLGEINKSTVGGSHFIFSQYLPPLLPADAVALVGAS 
Hela-EAVP35  .................................................................................................... 
Hela-EAVP80  .................................................................................................... 
    
             3001                                          3050                                              3100 
VBS53 EAV    LAGKAAKAACSVVDVYAPSFEPYLHPETLSRVYKIMIDFKPCRLMVWRNATFYVQEGVDAVTSALAAVSKLIKVPANEPVSFHVASGYRTNALVAPQAKI 
Hela-EAVP35  .................................................................................................... 
Hela-EAVP80  .................................................................................................... 
    
  
192
             3101                                          3150                      3176 
VBS53 EAV    SIGAYAAEWALSTEPPPAGYAIVRRYIVKRLLSSTEVFLCRRGVVSSTSVQTICALEGCKPLFNFLQIGSVIGPV- 
Hela-EAVP35  ...........................................................................- 
Hela-EAVP80  ...........................................................................- 
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Appendix 7. Alignment of amino acid sequences of E protein of VBS53 EAV,  
Hela-EAVP10, Hela-EAVP35, Hela-EAVP60, and Hela-EAVP80 
 
                     1                                               50 
E of VBS53 EAV       MGLVWSLISNSIQTIIADFAISVIDAALFFLMLLALAVVTVFLFWLIVAI 
E of Hela-EAVP10     .................................................. 
E of Hela-EAVP35     .................................................. 
E of Hela-EAVP60     .................................................. 
E of Hela-EAVP80     .................................................. 
 
                     51              68 
E of VBS53 EAV       GRSLVARCSRGARYRPV- 
E of Hela-EAVP10     ..S.V............- 
E of Hela-EAVP35     ..S.A............- 
E of Hela-EAVP60     ..C.A............- 
E of Hela-EAVP80     ..C.A............- 
         
 
 
 
Appendix 8. Alignment of amino acid sequences of GP2b protein of VBS53 EAV,  
Hela-EAVP10, Hela-EAVP35, Hela-EAVP60, and Hela-EAVP80 
                    
                     1                                               50 
GP2b of VBS53 EAV    MQRFSFSCYLHWLLLLCFFSGSLLPSAAAWWRGVHEVRVTDLFKDLQCDN 
GP2b of Hela-EAVP10  ..............L...............W................... 
GP2b of Hela-EAVP35  ..............S...............R................... 
GP2b of Hela-EAVP60  ..............S...............R................... 
GP2b of Hela-EAVP80  ..............S...............R................... 
                       
                     51                                             100 
GP2b of VBS53 EAV    LRAKDAFPSLGYALSIGQSRLSYMLQDWLLAAHRKEVMPSNIMPMPGLTP 
GP2b of Hela-EAVP10  ....................................VM............ 
GP2b of Hela-EAVP35  ....................................VV............ 
GP2b of Hela-EAVP60  ....................................LM............ 
GP2b of Hela-EAVP80  ....................................LM............ 
                               
                     101                                            150 
GP2b of VBS53 EAV    DCFDHLESSSYAPFINAYRQAILSQYSQELLLEAINCKLLAVVAPALYHN 
GP2b of Hela-EAVP10  ...........A...................................... 
GP2b of Hela-EAVP35  ...........T...................................... 
GP2b of Hela-EAVP60  ...........T...................................... 
GP2b of Hela-EAVP80  ...........T...................................... 
            
                     151                                            200 
GP2b of VBS53 EAV    YHLANLTGPATWVVPTVGQLHYYASSSIFASSVEVLAAIILLFACIPLVT 
GP2b of Hela-EAVP10  .................................................. 
GP2b of Hela-EAVP35  .................................................. 
GP2b of Hela-EAVP60  .................................................. 
GP2b of Hela-EAVP80  .................................................. 
            
                     201                      228 
GP2b of VBS53 EAV    RVYISFTRLMSPSRRTSSGTLPRRKIL- 
GP2b of Hela-EAVP10  ...........................- 
GP2b of Hela-EAVP35  ...........................- 
GP2b of Hela-EAVP60  ...........................- 
GP2b of Hela-EAVP80  ...........................- 
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Appendix 9. Alignment of amino acid sequences of GP3 protein of VBS53 EAV,  
Hela-EAVP10, Hela-EAVP35, Hela-EAVP60, and Hela-EAVP80 
 
                    1                                               50 
GP3 of VBS53 EAV    MGRAYSGPVALLCFFLYFCFICGSVGSNNTTICMHTTSDTSVHLFYAANV 
GP3 of Hela-EAVP10  .................................................. 
GP3 of Hela-EAVP35  .................................................. 
GP3 of Hela-EAVP60  .................................................. 
GP3 of Hela-EAVP80  .................................................. 
           
                    51                                             100 
GP3 of VBS53 EAV    TFPSHFQRHFAAAQDFVVHTGYEYAGVTMLVHLFANLVLTFPSLVNCSRP 
GP3 of Hela-EAVP10  .................................................. 
GP3 of Hela-EAVP35  .................................................. 
GP3 of Hela-EAVP60  .................................................. 
GP3 of Hela-EAVP80  .................................................. 
                     
                    101                                            150 
GP3 of VBS53 EAV    VNVFANASCVQVVCSHTNSTTGLGQLSFSFVDEDLRLHIRPTLICWFALL 
GP3 of Hela-EAVP10  ..............S...................L............... 
GP3 of Hela-EAVP35  ..............G...................P............... 
GP3 of Hela-EAVP60  ..............G...................P............... 
GP3 of Hela-EAVP80  ..............G...................P............... 
           
                    151        164 
GP3 of VBS53 EAV    LVHFLPMPRCRGS- 
GP3 of Hela-EAVP10  .............- 
GP3 of Hela-EAVP35  .............- 
GP3 of Hela-EAVP60  .............- 
GP3 of Hela-EAVP80  .............- 
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Appendix 10. Alignment of amino acid sequences of GP4 protein of VBS53 EAV,  
Hela-EAVP10, Hela-EAVP35, Hela-EAVP60, and Hela-EAVP80 
 
                    1                                               50 
GP4 of VBS53 EAV    MKIYGCIXGLLLFVGLPCCWCTFYPCHAAEARNFTYISHGLGHVHGHEGC 
GP4 of Hela-EAVP10  ...Y...L.......................................... 
GP4 of Hela-EAVP35  ...H...L.......................................... 
GP4 of Hela-EAVP60  ...H...L.......................................... 
GP4 of Hela-EAVP80  ...H...L.......................................... 
           
                    51                                             100 
GP4 of VBS53 EAV    RNFINVTHSAFLYLNPTTLTAPAITHCLLLVLAAKMEHPNATIWLQLQPF 
GP4 of Hela-EAVP10  .................................................. 
GP4 of Hela-EAVP35  .................................................. 
GP4 of Hela-EAVP60  .................................................. 
GP4 of Hela-EAVP80  .................................................. 
           
                    101                                            150 
GP4 of VBS53 EAV    GYHVAGDVIVNLEENKRHPYFKLLRAPALPLGFVAIVYVLLRLVRWAQQC 
GP4 of Hela-EAVP10  ........I......................................... 
GP4 of Hela-EAVP35  ........I......................................... 
GP4 of Hela-EAVP60  ........F......................................... 
GP4 of Hela-EAVP80  ........F......................................... 
           
                    151 
GP4 of VBS53 EAV    YL- 
GP4 of Hela-EAVP10  ..- 
GP4 of Hela-EAVP35  ..- 
GP4 of Hela-EAVP60  ..- 
GP4 of Hela-EAVP80  ..- 
           
 
 
Note: At position 8, X represents amino acid L (Leucine) or S (Serine). 
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Appendix 11. Alignment of amino acid sequences of GP5 protein of VBS53 EAV,  
Hela-EAVP10, Hela-EAVP35, Hela-EAVP60, and Hela-EAVP80 
 
                    1                                               50 
GP5 of VBS53 EAV    MLSMIVLLFLLWGAPSHAYFSYYTAQRFTDFTLCMLTDRGVIANLLRYDE 
GP5 of Hela-EAVP10  ........F......................................... 
GP5 of Hela-EAVP35  ........S......................................... 
GP5 of Hela-EAVP60  ........S......................................... 
GP5 of Hela-EAVP80  ........S......................................... 
                     
                    51                                             100 
GP5 of VBS53 EAV    HTALYNCSASKTCWYCTFLDEQIITFGTDCNDTYAVPVAEVLEQAHGPYS 
GP5 of Hela-EAVP10  ...............................................P.. 
GP5 of Hela-EAVP35  ...............................................L.. 
GP5 of Hela-EAVP60  ...............................................L.. 
GP5 of Hela-EAVP80  ...............................................L.. 
           
                    101                                            150 
GP5 of VBS53 EAV    VLFDDMPPFIYYGREFGIVVLDVFMFYPVLVLFFLSVLPYATLILEMCVS 
GP5 of Hela-EAVP10  .................................................. 
GP5 of Hela-EAVP35  .................................................. 
GP5 of Hela-EAVP60  .................................................. 
GP5 of Hela-EAVP80  .................................................. 
           
                    151                                            200 
GP5 of VBS53 EAV    ILFIIYGIYSGAYLAMGIFAATLAIHSIVVLRQLLWLCLAWRYRCTLHAS 
GP5 of Hela-EAVP10  .................................................. 
GP5 of Hela-EAVP35  .................................................. 
GP5 of Hela-EAVP60  .................................................. 
GP5 of Hela-EAVP80  .................................................. 
           
                    201                                            250 
GP5 of VBS53 EAV    FISAEGKVYPVDPGLPVAAAGNRLLVPGRPTIDYAVAYGSKVNLVRLGAA 
GP5 of Hela-EAVP10  .I...........................................R.... 
GP5 of Hela-EAVP35  .I...........................................K.... 
GP5 of Hela-EAVP60  .V...........................................R.... 
GP5 of Hela-EAVP80  .I...........................................R.... 
           
                    251 
GP5 of VBS53 EAV    EVWEP- 
GP5 of Hela-EAVP10  .....- 
GP5 of Hela-EAVP35  .....- 
GP5 of Hela-EAVP60  .....- 
GP5 of Hela-EAVP80  .....- 
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Appendix 12. Alignment of amino acid sequences of M protein of VBS53 EAV,  
Hela-EAVP10, Hela-EAVP35, Hela-EAVP60, and Hela-EAVP80 
 
                  1                                               50 
M of VBS53 EAV    MGAIDSFCGDGILGEYLDYFILSVPLLLLLTRYVASGLVYVLTALFYSFV 
M of Hela-EAVP10  .................................................. 
M of Hela-EAVP35  .................................................. 
M of Hela-EAVP60  .................................................. 
M of Hela-EAVP80  .................................................. 
         
                  51                                             100 
M of VBS53 EAV    LAAYIWFVIVGRAFSTAYAFVLLAAFLLLVMRMIVGMMPRLRSIFNHRQL 
M of Hela-EAVP10  .................................................. 
M of Hela-EAVP35  .................................................. 
M of Hela-EAVP60  .................................................. 
M of Hela-EAVP80  .................................................. 
         
                  101                                            150 
M of VBS53 EAV    VVADFVDTPSGPVPIPRSTTQIVVRGNGYTAVGNKLVDGVKTITSAGRLF 
M of Hela-EAVP10  .................................................. 
M of Hela-EAVP35  .................................................. 
M of Hela-EAVP60  .................................................. 
M of Hela-EAVP80  .................................................. 
         
                  151       163 
M of VBS53 EAV    SKRAAATAYKLQ- 
M of Hela-EAVP10  ............- 
M of Hela-EAVP35  ............- 
M of Hela-EAVP60  ............- 
M of Hela-EAVP80  ............- 
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Appendix 13. Alignment of amino acid sequences of N protein of VBS53 EAV,  
Hela-EAVP10, Hela-EAVP35, Hela-EAVP60, and Hela-EAVP80 
 
                  1                                               50 
N of VBS53 EAV    MASRRSRPQAASFRNGRRRQPTSYNDLLRMFGQMRVRKPPAQPTQAIIAE 
N of Hela-EAVP10  .................................................. 
N of Hela-EAVP35  .................................................. 
N of Hela-EAVP60  .................................................. 
N of Hela-EAVP80  .................................................. 
         
                  51                                             100 
N of VBS53 EAV    PGDLRHDLNQQERATLSSNVQRFFMIGHGSLTADAGGLTYTVSWVPTKQI 
N of Hela-EAVP10  .................................................. 
N of Hela-EAVP35  .................................................. 
N of Hela-EAVP60  .................................................. 
N of Hela-EAVP80  .................................................. 
         
                  101     111 
N of VBS53 EAV    QRKVAPPAGP- 
N of Hela-EAVP10  ..........- 
N of Hela-EAVP35  ..........- 
N of Hela-EAVP60  ..........- 
N of Hela-EAVP80  ..........- 
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Appendix 14. Thermacycling conditions for site-directed mutagenesis PCR reactions 
 
 
1st mutagenesis PCR reaction 
 
Component Amount per reaction 
Nuclease free water  40.6 µl 
10 × cloned Pfu reaction buffer 5.0 µl 
dNTPs (25 mM each dNTP) 0.4 µl 
pS45VBS53 DNA (1:20 dilution) 1.0 µl 
Positive primer C211156P (20 µM) 1.0 µl 
Negative mutagenic primer 11443N (20 µM) 1.0 µl 
Pfu Turbo DNA polymerase (2.5 U/µl) 1.0 µl 
Total reaction volume 50 µl 
 
 2nd mutagenesis PCR reaction 
 
Component Amount per reaction 
Nuclease free water  36.6 µl 
10 × cloned Pfu reaction buffer 5.0 µl 
dNTPs (25 mM each dNTP) 0.4 µl 
pS45VBS53 DNA (1:20 dilution) 1.0 µl 
1st mutagenesis PCR mixture 5.0 µl 
Reverse primer 11515N (20 µM) 1.0 µl 
Pfu Turbo DNA polymerase (2.5 U/µl) 1.0 µl 
Total reaction volume 50 µl 
 
  
Thermacycling conditions for both 1st and 2nd mutagenesis PCR 
        
Seg 1 
95ºC 
40ºC 
72ºC 
2 min 
1.5 min 
6 min 
 
1 cycle 
Seg 2 
95ºC 
40ºC 
72ºC 
45 sec 
1.5 min 
6 min 
 
5 cycles 
Seg 3 
95ºC 
50ºC 
72ºC 
45 sec 
45 sec 
6 min 
 
34 cycles 
Seg 4 72ºC 10 min  
Seg 5 4ºC 8   
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